ZA200203824B - 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity. - Google Patents
5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity. Download PDFInfo
- Publication number
- ZA200203824B ZA200203824B ZA200203824A ZA200203824A ZA200203824B ZA 200203824 B ZA200203824 B ZA 200203824B ZA 200203824 A ZA200203824 A ZA 200203824A ZA 200203824 A ZA200203824 A ZA 200203824A ZA 200203824 B ZA200203824 B ZA 200203824B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- group
- compound
- carbon atoms
- groups
- Prior art date
Links
- 230000002218 hypoglycaemic effect Effects 0.000 title description 10
- 230000000055 hyoplipidemic effect Effects 0.000 title description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 260
- 150000001875 compounds Chemical class 0.000 claims description 252
- 239000000203 mixture Substances 0.000 claims description 125
- 125000000217 alkyl group Chemical group 0.000 claims description 93
- 239000003795 chemical substances by application Substances 0.000 claims description 79
- 125000001424 substituent group Chemical group 0.000 claims description 62
- 125000000623 heterocyclic group Chemical group 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 51
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 39
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 36
- 229940002612 prodrug Drugs 0.000 claims description 33
- 239000000651 prodrug Substances 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000002252 acyl group Chemical group 0.000 claims description 31
- 125000004434 sulfur atom Chemical group 0.000 claims description 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 206010022489 Insulin Resistance Diseases 0.000 claims description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims description 24
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 18
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 16
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 14
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 14
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 14
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 14
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 17
- -1 nitrogen containing 5-membered heterocyclic compound Chemical class 0.000 description 237
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 225
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 113
- 238000000034 method Methods 0.000 description 93
- 239000000243 solution Substances 0.000 description 93
- 235000002639 sodium chloride Nutrition 0.000 description 87
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 86
- 125000005843 halogen group Chemical group 0.000 description 76
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 69
- 239000000460 chlorine Substances 0.000 description 69
- 229910052801 chlorine Inorganic materials 0.000 description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 68
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 68
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 68
- 239000011737 fluorine Substances 0.000 description 68
- 229910052731 fluorine Inorganic materials 0.000 description 68
- 150000002430 hydrocarbons Chemical group 0.000 description 68
- 238000001914 filtration Methods 0.000 description 66
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 65
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 65
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 65
- 229910052794 bromium Inorganic materials 0.000 description 65
- 239000011630 iodine Substances 0.000 description 65
- 229910052740 iodine Inorganic materials 0.000 description 65
- 238000006243 chemical reaction Methods 0.000 description 63
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 59
- 229920006395 saturated elastomer Polymers 0.000 description 53
- 239000011541 reaction mixture Substances 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000000706 filtrate Substances 0.000 description 44
- 239000002585 base Substances 0.000 description 43
- 239000010410 layer Substances 0.000 description 43
- 239000011780 sodium chloride Substances 0.000 description 43
- 229960002668 sodium chloride Drugs 0.000 description 43
- 239000000126 substance Substances 0.000 description 43
- 238000010898 silica gel chromatography Methods 0.000 description 42
- 238000002844 melting Methods 0.000 description 40
- 230000008018 melting Effects 0.000 description 40
- 239000013078 crystal Substances 0.000 description 39
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 37
- 239000002904 solvent Substances 0.000 description 36
- 125000003545 alkoxy group Chemical group 0.000 description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 32
- 125000002541 furyl group Chemical group 0.000 description 30
- 125000001544 thienyl group Chemical group 0.000 description 30
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 29
- 125000004076 pyridyl group Chemical group 0.000 description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 27
- 239000003814 drug Substances 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 125000001931 aliphatic group Chemical group 0.000 description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 125000001624 naphthyl group Chemical group 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 19
- 239000012280 lithium aluminium hydride Substances 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 239000002244 precipitate Substances 0.000 description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- 125000002723 alicyclic group Chemical group 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 14
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 description 14
- 230000003287 optical effect Effects 0.000 description 14
- 238000000926 separation method Methods 0.000 description 14
- 239000012312 sodium hydride Substances 0.000 description 14
- 229910000104 sodium hydride Inorganic materials 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 125000002971 oxazolyl group Chemical group 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 12
- 125000000335 thiazolyl group Chemical group 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- 206010003210 Arteriosclerosis Diseases 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 11
- 206010056997 Impaired fasting glucose Diseases 0.000 description 11
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 208000011775 arteriosclerosis disease Diseases 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 125000003373 pyrazinyl group Chemical group 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 238000000638 solvent extraction Methods 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 206010006895 Cachexia Diseases 0.000 description 10
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000032050 esterification Effects 0.000 description 10
- 238000005886 esterification reaction Methods 0.000 description 10
- 150000002170 ethers Chemical class 0.000 description 10
- UKJFVOWPUXSBOM-UHFFFAOYSA-N hexane;oxolane Chemical compound C1CCOC1.CCCCCC UKJFVOWPUXSBOM-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 150000008282 halocarbons Chemical class 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 8
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 125000003226 pyrazolyl group Chemical group 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 229940123208 Biguanide Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 229940100389 Sulfonylurea Drugs 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 125000001425 triazolyl group Chemical group 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 6
- 229940122199 Insulin secretagogue Drugs 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 125000003302 alkenyloxy group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 5
- 206010012655 Diabetic complications Diseases 0.000 description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000004423 acyloxy group Chemical group 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000013681 dietary sucrose Nutrition 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 229940083608 sodium hydroxide Drugs 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 239000004373 Pullulan Substances 0.000 description 4
- 229920001218 Pullulan Polymers 0.000 description 4
- 101150050070 RXRA gene Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000010575 fractional recrystallization Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 235000011118 potassium hydroxide Nutrition 0.000 description 4
- 235000019423 pullulan Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 101100202237 Danio rerio rxrab gene Proteins 0.000 description 3
- 101100309320 Danio rerio rxrga gene Proteins 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000005035 acylthio group Chemical group 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000001485 cycloalkadienyl group Chemical group 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000002903 organophosphorus compounds Chemical class 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- CUMMDIGNAWOGSG-UHFFFAOYSA-N (1-benzyl-5-propylpyrazol-4-yl)methanol Chemical compound CCCC1=C(CO)C=NN1CC1=CC=CC=C1 CUMMDIGNAWOGSG-UHFFFAOYSA-N 0.000 description 2
- WAAPEIZFCHNLKK-UFBFGSQYSA-N (2s,4s)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide Chemical compound C([C@H](OC1=CC=C(F)C=C11)C(=O)N)[C@@]21NC(=O)NC2=O WAAPEIZFCHNLKK-UFBFGSQYSA-N 0.000 description 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 2
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- RNBFXAADNUAKIM-UHFFFAOYSA-N 2-(1-benzyl-5-phenylpyrazol-4-yl)acetic acid Chemical compound C=1C=CC=CC=1C1=C(CC(=O)O)C=NN1CC1=CC=CC=C1 RNBFXAADNUAKIM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FHEYFIGWYQJVDR-ACJLOTCBSA-N 2-[[3-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1h-indol-7-yl]oxy]acetic acid Chemical compound C1([C@@H](O)CN[C@@H](CC=2C3=CC=CC(OCC(O)=O)=C3NC=2)C)=CC=CC(Cl)=C1 FHEYFIGWYQJVDR-ACJLOTCBSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000006024 2-pentenyl group Chemical group 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- 125000006041 3-hexenyl group Chemical group 0.000 description 2
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 2
- 125000006043 5-hexenyl group Chemical group 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 101150019028 Antp gene Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- YVIXXPCJZAUQHJ-YGRLFVJLSA-N Cp-114271 Chemical compound C([C@@H](C)NC[C@H](O)C=1N=C(SC=1)C(F)(F)F)C1=CC=C(OCC(O)=O)C=C1 YVIXXPCJZAUQHJ-YGRLFVJLSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010054805 Macroangiopathy Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010036018 Pollakiuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000037063 Thinness Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- RWDHIVOWIOXAGV-UHFFFAOYSA-N [2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]pyridin-4-yl]methanol Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC1=CC(CO)=CC=N1 RWDHIVOWIOXAGV-UHFFFAOYSA-N 0.000 description 2
- ZCJRQVMBBOEWFE-UHFFFAOYSA-N [5-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]pyridin-3-yl]methanol Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC1=CN=CC(CO)=C1 ZCJRQVMBBOEWFE-UHFFFAOYSA-N 0.000 description 2
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000012042 active reagent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940125682 antidementia agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- MSJHOJKVMMEMNX-UHFFFAOYSA-N benzylhydrazine;hydron;dichloride Chemical compound Cl.Cl.NNCC1=CC=CC=C1 MSJHOJKVMMEMNX-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 150000004691 decahydrates Chemical class 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229950005454 doxifluridine Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- OTCMYFXPYGOQQO-VAWYXSNFSA-N ethyl (e)-3-(1-benzyl-5-propylpyrazol-4-yl)prop-2-enoate Chemical compound CCCC1=C(\C=C\C(=O)OCC)C=NN1CC1=CC=CC=C1 OTCMYFXPYGOQQO-VAWYXSNFSA-N 0.000 description 2
- WZUKNPHHLXJVTE-UHFFFAOYSA-N ethyl 3-(1-benzyl-3-ethoxypyrazol-4-yl)propanoate Chemical compound N1=C(OCC)C(CCC(=O)OCC)=CN1CC1=CC=CC=C1 WZUKNPHHLXJVTE-UHFFFAOYSA-N 0.000 description 2
- YRARTXUNVDJSMR-UHFFFAOYSA-N ethyl 3-(2-benzyl-5-oxo-1h-pyrazol-4-yl)propanoate Chemical compound N1=C(O)C(CCC(=O)OCC)=CN1CC1=CC=CC=C1 YRARTXUNVDJSMR-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 235000002864 food coloring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 150000002244 furazanes Chemical class 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005368 heteroarylthio group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- XWLVOJZVWRCRMD-OFNKIYASSA-N n-[5-[(1r)-2-[[(1r)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide Chemical compound C1=C(O)C(NS(=O)(=O)C)=CC([C@@H](O)CN[C@H](CC=2C=CC=CC=2)C=2C=CC(OC(F)F)=CC=2)=C1 XWLVOJZVWRCRMD-OFNKIYASSA-N 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 239000002664 nootropic agent Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- XAWLJKYXEITGHB-UHFFFAOYSA-N (1-benzyl-3-phenylmethoxypyrazol-4-yl)methanol Chemical compound N1=C(OCC=2C=CC=CC=2)C(CO)=CN1CC1=CC=CC=C1 XAWLJKYXEITGHB-UHFFFAOYSA-N 0.000 description 1
- SPKKTGNYNYQGEO-UHFFFAOYSA-N (1-benzyl-5-phenylpyrazol-4-yl)methanol Chemical compound C=1C=CC=CC=1C1=C(CO)C=NN1CC1=CC=CC=C1 SPKKTGNYNYQGEO-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- VMDKRSNUUUUARH-MQDBWYGVSA-N (3s)-4-[[(2s)-1-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-[[2-[[(2s)-2-[[2-(4-sulfooxyphenyl)acetyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid Chemical compound N([C@@H](CCCC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCC)C(=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC)C(=O)CC1=CC=C(OS(O)(=O)=O)C=C1 VMDKRSNUUUUARH-MQDBWYGVSA-N 0.000 description 1
- BMHZAHGTGIZZCT-LJQANCHMSA-N (4r)-2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4,3'-pyrrolidine]-1,2',3,5'-tetrone Chemical compound C1([C@]2(C(NC(=O)C2)=O)C2=O)=CC(F)=CC=C1C(=O)N2CC1=CC=C(Br)C=C1F BMHZAHGTGIZZCT-LJQANCHMSA-N 0.000 description 1
- AAQIALLSQXGHHT-UHFFFAOYSA-N (5-methyl-2-phenyl-1,3-oxazol-4-yl)methanol Chemical compound OCC1=C(C)OC(C=2C=CC=CC=2)=N1 AAQIALLSQXGHHT-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AKHXXQAIVSMYIS-UHFFFAOYSA-N 1,1-dioxo-3-pentyl-6-(trifluoromethyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound FC(F)(F)C1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CCCCC)NC2=C1 AKHXXQAIVSMYIS-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical group C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- 125000005837 1,2-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([*:2])C1([H])[H] 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 125000005838 1,3-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:2])C([H])([H])C1([H])[*:1] 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
- 125000004958 1,4-naphthylene group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- OCVCULZEXCBFIA-UHFFFAOYSA-N 1-[[3,5-bis(phenylmethoxy)phenyl]methyl]-4-phenylpyrrole-3-carbaldehyde Chemical compound C1=C(C=2C=CC=CC=2)C(C=O)=CN1CC(C=C(OCC=1C=CC=CC=1)C=1)=CC=1OCC1=CC=CC=C1 OCVCULZEXCBFIA-UHFFFAOYSA-N 0.000 description 1
- NAJVSRHGEROHRY-UHFFFAOYSA-N 1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]pyrazole-4-carbaldehyde Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CN1C=C(C=O)C=N1 NAJVSRHGEROHRY-UHFFFAOYSA-N 0.000 description 1
- ANLAMQJEDVHUOS-UHFFFAOYSA-N 1-benzyl-4-(chloromethyl)-5-phenylpyrazole Chemical compound C=1C=CC=CC=1C1=C(CCl)C=NN1CC1=CC=CC=C1 ANLAMQJEDVHUOS-UHFFFAOYSA-N 0.000 description 1
- LTQVAKDEUMEINY-UHFFFAOYSA-N 1-benzyl-5-phenylpyrazole-4-carbaldehyde Chemical compound C=1C=CC=CC=1C1=C(C=O)C=NN1CC1=CC=CC=C1 LTQVAKDEUMEINY-UHFFFAOYSA-N 0.000 description 1
- XJDJNESGOSFQCB-UHFFFAOYSA-N 1-benzyl-5-propylpyrazole-4-carbaldehyde Chemical compound CCCC1=C(C=O)C=NN1CC1=CC=CC=C1 XJDJNESGOSFQCB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical group C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- 125000004959 2,6-naphthylene group Chemical group [H]C1=C([H])C2=C([H])C([*:1])=C([H])C([H])=C2C([H])=C1[*:2] 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- CILPHQCEVYJUDN-VWYCJHECSA-N 2-[(1s,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxyacetic acid Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1OCC(O)=O CILPHQCEVYJUDN-VWYCJHECSA-N 0.000 description 1
- ILNRQFBVVQUOLP-UHFFFAOYSA-N 2-[2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]-oxomethyl]-1-indolyl]acetic acid Chemical compound C=1C2=CC=CC=C2N(CC(=O)O)C=1C(=O)NC(SC=1)=NC=1C1=CC=CC=C1Cl ILNRQFBVVQUOLP-UHFFFAOYSA-N 0.000 description 1
- JPWLDJDVBYCHLU-UHFFFAOYSA-N 2-[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]ethyl methanesulfonate Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC1=CC=C(CCOS(C)(=O)=O)C=C1 JPWLDJDVBYCHLU-UHFFFAOYSA-N 0.000 description 1
- LUACLLSCZRRTIH-UPHRSURJSA-N 2-[[4-[(z)-4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione Chemical compound O1C(=O)NC(=O)N1CC(C=C1)=CC=C1OC\C=C/COC(C=C1)=CC=C1CN1C(=O)NC(=O)O1 LUACLLSCZRRTIH-UPHRSURJSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- OCYJXSUPZMNXEN-UHFFFAOYSA-N 2-amino-1-(4-nitrophenyl)propane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=C([N+]([O-])=O)C=C1 OCYJXSUPZMNXEN-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- JCCBZCMSYUSCFM-UHFFFAOYSA-N 2-chlorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1Cl JCCBZCMSYUSCFM-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZFTYCEAMBNUKMP-UHFFFAOYSA-N 2-methylpropoxy hydrogen carbonate Chemical compound CC(C)COOC(O)=O ZFTYCEAMBNUKMP-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- ZAXFYAFDJGAWFI-UHFFFAOYSA-N 3,5-dimethyl-1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]pyrazole-4-carbaldehyde Chemical compound CC1=C(C=O)C(C)=NN1CC(C=C1)=CC=C1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 ZAXFYAFDJGAWFI-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- UYGZODVVDUIDDQ-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)methyl]-2-methyl-n-pentylsulfonylbenzimidazole-5-carboxamide Chemical compound C12=CC(C(=O)NS(=O)(=O)CCCCC)=CC=C2N=C(C)N1CC1=CC=C(Cl)C=C1Cl UYGZODVVDUIDDQ-UHFFFAOYSA-N 0.000 description 1
- NHNYXDFEOCVFFF-UHFFFAOYSA-N 3-[(4-phenylmethoxyphenyl)methoxy]-1-[(4-phenylmethoxyphenyl)methyl]pyrazole-4-carbaldehyde Chemical compound N1=C(OCC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(C=O)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 NHNYXDFEOCVFFF-UHFFFAOYSA-N 0.000 description 1
- PJHABVRZSJSQEN-UHFFFAOYSA-N 3-[1-[[4-[(2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]-3-thiophen-2-ylpyrazol-4-yl]propanoic acid Chemical compound N1=C(C=2SC=CC=2)C(CCC(=O)O)=CN1CC(C=C1)=CC=C1OCC(N=1)=COC=1C1=CC=CC=C1 PJHABVRZSJSQEN-UHFFFAOYSA-N 0.000 description 1
- FPSBVGFMFSDJPX-UHFFFAOYSA-N 3-[1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]-3-thiophen-2-ylpyrazol-4-yl]propanoic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CN(N=1)C=C(CCC(O)=O)C=1C1=CC=CS1 FPSBVGFMFSDJPX-UHFFFAOYSA-N 0.000 description 1
- OXJACOAJOJRQEV-UHFFFAOYSA-N 3-[3-ethoxy-1-[[4-[(2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]pyrazol-4-yl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(OCC)=NN1CC(C=C1)=CC=C1OCC1=COC(C=2C=CC=CC=2)=N1 OXJACOAJOJRQEV-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VCTKYTBWZTZPHF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ClCC1=C(C)OC(C=2C=CC=CC=2)=N1 VCTKYTBWZTZPHF-UHFFFAOYSA-N 0.000 description 1
- QJEWQQYHYXDLRZ-UHFFFAOYSA-N 4-[[4-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl-1,3-oxazole Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC1=CC=C(CCl)C=C1 QJEWQQYHYXDLRZ-UHFFFAOYSA-N 0.000 description 1
- ZSXXPIJPPCNMGL-UHFFFAOYSA-N 4-[[4-(chloromethyl)pyridin-2-yl]oxymethyl]-5-methyl-2-phenyl-1,3-oxazole Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC1=CC(CCl)=CC=N1 ZSXXPIJPPCNMGL-UHFFFAOYSA-N 0.000 description 1
- AGNVLJTWTXOEMI-UHFFFAOYSA-N 4-[[4-[(3,5-dimethylpyrazol-1-yl)methyl]phenoxy]methyl]-5-methyl-2-phenyl-1,3-oxazole Chemical compound N1=C(C)C=C(C)N1CC(C=C1)=CC=C1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 AGNVLJTWTXOEMI-UHFFFAOYSA-N 0.000 description 1
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- PAEATPXKBRWURL-UHFFFAOYSA-N 4-methoxy-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 PAEATPXKBRWURL-UHFFFAOYSA-N 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- DSEPOQLSSZUOBI-UHFFFAOYSA-N 4-phenyl-1-[(4-phenylmethoxyphenyl)methyl]pyrrole-3-carbaldehyde Chemical compound C1=C(C=2C=CC=CC=2)C(C=O)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 DSEPOQLSSZUOBI-UHFFFAOYSA-N 0.000 description 1
- ZAZCTQSWZPGFAW-UHFFFAOYSA-N 4-phenyl-1-[(6-phenylmethoxynaphthalen-2-yl)methyl]pyrrole-3-carbaldehyde Chemical compound C1=C(C=2C=CC=CC=2)C(C=O)=CN1CC(C=C1C=C2)=CC=C1C=C2OCC1=CC=CC=C1 ZAZCTQSWZPGFAW-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010012669 Diabetic hyperosmolar coma Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 229940121931 Gluconeogenesis inhibitor Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- NMWQEPCLNXHPDX-UHFFFAOYSA-N Glybuzole Chemical compound S1C(C(C)(C)C)=NN=C1NS(=O)(=O)C1=CC=CC=C1 NMWQEPCLNXHPDX-UHFFFAOYSA-N 0.000 description 1
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- 101001103034 Homo sapiens Nuclear receptor ROR-beta Proteins 0.000 description 1
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 1
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 1
- 101000851700 Homo sapiens Steroid hormone receptor ERR1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010068961 Hypo HDL cholesterolaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- SMNOERSLNYGGOU-UHFFFAOYSA-N Mefruside Chemical compound C=1C=C(Cl)C(S(N)(=O)=O)=CC=1S(=O)(=O)N(C)CC1(C)CCCO1 SMNOERSLNYGGOU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OAZMPSJABPODOJ-UHFFFAOYSA-N N1=C(C=CC=C1)C=1C(=CNC1)C=O Chemical compound N1=C(C=CC=C1)C=1C(=CNC1)C=O OAZMPSJABPODOJ-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102100039617 Nuclear receptor ROR-beta Human genes 0.000 description 1
- 102100038512 Nuclear receptor subfamily 1 group I member 3 Human genes 0.000 description 1
- 102100022670 Nuclear receptor subfamily 6 group A member 1 Human genes 0.000 description 1
- 101710093927 Nuclear receptor subfamily 6 group A member 1 Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150078416 RXR gene Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 102100037997 Squalene synthase Human genes 0.000 description 1
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- BXNCIERBDJYIQT-PRDVQWLOSA-N [(2r,3s,4s,5r,6s)-6-[2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OC)O[C@H]1OC1=CC(C)=CC(O)=C1C(=O)CCC1=CC=C(OC=C2)C2=C1 BXNCIERBDJYIQT-PRDVQWLOSA-N 0.000 description 1
- FTUCCGGCCFARSQ-UHFFFAOYSA-N [1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]-4-phenylpyrrol-3-yl]methanol Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CN(C=1)C=C(CO)C=1C1=CC=CC=C1 FTUCCGGCCFARSQ-UHFFFAOYSA-N 0.000 description 1
- UZLJRDNKYPPHFN-UHFFFAOYSA-N [1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]-4-pyridin-2-ylpyrrol-3-yl]methanol Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CN(C=1)C=C(CO)C=1C1=CC=CC=N1 UZLJRDNKYPPHFN-UHFFFAOYSA-N 0.000 description 1
- PKFZBYSQFZBMFU-UHFFFAOYSA-N [1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]pyrazol-4-yl]methanol Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CN1C=C(CO)C=N1 PKFZBYSQFZBMFU-UHFFFAOYSA-N 0.000 description 1
- MHHXKZKHZMSINU-UHFFFAOYSA-N [3,5-bis(phenylmethoxy)phenyl]methanol Chemical compound C=1C(OCC=2C=CC=CC=2)=CC(CO)=CC=1OCC1=CC=CC=C1 MHHXKZKHZMSINU-UHFFFAOYSA-N 0.000 description 1
- TWIQVAVXDLKBBH-UHFFFAOYSA-N [3,5-bis(phenylmethoxy)phenyl]methyl methanesulfonate Chemical compound C=1C(OCC=2C=CC=CC=2)=CC(COS(=O)(=O)C)=CC=1OCC1=CC=CC=C1 TWIQVAVXDLKBBH-UHFFFAOYSA-N 0.000 description 1
- AQBMNQNRWFJSTP-UHFFFAOYSA-N [3-phenyl-1-[(4-phenylmethoxyphenyl)methyl]pyrazol-4-yl]methanol Chemical compound N1=C(C=2C=CC=CC=2)C(CO)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 AQBMNQNRWFJSTP-UHFFFAOYSA-N 0.000 description 1
- NLPDNACBFFIQJT-UHFFFAOYSA-N [4-[(3-methyl-1-pyridin-2-ylpyrazol-4-yl)methoxy]phenyl]methanol Chemical compound CC1=NN(C=2N=CC=CC=2)C=C1COC1=CC=C(CO)C=C1 NLPDNACBFFIQJT-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
- 229960004988 azosemide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- CYKIHIBNSFRKQP-UHFFFAOYSA-N benzo[f][1]benzothiole Chemical compound C1=CC=C2C=C(SC=C3)C3=CC2=C1 CYKIHIBNSFRKQP-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- VTFOWOFXLWPGBM-UHFFFAOYSA-N benzyl 3-(chloromethyl)benzoate Chemical compound ClCC1=CC=CC(C(=O)OCC=2C=CC=CC=2)=C1 VTFOWOFXLWPGBM-UHFFFAOYSA-N 0.000 description 1
- WBZVXXDRNVPTRX-UHFFFAOYSA-N benzyl 4-(chloromethyl)benzoate Chemical compound C1=CC(CCl)=CC=C1C(=O)OCC1=CC=CC=C1 WBZVXXDRNVPTRX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- QQFYLZXBFWWJHR-UHFFFAOYSA-M benzyl(triethyl)phosphanium;bromide Chemical compound [Br-].CC[P+](CC)(CC)CC1=CC=CC=C1 QQFYLZXBFWWJHR-UHFFFAOYSA-M 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 208000003770 biliary dyskinesia Diseases 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000005885 boration reaction Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 229960002492 clobenzorex Drugs 0.000 description 1
- LRXXRIXDSAEIOR-ZDUSSCGKSA-N clobenzorex Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- DZFSTAUMUPHORN-NRFANRHFSA-N cyclohexyl-[[4-[2-[[(2s)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenoxy]methyl]phosphinic acid Chemical compound C([C@H](O)COC=1C=CC(O)=CC=1)NCCC(C=C1)=CC=C1OCP(O)(=O)C1CCCCC1 DZFSTAUMUPHORN-NRFANRHFSA-N 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 229960005227 delapril Drugs 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- ZLSFWAPBBIIMKI-KVINTPOGSA-M dipotassium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxido-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [K+].[K+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H]([O-])C1(C)C ZLSFWAPBBIIMKI-KVINTPOGSA-M 0.000 description 1
- RLIRIVMEKVNVQX-UHFFFAOYSA-L disodium;(2-cycloheptyl-1-phosphonatoethyl)-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)CC1CCCCCC1 RLIRIVMEKVNVQX-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229950000269 emiglitate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229950007164 ethiazide Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DWYUSIUKGQJEFM-UHFFFAOYSA-N ethoxy hydrogen carbonate Chemical compound CCOOC(O)=O DWYUSIUKGQJEFM-UHFFFAOYSA-N 0.000 description 1
- KMBOXWOCAAZRNK-BUHFOSPRSA-N ethyl (e)-3-(1-benzyl-3-phenylmethoxypyrazol-4-yl)prop-2-enoate Chemical compound N1=C(OCC=2C=CC=CC=2)C(/C=C/C(=O)OCC)=CN1CC1=CC=CC=C1 KMBOXWOCAAZRNK-BUHFOSPRSA-N 0.000 description 1
- VHNPMCZOSAUDCX-BUHFOSPRSA-N ethyl (e)-3-(1-benzyl-5-phenylpyrazol-4-yl)prop-2-enoate Chemical compound C=1C=CC=CC=1C1=C(/C=C/C(=O)OCC)C=NN1CC1=CC=CC=C1 VHNPMCZOSAUDCX-BUHFOSPRSA-N 0.000 description 1
- JVFHEPCIIQIZNN-OQKWZONESA-N ethyl (e)-3-[3-[(4-phenylmethoxyphenyl)methoxy]-1-[(4-phenylmethoxyphenyl)methyl]pyrazol-4-yl]prop-2-enoate Chemical compound N1=C(OCC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(/C=C/C(=O)OCC)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 JVFHEPCIIQIZNN-OQKWZONESA-N 0.000 description 1
- TUZKGAOIUVKWDS-OBGWFSINSA-N ethyl (e)-3-[4-phenyl-1-[(4-phenylmethoxyphenyl)methyl]pyrrol-3-yl]prop-2-enoate Chemical compound C1=C(C=2C=CC=CC=2)C(/C=C/C(=O)OCC)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 TUZKGAOIUVKWDS-OBGWFSINSA-N 0.000 description 1
- UODCEQXAEINZJQ-FBMGVBCBSA-N ethyl (e)-3-[4-phenyl-1-[(6-phenylmethoxynaphthalen-2-yl)methyl]pyrrol-3-yl]prop-2-enoate Chemical compound C1=C(C=2C=CC=CC=2)C(/C=C/C(=O)OCC)=CN1CC(C=C1C=C2)=CC=C1C=C2OCC1=CC=CC=C1 UODCEQXAEINZJQ-FBMGVBCBSA-N 0.000 description 1
- DMUGMJVWYXVNDQ-UHFFFAOYSA-N ethyl 1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]-4-pyridin-2-ylpyrrole-3-carboxylate Chemical compound C1=C(C=2N=CC=CC=2)C(C(=O)OCC)=CN1CC(C=C1)=CC=C1OCC(=C(O1)C)N=C1C1=CC=CC=C1 DMUGMJVWYXVNDQ-UHFFFAOYSA-N 0.000 description 1
- AUKRWHRBQAJOCC-UHFFFAOYSA-N ethyl 1-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC(C=C1)=CC=C1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 AUKRWHRBQAJOCC-UHFFFAOYSA-N 0.000 description 1
- LBESOLJVVZUGNE-UHFFFAOYSA-N ethyl 2-(5-phenyl-1h-pyrazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CNN=C1C1=CC=CC=C1 LBESOLJVVZUGNE-UHFFFAOYSA-N 0.000 description 1
- ZTNPOMQGFFYKAX-UHFFFAOYSA-N ethyl 2-[1-[2-(4-hydroxyphenyl)ethyl]-3-phenylpyrazol-4-yl]acetate Chemical compound N1=C(C=2C=CC=CC=2)C(CC(=O)OCC)=CN1CCC1=CC=C(O)C=C1 ZTNPOMQGFFYKAX-UHFFFAOYSA-N 0.000 description 1
- GMUGDFOPLOOXGI-UHFFFAOYSA-N ethyl 2-[3-phenyl-1-[2-(4-phenylmethoxyphenyl)ethyl]pyrazol-4-yl]acetate Chemical compound N1=C(C=2C=CC=CC=2)C(CC(=O)OCC)=CN1CCC(C=C1)=CC=C1OCC1=CC=CC=C1 GMUGDFOPLOOXGI-UHFFFAOYSA-N 0.000 description 1
- HUNISAHOCCASGM-UHFFFAOYSA-N ethyl 2-dimethoxyphosphorylacetate Chemical compound CCOC(=O)CP(=O)(OC)OC HUNISAHOCCASGM-UHFFFAOYSA-N 0.000 description 1
- RGIDFMZLYGWPED-UHFFFAOYSA-N ethyl 3-(5-ethoxy-1h-pyrazol-4-yl)propanoate Chemical compound CCOC(=O)CCC1=CNN=C1OCC RGIDFMZLYGWPED-UHFFFAOYSA-N 0.000 description 1
- TWXGHHITZNFLIX-UHFFFAOYSA-N ethyl 3-(5-phenyl-1h-pyrazol-4-yl)propanoate Chemical compound CCOC(=O)CCC1=CNN=C1C1=CC=CC=C1 TWXGHHITZNFLIX-UHFFFAOYSA-N 0.000 description 1
- FJYNEZYHEYDXAW-UHFFFAOYSA-N ethyl 3-(5-propyl-1h-pyrazol-4-yl)propanoate Chemical compound CCCC1=NNC=C1CCC(=O)OCC FJYNEZYHEYDXAW-UHFFFAOYSA-N 0.000 description 1
- WLPDDSMOTCXSLJ-UHFFFAOYSA-N ethyl 3-[1-[(4-hydroxyphenyl)methyl]-4-phenylpyrrol-3-yl]propanoate Chemical compound C1=C(C=2C=CC=CC=2)C(CCC(=O)OCC)=CN1CC1=CC=C(O)C=C1 WLPDDSMOTCXSLJ-UHFFFAOYSA-N 0.000 description 1
- YYOWLRVBAKKNNS-UHFFFAOYSA-N ethyl 3-[3-ethoxy-1-[(4-phenylmethoxyphenyl)methyl]pyrazol-4-yl]propanoate Chemical compound N1=C(OCC)C(CCC(=O)OCC)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 YYOWLRVBAKKNNS-UHFFFAOYSA-N 0.000 description 1
- KQWWVLVLVYYYDT-UHFFFAOYSA-N ethyl 3-oxohexanoate Chemical compound CCCC(=O)CC(=O)OCC KQWWVLVLVYYYDT-UHFFFAOYSA-N 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950007256 fidarestat Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 1
- 229960003064 flavoxate hydrochloride Drugs 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229950005232 glybuzole Drugs 0.000 description 1
- 229950002888 glyclopyramide Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002396 hypoinsulinemic effect Effects 0.000 description 1
- 150000007928 imidazolide derivatives Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229950003977 lintitript Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940063718 lodine Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 229960004678 mefruside Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QGCCYBZITYJPJV-UHFFFAOYSA-N methoxy hydrogen carbonate Chemical compound COOC(O)=O QGCCYBZITYJPJV-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 238000006063 methoxycarbonylation reaction Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- LYMWBUFRNSLTSG-UHFFFAOYSA-N methyl 1-[[3,5-bis(phenylmethoxy)phenyl]methyl]-4-phenylpyrrole-3-carboxylate Chemical compound C1=C(C=2C=CC=CC=2)C(C(=O)OC)=CN1CC(C=C(OCC=1C=CC=CC=1)C=1)=CC=1OCC1=CC=CC=C1 LYMWBUFRNSLTSG-UHFFFAOYSA-N 0.000 description 1
- CAXQGZWMLZYMEA-UHFFFAOYSA-N methyl 2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(OCC2=C(OC(=N2)C=2C=CC=CC=2)C)=C1 CAXQGZWMLZYMEA-UHFFFAOYSA-N 0.000 description 1
- KKOUHTMLFUAAGG-UHFFFAOYSA-N methyl 2-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(Cl)=C1 KKOUHTMLFUAAGG-UHFFFAOYSA-N 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 description 1
- AGVFAOJLUNTLKV-UHFFFAOYSA-N methyl 4-phenyl-1-[(4-phenylmethoxyphenyl)methyl]pyrrole-3-carboxylate Chemical compound C1=C(C=2C=CC=CC=2)C(C(=O)OC)=CN1CC(C=C1)=CC=C1OCC1=CC=CC=C1 AGVFAOJLUNTLKV-UHFFFAOYSA-N 0.000 description 1
- LPLCDTHPUFVWPC-UHFFFAOYSA-N methyl 4-phenyl-1-[(6-phenylmethoxynaphthalen-2-yl)methyl]pyrrole-3-carboxylate Chemical compound C1=C(C=2C=CC=CC=2)C(C(=O)OC)=CN1CC(C=C1C=C2)=CC=C1C=C2OCC1=CC=CC=C1 LPLCDTHPUFVWPC-UHFFFAOYSA-N 0.000 description 1
- MYANRSMHTCQQPA-UHFFFAOYSA-N methyl 5-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(OCC2=C(OC(=N2)C=2C=CC=CC=2)C)=C1 MYANRSMHTCQQPA-UHFFFAOYSA-N 0.000 description 1
- KJJSHOHQQHACLE-UHFFFAOYSA-N methyl 5-hydroxypyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(O)=C1 KJJSHOHQQHACLE-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 229950002259 minalrestat Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- JJYKJUXBWFATTE-UHFFFAOYSA-N mosher's acid Chemical compound COC(C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-N 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 1
- 125000001326 naphthylalkyl group Chemical group 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950001707 penflutizide Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229960003890 pimagedine Drugs 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 101150075122 ppard gene Proteins 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- TZIRZGBAFTZREM-MKAGXXMWSA-N pramlintide Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 TZIRZGBAFTZREM-MKAGXXMWSA-N 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229960001187 propiverine hydrochloride Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical group C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- CRPGRUONUFDYBG-UHFFFAOYSA-N risarestat Chemical compound C1=C(OCC)C(OCCCCC)=CC=C1C1C(=O)NC(=O)S1 CRPGRUONUFDYBG-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- ZCBUQCWBWNUWSU-SFHVURJKSA-N ruboxistaurin Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 ZCBUQCWBWNUWSU-SFHVURJKSA-N 0.000 description 1
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 1
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 108010009573 talabostat Proteins 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000006209 tert-butylation Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
- 229960003069 tolrestat Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- WQEVDHBJGNOKKO-UHFFFAOYSA-K vanadic acid Chemical compound O[V](O)(O)=O WQEVDHBJGNOKKO-UHFFFAOYSA-K 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
- UTODFRQBVUVYOB-UHFFFAOYSA-P wilkinson's catalyst Chemical compound [Cl-].C1=CC=CC=C1P(C=1C=CC=CC=1)(C=1C=CC=CC=1)[Rh+](P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UTODFRQBVUVYOB-UHFFFAOYSA-P 0.000 description 1
- SXONDGSPUVNZLO-UHFFFAOYSA-N zenarestat Chemical compound O=C1N(CC(=O)O)C2=CC(Cl)=CC=C2C(=O)N1CC1=CC=C(Br)C=C1F SXONDGSPUVNZLO-UHFFFAOYSA-N 0.000 description 1
- 229950006343 zenarestat Drugs 0.000 description 1
- 229950005346 zopolrestat Drugs 0.000 description 1
Description
5-MEMBERED N-HETEROCYCLIC COMPOUNDS
WITH
HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY
: DESCRIPTION v
TECHNICAL FIELD i 5 The present invention relates to a novel nitrogen containing 5-membered heterocyclic compound having an excellent hypoglycemic action and hypolipidemic action, which is useful as an agent for preventing or treating diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, arteriosclerosis, etc.
The present invention also relates to an agent for preventing or treating diabetes mellitus, hyperlipidemia or impaired glucose tolerance, which comprises a nitrogen containing 5-membered heterocyclic compound.
The present invention further relates to a retinoid-related receptor function regulating agent or an insulin resistance improving agent, which comprises a nitrogen containing 5-membered heterocyclic compound.
JP-A 10-72434 discloses a 2,4-substituted aniline derivative of the formula:
R: 0 gh oh wherein R’ represents alkyl, haloalkyl, alkoxy, or the like;
R? represents hydrogen atom, alkyl, haloalkyl, or the like;
R?® represents alkyl, cycloalkyl, alkenyl, ox the like; X represents oxygen, sulfur, NR’ or a single bond; Q represents an azole or the like, and a herbicide comprising . it.
However, said derivative is not reported to possess v hypoglycemic action and hypolipidemic action.
Peroxisome proliferator-activated receptor gamma (PPAR7 ), a member of the intranuclear hormone receptor superfamily, which is typically exemplified by steroid hormone receptors and thyroid hormone receptors, plays an ‘4 important role as a master regulator in the differentiation of adipose cells with its expression induced in the very . 5 early stage of adipose cell differentiation. PPARYT forms a dimer with the retinoid X receptor (RXR) by binding to a ligand, and binds to a responsive site of the target gene in the nucleus to directly control (activate) transcription efficiency. In recent years, the possibility that 15- deoxy-A!*' prostaglandin J,, a metabolite of prostaglandin
D,, serves as an endogenous ligand for PPAR7, has been suggested, and it has been shown that a class of insulin resistance enhancers, typically exemplified by : thiazolidinedione derivatives, possess ligand activity for
PPAR7Y , and that its potency is proportional to its hypoglycemic action or adipose cell differentiation- promoting action [Cell, vol. 83, p. 803 (1995): the Journal of Biological Chemistry, vol. 270, p. 12953 (1995); Journal of Medicinal Chemistry, vol. 39, p. 655 (1996)].
Furthermore, in recent years, it has been shown that 1) PPAR 7 is expressed in cultured cells of human liposarcoma origin, whose proliferation is ceased by the addition of a PPAR7Y ligand [Proceedings of the National Academy of
Sciences of the United States of America, vol. 94, p. 237 (1997)), 2) nonsteroidal anti-inflammatory drugs, typically exemplified by indomethacin and fenoprofen, have
PPAR7 ligand activity [the Journal of Biological Chemistry, vol. 272, p. 3406 (1997)]), 3) PPAR7 is expressed at high levels in activated macrophages, with the transcription of a gene involved in inflammation inhibited by the addition of a ligand therefor [Nature, vol. 391, p. 79 (1998)]. and 4) PPART ligands suppress the production of inflammatory cytokines (TNFa, IL-18, IL-6) by monocytes [Nature, vol. , 391, p. 82 (1998)].
There is a demand for development of a novel compound useful as an agent for preventing or treating diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, arteriosclerosis etc., and having ‘ pharmaceutically excellent properties such as low side effects, etc. . 5
The present invention relates to (1) a compound of the formula: x'-R’
R'-X- (CH,) -Y —n)- (CH,), —5 yw C=0-R" (I) wherein R! represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted;
X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR‘(OR®’)- or -NR°- wherein each of R* and R® represents a hydrogen atom or a hydrocarbon group which may be substituted, R® represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3;
Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO,-, -NR’-, -CONR’- or -NR’CO- wherein R’ represents a hydrogen atom or a hydrocarbon group which may be substituted: ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group;
X' represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO,-, -0-SO,- or -NR'- wherein R!® represents a hydrogen atom or a hydrocarbon group which may be substituted;
R’ represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may , be substituted;
W represents a bond or a divalent hydrocarbon residue . 5 having 1 to 20 carbon atoms;
R® represents a group of the formula: -OR® (R® represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR°R (each of R’ and R'’, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted: R® and R' may bind together to form a ring); provided that R! is a heterocyclic group which may be substituted or R? is an aromatic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, when ring A is a benzene ring which may be substituted, and Y is an oxygen atom, a sulfur atom, -NH- or -CONH-: or a salt thereof; (2) a compound according to the above (1), wherein X' is a bond and ring B is a nitrogen-containing 5-membered heterocyclic ring: (3) a compound according to the above (1), wherein R’ is a heterocyclic group which may be substituted or a cyclic - hydrocarbon group which may be substituted; (4) a compound according to the above (1), wherein R! is a heterocyclic group which may be substituted; (5) a compound according to the above (1), wherein X is a bond; (6) a compound according to the above (1), wherein m is 1 or 2; (7) a compound according to the above (1), wherein Y is an ] oxygen atom; (8) a compound according to the above (1), wherein ring a is a benzene ring or pyridine ring, each of which may further have 1 to 3 substituents:
(9) a compound according to the above (1), wherein n is an integer of 1 to 3; . (10) a compound according to the above (1), wherein X! is a bond or an oxygen atom; . 5 (11) a compound According to the above (1), wherein W is a divalent hydrocarbon residue having 1 to 8 carbon atoms: (12) a compound according to the above (1), wherein R’ is a group of the formula: -OR® (R° represents a hydrogen atom or a hydrocarbon group which may be substituted): (13) a compound according to the above (1), which is 3-[3-ethoxy-1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]- 1H-pyrazol-4-yl]lpropionic acid, 3-[3-ethoxy-1-[4-(2-phenyl-4-oxazolylmethoxy)benzyl]- 1H-pyrazol-4-yl)propionic acid, 3-[3-ethoxy-1-[4-[3-methyl-1-(2-pyridyl)-1H-pyrazol- 4-ylmethoxylbenzyl]-1H-pyrazol-4-yllpropionic acid, 3-[1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3- (2 -thienyl)-1H-pyrazol-4-yl]propionic acid, 3-[1~[4-(2-phenyl-4-thiazolylmethoxy)benzyl]3-(2- thienyl)-1H-pyrazol-4-yl]propionic acid, or 3-[1-[4-(2-phenyl-4-oxazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazol-4-yl]propionic acid; (14) a prodrug of a compound as defined in the above (1); (15) a pharmaceutical composition comprising a compound of the formula:. :
X'-R’
R'-X=(CH,) ,-Y —r- (CH) , Tw (c=0)-R’ (11) wherein R' represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; :
X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, ~CR*(OR®)- or -NR®- wherein each of R' and R® represents a hydrogen atom or a hydrocarbon group which may be substituted, R®’ represents a hydrogen atom or a protective group for a hydroxyl group;
6 i m represents an integer of 0 to 3;
Y represents an oxygen atom, a sulfur atom, or a group . of the formula: -SO-, -SO,-, -NR’-, -CONR’- or -NR’CO- wherein R’ represents a hydrogen atomor a hydrocarbon group . 5 which may he substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents: n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group;
X! represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -8S0,-, -0-SO,- or -NR'°- wherein R’® represents a hydrogen atom or a hydrocarbon group which may be substituted;
R? represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted:
W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms;
R’ represents a group of the formula: -OR’ (R® represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR°R'® (each of R’ and R°, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R’ and R* may bind together to form a ring): or a salt thereof or a prodrug thereof; (16) a composition according to the above (15), wherein X! is a bond and ring B is a nitrogen-containing 5-membered heterocyclic ring; (17) an agent for preventing or treating diabetes mellitus comprising a compound of the formula (II) or a salt thereof or a prodrug thereof; (18) an agent for preventing or treating hyperlipidemia . comprising a compound of the formula (II) or a salt thereof or a prodrug thereof; (19) an agent for preventing or treating impaired glucose
. tolerance comprising a compound of the formula (II) or a salt thereof or a prodrug thereof;
. 5 (20) a retinoid-related receptor function requlating ayent comprising a compound of the formula (II) ox a salt thereof or a prodrug thereof;
(21) an agent according to the above (20), which is a ligand for peroxisome proliferator-activated receptors: (22) an agent according to the above (20), which is a ligand : for retinoid X receptors: (23) an insulin resistance improving agent comprising a compound of the formula (II) or a salt thereof or a prodrug thereof; (24) a method for preventing or treating diabetes mellitus : in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of the formula (II) or a salt thereof or a prodrug thereof; (25) a method for preventing or treating hyperlipidemia in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of the formula (II) or a salt thereof or a prodrug thereof; (26) a method for preventing or treating impaired glucose tolerance in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of the formula (II) or a salt thereof or a prodrug thereof; (27) a method for regulating a retinoid-related receptor function in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of the formula (II) or a salt thereof or a prodrug thereof; (28) use of a compound of the formula (II) or a salt thereof or a prodrug thereof, for the manufacture of a pharmaceutical preparation for preventing or treating diabetes mellitus;
(29) use of a compound of the formula (II) or a salt thereof or a prodrug thereof, for the manufacture of a . pharmaceutical preparation for preventing or treating ~ hyperlipidemia; . 5 (30) use of a compound of the tormula (Ll) or a salt thereof : or a prodrug thereof, for the manufacture of a pharmaceutical preparation for preventing or treating : impaired glucose tolerance; and (31) use of a compound of the formula (II) or a salt thereof or a prodrug thereof, for the manufacture of an agent for regulating a retinoid-related receptor function. (1) Definition of R’ (1-1) Definition of the "hydrocarbon group” in R!
The hydrocarbon group in the "hydrocarbon group which may be substituted” for R' in the formulae (I) and (II) is exemplified by aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, alicyclic-aliphatic hydrocarbon groups, aromatic-aliphatic hydrocarbon groups, and aromatic hydrocarbon groups. The number of carbon atoms in these hydrocarbon groups is preferably 1 to 14.
The aliphatic hydrocarbon groups are preferably aliphatic hydrocarbon groups having 1 to 8 carbon atoms.
Examples of the aliphatic hydrocarbon groups include saturated aliphatic hydrocarbon groups having 1 to 8 carbon atoms (e.g., alkyl groups), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, t.-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl. heptyl, and octyl; and unsaturated aliphatic hydrocarbon groups having 2 to 8 carbon atoms (e.g., alkenyl groups having 2 to 8 carbon } atoms, alkadienyl groups having 4 to 8 carbon atoms, alkenylalkynyl groups having 2 to 8 carbon atoms, : alkadiynyl groups having 4 to 8 carbon atoms), such as ethenyl, 1l-propenyl, 2-propenyl, 1l-butenyl, 2-butenyl, 3-butenyl, 2-methyl-l-propenyl, l-pentenyl, 2-pentenyl,
3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, l-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, l-heptenyl, 1- . octenyl, ethynyl, 1l-propynyl, 2-propynyl, l-butynyl, 2- butynyl, 3-butynyl, l-pentynyl, 2-pentynyl, 3-pentynyl, 3 5 4-pentyny!, t-hexynyl, 3 -hexynyl, 2,4 hexadiynyl, 5- hexynyl, l-heptynyl, and l-octynyl. © The alicyclic hydrocarbon groups are preferably alicyclic hydrocarbon groups having 3 to 7 carbon atoms.
Examples of the alicyclic hydrocarbon groups include saturated alicyclic hydrocarbon groups having 3 to 7 carbon atoms (e.g., cycloalkyl groups), such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl; and unsaturated alicyclic hydrocarbon groups having 5 to 7 carbon atoms (e.g., cycloalkenyl groups, cycloalkadienyl groups), such as l-cyclopentenyl, 2-cyclopentenyl, 3- cyclopentenyl, 1l-cyclohexenyl, 2-cyclohexenyl, 3- cyclohexenyl, l-cycloheptenyl, 2-cycloheptenyl, 3- cycloheptenyl, and 2,4-cycloheptadienyl.
The alicyclic-aliphatic hydrocarbon groups are exemplified by those resulting from binding of the aforementioned alicyclic hydrocarbon groups and aliphatic hydrocarbon groups (e.g., cycloalkyl-alkyl groups, cycloalkenyl-alkyl groups), with preference given to alicyclic-aliphatic hydrocarbon groups having 4 to 9 carbon atoms. Examples of the alicyclic-aliphatic hydrocarbon groups include cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2- cyclopentenylmethyl, 3-cyclopentenylmethyl, cyclohexylmethyl, 2-cyclohexenylmethyl., 3- cyclohexenylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, and cycloheptylethyl.
The aromatic-aliphatic hydrocarbon groups are preferably aromatic-aliphatic hydrocarbon groups having 7
: to 13 carbon atoms (e.g., aralkyl groups having 7 to 13 carbon atoms, arylalkenyl groups having 8 to 13 carbon ; atoms). Examples of the aromatic-aliphatic hydrocarbon groups include phenylalkyls having 7 to 9 carbon atoms, such . 5 as henzyl!l, phenethyl, 1. phenylethyl, l-phenylpropyl, 2- phenylpropyl, and 3-phenylpropyl: naphthylalkyls having 11 to 13 carbon atoms, such as @-naphthylmethyl, «- naphthylethyl, B-naphthylmethyl, and S-naphthylethyl; phenylalkenyls having 8 to 10 carbon atoms, such as styryl; 10 and naphthylalkenyls having 12 to 13 carbon atoms, such as 2-(2-naphthylvinyl).
The aromatic hydrocarbon groups are preferably aromatic hydrocarbon groups having 6 to 14 carbon atoms (e.g., aryl groups). Examples of the aromatic hydrocarbon groups include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, and biphenylyl, with preference given to phenyl, l-naphthyl, 2-naphthyl, etc.
Of the aforementioned hydrocarbon groups, cyclic hydrocarbon groups such as alicyclic hydrocarbon groups and aromatic hydrocarbon groups are preferred. The hydrocarbon groups are more preferably aromatic hydrocarbon groups having 6 to 14 carbon atoms, with preference given to phenyl, naphthyl etc. (1-2) Definition of the “heterocyclic group” in R?
The heterocyclic group in the "heterocyclic group which may be substituted” for R!' in the formulae (I) and (II) is exemplified by 5- to 7-membered monocyclic heterocyclic groups containing 1 to 4 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms, in addition to carbon atoms, as ring constituent atoms, or condensed heterocyclic groups. Examples of the condensed heterocyclic groups include groups resulting from condensation of these 5- to 7-membered monocyclic heterocyclic groups with a 6-membered ring containing 1 to
2 nitrogen atoms, benzene rings or a 5-membered ring containing 1 sulfur atom. } Specifically, examples of the heterocyclic groups include aromatic heterocyclic groups such as 2-furyl, . 5 3-furyl, 2-thienyl, 3-thienyl, 2-pyriyl, 3-pyridyl, 4- pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, l-pyrrolyl, 2 pyrrolyl, 3-pyrrolyl, l-imidazolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, 1l-pyrazolyl, 3- pyrazolyl, 4-pyrazolyl, isoxazolyl, isothiazolyl, 2- thiazolyl, 4-thiazolyl, S-thiazolyl, 2-oxazolyl, 4- oxazolyl, 5-oxazolyl, 1,2,4-oxadiazol-3-yl, 1,2,4- oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,3,4-thiadiazol- 2-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,3- triazol-1l-yl, 1,2,3-triazol-2-yl, 1,2,3-triazol-4-yl, tetrazol-1-yl, tetrazol-5-yl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 2-quinazolyl, 4-quinazolyl, 2-quinoxalyl, 2-benzoxazolyl, 2-benzothiazolyl, benzimidazol-1-yl1, benzimidazol-2-yl, indol-1-yl, indol-3-yl, 1H-indazol- 3-yl, 1lH-pyrrolo[2,3-blpyrazin-2-yl, 1lH-pyrrolo[2,3- blpyridin-6-yl, 1lH-imidazo[4,5-blpyridin-2-yl, 1H- imidazo[4.,5-c)lpyridin-2-yl, 1lH-imidazo[4,5-blpyrazin-2- yl and benztriazol-1-yl; and non-aromatic heterocyclic groups such as l-pyrrolidinyl, piperidino, morpholino, thiomorpholino, l-piperazinyl, hexamethyleneimin-1-y1l, . oxazolidin-3-yl, thiazolidin-3-yl, imidazolidin-3-yl, 2-oxoimidazolidin-1-yl, 2,4-dioxoimidazolidin-3-yl, 2,4-dioxooxazolidin-3-yl, 2,4-dioxothiazolidin-3-yl, 1- oxo-phthalazin-2-yl and 2-ox0-2,3-dihydro-4H-1,4- benzothiazin-4-yl.
The heterocyclic groups are preferably aromatic heterocyclic groups, and more preferably 5- or 6-membered aromatic heterocyclic groups which may be condensed with a benzene ring (preferably furyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl). Especially preferred are furyl,
thienyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, benzoxazolyl, . benzothiazolyl, quinolyl, etc. i 5 (1-3) Definition ot the "suhstituent” in R!
Each of the hydrocarbon group and heterocyclic group for R' in the formulae (I) and (II) may have l to 5, preferably 1 to 3, substituents at substitutable positions. Examples of the substituents include "halogen atoms”, "nitro groups”, "aliphatic hydrocarbon groups which may be substituted”, *alicyclic hydrocarbon groups which may be substituted”, "aromatic hydrocarbon groups which may be substituted”, "aromatic heterocyclic groups which may be substituted”, "non-aromatic heterocyclic groups which may be substituted”, "acyl groups which may be substituted”, : "amino group which may be substituted”, "hydroxy group which may be substituted”, "thiol group which may be substituted”, and "carboxyl group which may be esterified or amidated”.
Examples of the "halogen atoms” include fluorine, chlorine, bromine and iodine, with preference given to fluorine and chlorine.
The aliphatic hydrocarbon groups in “aliphatic hydrocarbon groups which may be substituted” are exemplified by straight-chain or branched aliphatic hydrocarbon groups having 1 to 15 carbon atoms, such as alkyl groups, alkenyl groups, and alkinyl groups.
Preferred examples of the alkyl groups include alkyl groups having 1 to 10 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. -butyl, t.-butyl, pentyl, isopentyl, neopentyl, l-ethylpropyl. hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3- dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, and decyl.
Preferred examples of the alkenyl groups include alkenyl groups having 2 to 10 carbon atoms, such as ethenyl,
l-propenyl, 2-propenyl, 2-methyl-1l-propenyl, l-butenyl. ) 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1l-pentenyl, . 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, l-hexenyl, 3-hexenyl, 5-hexenyl, l-heptenyl, and 1- : 5 octenyl.
Preferred examples of the alkynyl groups include alkynyl groups having 2 to 10 carbon atoms, such as ethynyl, l-propynyl, 2-propynyl, l-butynyl, 2. -butynyl, 3--butynyl, l1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl., 1l-heptynyl, and l-octynyl.
Examples of the substituents in "aliphatic hydrocarbon groups which may be substituted” include cycloalkyl groups having 3 to 10 carbon atoms, aryl groups having 6 to 14 carbon atoms (e.g., phenyl, naphthyl), : aromatic heterocyclic groups (e.g., thienyl, furyl, pyridyl, oxazolyl, thiazolyl), non-aromatic heterocyclic groups (e.g., tetrahydrofuryl, morpholino, thiomorpholino, piperidino, pyrrolidinyl, piperazinyl), aralkyl groups having 7 to 9 carbon atoms, amino group, amino group mono- or di-substituted by alkyl groups having 1 to 4 carbon atoms or acyl groups having 2 to 8 carbon atoms (e.g., alkanoyl groups), amidino group, acyl groups having 2 to 8 carbon atoms (e.g., alkanoyl groups), carbamoyl group, carbamoyl group mono- or di-substituted by alkyl groups having 1 to 4 carbon atoms, sulfamoyl group, sulfamoyl group mono- or di-substituted by alkyl groups having 1 to 4 carbon atoms, carboxyl group, alkoxycarbonyl groups having 2 to 8 carbon atoms, hydroxy group, alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkenyloxy groups having 2 to 5 carbon atoms which may be substituted by 1 . to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), cycloalkyloxy groups having 3 to 7 carbon atoms, aralkyloxy groups having 7 to 9 carbon atoms, aryloxy groups having 6 to 14 carbon atoms (e.g., phenyloxy, naphthyloxy). thiol group, alkylthio groups having 1 to 6 carbon atoms . which may be substituted by 1 to 3 halogen atoms (e.g.. fluorine, chlorine, bromine, iodine), aralkylthio groups . 5 having 7 to 9 carbon atoms, arylthio groups having 6 to 14 carbon atoms (e.g. ., phenylthio, naphthylthio), sulfo group, cyano group, azide group, nitro group, nitroso group. and halogen atoms (e.g., fluorine, chlorine, bromine, iodine).
The number of the substituents is, for example, 1 to 3.
The alicyclic hydrocarbon groups in "alicyclic hydrocarbon groups which may be substituted” are exemplified by saturated or unsaturated alicyclic oo hydrocarbon groups having 3 to 12 carbon atoms, such as cycloalkyl groups, cycloalkenyl groups, and cycloalkadinenyl groups.
Preferred examples of the cycloalkyl groups include cycloalkyl groups having 3 to 10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo{2.2.1]heptyl, bicyclol[2.2.2]Joctyl, bicyclo[3.2.1}octyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]lnonyl, and bicyclo[4.3.1]decyl.
Preferred examples of the cycloalkenyl groups include cycloalkenyl groups having 3 to 10 carbon atoms, such as 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1- yl, and 3-cyclohexen-1-yl.
Preferred examples of the cycloalkadienyl groups include cycloalkadienyl groups having 4 to 10 carbon atoms, such as 2,4-cyclopentadien-1-yl, 2,4-cyclohexadien-1-yl, and 2,5-cyclohexadien-1-yl. ) Preferred examples of the aromatic hydrocarbon groups in "aromatic hydrocarbon groups which may be substituted” . include aromatic hydrocarbon groups having 6 to 14 carbon atoms (e.g., aryl groups), such as phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, and biphenylyl,
with preference given to phenyl, l-naphthyl, 2-naphthyl etc.
Preferred examples of the aromatic heterocyclic } 5 groups in “Aromatic heterocyclic groups which may be substituted” include 5- to 7-membered aromatic monocyclic heterocyclic groups containing 1 to 4 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms, in addition to carbon atoms, as ring constituent atoms, such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3- oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3-thaidiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, and triazinyl; and bicyclic or tricyclic aromatic condensed heterocyclic groups having 3 to 13 carbon atoms and containing 1 to 5 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen atoms, in addition to carbon atoms, as ring constituent atoms, such as benzofuranyl, isobenzofuranyl, benzo[blthienyl, indolyl, isoindolyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolyl, quinazolyl, quinoxalinyl, phthalazinyl, naphthylidinyl, purinyl, pteridinyl, carbazolyl, a- carbonylyl, B -carbonylyl, 7 -carbonylyl, acridinyl, oo phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, indolizinyl, pyrrolo[l,2-b]pyridazinyl, pyrazolo[l,5-alpyridyl, imidazo[l,2-a]pyridyl, imidazo[l,5-alpyridyl, imidazo[l,2-b]pyridazinyl, imidazo[1,2-alpyrimidinyl, 1,2,4-triazolo(4,3-alpyridyl, and 1,2.4-triazolo[4,3-b]pyridazinyl.
Preferred examples of the non-aromatic heterocyclic groups in "non-aromatic heterocyclic groups which may be substituted” include non-aromatic heterocyclic groups le having 2 to 10 carbon atoms and containing 1 to 3 hetero atoms selected from oxygen atoms, sulfur atoms and nitrogen } atoms, in addition to carbon atoms, as ring constituent atoms, such as oxylanyl, azetidinyl, oxetanyl, thietanyl, ) 5 pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidinyl, piperidino, morpholino, and thiomorpholino.
Fxamples of the substituents in the aforementioned "alicyclic hydrocarbon groups which may be substituted”, "aromatic hydrocarbon groups which may be substituted”, "aromatic heterocyclic groups which may be substituted” and *non-aromatic heterocyclic groups which may be substituted” include alkyl groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g... fluorine, chlorine, bromine, iodine), alkenyl groups having 2 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), cycloalkyl groups having 3 to 10 carbon atoms, aryl groups having 6 to 14 carbon atoms (e.g., phenyl, naphthyl), aromatic heterocyclic groups (e.g., thienyl, furyl, pyridyl, oxazolyl, thiazolyl), non-aromatic heterocyclic groups (e.g., tetrahydrofuryl, morpholino, thiomorpholino, piperidino, pyrrolidinyl, piperazinyl), aralkyl groups having 7 to 9 carbon atoms, amino group, amino group mono- or di-substituted by alkyl groups having 1 to 4 carbon atoms or acyl groups having 2 to 8 carbon atoms (e.g.., alkanoyl groups), amidino group, acyl groups having 2 to 8 carbon atoms (e.g., alkanoyl groups), carbamoyl group, carbamoyl } groups mono- or di-substituted by alkyl groups having 1 to 4 carbon atoms, sulfamoyl group, sulfamoyl group mono- or di-substituted by alkyl groups having 1 to 4 carbon atoms, carboxyl group, alkoxycarbonyl groups having 2 to 8 carbon atoms, hydroxy group, alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkenyloxy groups having 2 to 5 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), cycloalkyloxy groups having 3 to 7 carbon atoms, ] aralkyloxy groups having 7 to 9 carbon atoms, aryloxy groups having 6 to 14 carbon atoms (e.g., phenyloxy, naphthyloxy). ] 5 thiol group, alkylthio groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), aralkylthio groups having 7 to 9 carbon atoms, arylthio groups having 6 to 14 carbon atoms (e.g., phenylthio, naphthylthio), sulfo group, cyano group, azide group, nitro group, nitroso group, and halogen atoms (e.g., fluorine, chlorine, bromine, iodine).
The number of the substituents is, for example, 1 to 3.
The acyl groups in "acyl groups which may be substituted” are exemplified by acyl groups having 1 to 13 carbon atoms, specifically formyl and groups of the formulae: -COR'', -SO,R', -SOR or -PO,R"R'®> wherein each of R!! and R'?, whether identical or not, represents a hydrocarbon group or an aromatic heterocyclic group.
The hydrocarbon group for R'! or R'? is exemplified by the hydrocarbon groups mentioned to exemplify R' above.
Especially preferred are alkyl groups having 1 to 10 carbon atoms, cycloalkyl groups having 3 to 10 carbon atoms, alkenyl groups having 2 to 10 carbon atoms, cycloalkenyl - 25 groups having 3 to 10 carbon atoms, and aryl groups having 6 to 12 carbon atoms.
The aromatic heterocyclic group for R!! or R? is exemplified by the aromatic heterocyclic groups mentioned to exemplify R! above. Especially preferred are thienyl, furyl, pyridyl, etc.
Preferred examples of the acyl groups include acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2-
cyclohexenecarbonyl, benzoyl, nicotinoyl, and isonicotinoyl. . . Said acyl group may have 1 to 3 substituents at substitutable positions. Examples of such substituents : 5 include , alkyl groups which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, iodine), C,, alkoxy groups which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino. “Amino group which may be substituted” is exemplified by an amino group which may be mono- or di-substituted by alkyl groups having 1 to 10 carbon atoms, cycloalkyl groups having 3 to 10 carbon atoms, alkenyl groups having 2 to 10 carbon atoms, cycloalkenyl groups having 3 to 10 carbon atoms, acyl groups having 1l to 13 carbon atoms or aryl groups having 6 to 12 carbon atoms.
Here, the acyl groups are exemplified by the same acyl groups as those mentioned above, and are preferably alkanoyl groups having 2 to 10 carbon atoms, arylcarbonyl groups having 7 to 13 carbon atoms, etc.
Examples of the substituted amino groups include methylamino, dimethylamino, ethylamino, diethylamino, propylamino, dibutylamino, diallylamino, cyclohexylamino, acetylamino, propionylamino, benzoylamino, phenylamino, and N-methyl-N-phenylamino. "Hydroxy group which may be substituted” is exemplified by hydroxy group which may be substituted by alkyl groups having 1 to 10 carbon atoms, alkenyl groups having 2 to 10 carbon atoms, aralkyls having 7 to 10 carbon atoms, acyl groups having 1 to 13 carbon atoms or aryl groups } having 6 to 12 carbon atoms, each of which groups may be substituted.
Examples of the substituents which may be possessed by these “alkyl groups having 1 to 10 carbon atoms”, . "alkenyl groups having 2 to 10 carbon atoms”, "aralkyl groups having 7 to 10 carbon atoms”, "acyl groups having . 5 1 to 13 carbon atoms” and "aryl groups having 6 to 12 carbon atoms” include halogen atoms (e.g., fluorine, chlorine, bromine, iodine), C, , alkoxy groups which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, hromine, iodine), hydroxy, nitro, and amino. The number of the substituents is, for example, 1 to 2.
Examples of the substituted hydroxy group include alkoxy groups, alkenyloxy groups, aralkyloxy groups, acyloxy groups, and aryloxy groups, each of which groups may be substituted. ’
Preferred examples of the alkoxy groups include alkoxy groups having 1 to 10 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec. -butoxy, t.-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy.
Preferred examples of the alkenyloxy groups include alkenyloxy groups having 2 to 10 carbon atoms, such as allyloxy, crotyloxy, 2-pentenyloxy. 3-hexenyloxy, 2- cyclopentenyloxy, and 2-cyclohexenyloxy. i
Preferred examples of the aralkyloxy groups include aralkyloxy groups having 7 to 10 carbon atoms, such as phenyl-C, , alkyloxys (e.g. benzyloxy, phenethyloxy).
Preferred examples of the acyloxy groups include acyloxy groups having 2 to 13 carbon atoms, with greater preference given to alkanoyloxys having 2 to 4 carbon atoms i (e.g., acetyloxy, propionyloxy, butyryloxy, isobutyryloxy). } Preferred examples of the aryloxy groups include aryloxy groups having 6 to 14 carbon atoms, such as phenoxy and naphthyloxy.
The aforementioned alkoxy groups, alkenyloxy groups. . aralkyloxy groups, acyloxy groups and aryloxy groups may have 1 to 2 substituents at substitutable positions. } 5 Examples of such snbstituents include halogen atoms (e.g... fluorine, chlorine, bromine, iodine), C,, alkoxy groups which may be substituted by 1 to 3 halogen atoms (e.g.. fluorine, chlorine, bromine, iodine), hydroxy, nitro, and amino. For example, examples of the substituted aryloxy : 10 groups include 4-chlorophenoxy and 2-methoxyphenoxy.
Thiol group which may be substituted is exemplified by thiol group which may be substituted by alkyls having 1 to 10 carbon atoms, cycloalkyls having 3 to 10 carbon atoms, aralkyls having 7 to 10 carbon atoms, acyls having 2 to 13 carbon atoms, aryls having 6 to 14 carbon atoms, heteroaryls, . etc.
Examples of the substituted thiol groups include alkylthios, cycloalkylthios, aralkylthios, acylthios, arylthios, and heteroarylthios. :
Preferred examples of the alkylthio groups include alkylthio groups having 1 to 10 carbon atoms, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec.-butylthio, t.-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, and nonylthio.: -
Preferred examples of the cycloalkylthio groups include cycloalkylthio groups having 3 to 10 carbon atoms, such as cyclobutylthio, cyclopentylthio, and cyclohexylthio.
Preferred examples of the aralkylthio groups include . aralkylthio groups having 7 to 10 carbon atoms, such as phenyl-C, , alkylthios (e.g., benzylthio, phenethylthio).
Preferred examples of the acylthio groups include acylthio groups having 2 to 13 carbon atoms, with greater preference given to alkanoylthio groups having 2 to 4 carbon atoms (e.g. , acetylthio, propionylthio, butyrylthio, isobutyrylthio). . Preferred examples of the arylthio groups include : arylthio groups having 6 to 14 carbon atoms, such as . 5 phenylthio and naphthylthio.
Preferred examples of the heteroarylthio groups include 2-pyridylthio, 3-pyridylthio, 2-imidazolylthio, and 1,2,4 -triazol-5-~ylthio.
Esterified carboxyl groups in the carboxyl groups which may be esterified are exemplified by alkoxycarbonyl groups having 2 to 5 carbon atoms (e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl), aralkyloxycarbonyl groups having 8 to 10 carbon atoms (e.g., benzyloxycarbonyl), and aryloxycarbonyl groups having 7 to 15 carbon atoms (e.g., phenoxycarbonyl, p- tolyloxycarbonyl) which may be substituted by 1 or 2 alkyl groups having 1 to 3 carbon atoms.
Amidated carboxyl groups in the carboxyl groups which may be amidated are exemplified by groups of the formula: -CON(R**) (R') wherein each of R*® and R'*, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted.
Here, the hydrocarbon group in the "hydrocarbon group which may be substituted” for RY and R is exemplified by the aliphatic hydrocarbon groups, alicyclic hydrocarbon groups and aromatic hydrocarbon groups mentioned to exemplify the hydrocarbon group in the "hydrocarbon group which may be substituted” for R'. In addition, the heterocyclic group in the "heterocyclic group which may be substituted” for R* and R' is exemplified by the i heterocyclic groups mentioned to exemplify the : heterocyclic group in the "heterocyclic group which may be substituted” for R!. These hydrocarbon groups and heterocyclic groups may have 1 to 3 substituents at ~ substitutable positions. Examples of such substituents . include halogen atoms (e.g., fluorine, chlorine, bromine, iodine), C,, alkyl groups which may be substituted by 1 to . 5 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine),
C,.; alkoxy groups which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino.
The substituents in the hydrocarbon group and heterocyclic group for R! in the formulae (I) and (II) are preferably: 1) alkyl groups having 1 to 10 (preferably 1 to 4) carbon atoms which may have 1 to 3 substituents selected from the group consisting of alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino; ’ 2) cycloalkyl groups having 3 to 10 (preferably 3 to 7) carbon atoms which may have 1 to 3 substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino; 3) aromatic heterocyclic groups (preferably furyl, thienyl, pyridyl, pyrazinyl, etc.) whichmay have 1 to 3 substituents : selected from the group consisting of alkyl groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine,
iodine), nitro, hydroxy, and amino; 4) aryl groups having 6 to 14 carbon atoms (preferably . phenyl, naphthyl, etc.) which may have 1 to 3 substituents selected from the group consisting of alkyl groups having ] 5 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.yg., fluorine, chlorine, bromine, iodine), alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino; etc. The number of the substituents is, for example, 1 to 3, preferably 1 or 2.
The substituents are preferably alkyl groups having 1 to 4 carbon atoms, furyl, thienyl, phenyl, naphthyl etc. (1-4) Preferred examples of R!
In the formulae (I) and (II), R! is preferably a heterocyclic group which may be substituted or a cyclic hydrocarbon group which may be substituted. R' is more preferably a heterocyclic group which may be substituted. ~~ Here, the heterocyclic group is preferably a 5- or 6- membered aromatic heterocyclic group (preferably furyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyrazolyl) which may be condensed with a benzene ring. Especially preferred are furyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, oxazolyl. thiazolyl, oxadiazolyl, benzoxazolyl, benzothiazolyl, © quinolyl, pyrazolyl, etc.
Preferred examples of the substituents which may be possessed by the aforementioned heterocyclic group or cyclic hydrocarbon group include : 1) furyl, thienyl, pyridyl, pyrazinyl, phenyl or naphthyl, each of which may have 1 to 3 substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.qg., fluorine, chlorine, bromine, iodine), alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro. . hydroxy, and amino; 2) alkyl groups having 1 to 4 carbon atoms or cycloalkyl . 5 groups having 3 to 7 carhon atoms, each of which may have 1 to 3 substituents selected from the group consisting of alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino.
The number of the substituents is, for example, 1 or 2.
R! is especially preferably pyridyl, oxazolyl, thiazolyl, triazolyl or pyrazolyl, each of which may have 1 to 2 substituents selected from the group consisting of alkyl groups having 1 to 3 carbon atoms, cycloalkyl groups having 3 to 7 carbon atoms, furyl, thienyl, pyridyl, phenyl and naphthyl. (2) Definition of X
In the formulae (I) and (II), X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR*‘(OR®)- or -NR®- wherein each of R‘ and R* represents a hydrogen atom or a hydrocarbon group which may be substituted, R® represents a hydrogen atom or a protective group for a hydroxyl group: and is preferably a bond, -CR‘(OR’)- or -NR®- wherein the symbols have the same meanings as above, more preferably a bond or -NR®- wherein the symbol has the same meaning as above. X is especially preferably a bond.
Here, the "hydrocarbon groups which may be substituted” for R* and R® is exemplified by the "hydrocarbon groups which may be substituted” mentioned to exemplify R! above. Said "hydrocarbon groups which may be substituted” are preferably alkyl groups having 1 to 4 carbon atoms which may be substituted, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, and t.-butyl.
Said alkyl groups may have 1 to 3 substituents at substitutable positions. Examples of such substituents . include halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkoxy groups having 1 to 4 carbon atoms (e.g.. . 5 methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy. sec. ~butoxy, t.-butoxy), hydroxy, nitro, amino, and acyl groups having 1 to 4 carbon atoms (e.g., alkanoyl groups having 1 to 4 carbon atoms, such as formyl, acetyl and propionyl).
R' and R® are preferably hydrogen atom or alkyl groups having 1 to 4 carbon atoms.
Examples of the protective groups for a hydroxyl group for R® include C, , alkyls (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl), phenyl, trityl, C,,, aralkyls (e.g., benzyl), formyl, C, ,alkyl-carbonyls (e.g., acetyl, propionyl), benzoyl, C,,, aralkyl-carbonyls (e.g., benzylcarbonyl), 2-tetrahydropyranyl, 2- tetrahydrofuranyl, silyls (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert- butyldimethylsilyl, tert-butyldiethylsilyl), and C, alkenyls (e.g., 1-allyl) . These groups may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), C, alkyls (e.g., methyl, ethyl, propyl), C,, alkoxy (e.g., methoxy, ethoxy, propoxy), nitro, or the like. (3) Definitions of m and Y¥Y
In the formulae (I) and (II), m represents an integer of 0 to 3, preferably an integer of 1 to 3, and more preferably 1 or 2.
In the formulae (I) and (II), Y represents an oxygen atom, a sulfur atom, or a group of the formula: -S0-, -
S0,-, -NR’-, -CONR’- or -NR'CO- wherein R’ represents a hydrogen atom or a hydrocarbon group which may be substituted, and is preferably an oxygen atom, a sulfur atom,
-NR’- or ~NR’CO- wherein the symbol has the same meaning as above. . Here, “hydrocarbon groups which may be substituted’ for R’ is exemplified by the “hydrocarbon groups which may . 5 be substituted” mentioned to exemplify R* and R® above. R’ is preferably a hydrogen atom. Y is especially preferably : an oxygen atom. (4) Definition of ring A
In the formulae (I) and (II), the “aromatic ring” in the "aromatic ring which may further have 1 to 3 substituents” for ring A is exemplified by benzene ring, condensed aromatic hydrocarbon rings, 5- or 6-membered aromatic hetero rings, and condensed aromatic hetero rings.
Here, examples of the "condensed aromatic hydrocarbon rings” include condensed aromatic hydrocarbon rings having 9 to 14 carbon atoms. Specifically, there may be mentioned naphthalene, indene, fluorene, anthracene, etc.
Examples of the "5- or 6-membered aromatic hetero rings” include 5- or 6-membered aromatic hetero rings containing 1 to 3 hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom, in addition to carbon atoms.
Specifically, there may be mentioned thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1.2,4- thiadiazole, 1,3,4-thiadiazole, furazane etc.
Examples of the "condensed aromatic hetero rings” include 9- to l4-membered (preferably 9- or 10-membered) condensed aromatic hetero rings containing 1 to 4 hetero atoms selected from nitrogen atom, sulfur atom, and oxygen atom, in addition to carbon atoms. Specifically, there may be mentioned benzofuran, benzothiophene, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b}thiophene, isoquinoline, quinoline, indole, guinoxaline, phenanthridine, phenothiazine, phenoxazine,
phthalazine, naphthyridine, quinazoline, cinnoline, carbazole, B -carboline, acridine, phenazine, phthalimide, . etc.
The "aromatic ring” is preferably benzene ring, a . 5 condensed aromatic hydrocarbon ring having 9 to 14 carbon atoms (preferably naphthalene, etc.), a 5- or 6 membered aromatic hetero ring (preferably, pyridine, isoxazole, etc.), or the like.
Examples of the “substituents” in the "aromatic ring which may further have 1 to 3 substituents” for ring A include aliphatic hydrocarbon groups (preferably alkyl groups) which may be substituted, hydroxy group which may be substituted, halogen atoms, acyl groups which may be substituted, nitro group, and amino group which may be . substituted. All of these substituents are those mentioned to exemplify the substituents in R!'. said substituents are preferably alkyl groups having 1 to 4 carbon atoms, hydroxy group, alkoxy groups having 1 to 4 carbon atoms, aralkyloxy groups having 7 to 10 carbon atoms (preferably benzyloxy), or halogen atoms.
Ring A is preferably "benzene ring or pyridine ring, each of which may further have 1 to 3 substituents”, more preferably benzene ring or pyridine ring, each of which may further have 1 to 3 substituents selected from the group consisting of alkyl groups having 1 to 4 carbon atoms, hydroxy group, alkoxy groups having 1 to 4 carbon atoms, aralkyloxy groups having 7 to 10 carbon atoms, and halogen atoms. Ring A is especially preferably benzene ring. (5) Definition of n
In the formulae (I) and (II), n represents an integer of 1 to 8, preferably an integer of 1 to 3. (6) Definition of ring B
In the formulae (I) and (II), the "nitrogen-containing 5-membered hetero ring” in the "nitrogen-containing 5- ; membered hetero ring which may further be substituted by an alkyl group” for ring B is exemplified by 5-membexed . 5 hetero rings which contain at least 1 nitrogen atom, in addition to carbon atoms, as ring constituent atoms, and which may further contain 1 to 3 hetero atoms selected from oxygen atom, sulfur atom and nitrogen atom.
Preferred examples of the nitrogen-containing 5- membered hetero rings include 5-membered aromatic hetero rings such as pyrrole, pyrazole, imidazole, thiazole, isothiazole, oxazole, isoxazole, 1,2,4-triazole, 1,2,3- triazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4- oxadiazole, furazane, 1,2,3-thiadiazole, 1,2,4- thiadiazole, 1,3,4-thiadiazole, and tetrazole:; and 5- membered non-aromatic hetero rings such as pyrrolidine, imidazolidine, and pyrazolidine. The nitrogen-containing 5. membered hetero rings are preferably 5-membered aromatic hetero rings which contain at least 1 nitrogen atom, in addition to carbon atoms, as ring constituent atoms, and which may further contain 1 hetero atom selected from oxygen atom, sulfur atom and nitrogen atom, such as pyrrole, pyrazole, imidazole, thiazole, isothiazole, oxazole, and isoxazole. Especially preferred are pyrrole, pyrazole, imidazole, etc.
The “alkyl group” in the "nitrogen-containing 5- membered hetero ring which may further be substituted by an alkyl group” is exemplified by alkyl groups having 1 to } 4 carbon atoms. Specifically, there may be mentioned methyl, ethyl, propyl, butyl, isobutyl, sec-butyl, t-butyl etc., with preference given to methyl and ethyl. . Ring B is preferably pyrrole, pyrazole or imidazole, each of which may further be substituted by an alkyl group having 1 to 4 carbon atoms. Ring B is especially preferably pyrazole.
(7) Definition of X'
In the formulae (I) and (II), X' represents a bond, . an oxygen atom, a sulfur atom, or a group of the formula: -80.-, -S80,-, -0-80,- or -NR'- wherein R'® represents a . 5 hydrogen atom or a hydrocarbon group which may be substituted.
Here, the “hydrocarbon group which may be substituted” for R!® is exemplified by the “hydrocarbon groups which may be substituted” mentioned to exemplify R*' and R® above.
X! is preferably a bond or an oxygen atom. (8) Definition of R®
In the formulae (I) and (II), the “hydrocarbon group which may be substituted” and "heterocyclic group which may be substituted” for R? is respectively exemplified by the “hydrocarbon groups which may be substituted” and "heterocyclic groups which may be substituted” mentioned to exemplify R’. (8-1) Cases where X' in the formulae (I) and (II) is a bond
The hydrocarbon group in the "hydrocarbon group which may be substituted” for R? is preferably an aliphatic hydrocarbon group having 1 to 8 carbon atoms (preferably an alkyl group) or an aromatic hydrocarbon group having 6 to 14 carbon atoms, and more preferably an aromatic : hydrocarbon group having 6 to 14 carbon atoms (e.g., phenyl, naphthyl).
The heterocyclic group in the “heterocyclic group which may be substituted” for R’ is preferably a 5- or 6 -membered aromatic heterocyclic group (e.g., furyl, thienyl, pyridyl).
The substituents in the aforementioned "hydrocarbon group which may be substituted” and “heterocyclic group which may be substituted” are preferably 1) halogen atoms (e.g., fluorine, chlorine, bromine, iodine), 2) alkyl groups having 1 to 4 carbon atoms (e.g., methyl,
trifluoromethyl, propyl, isopropyl) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, . chlorine, bromine, iodine), 3) alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, trifluoromethoxy) which may . 5S be substituted by 1 to 3 halogen atoms (e.g., fluorine, : chlorine, bromine, iodine), 4) aralkyloxy groups having 7 to 10 carbon atoms (e.g., benzyloxy), 5) aryloxy groups having 6 to 14 carbon atoms (e.g., phenoxy), 6) aromatic heterocyclic groups (e.g., furyl, thienyl), or the like.
The number of the substituents is, for example, 1 to 3.
R’ is preferably 1) aromatic hydrocarbon groups having 6 to 14 carbon atoms (e.g., phenyl, naphthyl) which may be substituted, or 2) 5- or 6-membered aromatic heterocyclic groups (e.g., furyl, thienyl, pyridyl) which may be substituted.
R? is more preferably 1) aromatic hydrocarbon groups having 6 to 14 carbon atoms (e.g., phenyl, naphthyl), or 2) 5. or 6-membered aromatic heterocyclic groups (e.g., furyl, thienyl, pyridyl). Especially preferred are phenyl, furyl, thienyl, etc. (8-2) Cases where X! in the formulae (I) and (II) is an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -S0,-, -0-S0,- or -NR'- wherein the symbol has the same meaning as above.
The hydrocarbon group in the “hydrocarbon group which may be substituted” for R? is preferably an aliphatic hydrocarbon group having 1 to 8 carbon atoms {preferably an alkyl group (e.g., methyl, ethyl, propyl, isopropyl)), an aromatic-aliphatic hydrocarbon group having 7 to 13 carbon atoms (preferably an aralkyl group (e.g., benzyl)), an aromatic hydrocarbon group having 6 to 14 carbon atoms (e.g., phenyl, naphthyl).
The heterocyclic group in the "heterocyclic group which may be substituted” for R? is preferably a 5- or
6-membered aromatic heterocyclic group (e.g., furyl, thienyl, pyridyl). : ) The substituents in the aforementioned “hydrocarbon group which may be substituted” and “heterocyclic group which may be substituted” are preferably 1) halogen atoms (e.g., fluorine, chlorine, bromine, iodine), 2) alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, trifluoromethyl) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), 3) aralkyloxy groups having 7 to 10 carbon atoms (e.g., benzyloxy), 4) [5- or 6-membered aromatic heterocyclic . groups (e.g., pyridyl, oxazolyl, thiazolyl, triazolyl) which may have 1 or 2 substituents selected from alkyl groups having 1 to 3 carbon atoms, cycloalkyl groups having 3 to 7 carbon atoms (e.g., cyclohexyl), furyl, thienyl, phenyl and naphthyl]-alkoxy groups having 1 to 6 carbon .atoms (e.g., methoxy, ethoxy), 5) aromatic heterocyclic groups (e.g., furyl, thienyl, pyridyl), 6) aryloxy groups having 6 to 14 carbon atoms (e.q., phenoxy), 7) alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, trifluoromethoxy) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), or the like. The number of the substituents is, for example, 1 to 3.
R? is preferably an aliphatic hydrocarbon group having 1 to 8 carbon atoms (preferably an alkyl group (e.g., methyl, ethyl, propyl, isopropyl)) which may be substituted, an : aromatic-aliphatic hydrocarbon group having 7 to 13 carbon atoms (preferably an aralkyl group (e.g., benzyl)) which may be substituted, or a heterocyclic group (preferably a 5- or 6-membered aromatic heterocyclic group (e.g., furyl, thienyl, pyridyl)) which may be substituted.
R? is more preferably an aliphatic hydrocarbon group having 1 to 8 carbon atoms (preferably an alkyl group (e.g., methyl, ethyl, propyl. isopropyl)) or an aromatic-
aliphatic hydrocarbon group having 7 to 13 carbon atoms (preferably an aralkyl group (e.g., benzyl)). (9) Definition of W . 5 In the formulae (1) and (IT), the "divalent hydrocarbon residue having 1 to 20 carbon atoms” for W is exemplified by "divalent non-cyclic hydrocarbon residues”, "divalent cyclic hydrocarbon residues”, and divalent groups obtained by combining 1 or more "divalent non-cyclic hydrocarbon residues” and 1 or more "divalent cyclic hydrocarbon residues”.
Here, examples of the "divalent non-cyclic hydrocarbon residues” include alkylenes having 1 to 20 . carbon atoms, alkenylenes having 2 to 20 carbon atoms, and alkynylenes having 2 to 20 carbon atoms.
Examples of the "divalent cyclic hydrocarbon residues” include divalent groups obtained by removing two optionally selected hydrogen atoms from cycloalkanes having 5 to 20 carbon atoms, cycloalkenes having 5 to 20 carbon atoms, or aromatic hydrocarbons having 6 to 20 carbon atoms (e.g., benzene, naphthalene, indene, anthracene).
Specifically, there may be mentioned 1, 2-cyclopentylene, 1,3-cyclopentylene, 1,2-cyclohexylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-cycloheptylene, 1,3- cycloheptylene, 1,4-cycloheptylene, 3-cyclohexen-1,4- ylene, 3-cyclohexen-1,2-ylene, 2,5-cyclohexadien-1,4- ylene, 1,2-phenylene, 1,3-phenylene, 1l,4-phenylene, 1,4-naphthylene, 1,6-naphthylene, 2,6-naphthylene, 2,7- naphthylene, 1,5-indenylene, 2,5-indenylene, etc.
The compounds wherein W in the formulae (I) and (II) is a divalent hydrocarbon residue having 1 to 20 carbon atoms possess more potent hypoglycemic and hypolipidemic actions than those wherein W is a bond.. It is therefore preferable that W be a divalent hydrocarbon residue having 1 to 20 carbon atoms. W is more preferably a "divalent hydrocarbon residue having 1 to 8 carbon atoms”, with
Preference given to: (1) C,, alkylenes (e.g., -CH,-, -(CH,),~, -(CH,),~, -(CH,),-, -(CH,);-, -(CH,)s-, -(CH,),-, -(CH,),~, -CH(CH;)-, -C(CH,),~, -(CH(CH,)),, ~(CH,),C(CH,),-, -(CH,),C(CH,),-); (2) C,, alkenylenes (e.g., CH=CH, ~-CH, CH=CH, -
C(CH,),-CH=CH-, -CH,-CH=CH-CH,-, -CH,-CH,-CH=CH-, -CH=CH-
CH=-, -CH=CH-CH,-CH,-CH,-):; or (3) C, , alkynylenes (e.g., -C=C-, -CH,-C=C-, -CH,-C =C-CH,-CH,-).
W is especially preferably -CH,-, -(CH,),-, -(CH;),-, -(CH,),-, -CH=CH-, or the like. (10) Definition of R’
In the formulae (I) and (II), R® is a group of the formula: -OR® (R® represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR°R' (each of R’ and
R!’, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R’ and R* may bind together to form a ring).
The "hydrocarbon group which may be substituted” for
R® is exemplified by the “hydrocarbon groups which may be substituted” mentioned to exemplify R'.
Said "hydrocarbon group which may be substituted” is preferably an "alkyl group having 1 to 4 carbon atoms”, an "aryl group having 6 to 10 carbon atoms which may have 1 to 3 substituents selected from alkyl groups having 1 to 4 carbon atoms and halogen atoms (e.g., fluorine, chlorine, bromine, iodine)”, or the like. Here, examples of the "alkyl group having 1 to 4 carbon atoms” include methyl, ethyl, propyl, butyl, isobutyl, sec-butyl, t-butyl etc., with preference given to methyl and ethyl. As a "halogen atom”, chlorine is preferred. Examples of the "aryl group having 6 to 10 carbon atoms” include phenyl and naphthyl, with preference given to phenyl.
The "hydrocarbon group which may be substituted” and } 5 "heterocyclic group which may be substituted” for R’ and
R!® are exemplified by the "hydrocarbon group which may be substituted” and "heterocyclic group which may be substituted” respectively mentioned to exemplify R!.
The “acyl group which may be substituted” for R’ and
RY is exemplified by the "acyl group which may be substituted” mentioned to exemplify a substituent in R’.
Examples of the ring formed by R’ and R'’ bound together include 5- to 7-membered cyclic amino groups, preferably l-pyrrolidinyl, l-piperidinyl, l-hexamethyleneiminyl, 4-morpholino, 4-thiomorpholino, etc.
R’ and R!® are preferably a hydrogen atom or an alkyl group having 1 to 4 carbon atoms (e.g., methyl, ethyl).
R?® is preferably a group of the formula: -OR® (the symbol has the same meaning as above), and R° is preferably a hydrogen atom or an alkyl group having 1 to 4 carbon atoms (e.g., methyl, ethyl). (11) Preferable compounds
Preferred examples of compounds of the formula (I) and (II) include the compounds below. (A) Compounds in which
R! is a 5- or 6-membered aromatic heterocyclic group (preferably furyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyrazolyl) which may be condensed with a benzene ring, and which may have 1 or 2 substituents selected from 1) furyl, thienyl, pyridyl, pyrazinyl, phenyl or naphthyl, each of which may have 1 to 3 substituents selected from the group consisting of alkyl groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkoxy groups having
1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, -and amino; and 2) alkyl groups having 1 to 4 carbon atoms or cycloalkyl groups having 3 to 7 carbon atoms, each of which may have 1 to 3 substituents selected from the group consisting of alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino;
X is a bond or -NR°- wherein R® is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; m is 1 or 2;
Y is an oxygen atom, a sulfur atom, -NH- or -NHCO-; ring A is benzene ring, a condensed aromatic hydrocarbon ring having 9 to 14 carbon atoms (preferably naphthalene, etc.) or a 5- or 6-membered aromatic hetero ring (preferably pyridine, isoxazole, etc. ), each of which ring may further have 1 to 3 substituents selected from the group consisting of alkyl groups having 1l to 4 carbon atoms, hydroxy group, alkoxy groups having 1 to 4 carbon atoms, aralkyloxy groups having 7 to 10 carbon atoms and halogen atoms; . n is an integer of 1 to 3; ring B is a "S5-membered aromatic hetero ring which : contains at least 1 nitrogen atom, in addition to carbon atoms, as ring constituent atoms, and which may further contain 1 hetero atom selected from oxygen atom, sulfur atom and nitrogen atom” (e.g., pyrrole, pyrazole, imidazole, thiazole, isothiazole, oxazole, isoxazole) which may further be substituted by an alkyl group having l to 4 carbon atoms;
X! is a bond;
R? is an aliphatic hydrocarbon group having 1 to 8 carbon atoms (preferably an alkyl group), an aromatic /
hydrocarbon group having 6 to 14 carbon atoms (e.g., phenyl, naphthyl) or a 5- or 6-membered aromatic heterocyclic group ; (e.g., furyl, thienyl, pyridyl), each of which may be substituted by 1 to 3 substituents selected from the group . 5 consisting of 1) halogen atoms (e.q., fluorine, chlorine, bromine, iodine), 2) alkyl groups having 1 to 4 carbon atoms (e.g., methyl, trifluoromethyl, propyl, isopropyl) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), 3) alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, trifluoromethoxy) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), 4) aralkyloxy groups having 7 to 10 carbon atoms (e.g., benzyloxy), 5) aryloxy groups having 6 to 14 carbon atoms (e.g., phenoxy) and 6) aromatic heterocyclic groups (e.g., furyl, thienyl):;
W is a C,, alkylene, a C,, alkenylene or a C,, alkynylene;
R? is -OR? (R® is a hydrogen atom, an "alkyl group having 1 to 4 carbon atoms” or an "aryl group having 6 to 10 carbon atoms which may have 1 to 3 substituents selected from alkyl groups having 1 to 4 carbon atoms and halogen atoms {(e.g., fluorine, chlorine, bromine, iodine)" ) or -NR°R'® (each of
R’ and R!’, whether identical or not, is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms). {B) Compounds in which
R' is a 5- or 6-membered aromatic heterocyclic group (preferably furyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, triazolyl, oxadiazqQlyl, pyrazolyl) which may be condensed with a benzene ring, and which may have 1 or 2 substituents selected from } 1) furyl, thienyl, pyridyl, pyrazinyl, phenyl or naphthyl, each of which may have 1 to 3 substituents selected from : the group consisting of alkyl groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), alkoxy groups having
1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen ] atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino; and . 5 2) alkyl groups having 1 to 4 carbon atoms or cycloalkyl groups having 3 to 7 carbon atoms, each of which may have 1 to 3 substituents selected from the group consisting of alkoxy groups having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), halogen atoms (e.g., fluorine, chlorine, bromine, iodine), nitro, hydroxy, and amino;
X is a bond or -NR®- wherein R® is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; mis 1 or 2; © 15 Y is an oxygen atom, a sulfur atom, ~NH- or -NHCO-: ring A is benzene ring, a condensed aromatic hydrocarbon ring having 9 to 14 carbon atoms (preferably naphthalene, etc.) or a 5- or 6-membered aromatic hetero ring (preferably pyridine, isoxazole, etc.), each of which ring may further have 1 to 3 substituents selected from the group consisting of alkyl groups having 1l to 4 carbon atoms, hydroxy group, alkoxy groups having 1 to 4 carbon atoms, aralkyloxy groups having 7 to 10 carbon atoms and halogen atoms; n is an integer of 1 to 3: ring B is a "5-membered aromatic hetero ring which contains at least 1 nitrogen atom, in addition to carbon atoms, as ring constituent atoms, and which may further contain 1 hetero atom selected from oxygen atom, sulfur atom and nitrogen atom” (e.g., pyrrole, pyrazole, imidazole, thiazole, isothiazole, oxazole, isoxazole) which may further be substituted by an alkyl group having 1 to 4 carbon atoms;
X! is a bond;
R? is an aliphatic hydrocarbon group having 1 to 8 carbon atoms (preferably an alkyl group (e.g., methyl,
ethyl, propyl, isopropyl)), an aromatic-aliphatic hydrocarbon group having 7 to 13 carbon atoms (preferably an aralkyl group (e.g., benzyl)) or a 5- or 6-membered. . aromatic heterocyclic group (e.g. , furyl, thienyl, pyridyl), each of which may be substituted by 1 to 3 substituents selected from the group consisting of 1) halogen atoms (e.g., fluorine, chlorine, bromine, lodine), 2) alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, trifluoromethyl) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), 3) aralkyloxy groups having 7 to 10 carbon atoms (e.g., benzyloxy), 4) [5- or 6-membered aromatic heterocyclic groups (e.g., pyridyl, oxazolyl, thiazolyl, triazolyl) which may have 1 or 2 substituents selected from alkyl groups having 1 to 3 carbon atoms, cycloalkyl groups having 3 to 7 carbon atoms (e.g., cyclohexyl), furyl, thienyl, phenyl and naphthyl) -alkoxy groups having 1 to 6 carbon atoms (e.g., methoxy, ethoxy). 5) aromatic heterocyclic groups (e.g., furyl, thienyl, pyridyl), 6) aryloxy groups having 6 to 14 carbon atoms (e.g., phenoxy) and 7) alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, trifluoromethoxy) which may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine);
W is a C,, alkylene, a C,, alkenylene or a C,, alkynylene;
R® is -OR® (R®’ is a hydrogen atom, an "alkyl group having 1 to 4 carbon atoms” or an "aryl group having 6 to 10 carbon atoms which may have 1 to 3 substituents selected from alkyl groups having 1 to 4 carbon atoms and halogen atoms (e.g., fluorine, chlorine, bromine, iodine)”") or -NR°R!® (each of
R’ and R!’, whether identical or not, is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms). (12) Salts
The salt of a compound of the formula (I) or (II) (hereinafter also referred to as Compound (I) or (II),
respectively) is preferably a pharmacologically acceptable salt, and is exemplified by salts with inorganic bases, ; salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino . 5 acids.
Preferred examples of the salts with inorganic bases include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; and aluminum salts and ammonium salts.
Preferred examples of the salts with organic bases include salts with trimethylamine, triethylamine, pyridine, " picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N-dibenzylethylenediamine, etc.
Preferred examples of the salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.
Preferred examples of the salts with organic acids include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, etc.
Preferred examples of the salts with basic amino acids include salts with arginine, lysine, ornithine, etc.
Examples of preferred salts with acidic amino acids include salts with aspartic acid, glutamic acid, etc.
Of the aforementioned salts, sodium salts, potassium salts, hydrochlorides, etc. are preferred. (13) Prodrugs etc.
A prodrug of Compound (II) refers to a compound capable of being converted to Compound (II) by reactions of an enzyme, gastric juice, or the like, under physiological conditions in vivo, specifically a compound capable of being converted to Compound (II) upon enzymatic oxidation, /
reduction, hydrolysis, or the like, or a compound capable of being converted to Compound (II) upon hydrolysis or the . like by gastric juice or the like. Examples of the prodrugs of Compound (II) include compounds derived by acylation, . 5 alkylation or phosphorylation of the amino group of
Compound (II) (e.g., compounds derived by eicosanoylation, alanylation, pentylaminocarbonylation, (5-methyl-2-oxo- 1,3-dioxolen-4~yl)methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation or tert-butylation of the amino group of Compound (II)); compounds derived by acylation, alkylation, phosphorylation or boration of the hydroxyl : group of Compound (II) (e.g., compounds derived by acetylation, palmitoylation, propanoylation, pivaloylation, succinylation, fumarylation, alanylation or dimethylaminomethylcarbonylation of the hydroxyl group of Compound (II)); and compounds derived by esterification or amidation of the carboxyl group of Compound (II) (e.g., compounds derived by ethyl esterification, phenyl esterification, carboxymethyl esterification, dimethylaminomethyl esterification, pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification, phthalidyl esterification, (5-methyl-2-oxo-1,3- dioxolen-4-yl)methyl esterification, cyclohexyloxycarbonylethyl esterification, or methylamidation of the carboxyl group of Compound (II)).
These compounds can be produced from Compound (II) by per se known methods.
The prodrug of Compound (II) may be one capable of being converted to Compound (II) under physiological conditions, as described in "Iyakuhin No Kaihatsu } (Development of Drugs)”, vol. 7, Molecular Designing, published by Hirokawa Shoten, 1990, pages 163 - 198.
Prodrugs of Compound (I) are exemplified by the same prodrugs as those of Compound (II). /
In addition, Compound (I) and Compound (II) may be labeled with an isotope (e.g., °H, Cc, *s, '¥I). . Furthermore, Compound (I) and Compound (II) may be anhydrides or hydrates. . 5 : (14) Formulations
Compounds (I) and (II) and salts thereof (hereinafter also referred to as "compound of the present invention”) are of low toxicity and can be used as an agent for preventing or treating the various diseases mentioned below in mammals (e.g., humans, mice, rats, rabbits, dogs, cats, bovines, horses, swine, monkeys), as such or in the form of pharmaceutical compositions prepared by admixing with a pharmacologically acceptable carrier, etc.
Here, the pharmacologically acceptable carriers are exemplified by various organic or inorganic carrier substances in common use as materials for pharmaceutical preparations, and they are formulated as excipients, lubricants, binders, and disintegrants for solid preparations; and as solvents, solubillizers, suspending agents, isotonizing agents, buffers, soothing agents, etc. for liquid preparations. In addition, other additives for pharmaceutical preparations, such as antiseptics, antioxidants, coloring agents, and sweetening agents, may also be used as necessary.
Preferred examples of the excipients include lactose, saccharose, D-mannitol, D-sorbitol, starch, gelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, carboxymethylcellulose sodium, gum arabic, dextrin, pullulan, light silicic anhydride, ] synthetic aluminum silicate, and magnesium metasilicate aluminate. :
Preferred examples of the lubricants include magnesium stearate, calcium stearate, talc, and colloidal silica.
Preferred examples of the binders include gelatinized starch, sucrose, gelatin, gum arabic, methylcellulose, . carboxymethylcellulose, carboxymethylcellulose sodium, - crystalline cellulose, saccharose, D-mannitol, trehalose, . 5 dextrin, pullulan, hydroxypropylcellunlose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.
Preferred examples of the disintegrants include lactose, saccharose, starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, light silicic anhydride, and low-substituted hydroxypropylcellulose.
Coe Preferred examples of the solvents include water for injection, physiological saline, Ringer's solution, . oo alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, and cottonseed oil. . Preferred examples of the solubilizers include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, and sodium acetate.
Preferred examples of the suspending agents include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and monostearic glycerol; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose; and polysorbates and polyoxyethylene-hardened castor oil. ’ Preferred examples of the isotonizing agents include sodium chloride, glycerol, D-mannitol, D-sorbitol, and glucose.
Preferred examples of the buffers include buffer solutions of phosphates, acetates, carbonates, citrates etc.
Preferred examples of the soothing agents include benzyl alcohol. . Preferred examples of the antiseptics include p- oxybenzoic acid esters, chlorobutanol, benzyl alcohol, , 5 phenethyl alcohol, dehydroacetic acid, and sorbic acid.
Preferred examples of the antioxidants include sulfites and ascorbates.
Preferred examples of the coloring agents include food colors such as water-soluble tar colors for food (e.g., Food
Color Red Nos. 2 and 3, Food Color Yellow Nos. 4 and 5, Food
Color Blue Nos. 1 and 2), water-insoluble lake colors (e.g., aluminum salts of the aforementioned water-soluble tar colors for food), and natural colors (e.g., B-carotene, chlorophyll, red oxide).
Preferred examples of the sweetening agents include saccharin sodium, dipotassium glycyrrhetinate, aspartame, and stevia. (15) Dosage forms
Examples of the dosage forms of the pharmaceutical composition include oral preparations such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, and suspensions; and non-oral preparations such as injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), external preparations (e.g., preparations for nasal administration, dermal preparations, ointments), suppositories (e.g., rectal suppositories, vaginal suppositories), pellets, drip infusions, and sustained- release preparations. These preparations can each be . orally or non-orally safely administered. ‘ The pharmaceutical composition can be prepared by } conventional methods in the fields of pharmaceutical manufacturing techniques, for example, methods described in the Japanese Pharmacopoeia. Specific production methods for such preparations are hereinafter described in detail. . An oral preparation, for instance, is produced by adding to the active ingredient an excipient (e.g., lactose, . 5 saccharose, starch, D-mannitol), a disintegrant (e.g., carboxymethylcellulose calcium), a binder (e.g., gelatinized starch, gum arabic, carboxymethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone) or a lubricant(e.g., talc, magnesium stearate, polyethyleneglycol 6000), compressionmolding the obtained mixture, then, if necessary coating by a per se known method using a coating base for the purpose of taste masking, enteric coating or sustained release.
Examples of the coating base include a sugar coating base, a water-soluble film coating base, an enteric film coating base, a sustained-release film coating base.
As the sugar coating base saccharose is employed.
Further, one or two or more species selected from talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax and the like may be used in combination.
Examples of the water-soluble film coating base include cellulose polymers such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose; synthetic polymers such as polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymer E [Eudragit E (trademark), Rhom
Pharma] and polyvinylpyrrolidone; polysaccharides such as oo pullulan.
Examples of the enteric film coating base include cellulose polymers such as hydroxypropylmethylcellulose ] phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose } acetate phthalate; acrylic acid polymers such as methacrylic acid copolymer L [Eudragit L (trademark), Rhom
Pharma], methacrylic acid copolymer LD [Eudragit L-30D55
(trademark), Rhom Pharma], methacrylic acid copolymer S [Eudragit S (trademark), Rhom Pharma]: natural products . such as shellac and the like.
Examples of the sustained-release film coating base . 5 include cellulose polymers such as ethylcellulose; acrylic acid polymers such as aminoalkyl methacrylate copolymer RS [Eudragit RS (trademark), Rhom Pharma) and an ethyl acrylate-methyl methacrylate copolymer suspension [Eudragit NE (trademark), Rhom Pharma].
Two or more of the above coating bases may be used in admixture in an appropriate ratio. On the occasion of coating, a shading agent such as titanium oxide, red ferric oxide may be used.
Injections are produced by dissolving, suspending or emulsifying the active ingredient in an aqueous solvent (e.g. distilled water, physiological saline, Ringer's solution) or an oleaginous solvent (e.g. vegetable oils ~ such as olive oil, sesame oil, cotton seed oil, corn oil; propylene glycol), together with a dispersant (e.g. polysorbate 80, polyoxyethylene-hardened castor oil 60), polyethylene glycol, carboxymethylcellulose, sodium alginate), a preservative (e.g. methylparaben, propylparaben, benzyl alcohol, chlorobutanol, phenol), an isotonizing agent (e.g. sodium chloride, glycerol, D- mannitol, D-sorbitol, glucose) and the like. If desirable, additives such as a solubilizer (e.g. sodium salicylate, sodium acetate), a stabilizer (e.g. human serum albumin), a soothing agent (e.g. benzyl alcohol), may be used. (16) Agents ]
The compound of the present invention can be used as } an insulin resistance improving agent, an insulin sensitivity enhancing agent, a retinoid-related receptor function regulating agent, a ligand for peroxisome proliferator-activated receptors, and a ligand for retinoid X receptor, etc. The term "function regulating agent” used here stands for both an agonist and an antagonist. The function regulating agent may be a partial . agonist or a partial antagonist.
The compound of the present invention has a . : S hypoglycemic action, a hypolipidemic action, a hypoinsulinemic action, an insulin resistance improving action, an insulin sensitivity enhancing action, and a retinoid-related receptor function regulating action.
The term "retinoid-related receptor” used here is classified as nuclear receptors, and is a DNA-binding transcription factor whose ligand is a signal molecule such as oil-soluble vitamins, etc., and may be any of a monomer receptor, a homodimer receptor and a heterodimer receptor.
Here, examples of the monomer receptor include retinoid O receptor (hereinafter, also abbreviated as ROR) a (GenBank Accession No. L14611), RORB (GenBank Accession
No.L14160), RORY (GenBank Accession No. U16997): Rev-erb a (GenBank Accession No. M24898), Rev-erb B (GenBank
Accession No. L31785); ERRa (GenBank Accession No. X51416),
ERR (GenBank Accession No. X51417); Ftz-Fla (GenBank
Accession No. S65876), Ftz-FIf (GenBank Accession No.
M81385); TIx (GenBank Accession No. S77482); GCNF (GenBank
Accession No. Ul4666).
Examples of the homodimer receptor include homodimers formed by retinoid X receptor (hereinafter, also abbreviated as RX R) a (GenBank Accession No. X52733), RXRf (GenBank Accession No. M84820), RXRy (GenBank Accession No.
U38480); COUPa (GenBank Accession No. X12795), COUPf (GenBank Accession No. M64497), COUPy (GenBank Accession
No. X12794); TR2a (GenBank Accession No. M29960), TR2( (GenBank Accession No. L27586); or HNF4a (GenBank Accession ] No. X76930), HNF4y (GenBank Accession No. 249826), etc.
Examples of the heterodimer receptor include heterodimers which are formed by the above-mentioned retinoid X receptor (RXRa, RXR} or RXTy) and one receptor selected from retinoid A receptor (hereinafter, also abbreviated as RAR) a (GenBank Accession No. X00614), RARP (GenBank Accession No. Y00291), RARy (GenBank Accession No. . M24857); thyroid hormone receptor (hereinafter, also abbreviated as TR) a (GenBank Accession No. M24748), TRB : 5 (GenBank Accession No. M26747): vitamin D receptor (VDR) - (GenBank Accession No. J03258): peroxisome proliferator-activated receptor (hereinafter. also abbreviated as PPAR) a (GenBank Accession No. L02932),
PPARB (PPAR 8) (GenBank Accession No. U10375), PPAR y (GenBank Accession No. L40904) ; LXRo (GenBank Accession No.
U22662), LXRP (GenBank Accession No. U14534); FXR (GenBank
Accession No. U18374); MB67 (GenBank Accession No. L29263);
ONR (GenBank Accession No. X75163): and NURa (GenBank
Accession No. L13740), NURB (GenBank Accession No. X75918) . and NURy (GenBank Accession No. Ul2767).
The compound of the present invention has an excellent ligand activity particularly to retinoid X receptors (RXRa,
RXRB, RXRy) and to peroxisome proliferator-activated receptors (PPARa, PPARf (PPARS), PPARy) among the above-mentioned retinoid-related receptors.
Further, the compound of the present invention has an excellent ligand activity to peroxisome proliferator- activated receptors in heterodimer receptors formed from a retinoid X receptor and a peroxisome proliferator- activated receptor, and preferably in heterodimer receptors formed from RXRa and PPARy.
Accordingly, the retinoid-related receptor ligand of the present invention can be used advantageously as a 1igand for peroxisome proliferator-activated receptors or a ligand for retinoid X receptors.
Of the compound of the present invention, especially ] one having a divalent hydrocarbon residue having 1 to 20 carbon atoms (especially alkylene such as methylene) for } W can be used preferably as a PPARy agonist or a PPARY partial agonist.
While, of the compound of the present invention, especially one having a bond for W can be used preferably : as a PPARy antagonist or a PPARy partial antagonist. (17) Target diseases
The compound of the present invention and the pharmaceutical composition of the present invention can be . used as, for example, an agent for preventing or treating diabetes (e.g., type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus); an agent for preventing or treating hyperlipidemia (e.g., hypertriglycemia, hypercholesterolemia, hypo-high- density-lipoproteinemia, postprandial hyperlipemia); an agent for enhancing insulin sensitivity: an agent for "15 improving insulin resistance; an agent for preventing or treating impaired glucose tolerance (IGT); and an agent for preventing progress from impaired glucose tolerance to diabetes mellitus.
Regarding diagnostic criteria of diabetes mellitus, new diagnostic criteria were reported by the Japan Diabetes
Society in 1998.
According to this report, diabetes mellitus is a condition wherein the fasting blood glucose level (glucose . concentration in venous plasma) is not less than 126 mg/dl, the 2-hour value (glucose concentration in venous plasma) of the 75 g oral glucose tolerance test (75 g OGTT) is not less than 200 mg/dl, or the non-fasting blood glucose level (glucose concentration in venous plasma) is not less than 200 mg/dl. In addition, a condition which does not fall within the scope of the above definition of diabetes mellitus, and which is not a "condition wherein the fasting . - blood glucose level (glucose concentration in venous plasma) is less than 110 mg/dl or the 2-hour value (glucose } concentration in venous plasma) of the 75 g oral glucose tolerance test (75 g OGTT) is less than 140 mg/dl” (normal type). is called the "borderline type”.
In addition, regarding diagnostic criteria for diabetes mellitus, new diagnostic criteria were reported . by ADA (American Diabetic Association) in 1997 and by WHO in 1998. . 5 According to these reports, diabetes mellitus is a condition wherein the fasting blood glucose level (glucose concentration in venous plasma) is not less than 126 mg/dl, and the 2: hour value (glucose concentration in venous plasma) of the 75 g oral glucose tolerance test is not less than 200 mg/dl.
In addition, according to the above reports, impaired glucose tolerance is a condition wherein the fasting blood glucose level (glucose concentration in venous plasma) is less than 126 mg/dl, and the 2-hour value (glucose concentration in venous plasma) of the 75 g oral glucose tolerance test is not less than 140 mg/dl and less than 200 mg/dl. Furthermore, according to the ADA report, a condition wherein the fasting blood glucose level (glucose concentration in venous plasma) is not less than 110 mg/dl and less than 126 mg/dl, is called IFG (impaired fasting glucose). On the other hand, according to the WHO report, a condition of IFG (impaired fasting glucose) as such wherein the 2-hour value (glucose concentration in venous plasma) of the 75 g oral glucose tolerance test is less than 140 mg/dl, is called IFG (impaired fasting glycemia).
The compound of the present invention and the pharmaceutical composition of the present invention can be used as an agent for preventing or treating diabetes mellitus, borderline type, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia) as defined by the above new diagnostic criteria. } Furthermore, the compound of the present invention and the pharmaceutical composition of the present invention can also be used to prevent the progression of the borderline type. impaired glucose tolerance, IFG (impaired fasting glucose) or IFG (impaired fasting glycemia) to diabetes mellitus.
The compound of the present invention and the . 5 pharmaceutical composition of the present invention can be used also as an agent for preventing or treating diabetic complications (e.g., neuropathy, nephropathy, retinopathy. cataract, macroangiopathy, osteopenia, diabetic hyperosmolar coma, infectious diseases (e.g., respiratory infection, urinary tract infection, gastrointestinal tract infection, dermal soft tissue infection, inferior limb infection), diabetic gangrene, xerostomia, lowered sense of hearing, cerebrovascular disease, peripheral circulatory disturbance, etc.), obesity, osteoporosis, cachexia (e.g., carcinomatous cachexia, tuberculous cachexia, diabetic cachexia, hemopathic cachexia, endocrinopathic cachexia, infectious cachexia, cachexia : induced by acquired immunodeficiency syndrome), fatty liver, hypertension, polycystic ovary syndrome, renal diseases (e.g., diabetic nephropathy, glomerular nephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, terminal renal disorder), muscular dystrophy, myocardiac infarction, angina pectoris, cerebrovascular disease (e.g., cerebral infarction, cerebral apoplexy), insulin resistant syndrome, syndrome
X, hyperinsulinemia, hyperinsulinemia-induced sensory disorder, tumor (e.g., leukemia, breast cancer, prostate cancer, skin cancer), irritable intestinum syndrome, acute or chronic diarrhea, inflammatory diseases (e.g., chronic rheumatoid arthritis, spondylitis deformans, osteoarthritis, lumbago, gout, postoperative or traumatic ’ } inflammation, remission of swelling, neuralgia, pharyngolaryngitis, cystitis, hepatitis (including steatohepatitis such as non-alcoholic steatohepatitis), pneumonia, pancreatitis, inflammatory colitis, ulcerative colitis), visceral obesity syndrome, etc.
The compound of the present invention and the pharmaceutical composition of the present invention . possess a total cholesterol lowering action and enhance a plasma anti-arteriosclerosis index [ (HDL . 5 cholesterol/total cholesterol) X100], and therefore, can be used as an agent for preventing or treating arteriosclerosis (e.g., atherosclerosis), etc.
Also, the compound of the present invention and the pharmaceutical composition of the present invention can be used for ameliorating bellyache, nausea, vomiting, or dysphoria in epigastrium, each of which is accompanied by gastrointestinal ulcer, acute or chronic gastritis, ‘ biliary dyskinesia, or cholecystitis.
Further, the compound of the present invention and the pharmaceutical composition of the present invention can control (enhance or inhibit) appetite and food intake, and therefore, can be used as an agent for treating leanness and cibophobia (the weight increase in administration subjects suffering from leanness ox cibophobia) or an agent for treating obesity.
The compound of the present invention and the pharmaceutical composition of the present invention can be also used as an agent for preventing or treating TNF- mediated inflammatory diseases. The TNF-a mediated inflammatory diseases mean inflammatory diseases which occur in the presence of TNF-a and can be treated by way of a TNF-a inhibitory action. Examples of such inflammatory diseases include diabetic complications (e.g., retinopathy, nephropathy, neuropathy, macroangiopathy), rheumatoid arthritis, spondylitis deformans, osteoarthritis, lumbago, gout, postoperative or traumatic inflammation, remission of swelling, neuralgia, pharyngolaryngitis, cystitis, hepatitis, pneumonia, gastric mucosal injury (including aspirin-induced gastric mucosal injury), etc.
The compound of the present invention and the pharmaceutical composition of the present invention have an apoptosis inhibitory activity, and can be used as an . agent for preventing or treating diseases mediated by promotion of apoptosis. Examples of the diseases mediated . 5 by promotion of apoptosis include viral diseases (e.qg.,
AIDS, fulminant hepatitis), neurodegenerative dlseases (e.g., Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration), myelodysplasia (e.g., aplastic anemia), ischemic diseases (e.g., myocardial infarction, cerebral apoplexy), hepatic diseases (e.g., alcoholic : hepatitis, hepatitis B, hepatitis C), joint-diseases (e.qg., osteoarthritis), atherosclerosis, etc.
The compound of the present invention and the pharmaceutical composition of the present invention can be used for reducing visceral fats, inhibiting accumulation of visceral fats, ameliorating glycometabolism, ameliorating lipidmetabolism, ameliorating insulin resistance, inhibiting production of oxidized LDIL, ameliorating lipoprotein metabolism, ameliorating coronary artery metabolism, preventing or treating cardiovascular complications, preventing or treating heart failure complications, lowering blood remnant, preventing or treating anovulation, preventing or treating hirsutism, “preventing or treating hyperandrogenism, etc.
The compound of the present invention and the pharmaceutical composition of the present invention can be used for secondary prevention and for inhibition in progress, of the various diseases described above (e.g... cardiovascular events such as myocardial infarction, etc.). :
The compound of the present invention and the pharmaceutical composition of the present invention can be used in combination with midazolam, ketoconazole, etc.
Although the doses of the compound of the present invention and the pharmaceutical composition of the present . invention vary depending on administration subject, administration route, target disease, clinical condition, ate, , it is desirable that the active ingredient, L.e., the compound of the present invention, be administered at a usual dosage per administration of about 0.01 to 100 mg/kg body weight, preferably 0.05 to 10 mg/kg body weight, more preferably 0.1 to 2 mg/kg body weight, 1 to 3 times a day. for oral administration to an adult diabetic patient, for instance. (18) Concomitant use of drugs
The compound of the present invention can be used in - 15 combination with a drug such as a therapeutic agent for diabetes mellitus, a therapeutic agent for diabetic complications, an antihyperlipidemic agent, a hypotensive agent, an antiobesity agent, a diuretic agent, a chemotherapeutic agent, an immunotherapecutic agent, a therapeutic agent for osteoporosis, an antidementia agent, an erection dysfunction ameliorating agent, a therapeutic agent for incontinentia or pollakiuria, and the like (hereinafter, abbreviated as a concomitant drug). On such occasions, the timing of administration of the compound of the present invention and that of the concomitant drug is not limited. They may be administered simultaneously or at staggered times to the administration subject. The dose of the concomitant drug can be appropriately selected based on the dose which is clinically employed. The proportion of the compound of the present invention and the concomitant drug can be appropriately selected according to the administration subject, administration route, target disease, clinical condition, combination, and other factors. In cases where the administration subject is human, for instance, the concomitant drug may be used in an amount of 0.01 to 100 parts by weight per part by weight of the compound of the present invention.
Examples of the therapeutic agent for diabetes . mellitus include insulin preparations (e.g., animal insulin preparations extracted from the bovine or swine . 5 pancreas; human insulin preparations synthesized by a genetic engineering technique using Escherichia coli or a yeast), insulin resistance improving agents (e.g.. pioglitazone hydrochloride, troglitazone, rosiglitazone or its maleate, GI-262570, JTT-501, MCC-555, YM-440,
KRP-297, CS-011, FK-614), a-glucosidase inhibitors (e.g., voglibose, acarbose, miglitol, emiglitate), biguanides (e.g., phenformin, metformin, buformin), insulin secretagogues [sulfonylureas (e.g.., tolbutamide, glibenclamide, gliclazide, chlorpropamide, tolazamide, acetohexamide, glyclopyramide, glimepiride, glipizide, glybuzole), repaglinide, senaglinide, nateglinide, mitiglinide or its calcium salt hydrate, GLP-1), amyrin agonist (e.g., pramlintide), phosphotyrosine phosphatase inhibitors (e.g., vanadic acid), dipeptidylpeptidase IV inhibitors (e.g., NVP-DPP-278, PT-100, P32/98), B3 agonists (e.g., CL-316243, SR-58611-A, UL-TG-307, SB- . 226552, AJ-9677, BMS-196085, AZ40140), gluconeogenesis inhibitors (e.g., glycogen phosphorylase inhibitors, glucose-6-phosphatse inhibitors, glucagon antagonists),
SGLT (sodium-glucose cotransporter) inhibitors (e.g.,
T-1095).
Examples of the therapeutic agent for diabetic complications include aldose reductase inhibitors (e.g., tolrestat, epalrestat, zenarestat, zopolrestat, minalrestat, fidarestat, SNK-860, CT-112), neurotrophic factors (e.g., NGF, NT-3, BDNF), PKC inhibitors (e.g.,
LY-333531), AGE inhibitors (e.g., ALT946, pimagedine, pyratoxathine, N-phenacylthiazolium bromide (ALT766),
EX0-226), active oxygen scavengers (e.g. thioctic acid). cerebral vasodilators (e.g., tiapuride, mexiletine).
Examples of the antihyperlipidemic agent include statin compounds which are cholesterol synthesis inhibitors (e.g., cerivastatin, pravastatin, simvastatin, . lovastatin, atorvastatin, fluvastatin, itavastatin or their salts (e.g., sodium salt)), squalene synthase . 5 inhibitors or tibrate compounds (e.qg., bezaftibrate, clofibrate, simfibrate, clinofibrate) having a triglyceride lowering action.
Examples of the hypotensive agent include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., losartan, candesartan cilexetil, losartan, eprosartan, valsartan, termisartan, irbesartan, tasosartan), calcium antagonist (e.g.. manidipine, nifedipine, amlodipine, efonidipine, nicardipine), clonidine.
Examples of the antiobesity agent include antiobesity drugs acting on the central nervous system (e.g. dexfenfluramine, fenfluramine, phentermine, sibutramine, anfepramon, dexamphetamine, mazindol, phenylpropanoclamine, clobenzorex), pancreatic lipase inhibitors (e.g. orlistat), B3 agonists (e.g. CL-316243,
SR-58611-A, UL-TG-307, SB-226552, AJ-9677, BMS-196085,
AZ40140), anorectic peptides (e.g. leptin, CNTF(Ciliary
Neurotrophic Factor)), cholecystokinin agonists (e.g. lintitript, FPL-15849).
Examples of the diuretic agent include xanthine derivatives (e.g., theobromine and sodium salicylate, theobromine and calcium salicylate), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide), antialdosterone preparations (e.g., ) spironolactone, triamterene), carbonate dehydratase inhibitors (e.g., acetazolamide), chlorobenzenesulfonamide preparations (e.g., chlorthalidone, mefruside, indapamide), azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide,
furosemide.
Examples of the chemotherapeutic agent include . alkylating agents (e.g., cyclophosphamide, ifosamide), metabolic antagonists (e.g., methotrexate, 5- . 5 fluorouracil), antitumor antibiotics (e.qg., mitomycin, adriamycin), plant-derived antitumor agents (e.g., vincristine, vindesine, Taxol), cisplatin, carboplatin, etoposide. Among these, 5 fluorouracil derivatives such as Furtulon and Neo-Furtulon are preferable.
Examples of the immunotherapeutic agent include microorganism- or bacterium-derived components (e.g., muramyl dipeptide derivatives, Picibanil), immunopotentiator polysaccharides (e.g., lentinan, schizophyllan, krestin), genetically engineered cytokines (e.g., interferons, interleukins (IL)), colony stimulating agents (e.g.., granulocyte colony stimulating factor, erythropoietin), etc. Among these, IL-1, IL-2, IL-12 and the like are preferable.
Examples of the therapeutic agent for osteoporosis include alfacalcidol, calcitriol, elcaltonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium.
Examples of the antidementia agent include tacrine, donepezil, rivastigmine, galantamine. "Examples of the erection dysfunction ameliorating agent include apomorphine, sildenafil citrate.
Examples of the therapeutic agent for incontinentia or pollakiuria include flavoxate hydrochloride, oxybutynin hydrochloride, propiverine hydrochloride.
Further, agents whose effects of ameliorating cachexia have been confirmed in animal models or clinically, namely cyclooxygenase inhibitors (e.g., indomethacin) (Cancer Research, vol. 49, pp. 5935-5939, 1989), } progesterone derivatives (e.g., megestrol acetate) (Journal of Clinical Oncology, vol. 12, pp. 213-225, 1994), glucocorticoids (e.g. dexamethasone), metoclopramide pharmaceuticals, tetrahydrocannabinol pharmaceuticals (the above references are applied to both), fat metabolism . ameliorating agents (e.g., eicosapentanoic acid) (British
Journal of Cancer, vol. 68, pp. 314.318, 1993), growth , 5 hormones, 1GF-1, and antibodies; to the cachexia-inducing factor TNF-a, LIF, IL-6 or oncostatin M, can also be used . in combination with the compound of the present invention.
The concomitant drug is preferably an insulin preparation, an insulin resistance improving agent, an a-glucosidase inhibitor, a biguanide, an insulin secretagogue (preferably sulfonylurea), etc. }
The above concomitant drugs can be used as a mixture of two or more species in an appropriate ratio. In the case of using two or more concomitant drugs, preferable combinations include the followings. 1) an insulin resistance improving agent and an insulin preparation; 2) an insulin resistance improving agent and an insulin secretagogue (preferably a sulfonylurea): 3) an insulin resistance improving agent and an a- glucosidase inhibitor; 4) an insulin resistance improving agent and a biguanide; 5) an insulin resistance improving agent, an insulin preparation and a biguanide; : 6) an insulin resistance improving agent, an insulin preparation and an insulin secretagogue (preferably a sulfonylurea); 7) an insulin resistance improving agent, an insulin preparation and an a-glucosidase inhibitor: 8) an insulin resistance improving agent, an insulin } secretagogue (preferably a sulfonylurea) and a biguanide; 9) an insulin resistance improving agent, an insulin secretagogue (preferably a sulfonylurea) and an a- glucosidase inhibitor; and 10) an insulin resistance improving agent, a biguanide and an a-glucosidase inhibitor.
When the compound or pharmaceutical composition of the . present invention are used in combination with a concomitant drug, the amount of each drug can be reduced } 5 within a safe range by taking their adverse effects into consideration. Particularly, the dose of an insulin resistance improving agent, an insulin secretagogue (preferably a sulfonylurea) and a biguanide can be reduced as compared with the normal dose. Accordingly, an adverse effect which may be caused by these agents can be safely prevented. In addition, the dose of an agent for diabetic complications, an anti-hyperlipemic agent and a hypotensive agent can be reduced whereby an adverse effect which may be caused by these agents can be effectively prevented. (19) Production method
The production method for the compound of the present invention is hereinafter described. Since Compound (I) is included in Compound (II), the production method for
Compound (II). is described.
Compound (II) can be produced by a per se known method, e.g., any of Methods A through F, and Method H below, or methods analogous thereto. [Method A] x'-R?
R'-X- (0H) ,=Y — A) (CH) ~L + AB i (00-1 (in : (1v)
ES (I) . wherein Z represents a hydroxy group, a halogen atom or a group of the formula: OSO,R*® whereinR'’ represents an alkyl group having 1 to 4 carbon atoms or an aryl group having
6 to 10 carbon atoms which may be substituted by an alkyl group having 1 to 4 carbon atoms; the other symbols have the same meanings as above.
Here, the alkyl group having 1 to 4 ‘carbon atoms in i 5 the "alkyl group having 1 to 4 carbon atoms” and "aryl group having 6 to 10 carbon atoms which may be substituted by an alkyl group having 1 to 4 carbon atoms” for RY” is exemplified : by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, and t.-butyl, with preference given to methyl.
The aryl group having 6 to 10 carbon atoms in the "aryl group having 6 to 10 carbon atoms which may be substituted : by an alkyl group having 1 to 4 carbon atoms” for RY is exemplified by phenyl and naphthyl, with preference given to phenyl.
In this method, Compound (II) is produced by a reaction : of Compound (III) and Compound (IV).
When 7 is a hydroxy group, this reaction is carried out by a per se known method, e.g., the method described in Synthesis, page 1 (1981), or a method analogous thereto.
Namely, this reaction is normally carried out in the presence of an organic phosphorus compound and an electrophilic agent in a solvent which does not interfere with the reaction.
Examples of the organic phosphorus compound include triphenylphosphine and tributylphosphine.
Examples of the electrophilic agent include diethyl azodicarboxylate, diisopropyl azodicarboxylate, and azodicarbonylpiperazine.
The amount of the organic phosphorus compound and electrophilic agent used is preferably about 1 to about 5 mole equivalents relative to Compound (IV).
Examples of the solvent which does not interfere with the reaction include ethers such as diethyl ether, tetrahydrofuran, and dioxane; halogenated hydrocarbons such as chloroform and dichloromethane; aromatic hydrocarbons such as benzene, toluene, and xylene; amides such as N,N-dimethylformamide; and sulfoxides such as \ dimethyl sulfoxide. These solvents may be used in mixture in appropriate ratios. } 5 The reaction temperature is normally about 50 to about 150C, preferably about -10 to about 100T.
The reaction time is normally about 0.5 to about 20 hours.
When Z is a halogen atom or a group of the formula:
OSO,R'*, this reaction is carried out by a conventional method in the presence of a base in a solvent which does . not interfere with the reaction.
Examples of the base include alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, and potassium carbonate; amines such as pyridine, triethylamine, N,N-dimethylaniline, and 1,8- diazobicyclo[5.4.0]undec-7-ene; metal hydrides such as potassium hydride and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium t.-butoxide.
The amount of these bases used is preferably about 1 to about 5 mole equivalents relative to Compound (IV).
Examples of the solvent which does not interfere with the reaction include aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and diethyl ether; ketones such as acetone and 2-butanone; halogenated hydrocarbons such as chloroform and dichloromethane; amides such as N,N-dimethylformamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be used in mixture in appropriate ratios.
The reaction temperature is normally about -50 to about 150°C, preferably about -10 to about 100TC.
The reaction time is normally about 0.5 to about 20 hours.
Compound (II) thus obtained may be isolated and purified by known means of separation and purification such . as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, . 5 redissolution and chromatography. : Compound (III) and Compound (IV), which are used as the starting compounds in Method A above, are known compounds. Compound (III) wherein Z is a hydroxy group, for example, is described in EP-A 710659. In addition,
Compound (III) is described in EP-A 629624 (JP-A 7(1995)-53555), WO 98/03505, etc. Furthermore, Compound (III) can also be produced by methods analogous to those : described in these patent publications.
On the other hand, Compound (IV) is described in, for example, Journal of Heterocyclic Chemistry, vol. 24, p. 1669 (1987); Journal of Organic Chemistry, vol. 62, p. 2649 (1997); Bioorganic & Medicinal Chemistry Letters, vol. 6, p- 1047 (1996), etc. In addition, Compound (IV) can also be produced by methods analogous to those described in these publications.
A compound of the formula (II) wherein R® is OR® and
W is -CH=CH- or -(CH,),- [Compound (II-2) or (II-3), respectively] can also be produced by Method B below. [Method B]
x'-R? 1 8
R'-X-(CH,) -Y a) (CH) — 5 (C=0) -0R ) (r1-1) . Process 1 x'-R’
R'-X-(CH,) -Y «Ay (CH, , — OR (0)
Process 2 x'-R’
R'-X= (CH,) ~Y —C A) (CH), — {3 3-o0 (vi)
Process 3 x'-R? / mn _np®
R'-X-(CH,) YA) — oT (C=0)-0R (K1-2)
Process 4 x'-R? -— - 8
R'-X- (CH,) -Y Ayn), — yen OR (11-3) wherein the symbols have the same meanings as above. (Process 1)
This reaction is carried out by a conventional method ’ in the presence of a reducing agent in a solvent which does not interfere with the reaction.
Examples of the reducing agent include sodium borohydride, lithium borohydride, lithium aluminum hydride, , and diisobutyl aluminum hydride.
The amount of the reducing agent used is preferably . 5 about 0.5 to about 10 mole equivalents relative to Compound (II-1).
Examples of the solvent which does not interfere with the reaction include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as chloroform and dichloromethane; ethers such as tetrahydrofuran, dioxane, and diethyl ether; water; and alcohols such as methanol, ethanol, and isopropanol.
These solvents may be used in mixture in appropriate ratios.
The reaction temperature is normally about -50 to about 150°C, preferably about -10 to about 100T.
The reaction time is normally about 0.5 to about 20 hours.
Compound (V) thus obtained may be isolated and purified by known means of separation and purification such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography.
Compound (II-1), which is used as the starting compound in Process 1 of Method B above, can be produced by, for example, Method A above. In addition, Compound (II-1) can also be produced by the method described in, for example, Journal of Heterocyclic Chemistry, vol. 24, p. 1669 (1987); Journal of Organic Chemistry, vol. 62, p. 2649 (1997): Bioorganic & Medicinal Chemistry Letters, vol. 6, p. 1047 (1996), etc., or a method analogous thereto. (Process 2)
This reaction is carried out by a conventional method in the presence of an oxidant in a solvent which does not interfere with the reaction.
Examples of the oxidant include metal oxidants such as manganese dioxide, pyridinium chlorochromate, , pyridinium dichromate, and ruthenium oxide.
The amount of the oxidant used is preferably about 1 . 5 to ahout 10 mnle equivalents relative to Compound (V).
Examples of the solvent which does not interfere with the reaction include aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and diethyl ether; and halogenated hydrocarbons such as chloroform and dichloromethane. These solvents may be used in mixture in appropriate ratios.
The reaction temperature is normally about -50 to about 150C, preferably about -10 to about 100T.
The reaction time is normally about 0.5 to about 20 hours.
In addition, Compound (VI) can also be produced by adding a reaction reagent such as sulfur trioxide-pyridine complex or oxalyl chloride to compound (V) in dimethyl sulfoxide or a solvent mixture of dimethyl sulfoxide and a halogenated hydrocarbon such as chloroform or dichloromethane, and reacting it with an organic base such as triethylamine or N-methylmorpholine.
The amount of the reaction reagent is preferably about 1 to about 10 mole equivalents relative to Compound (V).
The amount of the organic base used is preferably about 1 to about 10 mole equivalents relative to Compound (V).
The reaction temperature is normally about -50 to about 150C, preferably about -10 to about 100TC.
The reaction time is normally about 0.5 to about 20 hours. . Compound (VI) thus obtained may be isolated and purified by known means of separation and purification such i as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography.
(Process 3) . In this reaction, Compound (II-2) is produced by a reaction of an organic phosphorus reagent and Compound . 5 (VI).
This reaction is carried out by a conventional method in the presence of a base in a solvent which does not interfere with the reaction.
Examples of the organic phosphorus reagent include methyl dimethylphosphonoacetate, ethyl diethylphosphonoacetate, and ethyl dimethylphosphonoacetate.
The amount of the organic phosphorus reagent used is preferably about 1 to about 10 mole equivalents relative to Compound (VI).
Examples of the base include alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, and potassium carbonate; amines such as pyridine, triethylamine, N,N-dimethylaniline, and 1,8- diazobicyclo[5.4.0]undec-7-ene; metal hydrides such as potassium hydride and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, and potassium t.-butoxide. :
The amount of these bases used is preferably about 1 to about 5 mole equivalents relative to Compound (VI).
Examples of the solvent which does not interfere with the reaction include aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and diethyl ether; halogenated hydrocarbons such as chloroform and dichloromethane; amides such as N,N- dimethylformamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be used in mixture in ) appropriate ratios.
The reaction temperature is normally about -50 to about 150TC, preferably about -10 to about 100C.
The reaction time is normally about 0.5 to about 20 hours. . Compound (II-2) thus obtained may be isolated and . purified by known means of separation and purification such . 5 as concentration, concentration under reduced pregsure, solvent extraction, crystallization, recrystallization, . } redissolution and chromatography. (Process 4)
This reaction is carried out by a conventional method under a hydrogen atmosphere or in the presence of a hydrogen source (e.g., formic acid) and a metal catalyst in a solvent which does not interfere with the reaction.
Examples of the metal catalyst include transition metal catalysts such as palladium-carbon, palladium black, platinum oxide, Raney nickel, and Wilkinson's catalyst.
The amount of these transition metal catalysts used is preferably about 0.01 to about 10 mole equivalents relative to Compound (II-2).
Examples of the solvent which does not interfere with the reaction include aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and diethyl ether; halogenated hydrocarbons such as chloroform and dichloromethane; amides such as N,N- dimethylformamide; and alcohols such as methanol, ethanol, and isopropanol. These solvents may be used in mixture in appropriate ratios. }
The reaction temperature is normally about -50 to about 150C, preferably about -10 to about 100T.
The reaction time is normally about 0.5 to about 20 hours.
Compound (II-3) thus obtained may be isolated and ) purified by known means of separation and purification such . as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography.
[Method C]
X'-R , 3 RX-(CHy) 2 pow (An), — (5 reer (vin) (Vii) x'-g? 3 : AN 3
RRO), {AY (OH) — NB JH-C(=OR (11-4) wherein Y' represents an oxygen atom, a sulfur atom or group of the formula: -NR’- wherein R’ has the same meaning as above; the other symbols have the same meaning as above.
In this method, compound (II-4) is produced by the reaction of Compound (VII) and Compound (VIII). This reaction is carried out in the same manner as the reaction of Compound (III) and Compound (IV) in Method A. }
Compound (II-4) thus obtained may be isolated and purified by known means of separation and purification such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography.
Compound (VII), which is used as the starting compound in Method C above, is a known compound and described in, for example, Chemical and Pharmaceutical Bulletin, vol. 34,
Pp. 2840 (1986); Journal of Medicinal Chemistry, vol. 35, p. 2617 (1992); WO 98/03505, etc. Further, Compound (VII) can be produced by a method analogous to methods described in these publications. [Method D]
x'-R’
R'-X- (CH,) 1) (CH), — (5) (=0) OR’ : | (11-5) € bo? v XR
Hydrolysis — R ~X- (CH,) ay ~~ (CH,) — (5 we (<0) OH (11-6) wherein the symbols have the same meanings as above.
In this method, Compound (II-6) is produced by hydrolyzing Compound (II-5).
This hydrolytic reaction is carried out by a conventional method in the presence of an acid or a base in a hydrated solvent.
Examples of the acid include hydrochloric acid, sulfuric acid, acetic acid, and hydrobromic acid.
Examples of the base include alkall metal carbonates such as potassium carbonate and sodium carbonate; alkali metal alkoxides such as sodium methoxide:; and alkali metal hydroxides such as potassium hydroxide, sodium hydroxide, and lithium hydroxide.
The amount of the acid or base used is normally in excess to Compound (II-5). Preferably, the amount of the acid used is about 2 to about 50 equivalents relative to
Compound (II-5), and the amount of the base used is about 1.2 to about 5 equivalents relative to Compound (II-5).
Examples of the hydrated solvents include solvent mixtures of water and one or more solvents selected from alcohols such as methanol and ethanol: ethers such as tetrahydrofuran, dioxane, and diethyl ether; dimethyl . 25 sulfoxide and acetone.
The reaction temperature is normally about -20 to about 150C, preferably about -10 to about 100%.
The reaction time is normally about 0.1 to about 20 hours.
Compound (II-6) thus obtained may be isolated and purified by known means of separation and purification such . as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, v 5 redissolution and chromatography.
Compound (II-5), which is used as the starting material in Method D above, is produced by, for example,
Methods A through C above.
Compound (II-7) having NR’R'® for R® in the formula (II) can also be produced by Method E below. [Method E] (1-6) + HNRRY — (1%) oo . x'-R?
R'-X- (CH,) -Y — eH) — Swen NR'R"’ (11-7) wherein the symbols have the same meanings as above.
In this method, Compound (II-7) is produced by amidating Compound (II-6). This reaction is carried out by a per se known method, e.g., a method wherein Compound (II-6) and Compound (IX) are directly condensed by means of a condensing agent (e.g., dicyclohexylcarbodiimide), a method wherein a reactive derivative of Compound (II-6) and
Compound (IX) are reacted as appropriate, or the like. Here, the reactive derivative of Compound (11-6) is exemplified by acid anhydrides, acid halides (acid chlorides, acid bromides), imidazolides, or mixed acid anhydrides (e.g., anhydrides with methoxycarbonic acid, ethoxycarbonic acid, . or isobutoxycarbonic acid).
When an acid halide is used, for example, the reaction is carried out in the presence of a base in a solvent which does not interfere with the reaction.
Examples of the base include triethylamine, N- methylmorpholine, N,N-dimethylaniline, sodium hydrogen . carbonate, sodium carbonate, and potassium carbonate.
Examples of the solvent which does not interfere with . 5 the reaction include halogenated hydrocarbons such as chloroform and dichloromethane; aromatic hydrocarbons such as benzene and toluene; ethers such as tetrahydrofuran, dioxane, and diethyl ether: ethyl acetate, and water. :
These solvents may be used in mixture in appropriate ratios.
The amount of compound (IX) used is 0.1 to 10 mole equivalents, preferably 0.3 to 3 mole equivalents, relative to Compound (II-6). So
The reaction temperature is normally -30 to 100TC.
The reaction time is normally 0.5 to 20 hours. :
In addition, when a mixed acid anhydride is used,
Compound (II-6) and a chlorocarbonic acid ester (e.g., methyl chlorocarbonate, ethyl chlorocarbonate, isobutyl chlorocarbonate) are reacted in the presence of a base (e.qg., triethylamine, N-methylmorpholine, N,N-dimethylaniline, sodium hydrogen carbonate, sodium carbonate, potassium carbonate), and are further reacted with Compound (IX).
The amount of compound (IX) used is normally 0.1 to 10 mole equivalents, preferably 0.3 to 3 mole equivalents, relative to Compound (II-6).
The reaction temperature is normally -30 to 100C.
The reaction time is normally 0.5 to 20 hours.
Compound (1I-7) thus obtained may be isolated and purified by known means of separation and purification such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, . redissolution and chromatography.
Compound (II-6), which is used as the starting } compound in Method E above, can be produced by, for example,
Methods A through D above. }
[Method F]
XH
‘ R'-X-(CH,) -¥ (Day, —H 8 WCCO + 2'-R (11-8) on
XR’ i z= 3 — = RX-(CHp,Y CAH), N Wyre (11-9) wherein X? represents an oxygen atom, a sulfur atom or a group of the formula: -NR'*- wherein R'® has the same meaning as above; 2' represents a hydroxy group, a halogen atom or a group of the formula: OSO,R'’ wherein RY represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which may be substituted by an alkyl group having 1 to 4 carbon atoms; the other symbols have the same meanings as above.
The "alkyl group having 1 to 4 carbon atoms” and "aryl group having 6 to 10 carbon atoms which may be substituted by an alkyl group having 1 to 4 carbon atoms” for R' are exemplified by those mentioned to exemplify R'* above.
In this method, Compound (II-9) is produced by a reaction of Compound (II1-8) and Compound (XI). This reaction is carried out in the same manner as the reaction of Compound (III) and Compound (IV) in Method A.
Compound (II-9) thus obtained may be isolated and purified by known means of separation and purification such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography. . 25 Compound (II-8), which is used as the starting compound in Method F above, can also be produced by. for . example, the method described in Bioorganic & Medicinal
Chemistry Letters, vol. 6, p. 1047 (1996), etc., or a method analogous thereto. Furthermore, Compound (II-8) can also be produced by Methods A through E above.
Compound (VIII), which is used as the starting . 5 compound in Method €, can be produced by, for example,
Method G below. [Method G] we a(n), ~2 tM —— = i) (x) wherein the symbols have the same meaning as above.
This reaction is carried out in the same manner as the reaction of Compound (III) and Compound (IV) in Method A.
The condensing reaction may be carried out with the -Y'H moiety of Compound (X) protected, which moiety may be deprotected after the reaction. Useful protective groups include benzyl group, methoxymethyl group, and silyl groups (e.g., trimethylsilyl group, tert-butyldimethylsilyl group) .
Compound (II-10) having OH for R? and having -CH,- for
W in the formula (II) can also be produced by Method H below. [Method H]
x'-R’
R'-X-(CH,) -¥ —- (CH) — 5 9-cno : (v1) } Process b | : 1.2
X -R : Id
R'-X-(CH,) ,-Y ~ € A) (CH), NB CH, CN xin)
Process 6 1.2
X -R . 1 _ _
RX) ~~ A= (oH), {5 3on, cof (11-10) wherein the symbols have the same meaning as above. (Process 5)
Compound (XII) can be produced by reacting Compound (VI) and p-toluenesulfonylmethylisocyanide in the presence of base such as potassium t-butoxide, sodium hydride, and lithium hydride, in a solvent which does not interfere with the reaction, and then conducting alcoholysis.
The amount of p-toluenesulfonylmethylisocyanide used is preferably about 0.5 to about 10 mole equivalents, relative to Compound (VI). .
The amount of the base used is preferably about 0.5 to about 20 mole equivalents, relative to Compound (VI).
Examples of alcohols used in alcoholysis include "methanol, ethanol, propanol, butanol, and isopropanol. :
Examples of the solvent which does not interfere with the reaction include aroma tic hydrocarbons such as benzene, toluene, and xylene: halogenated hydrocarbons such as chloroform and dichloromethane; and ethers such as tetrahydrofuran, dioxane, diethyl ether, 1,2-
dimethoxyethane. These solvents may be used in mixture in appropriate ratios, . The reaction temperature is normally about -100 to about 150°C, preferably about 80 to about 100C. . 5 The reaction time is normally about 0.5 to about 20 hours.
Compound (XII) thus obtained may be isolated and purified by known means of separation and purification such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography.
Compound (VI), which is used as the starting compound in Process 5 of Method H above, can be produced by, for example, Process 2 of Method B above. (Process 6)
In this method, Compound (II-10) is produced by hydrolyzing Compound (XII).
This hydrolytic reaction is carried out by a conventional method in the presence of an acid or a base in a hydrated solvent.
Examples of the acid include hydrochloric acid, sulfuric acid, acetic acid, and hydrobromic acid.
Examples of the base include alkali metal carbonates such as potassium carbonate and sodium carbonate; alkali metal alkoxides such as sodium methoxide; and alkali metal hydroxides such as potassium hydroxide, sodium hydroxide, and lithium hydroxide.
The amount of the acid or base used is normally in excess to Compound (XII). Preferably, the amount of the acid used is about 2 to about 50 equivalents relative to
Compound (XII), and the amount of the base used 1s about 1.2 to about 5 equivalents relative to Compound (XII).
Examples of the hydrated solvents include solvent mixtures of water and one or more solvents selected from alcohols such as methanol and ethanol; ethers such as tetrahydrofuran, dioxane, and diethyl ether: dimethyl sulfoxide and acetone. ] The reaction temperature is normally about -20 to about 150, preferably about -10 to about 100T. . 5 The reaction time ig normally about: 0.1 to about 20 hours.
Compound (II-10) thus obtained may be isolated and purified by known means of separation and purification such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, redissolution and chromatography.
When the starting compound has amino, carboxy, hydroxy, or carbonyl as a substituent in the individual reactions . 15 described above, these groups may have a protective group in common use in peptide chemistry and other fields : introduced therein. The desired compound can be obtained by removing the protective group after the reaction, if necessary.
Examples of the protective groups for amino include formyl, C, alkyl-carbonyls (e.g., acetyl, propionyl) , Ci alkoxy-carbonyls (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl), benzoyl, C,,, aralkyl-carbonyls - (e.g., benzylcarbonyl), C,,, aralkyloxy-carbonyls (e.g., benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl), trityl, phthaloyl, N,N-dimethylaminomethylene, silyls (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyldimethylsilyl, tert-butyldiethylsilyl), andC,, alkenyls (e.g., 1-allyl). These groups may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), C, , alkoxys (e.g., methoxy. ethoxy, propoxy), nitro, or the like.
Examples of the protective groups for carboxy include
C,.¢ alkyls (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl), C,,, aralkyls (e.g., benzyl), phenyl, trityl. silyls (e.g., trimethylsilyl, triethylsilyl,
dimethylphenylsilyl, tert-butyldimethylsilyl, tert- butyldiethylsilyl), and C,, alkenyls (e.g., l-allyl). ; These groups may be substituted by 1 to 3 halogen atoms (e.g. , fluorine, chlorine, bromine, iodine), C, , alkoxys (e.g.. \ 5 methoxy, ethoxy, propoxy), nitro, or the like.
Examples of the protective groups for hydroxy include
C,.c alkyls (e.g., methyl, ethyl, propyl, isopropyl, butyl, tert-butyl), phenyl, trityl, C,,, aralkyls (e.g., benzyl), formyl, | C,., alkyl-carbonyls (e.g., acetyl, propionyl), benzoyl, C,,, aralkyl-carbonyls (e.g., benzylcarbonyl), 2-tetrahydropyranyl, 2-tetrahydrofuranyl, silyls (e.g., trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyldimethylsilyl, tert-butyldiethylsilyl), and C, alkenyls (e.g., l-allyl). These groups may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), C,, alkyls (e.g., methyl, ethyl, propyl), C,, alkoxys (e.g., methoxy, ethoxy, propoxy), nitro, or the like.
Examples of the protective groups for carbonyl include cyclic acetals (e.g., 1,3-dioxane) and non-cyclic acetals (e.g., di-C,, alkylacetals). :
In addition, these protective groups can be removed by a per se known method, e.g., the method described in
Protective Groups in Organic Synthesis, published by John ’ 25 Wiley and Sons (1980). For example, there may be used methods employing an acid, a base, ultraviolet rays, hydrazine, phenylhydrazine, sodium N- methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, a trialkylsilyl halide (e.g., trimethylsilyl iodide, trimethylsilyl bromide), or the like, the reduction method, and the like.
When compound (II) contains an optical isomer, a ~ stereomer, a position isomer, or a rotation isomer, these isomers are also contained as Compound (II) and can each be obtained as a single substance by means of a per se known :
Yai method of synthesis or separation. For example, when an optical isomer is present in Compound (II), the optical ] isomer separated from said compound is also included in
Compound (II). , 5 Optical lsomers can be produced by a per se known method. Specifically, optical isomers are obtained by using an optically active synthesis intermediate, or optically resolving a racemate of the final product by a conventional method.
Examples of the methods of optical resolution include per se known methods, such as the fractional recrystallization method, the chiral column method, and the diastereomer method. 1) Fractional recrystallization method
A method wherein a salt is formed between a racemate and an optically active compound [e.g., (+)-mandelic acid, (-)-mandelic acid, (+)-tartaric acid, (-)-tartaric acid, (+)-1-phenethylamine, (-)-1-phenethylamine, cinchonine, (-)-cinchonidine, brucine], which salt is separated by fractional recrystallization, etc., and, if desired, subjected to a neutralization process, to yield a free optical isomer. 2) Chiral column method . A method wherein a racemate or a salt thereof is applied to a column for optical isomer separation (chiral column) . Inthe case of liquid chromatography, for example, optical isomers are separated by adding a mixture of the optical isomers to a chiral column such as ENANTIO-OVM (produced by Tosoh Corporation) or CHIRAL series produced by DAICEL CHEMICAL IND., and developing it in water, various buffers (e.g., phosphate buffer), an organic solvent (e.g., ethanol, methanol, isopropanol, acetonitrile, trifluoroacetic acid, diethylamine), or a solvent mixture thereof. In the case of gas chromatography, for example,
a chiral column such as CP-Chirasil-DeX CB (produced by GL
Science) is used to separate optical isomers. 3) biastereomer method . 5 A method wherein a racemate mixture and an optically active reagent are chemically reacted to yield a diastereomer mixture, which is then subjected to ordinary means of separation (e.g., fractional recrystallization, chromatography) to obtain single substances, which are subjected to a chemical reaction such as acid hydrolysis to cut off the optically active reagent moiety, whereby the desired optical isomer is obtained. For example, when
Compound (I) has hydroxy or primary or secondary amino in the molecule thereof, said compound, an optically active organic acid (e.g.., MTPA [a -methoxy-Q- (trifluoromethyl )phenylacetic acid], (-)-menthoxyacetic acid) and the like may be subjected to a condensing reaction to yield a diastereomer of an ester or amide, respectively. ~ On the other hand, when Compound (I) has a carboxyl group, said compound and an optically active amine or an alcohol reagent may be subjected to a condensing reaction to yield . a diastereomer of an amide or ester, respectively. The diastereomer thus separated is converted to an optical isomer of the original compound by subjecting it to an acid hydrolysis or basic hydrolysis reaction.
The present invention is hereinafter described in more detail by means of, but is not limited to, the following
Test Examples, Reference Examples, Examples and
Preparation Examples. In addition, % in the Reference
Examples and Examples below means percent by weight, unless mentioned otherwise. Room temperature means the temperature of 1 to 30°C.
Abbreviations for bases, amino acids and others used in the present specification are based on abbreviations specified by the IUPAC-IUB Commission on Biochemical
Nomenclature or abbreviations in common use in relevant ) fields. Some examples are given below. When an optical isomer may be present in amino acid, it is of the L- } 5 configuration, unless otherwise mentioned.
The sequence numbers in the sequence listing in the present specification show the following respective sequences. [SEQ ID NO:1]}
Shows the base sequence of the primer PAG-U used in
Reference Example 1. ’ [SEQ ID NO:2]}
Shows the base sequence of the primer PAG-L used in
Reference Example 1. [SEQ ID NO:3]
Shows the base sequence of the primer XRA-U used in :
Reference Example 2. [SEQ ID NO:4] ’
Shows the base sequence of the primer XRA-I. used in
Reference Example 2. [SEQ ID NO:5]
Shows the base sequence of the primer PPRE-U used in
Reference Example 4. [SEQ ID NO:6)
Shows the base sequence of the primer PPRE-L used in
Reference Example 4. . [SEQ ID NO:7]
Shows the base sequence of the primer TK-U used in
Reference Example 4. [SEQ ID NO:8]
Shows the base sequence of the primer TK-L used in
Reference Example 4.
Test Example 1
Hypoglycemic and hypolipidemic actions in mice
Test compounds were mixed in a powdery diet (CE-2,
Japan Clea) at the concentration of 0.01% (compounds of ) Examples 12, 30, 89, 186), 0.005% (compounds of Examples 7, 80, 82, 181, 182, 184, 256, 262, 283), 0.001% (compounds } 5 of Examples 9, 104, 110, 15%, 156, 160, 167, 169, 172, 174, 176, 189), or 0.0003% (compounds of Examples 38, 40, 44), and freely given to KKAY mice (9 to 12 weeks old, 5 mice in a group), a model of obese and type 2 diabetes mellitus, for four days. During this period, water was given freely.
Blood was sampled from orbital venous plexus, and glucose and triglyceride levels in plasma separated from blood were determined enzymatically using L type Wako Glu2 (Wako Pure
Chemical Industries, Ltd.) or L type Wako TG'H (Wako Pure
Chemical Industries, Ltd.), respectively. The results are given in Table 1.
In the Table, the value of each treatment group is represented as percent reduction compared with the non- treatment group.
Table 1
Test compound Hypoglycemic Hypolipidemic {Example No.) action (%) action (%) 7 54 60 9 48 70 12 46 63 54 77 38 44 69 40 41 66 44 47 74 30 80 42 22 82 50 58 89 48 70 104 43 42 110 50 70 155 49 56 156 45 80
160 54 57 167 48 60 . 169 48 39 172 42 62 174 40 52 176 40 66 181 56 63 182 34 12 184 56 82 186 57 78 189 44 75 256 57 16 262 45 61 283 52 78
These results indicated that the compounds of the present invention possess potent hypoglycemic and hypolipidemic actions. Therefore, the compounds are proved to be useful as agents for preventing or treating diabetes mellitus, hyperlipidemia (especially hypertriglyceridemia), impaired glucose tolerance, etc.
Test Example 2
Total cholesterol lowering action and plasma anti- arteriosclerosis index-enhancing action in mice
Test compounds were mixed in a powdery diet (CE-2, . Japan Clea) at the concentration of 0.01% (compounds of
Examples 12, 30, 89), 0.005% (compounds of Examples 38, 40, 44, 181, 184, 262, 283), or 0.001% (compounds of Examples 9, 156, 167, 172, 174, 176, 189), and freely given to KKAY mice (9 to 12 weeks old, 5 mice per group). a model of obese and type 2 diabetes mellitus, for four days. During this period, water was given freely. Blood was sampled from orbital venous plexus and plasma was separated. Total cholesterol levels were determined by using L type Wako
Cholesterol (Wako Pure Chemical Industries, Ltd.).
Precipitation reagent for apoB containing lipoprotein was added to a part of the plasma to precipitate non-HDL . lipoprotein, and cholesterol (HDL cholesterol) in the resulting supernatant was determined. The plasma anti- } 5 arteriosclerosis index [ (HDL cholesterol/total cholesterol) X100] was calculated by using these cholesterol levels. The results are given in Table 2.
In the Table, "Total cholesterol lowering action (%)°" represents the percent reduction (%) of total cholesterol level in the treatment group, when the total cholesterol level in the non-treatment group is taken as 100%. “Plasma anti-arteriosclerosis index-enhancing action (%)” represents the percent increase (%) of plasma anti- arteriosclerosis index in the treatment group, when the plasma anti-arteriosclerosis index in the non-treatment group is taken as 100%.
Table 2
Test compound Total cholesterol Plasma anti-arterio- (Example No.) lowering action(%) sclerosis index- enhancing action (%) 9 16 12 12 15 24 27 16 38 24 21 40 19 22 44 23 21 89 8 15 30 156 20 15 167 19 9 172 20 11 174 19 10 176 23 11 181 25 21 184 27 17
189 21 20 262 22 9 283 24 19 . 5 These results indicated that the compounds of the present invention possess total cholesterol lowering and plasma anti-arteriosclerosis index-enhancing actions.
Therefore, the compounds are proved to be useful as agents for preventing or treating arteriosclerosis by improving plasma lipoprotein profiles of hypercholesterolemia and/or hypo-HDL-cholesterolemia.
Test Example 3 (PPAR7Y -RXRC heterodimer ligand activity)
A PPAR7T :RXR(C :4ERPP/CHO-K1 cells obtained in
Reference Example 5 described later were cultured in HAM
F12 medium (produced by NISSUI SEIYAKU) containing 10%
Fetal bovine serum (produced by Life Technologies, Inc.,
USA) and then inoculated to a 96-well white plate (produced by Corning Costar Corporation, USA) at the density of 2
X10* cells/well, and cultured in a CO,gas incubator at 37°C overnight.
After washing the 96 well white plate with PBS (Phosphate-buffered saline), 9041 of HAM F12 medium containing 0.1% fatty acid-free bovine serum albumin (BSA) and 10/1 of test compound were added, which was cultured in a CO gas incubator at 37°C for 48 hours. After removing the medium, 401] of PIKKAGENE 7.5 (produced by Wako Pure
Chemical Industries, Ltd.) was added. After stirring, the luciferase activity was determined using Lumistar (produced by BMG Labtechnologies GmbH, Germany).
A fold induction was calculated based on the luciferase activity of each test compound by taking the luciferase activity in the non-treatment group as 1. The values of the test compound concentration and the fold induction were analyzed using PRISM 2.01 (produced by
GraphPad Software Inc. USA) to calculate the EC,, values, the effective concentration of a test compound for 50% of . the maximum fold induction. The results are shown in Table 3. ) 5 Table 3
Test compound EC, (Example No.) (nM) 7 3.8 8 2.7 9 1.5 12 320 30 9.7 38 38 40 57 44 13 80 2.5 82 1.4 89 0.23 100 1.8 104 2.0 110 3.5 256 53 262 33 __ 283 0.22
These results indicated that the compounds of the present invention have potent PPAR? -RXR(Q heterodimer ligand activity.
Reference Example 1 (Human PPAR7 gene cloning)
A human PPAR7T gene was cloned using a heart cDNA (produced by Toyobo Co., Ltd., trade name: QUICK-Clone cDNA) as a template by means of a PCR method employing a primer set shown below which was prepared with reference to the base sequence of PPAR7T gene reported by Greene et al (Gene Expr., 1995, Vol.4(4-5), page 281 - 299). . PAG-U: 5'~-GTG GGT ACC GAA ATG ACC ATG GTT GAC ACA GAG-3' (Sequence ID Number: 1) } 5 PAG-L: 5'-GGG GTC GAC CAG GAC TCT C'I'G CTA GTA CAA GTC--3° {Sequence ID Number: 2)
The PCR reaction was performed by Hot Start method using AmpliWax PCR Gem 100 (produced by TAKARA SHUZO CO.,
LTD.). First, 241 of 10XLA PCR Buffer, 3/41 of 2.5 mM dNTP solution, 2.541 each of 12.54M primer solutions and 10 £1 of sterilized distilled water were mixed to obtain a bottom layer solution mixture. 141 of human heart cDNA (1 ng/ml) as a template, 3141 of 10XLA PCR Buffer, 141 of 2.5 mM ANTP solution, 0.541 of TaKaRa LA Taq DNA polymerase (produced. by TAKARA SHUZO CO., LTD.) and 24.541 of sterilized distilled water were mixed to obtain a top layer solution mixture. :
To the bottom layer solution mixture described above, added was one unit of AmpliWax PCR Gem 100 (produced by
TAKARA SHUZO CO., LTD.), which was treated at 70°C for 5 minutes and then in ice for 5 minutes. Then the top layer solution mixture was added to the mixture to prepare the reaction mixture of PCR. A tube containing the reaction mixture was set on a thermal cycler (produced by Perkin
Elmer, USA) and treated at 95°C for 2 minutes. After repeating the cycle of 95°C for 15 seconds and 68°C for 2 minutes a further 35 times, the tube was treated at 72°C for 8 minutes.
The PCR product thus obtained was subjected. to electrophoresis on agarose gel (1%), and 1.4 kb DNA fragment containing PPAR7Y gene was recovered from the gel, and then inserted into pT?7 Blue T vector (produced by TAKARA SHUZO
CO., LTD.) to obtain a plasmid pTBT-hPPARTY .
Reference Example 2 ’ " (Human RXR@ gene cloning)
A human RXR gene was cloned using a kidney cDNA (produced by Toyobo Co., Ltd., trade name: QUICK-Clone . cDNA) as a template by means of a PCR method employing a primer set shown below which was prepared with reference to the Lase sequence off RXR¢@ gene reported by Mangelsdorf,
D. J. et al (Nature, 1990, Vol. 345 (6272), page 224 -- 229).
XRA-U: 5'-TTA GAA TTC GAC ATG GAC ACC AAA CAT TTC CTG-3' (Sequence ID Number: 3)
XRA-L: 5'-CCC CTC GAG CTA AGT CAT TTG GTG CGG CGC CTC-3' (Sequence ID Number: 4)
The PCR reaction was performed by Hot Start method using AmpliWax PCR Gem 100 (produced by TAKAEA SHUZO CO.,
LTD.). First, 211 of 10XLA PCR Buffer, 311 of 2.5 mM dNTP solution, 2.541 each of 12.54 M primer solutions and 10
Ul of sterilized distilled water were mixed to obtain a bottom layer solution mixture. 141 of human kidney cDNA (1 ng/ml) as a template, 341 of 10XLA PCR Buffer, 141 of 2.5 mM dNTP solution, 0.54 1 of TaKaRa LA Taq DNA polymerase (produced by TAKARA SHUZO CO., LTD.) and 24.541 of sterilized distilled water were mixed to obtain a top layer solution mixture.
To the bottom layer solution mixture described above, added was one unit of AmpliWax PCR Gem 100 (produced by
TAKARA SHUZO CO., LTD.), which was treated at 70°C for 5 minutes and then in ice for 5 minutes. Then, the top layer solution mixture was added to the mixture to prepare the reaction mixture of PCR. A tube containing the reaction mixture was set on a thermal cycler (produced by Perkin
Elmer, USA) and treated at 95°C for 2 minutes. After repeating the cycle of 95°C for 15 seconds and 68°C for 2 minutes a further 35 times, the tube was treated at 72°C for 8 minutes. " The PCR product thus obtained was subjected to electrophoresis on agarose gel (1%), and 1.4 kb DNA fragment . 35 containing RXRa gene was recovered from the gel, and then inserted into pT7 Blue-T vector (produced by TAKARA SHUZO
CO., LTD.) to obtain a plasmid pTBT-hRXRC.
Reference Example 3 } 5 (Construction of plasmids for expressing Human PPARYT , RXR a)
A 7.8 kb FspI-NotI fragment of plasmid pVgRXR (produce . by Invitrogen, USA) was ligated to ‘a 0.9 kb Fspl-Notl fragment containing RXR«& gene of plasmid pTBT-hRXR CQ obtained in Reference Example 2 to prepare plasmid pVgRXR2.
Then, pVgRXR2 was digested with BstXI and then treated with
T4DNA polymerase (produced by TAKARA SHUZO CO., LTD.) to obtain a blunt terminal. Then digestion at Kpnl gave a 6.5 kb DNA fragment.
On the other hand, plasmid pTBT-hPPARTY obtained in
Reference Example 1 was digested with Sal I and then treated with T4DNA polymerase (produced by TAKARA SHUZO CO., LTD.) to obtain a blunt terminal. Then digestion at Kpnl gave a 1.4 kb DNA fragment containing human PPART gene.
The both DNA fragments were ligated to construct plasmid pVgRXR2-hPPARTYT .
Reference Example 4 (Construction of reporter plasmids)
A DNA fragment containing PPAR-responding element (PPRE) of an acyl CoA oxidase was prepared using the following 5°'-terminal phosphorylated synthetic DNA.
PPRE-U: 5’ -pTCGACAGGGGACCAGGACAAAGGTCACGTTCGGGAG- 3' (Sequence ID Number: 5)
PPRE-L: 5'-pTCGACTCCCGAACGTGACCTTTGTCCTGGTCCCCTG- 3' (Sequence ID Number: 6)
First, PPRE-U and PPRE-L were annealed and inserted to Sal I site of plasmid pBlue Script SK+. By determining : the base sequence of the inserted fragment, plasmid pBSS-PPRE4 in which 4 PPREs were ligated in tandem was selected. :
A HSV thymidine kinase minimum promoter (TK promoter) region was cloned using pRL-TK vector (produced by Promega. ] USA) as a template by means of a PCRmethod employing a primer set shown below which was prepared with reterence to the base sequence of the promoter region of thymidine kinase reported by Luckow, B et al (Nucleic Acids Res., 1987,
Vol.15(13), p.5490)
TK-U: 5°’'-CCCAGATCTCCCCAGCGTCTTGTCATTG-3' (Sequence
ID Number: 7)
TK-L: 5'-TCACCATGGTCAAGCTTTTAAGCGGGTC-3' (Sequence
ID Number: 8)
The PCR reaction was performed by Hot Start method using AmpliWax PCR Gem 100 ( TAKARA SHUZO CO., LTD.). First, 211 of 10XLA PCR Buffer, 341 of 2.5 mM ANTP solution, 2.5 ul each of 12.54 M primer solutions and 1041 of sterilized distilled water were mixed to obtain a bottom layer solution mixture. 141 of pRL-TK vector (produced by Promega, USA) as a template, 341 of 10XLA PCR Buffer, 1141 of 2.5 mM dNTP solution, 0.541 of TaKaRa I.A Taq DNA polymerase (produced by TAKARA SHUZO CO., LTD.) and 24.541 of sterilized distilled water were mixed to obtain a top layer solution mixture.
To the bottom layer solution mixture described above, added was one unit of AmpliWax PCR Gem 100 (produced by
TAKARA SHUZO CO., LTD.), which was treated at 70°C for 5 . minutes and then in ice for 5 minutes. Then, the top layer solution mixture was added to the mixture to prepare the reaction mixture of PCR. A tube containing the reaction mixture was set on a thermal cycler (produced by Perkin
Elmer, USA) and treated at 95°C for 2 minutes. After repeating the cycle of 95°C for 15 seconds and 68°C for 2 minutes a further 35 times, the tube was treated at 72°C for 8 minutes. .
The PCR product thus obtained was subjected to electrophoresis on agarose gel (1%), and 140 b DNA fragment containing TK promoter was recovered from the gel, and then inserted into pT7 Blue-T vector (produced by TAKARA SHUZO
CO., LTD.). By digesting the plasmid thus obtained with . the restriction enzymes Bgl II and NcoI, a fragment containing TK promoter was obtained, which was ligated to 5) the Bgl II-Ncol fragment: of plasmid pGL3-Basic vector (produced by Promega, USA) to obtain plasmid pGL3--TK.
A 4.9 kb NheI-Xhol fragment of plasmid pGL3-TK thus . obtained was ligated to a 200 b NheI-Xhol fragment of plasmid pBSS-PPRE4 to obtain plasmid pGL3-4ERPP-TK. 10 This plasmid pGL3-4ERPP-TK thus obtained was digested with BamHI (produced by TAKARA SHUZO CO., LTD.) and then treated with T4DNA polymerase (produced by TAKARA SHUZO CO. ,
LTD.) to form a blunt terminal, whereby obtaining a DNA fragment. 15 On the other hand, pGFP-Cl (produced by Toyobo Co.,
Ltd.) was digested with Bsu36I (NEB) and then treated with
T4DNA polymerase (produced by TAKARA SHUZO CO., LTD.) to form a blunt terminal whereby obtaining a 1.6 kb of a DNA fragment. 20 The both DNA fragments were ligated to construct a reporter plasmid pGL3-4ERPP-TK neo.
Reference Example 5 (Introduction of human PPAR? -and RXR ¢ -expressing plasmid 25 and reporter plasmid into CHO-K1 cell and establishment of expressed cell)
After a CHO-K1 cell cultured in a 750 ml tissue culture flask (produced by Corning Costar Corporation, USA) } containing HAM F12 medium (produced by NISSUI SEIYAKU) 30 supplemented with 10% Fetal Bovine Serum (produced by Life
Technologies, Inc., USA) was scraped by treating with 0.5 g/L trypsin-0.2 g/L EDTA (ethylenediaminetetraacetic acid) (produced by Life Technologies, Inc., USA), the cell i was washed with PBS (phosphate-buffered saline) (produced 35 by Life Technologies, Inc., USA), centrifuged (1000 rpm, minutes), and then suspended in PBS. Subsequently, a DNA was introduced into the cell under the condition shown below using GENE PULSER (produced by Bio-Rad Laboratories, USA). . Namely, to a cuvette having a 0.4 cm gap, added were 8X 10° cells and 10pg of plasmid pVgRXR2-hPPAR7Y obtained in Reference Example 3 and 10pg of reporter plasmid
PGL3-4ERPP-TK neo obtained in Reference Example 4, which was subjected to electroporation at the voltage of 0.25 kV under the capacitance of 960 pF. Subsequently, the cell was transferred into a HAM F12 medium containing 10% Fetal
Bovine Serum and cultured for 24 hours and then the cell was scraped again and centrifuged, and then suspended in
HAM F12 medium containing 10% Fetal Bovine Serum supplemented with 500pg/ml of GENETICIN (produced by Life
Technologies, Inc., USA) and 250png /ml of ZEOCIN (produced by Invitrogen, USA) and diluted to the density of 10‘ cells/ml upon inoculation to a 96-well plate (produced by
Corning Costar Corporation, USA), which was cultured in a
CO,gas incubator at 37°C, whereby obtaining a GENETICIN- "and ZEOCIN-resistant transformant.
Subsequently, after the transformant cell line thus obtained was cultured in a 24-well plate (produced by
Corning Costar Corporation, USA), selected was a cell line in which the luciferase was expressed and induced, i.e.,
PPAR7 :RXR @ : 4ERPP/CHO-K1 cell by addition of 10pM pioglitazone hydrochloride.
Reference Example 6
Lithium aluminium hydride (2.53 g) was added to a solution of methyl 1-(4-benzyloxybenzyl)-4- phenylpyrrole-3-carboxylate (21.52 g) in tetrahydrofuran (100 ml) at 0°C, and the mixture was stirred at room temperature for one hour. Sodium sulfate decahydrate (30.00 g) and hexane (100 ml) were added to the reaction mixture and the mixture was stirred at room temperature for one hour. After the precipitate was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and [1-(4- benzyloxybenzyl)-4-phenyl-3-pyrrolyl]lmethanol (19.68 g, . yield: 98%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). Thiswas recrystallized fromethyl acetate-hexane.
Melting point: 122 - 123°C.
Reference Example 7
A mixture of [l-(4-benzyloxybenzyl)-4-phenyl-3- pyrrolyllmethanol (19.00 g), activated manganese dioxide(41.19 g)., and tetrahydrofuran (300 ml) was stirred at room temperature overnight. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and 1-(4-benzyloxybenzyl)-4- phenylpyrrole-3-carbaldehyde (18.56 g, yield: 98%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was . recrystallized from ethyl acctate--hexane. Melting point: 100 - 101°C.
Reference Example 8
A mixture of ethyl (E)-3-[1-(4-benzyloxybenzyl)-4- phenyl-3-pyrrolyl]propenoate (19.50 g), 5% palladium- : carbon (20.00 g), and tetrahydrofuran (200 ml) was stirred overnight at room temperature under a hydrogen atmosphere.
After the palladium-carbon was removed by filtration, the : filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-(4- hydroxybenzyl)-4-phenyl-3-pyrrolyl]propionate (14.92 g, yield: 96%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). .
NMR(CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 2.44-2.58(2H, m), 2.88-3.02(2H, m), 4.08(2H, q, J=7.0 Hz), 4.93(2H, s), 6.46-6.54(1H, m), 6.66-6.84(3H, m), 7.02-7.12(2H, m),
7.14-7.44(5H, m). . Reference Example 9
Lithium aluminium hydride (232 mg) was added to a } 5 mixture of methyl 1. [4 - (5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-4--phenylpyrrole- 3. carboxylate (2.92 g), diethyl ether (50 ml), and tetrahydrofuran (25 ml) at 0°C, and the mixture was stirred at 0°C for 3 hours.
After water was added to the reaction mixture, the precipitate was removed by filtration. The filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and [1- [4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4- phenyl-3-pyrrolyl]methanol (2.37 g, yield: 86%) was obtained as a colorless amorphous substance from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio).
NMR (CDC1,) 6 :2.43(3H, s), 4.64(2H, s), 4.99(4H, s like), 6.73-6.77(1H, m), 6.80-6.83(1H, m), 7.04(2H, 4, J=8.6 Hz), oC 7.12-7.56(10H, m), 7.98-8.04(2H, m).
Reference Example 10
A mixture of [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-4-phenyl-3-pyrrolyljmethanol (3.98 g), activated manganese dioxide (8.00 g), and toluene (50 ml) was stirred at 80°C for 10 hours. After the . manganese dioxide was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and 1-[{4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl)-4-phenylpyrrole-3-carbaldehyde (2.85 g, yield: 72%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio). This was recrystallized fromethyl acetate-hexane.
Melting point: 117 - 118°C.
Reference Example 11 . Lithium aluminium hydride (305 mg) was added to a solution of methyl 1-[4-[2-[N-methyl-N-(2- . 5 pyridyl)aminolethoxylbenzyl]-4-phenyl-3- pyrrolecarboxylate (1.78 g) in tetrahydrofuran (40 ml) at 0°C, and the mixture was stirred at room temperature for 6 hours. After water was added to the reaction mixture, the precipitate was removed by filtration and the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and [1-[4-[2-[N-methyl-N-(2- pyridyl)amino]ethoxy]lbenzyl]-4-phenyl-3- pyrrolyl]lmethanol (1.45 g, yield: 87%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 : 1.35-1.5(1H, m), 3.15(3H, s), 3.99(2H, t,
J=5.5 Hz), 4.18(2H, t. J=5.5 Hz), 4.63(2H, 4. J=4.5 Hz), 4.96(2H, s), 6.45-6.6(2H, m), 6.73(1H, d, J=2.5 Hz), 6.79(1H, 4, J=2.5 Hz), 6.87(2H, 4, J=9.0 Hz), 7.12(2H, 4,
J=9.0 Hz), 7.15-7.6(6H, m), 8.1-8.2(1H, m).
Reference Example 12 : A mixture of [1-[4-[2-[N-methyl-N-(2- pyridyl)aminolethoxy)benzyl)-4-phenyl-3- pyrrolyl]lmethanol (1.45 g), activated manganese dioxide (4.0 g), and tetrahydrofuran (60 ml) was stirred at room temperature for 3 hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated to obtain 1-[4-[2-[N-methyl-N-(2- pyridyl)aminolethoxylbenzyl]-4-phenylpyrrole-3- ’ carbaldehyde (1.40 g, yield: 97%) as an oily substance.
NMR(CDC1,) 0 : 3.15(3H, s), 3.99(2H, t, J=5.5 Hz), 4.19(2H, t, J=5.5 Hz), 5.02(2H, s)., 6.45-6.6(2H, m), 6.73(1H, d,
J=2.0 Hz), 6.90(2H, 4, J=8.5 Hz), 7.15(2H, 4, J=8.5 Hz), 7.2-7.5(TH, m), 8.1-8.2(1H, m), 9.84(1H, s).
Reference Example 13
Lithium aluminium hydride (0.258 g) was added to a . solution of methyl 1-(6-benzyloxy-2-naphthylmethyl)-4- phenylpyrrole-3-carboxylate (3.04 g) in tetrahydrofuran (30 ml) at 0°C, and the mixture was stirred at room temperature for one hour. Sodium sulfate decahydrate (2.19 g) and hexane (30 ml) were added to the reaction mixture and the mixture was stirred at room temperature for 30 minutes. After the precipitate was removed by filtration, the filtrate was concentrated. The colorless crystals obtained were collected by filtration to yield [1-(6-benzyloxy-2-naphthylmethyl)-4-phenyl-3- pyrrolyl]lmethanol (2.54 g, yield: 89%). This was - recrystallized from ethyl acetate-hexane. Melting point: 116 - 117°C.
Reference Example 14 :
A mixture of [1l-(6-benzyloxy-2-naphthylmethyl)-4- phenyl-3-pyrrolyl]methanol (2.39 g)., activated manganese dioxide (4.80 g), and tetrahydrofuran (50 ml) was stirred at room temperature for one hour. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The colorless crystals obtained were collected by filtration to yield 1-(6-benzyloxy-2- naphthylmethyl) -4-phenylpyrrole-3-carbaldehyde (2.24 g, yield: 94%). This was recrystallized from : tetrahydrofuran-hexane. Melting point: 140 - 141°C.
Reference Example 15
A mixture of ethyl (E)-3-[1-(6-benzyloxy-2- naphthylmethyl) -4-phenyl-3-pyrrolyl]propenoate (1.46 g), 5¢ palladium-carbon (1.5 g), ethanol (15 ml), and tetrahydrofuran (15 ml) was stirred for 4 hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-{1-(6-hydroxy--2- naphthylmethyl)-4-phenyl-3-pyrrolyl]lpropionate (1.08 g, . yield: 90%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 :1.17(3H, t, J=7.2 Hz), 2.53(2H, t, J=7.6 Hz), 2.97(2H, t, J=7.6 Hz), 4.07(2H, q, J=7.2 Hz), 5.10(2H, s), 5.57(1H, br.s), 6.55(1H, d, J=2.4 Hz), 6.76(1H, d, J=2.4
Hz), 7.07-7.45(8H, m), 7.54(1H, s), 7.60-7.71(2H, m). :
Reference Example 16
Lithium aluminium hydride (0.25 g) was added to a solution of ethyl 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl}-4-(2-pyridyl)pyrrole-3- carboxylate (2.40 g) in tetrahydrofuran (30 ml) at 0° C, and the mixture was stirred at 0° C for 30 minutes. After sodium sulfate decahydrate (2.13 g) and hexane (30 ml) were added to the reaction mixture, the mixture was stirred at room temperature for 30 minutes. After the precipitate was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and [1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]- 4-(2-pyridyl)-3-pyrrolyllmethanol (2.09 g, yield: 95%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 6:2.44(3H, s), 4.55(2H, s), 4.99(4H, s), 6.68 (1H, d, J=2.2 Hz), 6.94-7.22(6H, m), 7.36-7.69(5H, m), 7.96- 8.08(2H, m), 8.46-8.53(1H, m). ~~ 30 Reference Example 17
A mixture of [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-4-(2-pyridyl)-3- pyrrolyl]methanol (2.01 g), activated manganese dioxide (5.09 g), and tetrahydrofuran (50 ml) was stirred at room temperature overnight. After the manganese dioxide was : removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography. . and 1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]- : 4-(2-pyridyl)pyrrole-3-carbaldehyde (1.71 g, yield: 85%) was obtained as an oily substance from the fraction eluted . 5 with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 : 2.44(3H, s), 5.00(2H, s), 5.06(2H, s), 6.96-7.28(6H, m), 7.38-7.49(4H, m), 7.62-7.74(1H, m), 7.79.-7.86(1H, m), 7.96-8.08(2H, m), 8.54-8.60(1H, m), 10.16(1H, s). :
Reference Example 18 ~ Methanesulfonyl chloride (5.03 ml) was slowly added to a mixture of 3,5-dibenzyloxybenzyl alcohol (16.0 g), triethylamine (9.06 ml), and tetrahydrofuran (200 ml), and the mixture was stirred at room temperature for 30 minutes.
The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was . washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The colorless crystals obtained were collected by filtration to yield 3,5-dibenzyloxybenzyl methanesulfonate (22.20 g, yield: 91%). This was recrystallized from ethyl acetate-hexane. : Melting point: 85 - 86°C.
Reference Example 19 : Lithium aluminium hydride (1.97 g) was added to a’ solution of methyl 1-(3,5-dibenzyloxybenzyl)-4-phenyl- 3-pyrrolecarboxylate (26.29) in tetrahydrofuran .(250 ml) at 0°C, and the mixture was stirred at room temperature for one hour. Sodium sulfate decahydrate (16.1 g) and hexane (250 ml) were added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. After the precipitate was removed by filtration, the filtrate was concentrated. The colorless crystals obtained were collected by filtration to yield [1-(3,5- dibenzyloxybenzyl)-4-phenyl-3-pyrrolyl]lmethanol (24.204,
.yield: 98%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 115 .. 116°C.
Reference Example 20 . 5 A mixture of [1-(3,%-dibenzyloxybenzyl)-4-phenyl- 3-pyrrolyl]lmethanol (23.8 g), activated manganese dioxide (50.00 g), and tetrahydrofuran (200 ml) was stirred at room . temperature for two hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The colorless crystals obtained were collected by filtration to yield 1-(3,5-dibenzyloxybenzyl)-4-phenylpyrrole -3- carbaldehyde (23.10 g, yield: 97%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 117 - 118°C.
Reference Example 21
A mixture of ethyl (E)-3-{1-(3,5- dibenzyloxybenzyl)-4-phenyl--3-pyrrolyl]propenocate (19.0 g). 5% palladium-carbon (40.0 g), ethanol (200 ml), and tetrahydrofuran (200 ml) was stirred for 4 hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-(3.,5- dihydroxybenzyl)-4-phenyl-3-pyrrolyl]propionate (12.104g, yield: 95%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (3:2, volume ratio). :
NMR(CDC1,) 0 :1.13(3H, t, J=7.2 Hz), 2.49(2H, t, J=7.4 Hz), 2.93(2H, t, J=7.4 Hz), 4.01(2H, gq, J=7.2 Hz), 4.77(2H, s), 6.09(2H, 4, J=2.2 Hz), 6.24(1H, t, J=2.2 Hz), 6.33(2H, s), 6.42(1H, 4, J=2.4 Hz), 6.65(1H, d, J=2.4 Hz), 7.14-7.37(5H, m).
Reference Example 22
Lithium aluminium hydride (884 mg) was added to a solution of ethyl 1-(4-benzyloxybenzyl)-3-phenyl-1H- . pyrazole-4-carboxylate (9.61 g) in tetrahydrofuran (50 ml) at 0°C, and the mixture was stirred at 0°C for one hour. } 5 After adding water, the reactlon mixture was stirred at room temperature for one hour. After the precipitate was removed by filtration, the filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The crystals obtained were collected by filtration to yield [1-(4- benzyloxybenzyl)-3-phenyl-1H-pyrazol-4-yl]methanol (23.10 g, yield: 97%). This was recrystallized from ethyl acetate-hexane. Melting point: 88 - 89°C.
Reference Example 23
Thionyl chloride (1.83 ml) was added dropwise to a solution of [l1-(4-benzyloxybenzyl)-3-phenyl-lH-pyrazol- 4-yllmethanol (8.43 g) in toluene (100 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSo0,), and then concentrated. The residue was dissolved in tetrahydrofuran (30 ml), and this solution was added to a mixture of diethyl malonate (18.3 g), sodium hydride (60%, oily, 3.65 g), and tetrahydrofuran (100 ml) at 0°C. The above mixture was stirred at 0° C for one hour and then at room temperature for 6 hours. The reaction mixture was acidified with diluted hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and then concentrated. The residue was subjected to silica gel column chromatography, and diethyl ‘ 35 2-[1-(4-benzyloxybenzyl)-3-phenyl-1H-pyrazol-4- yvl]lmehtylmalonate (9.50 g, yield: 81%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). . NMR(CDC1,) 6 :1.15(6H, t, J=7.1 Hz), 3.21(2H, d, J=8.0 Hz), 3.52(1H, t, J=8.0 Hz), 4.08(4H, gq, J=7.1 Hz), 5.06(2H, s). 5.21(2H, s), 6.94(2H, 4d, J=8.8 Hz), 7.15 7.47(11H, mn). 7.60--7.66(2H, m).
Reference Example 24
A mixture of methyl 3-[1-(4-benzyloxybenzyl)-3- phenyl-1H-pyrazol-4-yllpropionate (500 mg), 5% palladium-carbon (1.00 g), and tetrahydrofuran (10 ml) was stirred for 18 hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and methyl 3-[1-(4-hydroxybenzyl)-3-phenyl-1lH-pyrazol-4- yllpropionate (325 mg, yield: 80%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 87 ~- 88°C.
Reference Example 25
Methanesulfonyl chloride (3.37 g) was added dropwise to a mixture of 2-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)phenyllethan-1-0l (7.0 g), triethylamine (2.97 g), and ethyl acetate (300 ml) at 0°C, and the mixture was stirred for 3 hours at room temperature. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate, 1N hydrochloric acid and then with saturated aqueous sodium chloride solution, then dried (MgSO,), and concentrated. The crystals obtained were collected by filtration to yield 2-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)phenyl]ethyl methanesulfonate (8.44 g, yield: 96%). This was recrystallized from ethyl acetate-hexane. Melting point: 66 - 67°C.
Reference Example 26
A nixture of 4-[4-(3,5-dimethyl-1H-pyrazol-1- ylmethyl)phenoxymethyl] 5-methyl:-2-phenyloxazole (1.62 g). phosphorus oxychloride (1.00 g), and N,N- dimethylformamide (20 ml) was stirred for 5 days at room temperature. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate and with saturated aqueous sodium chloride solution, then dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography, and 3,5-dimethyl- 1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H- pyrazole-4-carbaldehyde (950 mg, yield: 55%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1l,) 6 : 2.43(3H, s), 2.47(6H, s), 4.97(2H, s), 5.18(2H, s), 6.98(2H, 4, J=9 Hz), 7.10(2H, d, J=9 Hz), 7.4-7.5(3H, m), 7.95-8.05(2H, m), 9.92(1H, s). . Reference Example 27
Lithium aluminium hydride (262 mg) was added to a solution of methyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yl]lpropionate (3.50 g) in diethyl ether (50 ml) at 0°C, and the mixture was stirred at 0°C for one hour. After adding water, the reaction mixture was acidified with diluted hydrochloric acid, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous ) sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and 3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-3-phenyl-lH-pyrazol-4- yllpropan-1-ol (3.04 g, yield: 92%) was obtained as a:
colorless oily substance from the fraction eluted with ethyl acetate-hexane (3:2, volume ratio). . NMR(CDC1,) 0 :1.72-1.87(2H, m), 2.44(3H, s), 2.65-2.74(2H, m), 3.63(2H, t, J=6.4Hz), 4.99(2H, s), 5.25(2H, s), 7.00(2H, : 5 a, J=B.8 Hz), 7.17-7.46(9H, m), 7.62 7.68(2H, m), 7.98- 8.04(2H, m).
Reference Example 28 } oo Methanesulfonyl chloride (0.625 ml) was added to a mixture of 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yllpropan-1-0l (2.98 g), triethylamine (1.74 ml), and ethyl acetate (50 ml) at 0°C, and the mixture was stirred for 30 minutes. The reaction mixture was washed with water and then with saturated aqueous sodium chloride solution, dried (MgSo,), and then concentrated. After the residue was dissolved in acetone (50ml), sodium iodide (1.86 g) was added and the solution was stirred at 50°C for 3 hours.
After the solvent was removed undcr reduced pressure, the residue was dissolved in water, which was extracted with ether acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and then concentrated to obtain 1-iodo-3-[1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3-phenyl-1H- pyrazol-4-yllpropane (3.60 g, yield: 98%) as a colorless oily substance.
NMR (CDC1,) 0 11.96-2.08(2H, m), 2.44(3H, s), 2.69-2.77(2H, m), 3.15(2H, t, J=6.8Hz), 4.99(2H, s), 5.25(2H, s), 7.01(2H, d, J=8.8 Hz), 7.19-7.48(9H, m), 7.60-7.66(2H, m), 7.98- 8.04(2H, m). . Reference Example 29
A mixture of 1-iodo-3-[1-[4-(5-methyl-2-phenyl-4- . oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- ' yl]propane (1.75 g), sodium cyanide (291 mg), and dimethyl sulfoxide (5 ml) was stirred at 60°C for 2 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with . saturated aqueous sodium chloride solution, dried (MgSoO,). and then concentrated. The residue was subjected to silica . 5 gel column chromatography, and 4-[1-[4- (5 methyl 2. phenyl-4-oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yl]butyronitrile (1.34 g, yield: 92%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio).
NMR(CDC1l,) 0 :1.76-1.92(2H, m), 2.28(2H, t, J=7.0 Hz), 2.44(3H, s), 2.78(2H, t, J=7.5 Hz), 4.99(2H, s)., 5.25(2H, s), 7.01(2H, d, J=8.8 Hz), 7.19-7.47(%9H, m), 7.58-7.64(2H, m), 7.98-8.04(2H, m).
Reference Example 30
Sodium hydride (60%, oily, 476 mg) was added to. a solution of diethyl malonate (2.37 g) in tetrahydrofuran (50 ml) at 0°C, and the mixture was stirred for 30 minutes.
A solution of 1-iodo--3--[1-[4--(S-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yllpropane (1.75 g) in tetrahydrofuran (15 ml) was added dropwise to the above mixture, which was stirred at room temperature for 13 hours. The reaction mixture was acidified with diluted hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and diethyl 2-[3-{1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl] -3-phenyl:-1H-pyrazol-4- yl]lpropyllmalonate (1.63 g, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). | :
NMR(CDC1,) 60 : 1.23(6H, t, J=7.1 Hz), 1.50-1.65(2H, m), 1.86-1.98(2H, m), 2.43(3H, s), 2.63(2H, t, J=7.7 Hz), 3.29(1H, t, J=7.6 Hz), 4.15(4H, q, J=7.1 Hz), 4.99(2H, s),
5.24(2H, s), 7.00(2H, 4, J=8.8 Hz), 7.17-7.47(9H, m), 7.59-7.65(2H, m), 7.98-8.04(2H, m).
Reference Example 31 } 5 Lithium aluminium hydride (2.03 q) was added to a solution of ethyl 1-[{4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl}-3-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyloxy] -1H-pyrazole-4-carboxylate (40.00 g) in tetrahydrofuran (150 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes.
After water was added to the reaction mixture, the precipitate was removed by filtration and the filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The crystals obtained were collected by filtration to yield [1-[4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3-[4-(5- " methyl-2-phenyl-4-oxazolylmethoxy)benzyloxy]-1H- pyrazol-4-yl]methanol (35.91 g, yield: 95%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 157 - 158°C.
Reference Example 32
A mixture of [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyloxy]-1H-pyrazol-4-yl]lmethanol (27.02 g), activated manganese dioxide (52.29 g)., chloroform (50 ml), and tetrahydrofuran (300 ml) was stirred at room temperature for 3 hours. After the - manganese dioxide was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-[4-(5-methyl-2-phenyl-4- ] oxazolylmethoxy)benzyloxy]-1H-pyrazole-4-carbaldehyde (25.69 g, yield: 95%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 155 - 156°C.
Reference Example 33 ; Lithium aluminium hydride (0.98 g) was added to a solution of ethyl 1-{4-[2-(2-furyl)-5-methyl-4- . 5 oxazolylmethoxylbenzyl]-3-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyloxy] 1H -pyrazole 4 -carboxylate (19.16 g) in tetrahydrofuran (75 ml) at 0°C, and the mixture : was stirred at room temperature for 30 minutes. After water was added to the reaction mixture, the precipitate was . removed by filtration and the filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The crystals obtained were collected by filtration to yield [1-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxylbenzyl}-3-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxylbenzyloxy]-1H-pyrazol-4- yl]lmethanol (17.25 g, yield: 96%). This was recrystallized from ethyl acetate hexane. Melting point: 80 ~ 81°C. :
Reference Example 34
A mixture of [1-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyl]-3-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyloxy]-1H-pyrazol-4-yl]lmethanol (16.59 g), activated manganese dioxide (35.19 g) and tetrahydrofuran (100 ml) was stirred at room temperature for 3 hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield 1-[4-[2- ‘30 (2-furyl)-5-methyl-4-oxazolylmethoxylbenzyl]-3-[4-[2- (2-furyl)-5-methyl-4-oxazolylmethoxylbenzyloxy]-1H- pyrazole-4-carbaldehyde (14.73 g, yield: 89%). This was recrystallized from ethyl acetate-hexane. Melting point: ) 109 - 110°C.
Reference Example 35
Lithium aluminium hydride (0.58 g) was added to a ; solution of methyl 3-isopropyl-1-[4-(5-methyl-2-phenyl- . 4-oxazolylmethoxy)benzyl]-1H-pyrazole-4-carboxylate (9.02 g) in tetrahydrofuran (50 ml) at 0°C, and the mixture . 5 was stirred at room temperature for 30 minutes. After water was added to the reaction mixture, the precipitate was removed by filtration and the filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The residue was subjected to silica gel column chromatography, and [3-isopropyl-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl)]-1H-pyrazol-4- yl]lmethanol (8.20 g, yield: 97%) was obtained from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane.
Melting point: 98 - 99°C.
Reference Example 36
A mixture of ethyl 3-oxohexanoate (15.80 g) and
N,N-dimethylformamide dimethylacetal (17.9 g) was refluxed for 2.5 hours and the reaction mixture was concentrated under reduced pressure. After the residue was dissolved in ethanol (200 ml) and degassed, benzylhydrazine dihydrochloride (22.0 g) was added and the solution was refluxed for 2 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure.
The residue was dissolved in ethyl acetate and washed with water and then with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 1l-benzyl-5-propyl-1H-pyrazole-4-carboxylate (22.81 g, yield: 84%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- hexane (1:9, volume ratio).
NMR(CDC1l,) 0 :0.92(3H, t, J=7.2Hz), 1.34(3H, t, J=7.2 Hz), 1.39-1.59(2H, m), 2.84-2.92(2H, m), 4.28(2H, q, J=7.2 Hz),
5.32(2H, s), 7.08-7.13(2H, m), 7.26-7.34(3H, m), 7.92(1H, s).
Reference Example 37 ‘ 5 Lithium aluminium hydride (2.58 g) was added to a solution of ethyl 1l-benzyl-5-propyl-lH-pyrazole-4- carboxylate (18.50 g) in tetrahydrofuran (300 ml) at 0°C, and the mixture was stirred at room temperature for one hour.
Sodium sulfate decahydrate (21.88 g) and hexane (100 ml) were added to the reaction mixture and the mixture was stirred at room temperature for 30 minutes. After the precipitate was removed by filtration, the filtrate was concentrated to obtain (l-benzyl-5-propyl-lH-pyrazol-4- yl)methanol (14.99 g, yield: 96%) as a colorless oily substance. | : : _NMR(CDC1,) 6 : 0.90(3H, t, J=7.6 Hz), 1.38-1.57(2H, m), 2.59(2H, t, J=7.6 Hz), 4.52(2H, s). 5.29(2H, s), 7.06- 7.11(2H, m), 7.21-7.36(3H, m), 7.51(1H, s).
Reference Example 38
A mixture of (l-benzyl-5-propyl-1H-pyrazol-4- yl)methanol (14.99 g), activated manganese dioxide(30.0 g) and, tetrahydrofuran (300 ml) was stirred at room : " temperature for 3 days. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and l-benzyl-5-propyl-lH-pyrazole-4-carbaldehyde (10.69 g, yield: 72%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 : 0.93(3H, t, J=7.0 Hz), 1.43-1.58(2H, m), 2.89(2H, t, J=8.0 Hz), 5.33(2H, s), 7.11-7.16(2H, m), 7.26-7.37(3H, m), 7.96(1H, s), 9.88(1lH, s).
Reference Example 39 y
Sodium hydride (60%, oily, 2.25 g) was added to a mixture of 1-benzyl-5-propyl-lH-pyrazole-4-carbaldehyde . (12.60 g)., ethyl diethylphosphonoacetate (10.69 g), and
N,N-dimethylformamide (150 ml) at 0°C, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was poured into ice water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water and then with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl (E)-3-(1-benzyl-5-propyl-lH-pyrazol-4- yl)propenoate (11.90 g, yield: 85%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR (CDC1,) 0 :0.90(3H, t, J=7.2 Hz), 1.32(3H, t, J=7.2 Hz), 1.36-1.60(2H, m), 2.65(2H, t, J=7.6 HZ)), 4.24(2H, q, J=7.2
Hz), 5.30(2H, s), 6.17(1H, 4, J=15.6 Hz), 7.07-7.12(2H, m), 7.26-7.37(3H, m), 7.50(1H, 4, J=15.6 Hz), 7.77(1H, s).
Reference Example 40
A mixture of ethyl (E)-3-(1-benzyl-5-propyl-1H- pyrazol-4-yl)propenoate (6.00 g), 5% palladium-carbon : (12.0 g). formic acid (50 ml), and ethanol (100 ml) was refluxed for 16 hours. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium bicarbonate and then with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-(3-propyl-1H- pyrazol-4-yl)propionate (3.45 g, yield: 82%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). :
NMR(CDC1,) 8 : 0.97(3H, t, J=7.2 Hz), 1.25(3H, t, J=7.2 Hz), 1.56-1.76(2H, m), 2.50-2.79(6H, m), 4.13(2H, q, J=7.2 Hz), 7.34(1H, s).
Reference Example 41 . A mixture of ethyl benzoylacetate (20.0 g) and
N,N-dimethylformamide dimethylacetal (18.59 g) was . : 5 refluxed for 1.5 hours and the reaction mixture was concentrated under reduced pressure. After the residue was dissolved in ethanol (200 ml) and degassed, benzylhydrazine dihydrochloride (22.25 g) was added and the solution was refluxed for 2 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water and then with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 1l-benzyl-5-phenyl-1H- pyrazole-4-carboxylate (20.9 g, yield: 66%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:6, volume ratio). This was. recrystallized from ethyl acetate-hexane. Melting point: 78 - 79°C.
Reference Example 42
Lithium aluminium hydride (2.50 g) was added to a solution of ethyl 1l-benzyl-5-phenyl-1lH-pyrazole-4- carboxylate (20.2 g) in tetrahydrofuran (300 ml) at 0°C, and the mixture was stirred at room temperature for one hour.
Sodium sulfate decahydrate (21.23 g) and hexane (100 ml) were added to the reaction mixture, and the mixture was stirred at room temperature for one hour. After the precipitate was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and (1l-benzyl-5-phenyl-1H- pyrazol-4-yl)methanol (17.4 g, yield: 100%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 6 :4.46(2H, s), 5.25(2H, s), 6.99-7.04(2H, m),
7.23-7.32(5H, m), 7.41-7.45(3H, m), 7.69(1H, s). . Reference Example 43
A mixture of (l-benzyl-5-phenyl-1H-pyrazol-4- 3 Co) yvl)methanol (9.76 gy), activated manganese dioxide (20.04), and tetrahydrofuran (200 ml) was stirred at room temperature for 12 hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography. and 1-benzyl-5-phenyl- 1H-pyrazole-4-carbaldehyde (7.309, yield: 75%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized fromethyl acetate-hexane.
Melting point: 99 - 100°C.
Reference Example 44 :
Sodium hydride (60%, oily, 1.28 g) was added to a mixture of l-benzyl-5-phenyl-lH-pyrazole-4-carbaldehyde (7.00 g), ethyl diethylphosphonoacetate (6.59 g). and
N,N-dimethylformamide (100 ml) at 0°C, and the mixture was : stirred at room temperature for 2.5 days. The reaction mixture was poured into ice water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water and then with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl (E)-3-(l-benzyl-S5-phenyl-1H-pyrazol-4- yl)propenoate (6.30 g, yield: 71%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 62 - 63°C. i Reference Example 45
A mixture of ethyl (E)-3-(l-benzyl-5-phenyl-1H- pyrazol-4-yl)propenoate (300mg), 5% palladium-carbon (600
~~ mg), formic acid (3 ml), and ethanol (10 ml) was refluxed for 2 hours. After the palladium-carbon was removed by : filtration, the filtrate was concentrated. The residue was dissolved in ethyl acetate, washed with saturated : 5H ameons sodium bicarbonate and then with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-(3-phenyl-1lH-pyrazol-4- vl)propionate (120 mg, yield: 55%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio).
NMR(CDC1,) 0 :1.23(3H, t, J=7.2 Hz), 2.58(2H, t, J=7.6 Hz), 2.98(2H, t, J=7.6 Hz), 4.12(2H, q, J=7.2 Hz), 7.38-7.58(6H, m).
Reference Example 46
Lithium aluminium hydride (1.93 g) was added to a solution of ethyl 3-methyl-l-(2-pyridyl)-1lH-pyrazole-4- carboxylate (15.00 g) in tetrahydrofuran (150 ml) at 0°C, and the mixture was stirred at room temperature for one hour.
Sodium sulfate decahydrate (21.03 g) and hexane (100 ml) were added to the reaction mixture, and the mixture was stirred at room temperature fox one hour. After the precipitate was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield [3-methyl-1-(2-pyridyl)-1H-pyrazol- 4-yllmethanol (11.38 g). This was recrystallized from acetone-hexane. Melting point: 116 - 117°C.
Reference Example 47 "Sodium hydride (60%, oily, 0.80 g) was added to a solution of [3-methyl-1-(2-pyridyl)-1lH-pyrazol-4- yl])methanol (3.20 g) in N,N-dimethylformamide (50 ml) at } 0°C, and the mixture was stirred at room temperature for one hour. 4-fluorobenzaldehyde (2 ml) was added to the reaction mixture, and the mixture was stirred overnight at
50°C. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer . was washed with saturated aqueous sodium chloride solution, © dried (MgsS0O,), and then concentrated. The residue was . 5 subjected to silica gel column chromatography, and 4. [3-methyl-1-(2-pyridyl)-1H-pyrazol-4- vlmethoxy)benzaldehyde (4.26 g, yleld: 86%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 84 - 85°C.
Reference Example 48
Sodium borohydride (0.25 g) ‘was added to a mixture of 4-[3-methyl-1-(2-pyridyl)-1H-pyrazol-4- ylmethoxylbenzaldehyde (3.50 g), methanol (5 ml), and tetrahydrofuran (25 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. After the reaction mixture was concentrated under reduced pressure, diluted hydrochloric acid was added to the residue, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and 4- [3-methyl-1-(2-pyridyl)- 1H-pyrazol- 4-ylmethoxy)benzyl alcohol (3.41 g, yield: 97%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 83 - 84°C.
Reference Example 49 )
Sodium hydride (60%, oily, ‘180 mg) was added to a mixture of ethyl 3-(3-phenyl-l1H-pyrazol-4-yl)propionate } (1.00 g), benzyl 4-chloromethylbenzoate (1.17 g), and
N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred for 2.5 days at room temperature. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with . saturated aqueous sodium chloride solution, dried (MgsSoO,). and then concentrated. The residue was subjected to silica . 5 gel column chromatography, and benzyl 4-[4-(3-ethoxy-3- oxo-1-propyl)-3-phenyl-1H--pyrazole-1l-ylmethyl]benzoate (1.68 g, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- hexane (1:4, volume ratio).
NMR(CDC1,) 0 :1.18(3H, t, J=7.0 Hz), 2.53(2H, t, J=7.6 Hz), 2.96(2H, t, J=7.6 Hz), 4.07(2H, q, J=7.0 Hz), 5.35(4H, s), 7.25-7.46(11H, m), 7.60-7.66(2H, m), 8.02-8.07(2H, m).
Reference Example 50 + 15 A mixture of benzyl 4-[4-(3-ethoxy-3-oxo-1- propyl) -3-phenyl-1H-pyrazol-1l-ylmethyl]benzoate (1.67 g), 5% palladium-carbon (2.00 g), and ethanol (50 ml) was stirred for 5 hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by - 20 filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield 4-[4-(3- ethoxy-3-oxo-1-propyl)-3-phenyl-1H-pyrazol-1- ylmethyl)benzoate (1.08 g, yield: 79%). This was recrystallized from ethyl acetate-hexane. Melting point: 97 - 98°C. :
Reference Example 51
Sodium hydride (60%, oily. 850 mg) was added to a mixture of ethyl 3-(3-phenyl-1H-pyrazol-4-yl)propionate (4.69 g), benzyl 3-chloromethylbenzoate (5.50 g), and
N,N-dimethylformamide (50 ml) at 0°C, and the mixture was stirred for 2.5 days at room temperature. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO), and then concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl . acetate-hexane (1:4, volume ratio). A mixture of the oily ~ substance obtained, 5% palladium-carbon (12.0 g), and . 5 ethanol (200 ml) was stirred for $ hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated.
The crystals obtained were collected by filtration to yield 3-[4-(3-ethoxy-3-oxo-1l-propyl)-3-phenyl-1H- pyrazol-l-ylmethyllbenzoate (2.41 g, yield: 33%). This was recrystallized from ethyl acetate-hexane. Melting point: 101 - 102°C.
Reference Example 52
Thionyl chloride (4.35 g) was added to a solution of (1-benzyl-5-phenyl-1H-pyrazol-4-yl)methanol (8.06 g) in toluene (100 ml) dropwise at 0°C, and the mixture was stirred at room temperature for one hour and then refluxed for ten minutes. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium bicarbonate and then with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and 1- benzyl-4-chloromethyl-5-phenyl-1H-pyrazole (8.31 g, yield: 96%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 0 : 4.44(2H, s), 5.23(2H, s), 6.99-7.04(2H, m), 7.22-7.36(5H, m), 7.42-7.47(3H, m), 7.72(1H, s). ] Reference Example 53
A mixture of 1l-benzyl-4-chloromethyl-5-phenyl-1H- pyrazole (8.31 g), potassium cyanide (2.87 g), and N,N- dimethylformamide (100 ml) was stirred for 15 hours at 90°C, and poured into water, which was extracted with ethyl lla acetate. The ethyl acetate layer was washed with water and ‘then with saturated aqueous sodium chloride solution, dried . (MgSoO,), and then concentrated. The residue was subjected to silica gel column chromatography, and (l-benzyl-5- } 5 phenyl-1H-pyrazol-4-yl)acetonitrile (3.50 g, yield: 44%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 :3.45(2H, s), 5.21(2H, s), 6.97-7.02(2H, m), 7.19-7.30(5H, m), 7.43-7.50(3H, m), 7.67(1H, s).
Reference Example 54
A mixture of (1-benzyl-5-phenyl-1H-pyrazol-4- . yl)acetonitrile (3.50 g), a 4N aqueous potassium hydroxide solution (16 ml), and ethanol (50 ml) was refluxed for 4 hours. The reaction mixture was acidified with 1N hydrochloric acid, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated to obtain (1-benzyl-5-phenyl-1H-pyrazol-4-yl)acetic acid (3.70 g, yield: 99%) as a colorless oily substance.
NMR(CDC1,) 0: 3.42(2H, s), 5.22(2H, s), 6.97-7.02(2H, m), 7.22-7.26(5H, m), 7.40-7.44(3H, m), 7.65(1H, s).
Reference Example 55
A mixture of (1-benzyl-5-phenyl-1H-pyrazol-4- yl)acetic acid (3.70 g), concentrated sulfuric acid (0.5 ml), and ethanol (200 ml) was refluxed for 5 hours. The reaction mixture was alkalinized with saturated aqueous sodium bicarbonate, which was extractedwith ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,)., and concentrated.
The residue was subjected to silica gel column chromatography, and ethyl (1l-benzyl-5-phenyl-1lH- pyrazol-4-yl)acetate (3.62 g, yield: 89%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:6, volume ratio).
NMR(CDC1,) 6 : 1.22(3H, t, J=7.2 Hz), 3.38(2H, s), 4.11(2H, q, J=7.2 Hz), 5.21(2H, s), 6.98-7.03(2H, m), 7.21-7.28(5H, m), 7.37-7.44(3H, m), 7.63(1H, s).
Reference kKxample 56
A mixture of ethyl (l-benzyl-S-phenyl-lH-pyrazol- 4-yl)acetate (3.60g), 5% palladium-~carbon (7.00g), formic acid (40 ml), and ethanol (150 ml) was refluxed for 2 hours.
After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium bicarbonate and then with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain ethyl (3-phenyl-1H-pyrazol-4-yl)acetate (2.33 g, yield: 90%) as a colorless oily substance.
NMR (CDC1,) 60: 1.23(3H, t, J=7.2 Hz), 3.61(2H, s), 4.15(2H, q, J=7.2 Hz), 7.36-7.64(6H, m).
Reference Example 57
A mixture of ethyl (1-[2-(4- benzyloxyphenyl)ethyl]-3-phenyl-1H-pyrazol-4-yl)acetate (800mg), 5% palladium-carbon (1.50 g), tetrahydrofuran (20 ml), and ethanol (30 ml) was stirred for 3 hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl [1-[2-(4- hydroxyphenyl)ethyl]-3-phenyl-1H-pyrazol-4-yl]acetate (400 mg, yield: 63%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 0 : 1.23(3H, t, J=7.0 Hz), 3.11(2H, t, J=7.2 Hz), 3.57(2H, s), 4.13(2H, q, J=7.0 Hz), 4.29(2H, t, J=7.2 Hz), 5.36(1H, br.s), 6.69-6.74(2H, m), 6.93-6.98(2H, m), 7.26-7.45(4H, m), 7.58-7.62(2H, m).
Reference Example 58
Lithium aluminium hydride (323 mg) was added to a : mixture of ethyl 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazole-4-carboxylate (3.55 ¢g), diethyl ether (24% ml), and tetrahydrofuran (25 ml) at 0° C, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into a 1N aqueous sodium hydroxide solution, which was extracted with diethyl ether. The diethyl ether layer was washed with water and then with saturated aqueous sodium chloride solution, dried (MgSo0,)., and then concentrated. The crystals obtained were filtrated to obtain [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]lmethanol (2.93 g, yield: 92%). This was recrystallized from ethyl acetate-hexane. Melting point: 100 - 101°C.
Reference Example 59.
A mixture of [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl] 1H pyrazol-4-yl]methanol (2.82 g), activated manganese dioxide (6.00 g), and tetrahydrofuran (50 ml) was stirred at room temperature for 2 hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and 1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H- pyrazole-4-carbaldehyde (2.63 g, yield: 94%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1l,) 6 : 2.44(3H, s), 5.00(2H, s), 5.27(2H, s), 7.03(2H, 4, J=8.8 Hz), 7.24(2H, 4, J=8.8 Hz), 7.40-7.48(3H, m), 7.84(1H, s), 7.97-8.04(3H, m), 9.82(1H, s).
Reference Example 60 i Sodium hydride (60%, oily, 880 mg) was added to a mixture of 3,5-dimethylpyrazole (2.11 g) and tetrahydrofuran (50 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. After 4-(4- chloromethylphenoxymethyl) -5-methyl 2--phenyloxazole (6.28 g) was added to the reaction mixture, the mixture was refluxed for 24 hours. The reaction mixture was poured into . 5 water, which was cxtracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated.
The residue was subjected to silica gel column chromatography, and 3,5-dimethyl-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazole (5.49 g, yield: 74%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane.
Melting point: 86 - 87°C.
Reference Example 61
A mixture of ethyl 3-hydroxy-1lH-pyrazole-4- carboxylate (11.53 g), benzyl bromide (18 ml), potassium carbonate (21.12 g), and N,N-dimethylformamide (300 ml) was stirred for 5 hours at 80°C. The reaction mixture was poured into water, which was extracted with ethyl acetate. " The ethyl acetate layer was washed with diluted hydrochloric acid and then with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl l1-benzyl-3-benzyloxy-1H- pyrazole-4-carboxylate (13.52 g, yield: 95%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 71 - 72°C.
Reference Example 62
Lithium aluminium hydride (6.64 g) was added to a solution of ethyl l1l-benzyl-3-benzyloxy-lH-pyrazole-4- carboxylate (58.90 g) in tetrahydrofuran (500 ml) at 0°C,
: and the mixture was stirred at room temperature for 30 minutes. After the reaction mixture was poured into water and the precipitate was removed by filtration, the filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueons sodimm chloride solntion, dried (MgSoO,), ‘and then concentrated. The residue was subjected to silica gel column chromatography, and (1- benzyl-3-benzyloxy-1H-pyrazol-4.-yl)methanol (45.30 gq, yield: 88%) was obtained as colorless crystals from the fraction eluted with ethyl acetate. This was recrystallized from ethyl acetate-hexane. Melting point: 79 - 80°C.
Reference Example 63 : :
A mixture of (l-benzyl-3-benzyloxy-1H-pyrazol-4- yl)methanol (14.70 g), activated manganese dioxide (30.00 g), and tetrahydrofuran (200 ml) was stirred at room temperature for 2 hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield l-benzyl-3-benzyloxy-1H-pyrazole-4-carbaldehyde (13.10 gq, yield: 90%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 85 - 86°C.
Reference Example 64
Sodium hydride (60%, oily, 1.94 g) was added to a mixture of l-benzyl-3-benzyloxy-1H-pyrazole-4- carbaldehyde (12.90 g), ethyl diethylphosphonoacetate (9.60 ml), and N,N-dimethylformamide (200 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours.
The reaction mixture was poured into water, which was : extracted with ethyl acetate. The ethyl acetate layer was washed with diluted hydrochloric acid and then with ) saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The crystals obtained were collected by filtration to yield ethyl (E)-3-(l1-benzyl-
3-benzyloxy-1H-pyrazol-4-yl)propenoate (14.50 g, yield: 91%). This was recrystallized from ethyl acetate-hexane. : Melting point: 88 - 89°C.
Reference Example 65
A mixture of ethyl (E)-3-(l-benzyl-3-benzyloxy-1H- pyrazol-4-yl)propenoate (14.30 g), 5% palladium-carbon (28.00 gq), ethanol (150 ml), and tetrahydrofuran (150 ml) was stirred at room temperature for 3 hours under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield ethyl 3- (1-benzyl-3-hydroxy-1H-pyrazol-4-yl)propionate (9.01 g, yield: 83%). This was recrystallized from ethyl acetate-hexane. Melting point: 75 - 76°C.
Reference Example 66
Sodium hydride (60%, oily, 1.28 g) was added to a solution of ethyl 3-(l-benzyl-3-hydroxy-lH-pyrazol-4- vl)propionate (8.78 g) in N,N-dimethylformamide (100 ml) at 0°C, and the mixture was stirred for 30 minutes.
Iodoethane (2.82 ml) was added to the reaction mixture, and the mixture was stirred at room temperature for one hour.
The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with 1N hydrochloric acid and then with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel : column chromatography, and ethyl 3-(1-benzyl-3-ethoxy- 1H--pyrazol-4-yl)propionate (8.80 g. yield: 91%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:5, volume ratio).
NMR(CDC1,) 6 : 1.21 (3H, t, J=7.2Hz), 1.37 (3H, t, J=7.0Hz), ] 2.48-2.55 (2H, m), 2.62-2.70 (2H, m), 4.09 (2H, q, J=7.2
Hz), 4.22 (2H, q, J=7.0 Hz), 5.07 (2H, s), 6.96 (1H, s), 7.13-7.18 (2H, m), 7.26-7.37 (3H, m).
Reference Example 67 : A mixture of ethyl 3-(l-benzyl-3-ethoxy-1H- pyrazol-4-yl)propionate (21.20 g), 5% palladium-carbon : 5 (40.00 gq), ethanol (200 ml), and formic acid (100ml) was refluxed for one hour. After the palladium--carbon was removed by filtration, the filtrate was concentrated. The residue was dissolved in ethyl acetate, which was washed with saturated aqueous sodium bicarbonate and then with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-(3-ethoxy-1H- pyrazol-4-yl)propionate (10.70 g, yield: 72%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 : 1.24 (3H, t, J=7.2Hz), 1.39 (3H, t, J=7.0Hz), 2.51-2.59 (2H, m), 2.66-2.74 (2H, m), 4.12 (2H, q, J=7.2
Hz), 4.24 (2H, gq, J=7.0 Hz), 7.18 (1H, s), 9.15 (1H, s).
Reference Example 68 :
A mixture of ethyl 3-[1-(4-benzyloxybenzyl)-3- ethoxy-1H-pyrazol-4-yl]propionate (5.32 g), 5% palladium-carbon (3.45 g), and tetrahydrofuran (100ml) was stirred for 3 hours at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-(4-hydroxybenzyl)-1H-pyrazol-4- vl}propionate (3.56 g, yield: 86%) was obtained as a colorless olly substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0 :1.22 (3H, t, J=7.4 Hz), 1.35 (3H, t, J=7.4 Hz), 2.44-2.72 (4H, m), 4.03-4.29 (4H, m), 4.96 (2H, s), ] 6.58-6.68 (2H, m), 6.90-7.03 (3H, m).
Reference Example 69
Lithium aluminium hydride (1.52 g) was added to a solution of ethyl 1-(4-benzyloxybenzyl)-3-(4- ‘ benzyloxybenzyloxy)-1H-pyrazole-4-carboxylate (11.00 ag) in tetrahydrofuran (200 ml) at 0°C, and the mixture was , 5 stirred at room temperature for one hour. After water was added to the reaction mixture, the precipitate was removed oo by filtration and the filtrate was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The crystals obtained were collected by filtration to yield [1-(4-benzyloxybenzyl)-3-(4- benzyloxybenzyloxy)-1H-pyrazol-4-yl]lmethanol (7.11 g, yield: 70%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 128 - 129°C.
Reference Example 70
A mixture of [1l-(4-benzyloxybenzyl)-3-(4- benzyloxybenzyloxy)-1H-pyrazol-4-yllmethanol (6.84 g), activated manganese dioxide (14.00 g), and tetrahydrofuran (70 ml) was stirred at room temperature for one hour. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield 1-(4-benzyloxybenzyl)- 3-(4-benzyloxybenzyloxy)-1H-pyrazole-4-carbaldehyde (6.50 g, yield: 95%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 138 - 139°C.
Reference Example 71
A mixture of ethyl (E)-3-[1-(4-benzyloxybenzyl)-3- (4-benzyloxybenzyloxy) -1H-pyrazol-4-yl)propenoate (6.61 g)., 5% palladium-carbon (13.00 g), ethanol (150 ml), and tetrahydrofuran (150 ml) was stirred for one hour at room temperature under a hydrogen atmosphere. After the . palladium-carbon was removed by filtration, the filtrate was concentrated. The crystals obtained were collected by filtration to yield ethyl 3-[1-(4-hydroxybenzyl)-3-
hydroxy-1H-pyrazol-4-yllpropionate (2.98 g, yield: 89%).
This was recrystallized from ethyl acetate hexane. : Melting point: 143 - 144°C. . 5 Reference Example 72
Sodium hydride (60%, oily, 2.40 g) was added to a solution of 5-methyl-2-phenyl-4-oxazolylmethanol (9.46 g) in N,N-dimethylformamide (50 ml) at 0°C, which was stirred for 15 minutes. A solution of methyl 2- chloro-4-pyridinecarboxylate (8.58 g) in tetrahydrofuran (50 ml) was added to the mixture. After being stirred at room temperature for 1 hour, the reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsSoO,)., and concentrated. The residue was subjected to silica gel column chromatography to obtain methyl 2- (5-methyl.2-phenyl-4-oxazolylmethoxy) -4- pyridinccarboxylate (2190 mg, yield 14%) as colorless crystals from the fraction eluted with ethyl acetate- hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 106-107°C.
Reference Example 73°
Lithium aluminium hydride (228 mg) was added to a solution of methyl 2-(5-methyl-2-phenyl-4- oxazolylmethoxy)-4-pyridinecarboxylate (1.95 g) in tetrahydrofuran (20 ml) at 0°C, which was stirred at room temperature for 30 minutes. Sodium sulfate-‘decahydrate (1.93 g) was added to the reaction mixture, which was stirred at room temperature for 30 minutes. The precipitates were removed by filtration, the filtrate was concentrated. The resulting colorless crystals were i collected by filtration to obtain 2-(5-methyl-2- phenyl-4-oxazolylmethoxy)-4-pyridylmethanol (1.37 g, yield 77%). This was recrystallized from ethyl acetate-hexane. Melting point: 100-101°C - Reference Example 74
A mixture of 2-(5-methyl-2-phenyl-4- oxazolylmethoxy) 4 pyridylmethanol (1.19 g) and thionyl chloride (4 ml) was stirred at room temperature for 1 hour.
After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain 4-chloromethyl-2-(5-methyl- 2-phenyl-4-oxazolylmethoxy)pyridine (680 mg, yield 54%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 104-105°C
Reference Example 75
A mixture of methyl 5-hydroxy-3- pyridinecarboxylate (9.84 g), 4-chloromethyl-5- methyl-2-phenyloxazole (13.40 g), potassium carbonate (8.90 g) and N,N-dimethylformamide (100 ml) was stirred at B0°C overnight. The reaction mixture was poured into _water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain methyl 5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridinecarboxylate (12.42 g, yield 59%) as pale yellow crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was : recrystallized from ethyl acetate-hexane. Melting" point: 119-120°C
Reference Example 76 ce oo + Eithium aluminium hydride (1.02 g) was added to a oo solution of methyl 5-(5-methyl-2-phenyl-4- . - oxazolylmethoxy)-3-pyridinecarboxylate (10.70 g) in tetrahydrofuran (100ml) at 0°C, which was stirred at room temperature for 30 minutes. Sodium sulfate'decahydrate (8.93 g) was added to the reaction mixture, which was stirred at room temperature for 30 minutes. The : : precipitate was removed by filtration, and the filtrate was concentrated. The resulting colorless crystals were collected by filtration to obtain 5-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethanol (8.93g g, .yield 91%). This was recrystallized from ethyl acetate-hexane. Melting point: 111-112°C
Reference Example 77
A mixture of 5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3 -pyridylmethanol (1.33 g) and thionyl chloride (4ml) was stirred at room temperature for 1 hour.
After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added to the mixture, which was extracted with ethyl acetate. The
SE ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain 3-chloromethyl-5-(5-methyl- '2-phenyl-4-oxazolylmethoxy)pyridine (911 mg, yield 64%) as colorless crystals from the fraction eluted with tetrahydrofuran-hexane (1:1, volume ratio). This was recrystallized from tetrahydrofuran-hexane. Melting point: 98-99°C
Reference Example 78
Sodium borohydride (0.378 g) was added to a mixture of 4-methoxy-3-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzaldehyde (3.23 g), tetrahydrofuran _ Amended Sheet — 2004-01-27 t ~
2h ! : i (15 ml) and methanol (15 ml) at room temperature, which : ar was stirred at room temperature for 30 minutes. - The : ) . reaction mixture was poured into water, ‘which was : extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with anhydrous magnesium sulfate and concentrated “to obtain crystals of 4 methoxy 3 (5 methyl 2 phenyl oo 4-oxazolylmethoxy)benzyl alcohol. This was recrystallized from tetrahydrofuran-hexane to obtain pale yellow plates (3.22 g, 99%). Melting point: 144- 145°C
Reference Example 79 :
A mixture of 4-methoxy-3-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl alcohol (3.22g), thionyl chloride (0.73 ml) and toluene (50 ml) was refluxed for 1 hour. After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added to the mixture, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel «column chromatography to obtain 4-(5-chloromethyl-2- : methoxyphenoxymethyl)-5-methyl-2-phenyloxazole (2.594, yield 75%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting : point: 129-130°C
Reference Example 80
Sodium borohydride (378mg) was added slowly to a mixture of 3-ethoxy-4-{(5-methyl-2-phenyl-4- oxazolylmethoxy)benzaldehyde (3.37 g), tetrahydrofuran (50 ml) and methanol (50 ml) at room temperature, which was stirred for 30 minutes. The reaction mixture was poured into water, which was extractedwith ethyl acetate.
The ethyl acetate layer was washed with saturated , Amended Sheet - - 2004-01-27
Y ~ aqueous sodium chloride solution, dried (MgSO,) and concentrated to obtain 3-ethoxy-4- (5-methyl-2-phenyl- . 4-oxazolylmethoxy)benzyl alcohol (3.28 g, yield 97%) as colorless crystals. This was recrystallized from . 5 tetrahydrotfuran-hexane. Melting point: 130-131°C
Reference Example 81
Thionyl chloride (0.73 ml) was added slowly to a mixture of 3-ethoxy-4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl alcohol (3.05 g). tetrahydrofuran (25 ml) and toluene (50 ml) at room temperature, which was stirred at 80°C for 30 minutes. . After cooling, the reaction mixture was poured into an aqueous saturated sodium bicarbonate solution, which was : 15 extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate solution, dried (MgSO,) and concentrated to obtain 4- (4-chloromethyl-2-ethoxyphenoxymethyl) 5 -methyl-2- phenyloxazole (2.94 gy, yield 91%) as colorless crystals.
This was recrystallized from tetrahydrofuran-hexane.
Melting point: 138-139°C
Reference Example 82
Sodium hydride (60%, oily, 1.40 g) was added to a solution of methyl 3-hydroxyisoxazole-5-carboxylate (5.01 g) in N,N-dimethylformamide (70 ml) at 0°C, which was stirred for 15 minutes. 4-Chloromethyl-5-methyl- 2-phenyloxazole (7.26 g) was added to the mixture. After being stirred at 60°C for 2 hours, the reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica } gel column chromatography to obtain methyl 3-(5- methyl-2-phenyl-4-oxazolylmethoxy)-5- isoxazolecarboxylate (7.96g, yield 72%) as colorless ay : crystals. This was recrystallized from Co : o tetrahydrofuran-hexane. Melting point: 123-124°C. CL
Reference Example 83 | : 5S Diisobutylaluminium hydride (1.0M tetrahydrofuran solution, 60 ml) was added slowly to a solution of methyl 3- (5-methyl-2-phenyl--4 -oxazolylmethoxy) 5 isooxazolecarboxylate (7.86 g) in tetrahydrofuran (150 ml) at 0°C, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with a saturated : aqueous sodium chloride solution, dried (MgSO,). and concentrated to obtain 3-(5-methyl-2-phenyl-4- -oxazolylmethoxy)-5-isoxazolylmethanol (5.93 g, yield 86%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 99-100°C
Reference Example 84
Thionyl chloride (0.80 ml) was added slowly to a solution of 3-(5-methyl-2-phenyl-4-oxazolylmethoxy)- 5-isoxazolylmethanol (2.86 g) in toluene (50 ml) at room temperature, which was stirred for 30 minutes under reflux.
After cooling, the reaction mixture was poured into saturated aqueous sodium bicarbonate solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain 5-chloromethyl-3-(5-methyl-2-phenyl-4- oxazolylmethoxy)isoxazole (2.70 g, yield 89%) as colorless crystals. This was recrystallized from ethyl : acetate-hexane. Melting point: 105-106°C
Reference Example 85
Sodium borohydride (620 mg) was added to a mixture of 4-[2-[1-0x0-2(1H)-phthaladinyl]lethoxy]benzaldehyde
Amended Sheet — 2004-01-27
(4.90 g), methanol (20 ml) and tetrahydrofuran (20 ml) at 0°C, which was stirred at room temperature for 30 ) minutes. Dilute hydrochloric acid was added to the reaction mixture, and the resulting colorless crystals were collected by tiltration to obtain 4. [2 [l-ox0- 2(1H)~phthaladinyl]ethoxylbenzyl alcohol (4.53 g, yield 92%). This was recrystallized from acetone-hexane.
Melting point: 142-143°C
Reference Example 86
Sodium borohydride (600 mg) was added to a mixture of 3-{2-[1-0ox0-2(1H)-phthaladinyl])ethoxy]benzaldehyde (5.00 g), methanol (30 ml) and tetrahydrofuran (30 ml) at 0°C, which was stirred at room temperature for 30 minutes. Dilute hydrochloric acid was added to the reaction mixture, and the resulting colorless crystals were collected by filtration to obtain 3-[2-[1-oxo0- 2(1H) -phthaladinyl ]ethoxy]lbenzyl alcohol (4.80 g, yield 95%). This was recrystallized from ethyl acetatc hexane.
Melting point: 133-134°C
Reference Example 87
Thionyl chloride (1 ml) was added slowly to a solution of 4-[2-[1-0x0-2(1H)- phthaladinyl}ethoxylbenzyl alcohol (3.80 g) in toluene (40 ml) at room temperature, which was stirred at 90°C for 30 minutes. After cooling, the reaction mixture was poured into saturated aqueous sodium bicarbonate solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0,). and concentrated to obtain 2-[2-(4-chloromethylphenoxy)ethyl]}-1(2H)- phthaladinone (3.62 g, yield 95%) as a colorless oily substance.
NMR(CDC1,) 0: 4.37-4.47(2H, m), 4.54(2H, s). 4.60-4.70(2H, m), 6.86-6.96(2H, m), 7.24-7.34(2H, m), 7.66-7.86(3H, m),
8.19(1H, s), 8.40-8.48(1H, m) } Reference Example 88 . Thionyl chloride (1.3 ml) was added slowly to a : . 5 solution of 3-[2-[1l-0ox0-2(1H) phthaladinyl]ethoxylbenzyl alcohol (4.59 g) in toluene (30 ml) at room temperature, which was stirred at 90°C for 30 minutes. After cooling, the reaction mixture was poured into saturated aqueous sodium bicarbonate solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain 2-[2-(3-chloromethylphenoxy)ethyl]-1(2H)- phthaladinone (4.39 g., yield 95%) as a colorless oily substance.
NMR (CDC1,) 0:4.40-4.48(2H, m), 4.51(2H, s), 4.62-4.70(2H, m), 6.84-7.00(3H, m), 7.18-7.26(1H, m), 7.64-7.88(3H, m), 8.19(1H, s), 8.40-8.50(1H, m).
Reference Example 89
Sodium hydride (60%, oily, 1.80 g) was added to a solution of 5-methyl-2-phenyl-4-oxazolylmethanol (8.51 g) in tetrahydrofuran (100 ml) at 0°C, which was stirred at room temperature for 15 minutes. A solution of methyl 6-chloro-2-pyridinecarboxylate (7.72 g) in tetrahydrofuran (75 ml) was added to the mixture. After being stirred at 40°C for 5 hours, the reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgSsoO,), and concentrated to obtain methyl 6-(5-methyl-2- phenyl-4-oxazolylmethoxy)-2-pyridinecarboxylate (7.41 g. yield 51%) as yellow crystals. This was ) recrystallized from ethyl acetate-hexane. Melting point: 97-98°C.
Reference Example 90
Lithium aluminium hydride (759 mg) was added to a : solution of methyl 6-~(5-methyl-2-phenyl-4- } oxazolylmethoxy)-2-pyridinecarboxylate (6.49 g) in . 5 tetrahydrofuran (60 m1) at 0°, which was stirred at room temperature for 30 minutes. Sodium sulfate‘°decahydrate (6.44 g) was added to the reaction mixture, which was stirred at room temperature for 30 minutes. The precipitate was removed by filtration, and the filtrate was concentrated. A mixture of the residue and thionyl chloride (20 ml) was stirred at room temperature for 1 hour. The reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 2-chloromethyl-6-(5-mehyl-2-phenyl-4- oxazolylmethoxy)pyridine (2.74 g, yield 44%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 85-86°C
Reference Example 91
Lithium aluminium hydride (2.43 g) was added to a solution of methyl 6-phenyl-3-pyridinecarboxylate (14.00 g) in tetrahydrofuran (200 ml) at 0°C, which was stirred at room temperature for 30 minutes. Sodium sulfate-decahydrate (22.50 g) was added to the reaction mixture, which was stirred at room temperature for 30 minutes. The precipitate was removed by filtration, and the filtrate was concentrated to obtain 6-phenyl-3- . pyridylmethanol (11.63 g, yield 96%) as a pale yellow oily substance. ] NMR(CDC1,) 0 : 1.91(1H, br.s), 4.78(2H, 4, J=5.6 Hz), 7.34-7.54(3H, m), 7.70-7.84(2H, m), 7.93-8.04(2H, m), 8.64-8.71(1H, m).
Reference Example 92 . Thionyl chloride (10 ml) was slowly added to a solution of 6-phenyl-3-pyridylmethanol (11.60 g) in : 5 toluene (100 ml) at room temperature, which was stirred at 100°C for 1 hour. After cooling, the reaction mixture was poured into saturated aqueous sodium bicarbonate solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated to obtain 5-chloromethyl-2-phenylpyridine (11.49 g, yield 89%) as colorless crystals. This was ‘recrystallized from ethyl acetate-hexane. Melting point: 95-96°C
Reference Example 93 "Sodium hydride (60%, oily, 2.88 g) was added to a mixture of 2-(2-furyl)-H-methyl-4-oxazolylmethanol (10.80 g), methyl 2-chloro--4-pyridinecarboxylate (10.30 4g), tetrahydrofuran (100 ml) and N,N-dimethylformamide (100 ml) at 0°C, and the mixture was .stirred at room temperature for 2 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 2-[2-(2-furyl)-5- methyl-4-oxazolylmethoxyl-4-pyridinecarboxylate (2.86 g, yield 15%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 80-81°C ’ Reference Example 94 } Lithium aluminium hydride (304 mg) was added to a solution of ethyl 2-[2-(2-furyl)-5-methyl-4-~ oxazolylmethoxy]-4-pyridinecarboxylate (2.63 g} in
I tetrahydrofuran (30ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. Sodium sulfate- , decahydrate (2.58 g) was added to the reaction mixture, which was stirred at room temperature for 30 minutes. The . 5 precipitate was removed by filtration, and the filtrate was concentrated. A mixture of the residue, thionyl chloride (10 ml) and toluene (5 ml) was stirred at room temperature for 1 hour. After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate © 10 solution was added to the residue, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 4- chloromethyl-2-[2-(2-furyl)-5-methyl-4- oxazolylmethoxy]pyridine (1020 mg, yield 42%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 107-108°C
Reference Example 95
Sodium hydride (60%, oily, 2.00 g) was added to a mixture of 5-chloroimidazo[l,2-a]pyridin-2-ylmethanol (8.77g), methyl 2-chloro-4-pyridinecarboxylate (8.24 g) and N,N-dimethylformamide (150ml) at 0°C, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgS04), and concentrated. The residue was subjected to silica gel column chromatography to obtain methyl 2- : (5-chloroimidazo[l,2-alpyridin-2-ylmethoxy)-4- pydinecarboxylate (2.78 g, yield 18%) as colorless crystals from the fraction eluted with tetrahydrofuran.
This was recrystallized from tetrahydrofuran-hexane.
Melting point: 157-158°C . Reference Example 96
Diisobutylaluminium hydride (1.0M tetrahydrofuran . 5 solution, 30 ml) was added to a solution of methyl 2- (5.-chloroimidazo[l,2-alpyridin-2-ylmethoxy)-4- pyridinecarboxylate (3.97 g) in tetrahydrofuran (150 ml) at 0°C, which was stirred at room temperature for 30 minutes. Sodium sulfate-decahydrate (12.2 g) was added to the reaction mixture, which was stirred at room temperature for 1 hour. The precipitate was removed by filtration, and the filtrate was concentrated. The resulting colorless crystals were collected by filtration to obtain 2-(5-chloroimidazo[l,2- a)pyridin-2-ylmethoxy)-4-pyridylmethanol (3.12 g, yield 86%). This was recrystallized from tetrahydrofuran- hexane. Melting point: 143-144°C
Reference Example 97
A mixture of 2-(5-chloroimidazo[l,2-a)pyridin-2- ylmethoxy)-4-pyridylmethanol (2.90 g) and thionyl chloride (10 ml) was stirred at room temperature for 1 hour. After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 5-chloro-2-(4- chloromethyl-2-pyridyloxymethyl)imidazol[1l,2- a)lpyridine (2.63 g, yield 85%) as colorless crystals from ) the fraction eluted with tetrahydrofuran. This was recrystallized from tetrahydrofuran-hexane. Melting : ] point: 118-119°C
Reference Example 98
Sodium hydride (60%, oily, 2.88 g) was added to a solution of methyl 5-hydroxy-3-pyridinecarboxylate ; (10.00 g) and N-phenyltrifluoromethanesulfonimide (24.00 g) in tetrahydrofuran (200 ml) at 0°C, and the . 5 mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer ) was washed with saturated aqueous sodium bicarbonate solution, then with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain methyl 5-trifluoromethanesulfonyloxy-3- : pyridinecarboxylate (18.06 g, yield 97%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 0 : 4.01(3H, s), 8.23(1H, dd, J=1.4, 2.6 Hz), 8.77(1H, d, J=2.6 Hz), 9.26(1H, 4, J=1.4 Hz).
Reference Example 99
A mixture of methyl 5- trifluoromethanesulfonyloxy-3-pyridinecarboxylate (18.00 g), phenylboronic acid (7.88 gq). tetrakis (triphenylphosphine)palladium (3.01 g), sodium carbonate (13.51 g). ethanol (80 ml), water (80 ml) and toluene (500 ml) was refluxed overnight under an argon atmosphere. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 5-phenyl-3-pyridinecarboxylate (8.63 g, . yield 60%) as a colorless oily substance from the fraction eluted with ethyl acetate. i NMR(CDC1,) 6 : 1.44(3H, t, J=6.8 Hz), 4.46(2H, q, J=6.8 Hz), 7.42-7.70(5H, m), 8.44-8.56(1H, m), 9.00(1H, 4, J=2.2 Hz), 9.20(1H, d, J=1.8 Hz).
135°
Reference Example 100 y Lithium aluminium hydride (1.45 g) was added to a solution of ethyl 5-phenyl-3-pyridinecarboxylate (8.60 . 5 g) in tetrahydrofuran (100 ml) at 0°C, which was stirred at room temperature for 30 minutes. Sodium sulfate- decahydrate (13.40 g) was added to the reaction mixture, which was stirred at room temperature for 30 minutes. The precipitate was removed by filtration, and the filtrate was concentrated. The resulting colorless crystals were collected by filtration to obtain 5-phenyl-3- pyridylmethanol (4.82 g, yield 69%). This was recrystallized from ethyl acetate-hexane. Melting point: 71-72°C }
Reference Example 101
A mixture of 5-phenyl-3-pyridylmethanol (4.50 g) and thionyl chloride (5 ml) was stirred at room temperature for 1 hour. After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added to the mixture, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain 3-chloromethyl-5- : phenylpyridine (4.28 g, yield 86%) as colorless crystals from the fraction eluted with tetrahydrofuran. This was ~~ recrystallized from ethyl acetate-hexane. Melting point: 75-76°C
Reference Example 102 “ A mixture of methyl 3-hydroxyisoxazole-5- carboxylate (5.01 g), 2-chloromethylguinoline . hydrochloride (8.99 g), potassium carbonate (14.50 g) and
N,N-dimethylformamide (100 ml) was stirred at 60°C for 2 hours. The reaction mixture was poured into water,
which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium . chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography p 5 to obtain methyl 3-(2-quinolylmethoxy) -5- isoxazolecarboxylate (7.78 g, yield 78%) as colorless crystals. This was recrystallized from tetrahydrofuran-hexane. Melting point: 133-134°C
Reference Example 103
Diisobutylaluminium hydride (1.0M tetrahydrofuran solution, 60 ml) was added slowly to a solution of methyl 3-(2-quinolylmethoxy)-5-isoxazolecarboxylate (7.39 g) in tetrahydrofuran (150 ml) at 0°C, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain 3-(2-quinolylmethoxy)-5-isoxazolylmethanol (4.95 g, yield 74%) as colorless crystals. This was recrystallized from tetrahydrofuran-hexane. Melting point: 111-112°C
Reference Example 104
A mixture of 3-(2-quinolylmethoxy)-5- isoxazolylmethanol (1.54 g) and thionyl chloride (5 ml) was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate. , The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated , to obtain 2-(5-chloromethyl-3- . 35 isoxazolyloxymethyl)quinoline (1.61 g, yield 98%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 126-127°C . Reference Example 105 tert-Butyl Lithium (1.7M pentane solution, 15 ml) : 5 was added slowly to a solution of 5-chloro-2- phenylpyridine (4.70 g) in tetrahydrofuran (50 ml) at ~78°C under a nitrogen atmosphere, which was stirred for 1 hour. N,N-Dimethylformamide (2.3 ml) was added to the oo mixture slowly, which was stirred for 1 hour while raising the temperature to room temperature. After addition of dilute hydrochloric acid the mixture was stirred at room temperature for 30 minutes.The reaction mixture was neutralized with saturated aqueous sodium bicarbonate ~ solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgSO,), and concentrated.
Sodium borohydride (946 mg) was added slowly to a mixture of the residue, tetrahydrofuran (50 ml) and methanol (50 ml) at room temperature, which was stirred for 1 hour.
The reaction mixture was poured into water, which was - extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 3-chloro-6-phenyl-2-pyridylmethanol (2.35 g, vield 43%) as pale yellow crystals from the fraction eluted with ethyl acetate-hexane (1:6, volume ratio).
This was recrystallized from ethyl acetate-hexane.
Melting point: 69-70°C
Reference Example 106
A mixture of 3-chloro-6-phenyl-2-pyridylmethanol (2.20 g), 5% palladium-carbon (1.10g), triethylamine (1.4 ml), methanol (20 ml) and tetrahydrofuran (20 ml) was stirred at room temperature under a hydrogen atmosphere. After palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography to . obtain 6-phenyl-2-pyridylmethanol (1.76 g, yield 95%) as a colorless oily substance from the fraction eluted with i" : 5 ethyl acetate-hexane (1:5, volume ratio).
NMR(CDC1,) 0 : 4.20(1H, t, J=3.8 Hz), 4.82(2H, 4d, J=3.8 Hz), 7.16(1H, 44, J=0.8, 7.6 Hz), 7.38-7.54(3H, m), 7.64(1H, 44,
J=0.8, 7.6 Hz), 7.76(1H, t, J=7.6 Hz), 7.99-8.05(2H, m).
Reference Example 107
A mixture of 3-chloro-6-phenyl-2-pyridylmethanol (2.20 g) and thionyl chloride (15 ml) was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and agueous saturated sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain 3-chloro-2-chloromethyl-5-phenylpyridine (2.25 g, yield 94%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 74-75°C
Reference Example 108
A mixture of 6-phenyl-2-pyridylmethanol (1.76 g) and thionyl chloride (10 ml) was stirred at room temperate for 1 hour. The reaction mixture was concentrated under reduced pressure, and agueous saturated sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain 2-chloromethyl-S-phenylpyridine (1.91 g, yield 99%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:5, volume ratio).
NMR(CDC1,) 0 : 4.75(2H, s), 7.36-7.52(4H, m), 7.64(1H, ad,
J=1.0, 7.6 Hz), 7.77(1H, t, J=7.6 Hz), 7.96-8.02(2H, m).
Reference Example 109 ) 5 Sodium hydride (60%, oily, 1.40 yg) was Added to a solution of 2-phenyl-4-thiazolylmethanol (6.69 g) and methyl 6-chloro-3-pyridinecarboxylate (6.01 g) in
N,N-dimethylformamide (100 ml) at 0°C, and the mixture was stirred for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
Lithium aluminium hydride (1.33 g) was added to a solution of the residue in tetrahydrofuran (150 ml) at 0°C, which was stirred at room temperature for 10 minutes.
Sodium sulfate decahydrate (11.3 g) was added to the reaction mixture, which was stirred for 30 minutes at room temperature. The precipitate was removed by filtration, and the tiltrate was concentrated. The residue was subjected to silica gel column chromatography to obtain 6-(2-phenyl-4-thiazolylmethoxy)-3-pyridylmethanol (5.81 g, yield 56%) as colorless crystals from the fraction eluted with tetrahydrofuran. This was recrystallized from tetrahydrofuran-hexane. Melting point: 134-135°C
Reference Example 110
Sodium hydride (60%, oily, 1.58g) was added to a solution of 2-quinolylmethanol (6.29 g) and methyl 6- chloro-3-pyridinecarboxylate (6.78g) in N,N- dimethylformamide (100 ml) at 0°C, and the mixture was stirred for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
Lithium aluminium hydride (1.50 g) was added to a solution of the residue in tetrahydrofuran (150 ml) at 0°C, which was stirred at room temperature for 10 minutes. Sodium : sulfate'decahydrate (12.7 g) was added to the reaction mixture, which was stirred at room temperature for 1 hour. ’ S The precipitate was removed by filtration, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography to obtain 2-(2- quinolylmethoxy)-5-pyridylmethanol (5.31 ¢g, yield 50%) as colorless crystals from the fraction eluted with ethyl acetate. This was recrystallized from ethyl acetate- hexane. Melting point: 124-125°C
Reference Example 111
A mixture of 6-(2-quinolylmethoxy)-3- pyridylmethanol (2.66 g) and thionyl chloride (10 ml) was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The residue was subjected to silica gel column chromatography to obtain 2-(5-chloromethyl-2- pyridyloxymethyl)quinoline (2.50 g, yield 88%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 118-119°C
Reference Example 112
A mixture of 6-(2-phenyl-4-thiazolylmethoxy)-3- k pyridylmethanol (2.98g) and thionyl chloride (15 ml) was stirred at room temperature for 1 hour. The reaction } mixture was concentrated under reduced pressure, and saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous } sodium chloride solution, dried (MgS0O,) and concentrated.
The residue was subjected to silica gel column chromatography to obtain 5. .chloromethyl-2-(2-phenyl- i 5 4-thiazolylmethoxy)pyridine (2.40 g, yield 76%) as colorless crystals from the fraction eluted with ethyl acetate. This was recrystallized from tetrahydrofuran-hexane. Melting point: 117-118°C
Reference Example 113
A mixture of 3-methyl-1-(2-pyridyl)-1H-pyrazol- 4-ylmethanol (3.00 g), thionyl chloride (2.5 ml) and toluene (50 ml) was stirred at 70°C for 2 hours. The reaction mixture was concentrated under reduced pressure, and saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate. The ethyl acetate layer was washed with : saturated aqueous sodium chloride solution, dried (MgSo,), and concentrated to obtain 4. chloromethyl-3-methyl-1- (2-pyridyl)-1H-pyrazole (3.10 g, yield 94%) as a colorless oily substance.
NMR (CDC1,) 0 : 2.44(3H, s), 4.58(2H, s), 7.46-7.60(1H, m), 8.18-8.42(2H, m), 8.50-8.60(1H, m), 9.43(1H, s)
Reference Example 114 ‘ A mixture of 2-methyl-5-(5-methyl-2-phenyl-4- oxazolylmethoxy)pyridine (18.04 g), 3-chloroperbenzoic acid (18.85 g) and tetrahydrofuran (100 ml) was stirred at room temperature overnight, and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with tetrahydrofuran. A solution of the obtained colorless oily substance in acetic anhydride (100 ml) was added slowly to acetic anhydride (200 ml) heated at 130°C, which was stirred for 2 hours, and concentrated. The residue was dissolved in ethyl acetate, which was washed with an aqueous saturated sodium bicarbonate solution, then with a saturated aqueous sodium chloride solution, } dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain . 5 [5-(5-methyl-2-phenyl-4-oxazolylmethoxy) 2 pyridylmethyl] acetate (18.09g, yield 83%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 2.13(3H, s), 2.45(3H, s), 5.05(2H, s), 5.16(2H, s), 7.26-7.50(5H, m), 7.94-8.05(2H, m), 8.38- 8.43(1H, m). :
Reference Example 115 ‘A mixture of [5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-2-pyridylmethyl] acetate (18.00 g), 1N aqueous sodium hydroxide solution (75 ml) and methanol (100 ml) was stirred at room temperature for 3 hours, and concentrated. The residue was dissolved inethyl acetate, which was washed with water and saturated aqueous sodium chloride solution. The organic layer was dried (MgSoO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 5-(5-methyl-2- phenyl-4-oxazolylmethoxy)-2-pyridylmethanol (14.29 g, yield 91%). This was recrystallized from ethyl acetate-hexane. Melting point: 125-126°C
Reference Example 116 :
Sodium borohydride (835 mg) was added gradually to a solution of 6-(5-methyl-2-phenyl-4- oxazolylmethoxy)nicotinaldehyde (13.0 g) in tetrahydrofuran (150 ml)-methanol (10 ml) at 0°C. After stirring for 30 minutes, water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated to obtain crystals of 6~(5-methyl-2-phenyl-4-oxazolylmethoxy)-3-
pyridylmethanol. This was recrystallized from acetone-isopropyl ether to obtain colorless prism crystals (12.4 g., yield 95%). Melting point: 121-122°C ‘ 5 Reference Exumple 117
Thionyl chloride (5.39 g) was added to a mixture of 6-~(5-methyl-2-phenyl-4-oxazolylmethoxy) -3- pyridylmethanol (12.2 g) and toluene (200 ml), which was stirred at room temperature for 1 hour. Ice water was added to the reaction mixture, which was neutralized with saturated aqueous sodium bicarbonate solution, and was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was subjected to silica gel column chromatography to obtain 5-chloromethyl-2- (5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine (11.7 g, yield 90%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane to obtain colorless prism crystals. Melting point: 86-87°C
Reference Example 118
Sodium borohydride (410 mg) was added to a mixture of 6-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylnicotinaldehyde (3.10 g). tetrahydrofuran (50 ml) and ethanol (50 mL) at room temperature, which was stirred at room temperature for minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The organic 30 layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated to obtain 6-[2-(2-furyl)-5-methyl-4- oxazolylmethoxy]-3-pyridylmethanol (2.86 g, yield 92%) } as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 120-121°C
Reference Example 119
A mixture of 6-[2-(2-furyl)-5-methyl-4- . oxazolylmethoxy]-3-pyridylmethanol (1.87 g) and thionyl chloride (15 ml) was stirred at room temperature for 1 . 5 hour. The reaction mixture was concentrated under reduced pressure, and saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain 5-chloromethyl-2--[2-(2-furyl)-5-methyl-4- oxazolylmethoxylpyridine (1.41 g, yield 71%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 95-96°C
Reference Example 120
Lithium aluminium hydride (1.33 g) was added to a solution of ethyl 1-(4-benzyloxybenzyl)-3-(4- fluorophenyl)-1H-pyrazole-4-carboxylate (15.1 g) in tetrahydrofuran (300ml) at 0°C, which was stirred at room temperature for 1 hour. Sodium sulfate‘'decahydrate (12.26 g) and hexane (100 ml) was added to the reaction mixture, which was stirred at room temperature for 1 hour.
After the precipitate was removed by filtration, the filtrate was concentrated to obtain 1-(4- benzyloxybenzyl)-3-(4-fluorophenyl)-1H-pyrazol-4- } ylmethanol (12.9 g, yield 95%) as colorless crystals.
This was recrystallized from ethyl acetate-hexane. } Melting point: 112-113°C . Reference Example 121
A mixture of 1-(4-benzyloxybenzyl)-3-(4- fluorophenyl)-1H-pyrazol-4-ylmethanol (11.7 g), active -
manganese dioxide (20.0 g) and tetrahydrofuran (150 ml) ‘was stirred at room temperature for 2 hours. After the . manganese dioxide was removed by filtration, the filtrate was concentrated to obtain 1-(4-benzyloxybenzyl)-3- : 5 (4-finorophenyl) lH.-pyrazole 4. -carbaldehyde (10.9 gq, yield 94%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 97-98°C
Reference Example 122
A mixture of 5-hydroxy-2-methylpyridine (8.46 gq), 4-chloromethyl-5-methyl-2-phenyloxazole (15.20 g), potassium carbonate (15.98 g) and N,N-dimethylformamide © (200 ml) was stirred at 80°C for 3 hours, poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,} and concentrated. The residue was subjected to silica gel column chromatography to obtain 2-methyl-5-(5-methyl-2-phenyl-4- : oxazolylmethoxy)pyridine (19.68g, yield 96%) as pale yellow crystals from the fraction eluted with tetrahydrofuran-hexane (1:1, volume ratio). This was recrystallized from acetone-hexane. Melting point: 103-104°C
Reference Example 123
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-3- phenyl-1H-pyrazol-4-yl]propionate (2.02 g)., 1,2- dibromoethane (20 ml), potassium carbonate (1.68 g) and
N,N-dimethylformamide (20 ml) was stirred at 90°C for 24 hours. The reaction mixture was poured into water, which . was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride . solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[4-(2-bromoethoxy)benzyl]-3-phenyl-
1H-pyrazol-4-yllpropionate (1530 mg, yield 58%) as a colorless oily substance from the fraction eluted with . ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 0: 1.19(3H, t, J=7.0 Hz), 2.46-2.58(2H, m), : 5 2.88-3.00(2H, m), 3.59-3.70(2H, m), 4.08(2H, gq, J=7.0 Hz), 4.24-4.35(2H, m), 5.24(2H, s), 6.84.6.94(2H, m), 7.16- 7.52(6H, m), 7.58-7.68(2H, m).
Reference Example 124
A solution of p-toluenesulfonylmethylisocyanide (12.3 g) in dimethoxyethane (60 ml) was added to a mixture of potassium t-butoxide (13.5 g) and dimethoxyethane (60 ml) at -78°C, and the resultant was stirred for 5 minutes.
A solution of l-benzyl-5-phenyl-l1H-pyrazol-4- carbaldehyde (13.0g) in dimethoxyethane (60 ml) was added to the mixture. After stirring at the same temperature for 1 hour, the mixture was stirred for 1 hour while raising the temperature. Methanol (180 ml) was added to the mixture, and refluxed for 1 hour. After cooling, the reaction solution was poured into saturated aqueous ammonium chloride solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the resulting colorless oily substance, 4N aqueous sodium hydroxide solution (100ml), tetrahydrofuran (100ml) and ethanol (100 ml) was refluxed for 3 days. After cooling, the mixture was neutralized with dilute hydrochloric acid, . which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium . chloride solution, dried (MgSO,) and concentrated. a mixture of the residue, ethyl iodide (6.5 ml), potassium carbonate (14.9 g) and N,N-dimethylformamide (150 m1) was stirred at room temperature for 3 hours. The reaction mixture was poured into water, which was extracted with . ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,). . 5 and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl : acetate-hexane (1:2, volume ratio). A mixture of the resulting oily substance. 5% palladium-carbon (30.0g), formic acid (80ml) and ethanol (160 ml) was refluxed for 1 hour. After cooling, the palladium-carbon was removed by filtration, and the filtrate was concentrated. The residue was dissolved in ethyl acetate, which was washed with saturated aqueous sodium bicarbonate solution, then with saturated aqueous sodium chloride solution, dried (MgsSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3- phenyl-1H-pyrazol-4-ylacetate (4.65 g, yield 34%) as a colorless oily substance from the fraction eluted with } 20 ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 : 1.23(3H, t, J=7.0 Hz), 3.61(2H, s), 4.14(2H, q, J=7.0H=z), 7.32-7.47(3H, m), 7.51-7.59(3H, m), 11.38(1H, oo br.s).
Reference Example 125
Lithium aluminium hydride (300 mg) was added gradually to a solution of ethyl 1-[6-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-3~-phenyl- lH-pyrazole-4-carboxylate (1.56 g) in tetrahydrofuran (70 ml) at 0°C, which was stirred for 2 hours. Sodium sulfate-decahydrate (3.40 g) was added to the reaction : mixture, and the precipitate was filtered. The filtrate was concentrated, and residue was subjected to silica gel column chromatography to obtain 1-[6-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3~-pyridylmethyl]-3-phenyl- 1H-pyrazol-4-ylmethanol (1.27 g, yield 89%) as a colorless oily substance from the fraction eluted with acetone-hexane (2:3, volume ratio). ’ . NMR(CDC1,) 0 :1.60(1H, t. J=5.5Hz), 2.48(3H, s), 4.68(2H, d, J=5.5 Hz), 5.26(2H, s), 5.30(2H, s), 6.82(1H, 4, J=8.5 . 5 Hz), 7.25-7.5 (7H, m), 7.56(1H4, dd, J=8.5, ZHz), 7.7--7.8(2H, m), 7.95-8.05(1H, m), 8.15(1H, 4, J=2 Hz).
Reference Fxample 126
A mixture of 1-[6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridylmethyl}-3-phenyl-1H- pyrazol-4-ylmethanol (1.25 g), active manganese dioxide (3.00 g) and ethyl acetate (80 ml) was stirred at room temperature for 3 hours. After manganese dioxide was ’ separated by filtration, the filtrate was concentrated.
The residue was subjected to silica gel column chromatography to obtain 1-[6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridylmethyl]}-3-phenyl-1H- pyrazole-4-carboaldehyde (1.20 g, yield 96%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0:2.48(3H, s), 5.30(2H, s), 5.31(2H, s), 6.85(1H, . d, J=8.5 Hz), 7.4-7.6(7H, m), 7.59(1H, 4d, J=8.5, 2.5 Hz), 7.65-7.8(2H, m), 7.97(1H, s), 8.0-8.05(2H, m), 8.21(1H, 4,
J=2 Hz), 9.93(1H, s).
Reference Example 127
A solution of p-toluenesulfonylmethylisocyanide (3.08 g) in dimethoxyethane (15 ml) was added to a mixture of potassium t-butoxide (3.37 g) and dimethoxyethane (15 ml) at -78°C, and the resultant was stirred for 5 minutes.
A solution of 1-(4-benzyloxybenzyl)-3-(4- fluorophenyl)-1H-pyrazole-4-carbaldehyde (5.80 g) in dimethoxyethane (30 ml) was added to the mixture. After } stirring at the same temperature, the mixture was stirred for 1 hour while raising the temperature. Methanol (45 ml) was added to the mixture, which was refluxed for 1 hour. After cooling, the reaction mixture was poured into saturated aqueous ammonium chloride solution, which - was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride . 5 solntion, dried (MgSsS0O,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 1.-(4-benzyloxybenzyl)-3-(4-fluorophenyl)-1H- pyrazol -4--ylacetonitrile (4.52 gq, yield 76%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 86-87°C
Reference Example 128
A mixture of ethyl 1-(4-phenoxybenzyl)-3-(4- phenoxybenzyloxy)-1H-pyrazole-4-carboxylate (21.50 g), 5% palladium-carbon (10.43 g) and tetrahydrofuran (300 ml) was stirred overnight under a hydrogen atmosphere.
After the palladium-carbon was removed by filtration, the filtrate was concentrated to obtain ethyl 3- hydroxy-1-(4-phenoxybenzyl)-1H-pyrazole-4-carboxylate (13.35 g, yield 96%) as colorless crystals. This was recrystallized from acetone-hexane. Melting point: 117-118°C oo
Reference Example 129 :
Lithium aluminium hydride (205 mg) was added gradually to a solution of methyl 1-[6-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-4- phenylpyrrole-3-carboxylate (1.30 g) in tetrahydrofuran (40 m1) at 0°C, and the resultant was stirred for 3 hours. . Sodium sulfate'decahydrate (2.80 g) was added to the reaction mixture, and the precipitate was removed by filtration. The filtrate was concentrated, and the residue was subjected to silica gel column chromatography to obtain [1-[6-(5-methyl-2-phenyl-4-
oxazolylmethoxy)-3-pyridylmethyl]-4-phenyl-3- pyrrolyllmethanol (1.15 g, yield 94%) as a colorless oily - substance from the fraction eluted with ethyl acetate-hexane (3:2, volume ratio). : © 5 NMR(CDC1,) 6 :2.48(3H, s), 4.63(2H, br s), 4.98(2H, «), 5.30(2H, 8), 6.7-6.85(2H, m), 7.2--7.55(10H, m), 7.95- 8.1(3H, m).
Reference Example 130
A mixture of [1-[6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridylmethyl]-4-phenyl-3- pyrrolyl]lmethanol (1.15 g), active manganese dioxide (2.30 g) and ethyl acetate (80 ml) was stirred at room temperature for 2 hours. After the manganese dioxide was removed by filtration, the filtrate was concentrated to obtain 1-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-3- pyridylmethyl]-4-phenylpyrrole-3-carbaldehyde (1.06 g, yield 93%) as a colorless oily substance.
NMR(CDC1,) 6 :2.48(3H, 5). 5.04(2H, s), 5.31(2H, s), 6.75(1H, 4d, J=2 Hz), 6.84(1H, 4, J=8.5 Hz), 7.25-7.5(10H, m), 7.95-8.15(3H, m), 9.86(1H, s).
Reference Example 131
A mixture of ethyl (E)-3-[1-(4-benzyloxybenzyl)- 3-phenyl-lH-pyrazol-4-yllpropenoate (12.13 g), 5% palladium-carbon (10.22 g) and tetrahydrofuran (100 ml) was stirred for 5 hours under a hydrogen atmosphere.
After the palladium-carbon was removed by filtration, the filtrate was concentrated to obtain ethyl 3-[1- (4-hydroxybenzyl)-3-phenyl-1H-pyrazol-4-yllpropionate (9.52 g, yield 98%) as a colorless oily substance. . NMR (CDC1,) 0 : 1.19(3H, t, J=7.2 Hz), 2.48-2.58(2H, m), 2,88-3.00(2H, m), 4.08(2H, gq, J=7.2 Hz), 5.19(2H, s), . 6.62-6.74(2H, m), 6.98-7.10(2H, m), 7.18-7.45(4H, m), 7.56-7.66(2H, m).
Reference Example 132
A mixture of ethyl (E)-3-[1-(4-benzyloxybenzyl)- : 3-(4-fluorophenyl)-1H-pyrazol-4-yl]lpropenoate (10.049). 5% palladium-carbon (20.0 g), ethanol (100 ml) and : 5 tetrahydrofuran (100 m1) was stirred for 1 hour nnder a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated to obtain ethyl 3-[3-(4-fluorophenyl) 1--(4. hydroxybenzyl)-1H-pyrazol-4-yl]propionate (7.15 g, yield 88%) as a colorless oily substance.
NMR(CDC1,) 6 : 1.19(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.6 Hz), 2,90(2H, t, J=7.6 Hz), 4.08(2H, q, J=7.2 Hz), 5.15(2H, s), 6.57(2H, d, J=8.4 Hz), 6.97(2H, 4, J=8.4 Hz), 7.07(2H, t,
J=8.8Hz), 7.24(1H, s), 7.56(2H, dad, J=5.4, 8.8Hz), 7.59(1H,
Ss).
Reference Example 133
A mixture of 5-phenyl-2-pyridylmethyl acetate (3.68 g). a 1N aqueous sodium hydroxide solution (30 ml), tetrahydrofuran (30 ml) and methanol (300 ml) was stirred at room temperature for 3 hours, which was concentrated.
The residue was dissolved in ethyl acetate, and then the solution was washed with water, then with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residual colorless crystals were collected by filtration to obtain 5-phenyl-2- pyridylmethanol (2.84 g, yield 95%). This was recrystallized from ethyl acetate-hexane. Melting point: 86-87°C
Reference Example 134
A mixture of 5-phenyl-2-pyridylmethanol (1.98g), thionyl chloride (1.6 ml) and toluene (30 m1) was stirred . at 70°C for 2 hours. After the reaction mixture was concentrated, saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted
" with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried . (Mgs0O,), and concentrated. A mixture of the residue, 4-hydroxybenzyl alcohol (1.37 g), potassium carbonate : 5 (3.18 ¢) and N,N-dimethyltformamide (50 ml) was stirred : at 80°C overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The residuewas subjected to silica gel column chromatography to obtain 4-(5-phenyl-2-pyridylmethoxy)benzyl alcohol (2.69 g, yield 86%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate- hexane. Melting point: 159-160°C
Reference Example 135 : :
Sodium borohydride (0.36 ¢g) was added to a mixture of 4-(2-phenyl-4-oxazolylmethoxy)benzaldehyde (2.65 g) and methanol (50 ml) under ice-cooling, which was stirred at room temperature for 1 hour. Dilute hydrochloric acid and water were added to the reaction mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated to obtain 4- (2-phenyl-4-oxazolylmethoxy)benzyl alcohol (2.43 g, yield 91%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 141-142°C : ‘ :
Referencc Example 136 } A mixture of 4-(2-phenyl-4- oxazolylmethoxy)benzylalcohol (2.39 g), thionyl chloride (0.69 ml) and toluene (50 ml) was stirred at 40°C overnight, and then the reaction mixture was concentrated.
Saturated aqueous sodium bicarbonate solution was added to the residue, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous . sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column : 5 chromatography to obtain 4-(4- chloromethylphenoxymethyl)-2.-phenyloxazole (2.34 g, vield 92%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 129-130°C
Reference Example 137
Lithium aluminum hydride (320 mg) was added gradually to a solution of methyl 3-(5-methyl-2- phenyl-4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H- pyrazole-4-carboxylate (4.00g) in tetrahydrofuran (30 ml) at 0°C, which was stirred for 2 hours. Sodium sulfate* decahydrate (2.95 g) was added to the reaction mixture, and the precipitate was separated by filtration. The a 20 filtrate was concentrated, and the residue was subjected to silica gel column chromatography to obtain [3-(5- methyl-2-phenyl-4-oxazolylmethoxy)-1-(4- phenoxybenzyl)-1H-pyrazol-4-yl]methanol (3.56 g, yield 97%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 103-104°C
Reference Example 138
A mixture of [3-(5-methyl-2-phenyl-4- oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H-pyrazol-4- vyl)methanol (2.85 g), active manganese dioxide (8.42 g) and tetrahydrofuran (50 ml) was stirred at room : temperature overnight. After the manganese dioxide was separated by filtration, the filtrate was concentrated. . The residue was subjected to silica gel column chromatography to obtain 3-(5-methyl-2-phenyl-4- oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H-pyrazole-4-
carbaldehyde (2.61 g, yield 92%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, : volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 129-130°C : 5
Reference Example 139
Amixture of 4. (2-bromoethoxy)benzaldehyde (4.97g). : 1(2H) -phthalazinone (3.27 g), potassium carbonate (6.20 g) and N,N-dimethylformamide (50 ml) was stirred at 80°C for 5 hours. After cooling, the reaction mixture was poured into water, which was extractedwith ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated "to obtain 4-[2-[l-ox0-2(1H)- phthalazinyllethoxylbenzaldehyde (5.36 g, yield 84%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point: 126-127°C
Reference Example 140
Amixture of 3- (2-bromoethoxy)benzaldehyde (6.00 g), 1(2H) -phthalazinone (4.21 g), potassium carbonate (7.24 g) and N,N-dimethylformamide (40 ml) was stirred at 80°C for 5 hours. After cooling, the reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous : sodium chloride solution, dried (MgSO,) and concentrated to obtain 3-[2-[1l-0x0-2(1H)- phthalazinyllethoxylbenzaldehyde (6.94 g, yield 90%) as colorless crystals. This was recrystallized from. acetone-hexane. Melting point: 110-111°C . Reference Example 141 :
A mixture of ethyl 3-methyl-lH-pyrazole-4- } carboxylate (7.59 g), 2-chloropyridine (5 ml), sodium hydride (60%, oily, 2.32 g) and N,N-dimethylformamide (150 ml) was stirred at 180°C overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with . saturated aqueous sodium chloride solution, dried (MgSoO,) and concentrated. The residue was subjected to silica . 5 gel column chromatography to obtain ethyl 3-methyl-1- (2-pyridyl)-1H-pyrazole-4-carboxylate (8.31 g, yield 73%) from the fraction €luted with ethyl acetate-hexane © (1:9, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 79-80°C
Reference Example 142
Sodium borohydride (0.45 g) was added to a mixture of 4- (2-phenyl-4-thiazolylmethoxy)benzaldehyde (6.3549), tetrahydrofuran (30 ml) and methanol (20 ml) under ice-cooling, which was stirred at room temperature for 30 minutes. The reaction mixture was neutralized with } dilute hydrochloric acid and water to give a precipitate, which was collected by filtration and then air-dried to obtain crystals of 4-~(2-phenyl-4- thiazolylmethoxy)benzyl alcohol (5.76 g. yield 90%).
This was recrystallized from ethyl acetate-hexane to obtain colorless needles . Melting point: 145-146°C
Reference Example 143
A solution of thionyl chloride (1.5 ml) in toluene (5 ml) was added to a mixture of 4-(2-phenyl-4- thiazolylmethoxy)benzyl alcohol (4.35 g), tetrahydrofuran (50 ml) and toluene (50 ml) under ice-cooling, which was stirred at room temperature for 2 hours. The reaction mixture was concentrated. The : residue was dissolved in ethyl acetate, and the solution . was washed with saturated aqueous sodium bicarbonate solution, then with saturated aqueous sodium chloride . solution. The organic layer was dried over anhydrous magnesium sulfate and concentrated to obtain colorless crystals of 4-(4-chloromethylphenoxymethyl)-2-
phenylthiazole (4.10 g, yield 89%). Melting point: 98-99°C
Reference Example 144
A mixture of 4 chloromethyl-5-methyl 2. phenylthiazole (5.40 g), 4-hydroxybenzaldehyde (2.91 g), anhydrous potassium carbonate (4.95 g) and N,N- dimethylformamide (50 ml) was stirred at 80°C for 3 hours.
The reaction mixture was poured into water, the precipitated solid was collected by filtration, and air-dried to obtain crystals of 4-(5-methyl-2-phenyl- 4-thiazolylmethoxy)benzaldehyde (6.85 g, yield 93%).
This was recrystallized from ethyl acetate-hexane to obtain colorless prisms. Melting point: 118-119°C
Reference Example 145 .
Sodium borohydride (0.38 g) was added to a mixture , of 4-(5-methyl-2-phenyl-4- thiazolylmethoxy)benzaldehyde (6.00 g), tetrahydrofuran (30 m1) and methanol (20 ml) under ice-cooling, which was stirred at room temperature for 30 minutes. The reaction mixture was neutralized with dilute hydrochloric acid and water to give a precipitate, which was collected by filtration and air-dried to obtain crystals of 4-(5- methyl-2-phenyl-4-thiazolylmethoxy)benzyl alcohol (5.68 g, yield 94%). This was recrystallized from ethyl acetate-hexane to obtain colorless prisms. Melting point: 94-95°C
Reference Example 146
A solution of thionyl chloride (1.5 mL) in toluene } (5 mL) was added to a mixture of 4-(5-methyl-2- phenyl-4-thiazolylmethoxy)benzyl alcohol (4.50 g), . tetrahydrofuran (50 mL) and toluene (50 mL) under ice-cooling, which was stirred at room temperature for 2 hours. The reaction mixture was concentrated. The residue was dissolved in ethyl acetate, which was washed with saturated aqueous sodium bicarbonate solution, then . with saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate, . 5 and concentrated to obtain colorless crystals of 4 (4-chloromethylphenoxymethyl) -5-methyl-2- phenylthiazole (4.50 g, yield 94%). Melting point: 100-101°C
Reference Example 147 : A mixture of 4-chloromethyl-2-phenylthiazole (8.60 g), sodium acetate (10.1 g) and N,N-dimethylformamide (80 ml) was stirred at 80°C for 6 hours. After cooling, the : reaction solution was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. A mixture of the residue, 4N aqueous sodium hydroxide solution (25ml), tetrahydrofuran (50 ml) and methanol (50 ml) was stirred at room temperature for 5 minutes, and poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 2-phenyl-4-thiazolylmethanol (7.05 g, yield 90%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from hexane. Melting point: 71-72°C
Reference Example 148
A mixture of 2-chloromethylquinoline hydrochloride (21.4 g), sodium acetate (32.8 g) and N,N- dimethylformamide (200 ml) was stirred at 60°C overnight. . After cooling, the reaction solution was poured into ~ 35° water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. A mixture of the residue, 4N aqueous sodium hydroxide . solution (50 ml), tetrahydrofuran (100 ml) and methanol (100 ml) was stirred at room temperature for 1 hour, and . 5 poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,) and concentrated. :
The residue was subjected to silica gel column chromatography to obtain 2-quinolylmethanol (14.0 g, yield 88%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting : point: 68-69°C
Reference Example 149
Sodium hydride (60%, oily, 5.01 g) was added to a solution of S5-hydroxy-2-methylpyridine (12.45 g) and
N-phenyltrifluoromethanesulfonimide (40.80 g) in tetrahydrofuran (500 ml) at 0°C, which was stirred at room temperature for 1 hour, and concentrated. The residue was dissolved in ethyl acetate, which was washed with saturated aqueous sodium bicarbonate solution, and with saturated aqueous sodium chloride solution, and then dried (MgSO,) and concentrated. The residue was . 25 subjected to silica gel column chromatography to obtain 6-methyl-3-pyridyl trifluoromethanesulfonate (23.10 g, yield 84%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 6 : 2.61(3H, s), 7.27(1H, 4, J=8.4 Hz), 7.52(1H, dd, J=2.8, 8.4 Hz), 8.47(1H, 4d, J=2.8 Hz).
Reference Example 150
A mixture of 6-methyl-3-pyridyl } tifluoromethanesulfonate (23.00 g), phenylboronic acid (11.83 g), tetrakis(triphenylphosphine)palladium (5.00 g)., sodium carbonate (22.43 g), ethanol (100 ml), water
- (100 ml) and toluene (500 ml) was refluxed overnight under an argon atmosphere. The reaction mixture was poured . into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous . 5 sodium chloride solution, dried (MySo0,) and concentrated.
The residue was subjected to silica gel column chromatography to obtain 2-methyl-5-phenylpyridine (15.24 g, yield 94%) as a colorless oily substance from the fraction eluted with ethyl acetate. : 10 NMR (CDC1,) 0 : 2.61(3H, s), 7.23(1H, 4d, J=8.0 Hz), 7.32- 7.63(5H, m), 7.78(1H, dd, J=2.6, 8.0 Hz), 8.73(1H, 4, J=2.6
Hz).
Reference Example 151
A mixture of 2-methyl-5-phenylpyridine (3.00 g), } o 3-chloroperbenzoic acid (4.79 g) and tetrahydrofuran (50 ml) was stirred at room temperature overnight, and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with tetrahydrofuran.
A solution of the resulting colorless oily substance in acetic anhydride (50 ml) was added slowly to acetic anhydride (50 ml) heated at 130°C, which was stirred at 2 hours, and concentrated. The residue was dissolved in ethyl acetate, which was washed with saturated agueous sodium bicarbonate solution, and with saturated aqueous sodium chloride solution, and then dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain 5-phenyl-2- pyridylmethyl acetate (3.68 g, yield 92%) as colorless : : crystals from the fraction eluted with ethyl acetate- hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 71-72°C
Reference Example 152
A solution of p-toluenesufonylmethylisocyanide
(10.3 g) in dimethoxyethane (50 ml) was added to a mixture of potassium t-butoxide (11.2 g) and dimethoxyethane (50 : ml) at -78°C, and the mixture was stirred for 5 minutes.
A solution of l-benzyl-3-benzyloxy-lH-pyrazole-4- : 5 carbaldehyde (14.6 g) in dimethoxyethane (50 ml) was added } to the mixture. After stirring at the same temperature for 1 hour, the mixture was stirred for 1 hour while raising the temperature. Methanol (150 ml) was added to the mixture, which was refluxed for 1 hour. After cooling, the reaction solution was poured into saturated aqueous ammonium chloride solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain 1-benzyl-3- benzyloxy-1H-pyrazol-4-ylacetonitrile (13.1 g, yield 86%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 3.42(2H, s)., 5.11(2H, s), 5.24(2H, s), 7.18-7.24(3H, m), 7.27-7.47(8H, m).
Reference Example 153
A mixture of 1l-benzyl-3-benzyloxy-lH-pyrazol-4- } ylacetonitrile (13.0 g). 4N aqueous sodium hydroxide solution (100 ml), tetrahydrofuran (100 ml) and ethanol (100 ml) was refluxed for 3 days. After cooling, the mixture was neutralized with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. A mixture of the residue, ethyl iodide (5.2 ml), potassium carbonate (11.9 g) and N,N-dimethylformamide (100 m1) was stirred at room temperature for 3 hours. The reaction } mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSo,),
l61 and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 1-benzyl-3- : benzyloxy-1H-pyrazol-4-ylacetate (14.9 g, yield 99%) as a colorless oily substance from the fraction eluted with : 5 ethyl acetate-hexane (1:2, volume ratlo).
NMR(CDC1,) 0 : 1.22(3H, t, J=7.2 Hz), 3.39(2H, s), 4.12(2H, q, J=7.2 Hz), 5.12(2H, s), 5.24(2H, s), 7.17-7.26(3H, m), 7.28-7.49(8H, m).
Reference Example 154
A mixture of ethyl 1-benzyl-3-benzyloxy-1H- pyrazol-4-ylacetate (14.9 g), 5% palladium-carbon (15.0 g), tetrahydrofuran (150 ml) and ethanol (150 ml) was stirred for 2 hours under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated to obtain ethyl 1l-benzyl-3- hydroxy-1H-pyrazol-4-ylacetate (9.76 g, yield 88%) as colorless crystals. This was recrystallized from tetrahydrofuran-hexane. Melting point: 156-157°C
Reference Example 155
Sodium hydride (60%, oily, 1.20 g) was added to a solution of ethyl 1l-benzyl-3-hydroxy-1H-pyrazol-4- ylacetate (7.81 g) in N,N-dimethylformamide (100 ml) at 0°C, which was stirred at room temperature for 15 minutes.
Ethyl iodide (2.40 ml) was added to the mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with - ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica } gel column chromatography to obtain ethyl l1l-benzyl-3- ethoxy-1H-pyrazol-4-ylacetate (7.52 g, yield 87%) as a . colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 0 : 1.25(3H, t, J=7.0 Hz), 1.35(3H, t, J=7.0 Hz),
3.36(2H, s), 4.14(2H, q, J=7.0 Hz), 4.23(2H, q, J=7.0 Hz), 5.10(2H, s), 7.16-7.38(6H, m).
Reference Example 156 : 5 A mixture of ethyl 1. benzyl 3-.ethoxy-1H pyrazol- 4-ylacetate (7.50 g), 5% palladium-carbon (15.0 g),. formic acid (50 ml) and ethanol (100 ml) was refluxed for 1 hour. After cooling, the palladium-carbon was removed by filtration, and the filtrate was concentrated. The residue was dissolved in ethyl acetate. which was washed with saturated aqueous sodium bicarbonate solution, and with a saturated aqueous sodium chloride solution, dried (MgsSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3- ethoxy-1H-pyrazol-4-ylacetate (2.79 g, yield 54%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 6: 1.27(3H, t, J=7.2 Hz), 1.38(3H, t, J=7.0 Hz), 3.41(2H, s), 4.14(2H, q, J=7.2 Hz), 4.25(2H, q, J=7.0 Hz), 7.38(1H, s), 9.38(1H, br.s).
Reference Example 157
Lithium aluminium hydride (1100 mg) was added gradually to a solution of ethyl 1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H- pyrazole-4-carboxylate (14.39g) in tetrahydrofuran(50ml) at 0°C, which was stirred for 30 minutes. Sodium sulfate decahydrate (12.14 g) was added to the reaction mixture, and the precipitate was removed by filtration.The filtrate was concentrated, and the residue was subjected to silica gel column chromatography to obtain [1-[4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3~-(2- thienyl)-1H-pyrazol-4-yl]methanol (12.20g, yield : 93%) as . pale yellow oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6: 2.44(3H, s), 4.69(2H, 4, J=5.4 Hz), 4.99(2H,
s), 5.24(2H, s), 6.96-7.13(3H, m), 7.20-7.34(4H, m), 7.38-7.48(4H, m), 7.96-8.06(2H, m).
Reference Example 158 : 5 A mixture of [1 [4 (5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2- -thienyl) 1H-pyrazol-~4- yllmethanol (12.15g), activated manganese dioxide (37.039), and tetrahydrofuran (200ml) was stirred at room temperature overnight. After the manganese dioxide was removed by filtration, the filtrate was concentrated to obtain 1- [4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazole-4-carbaldehyde (11.68g, yield : 96%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point : 136~137T.
Reference Example 159
Lithium aluminium hydride (540 mg) was added gradually to a solution of ethyl 1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]~3-~(2-thlenyl)-1H-pyrazole-4- carboxylate (7.10g) in tetrahydrofuran(50ml) at 0°C, which was stirred for 30 minutes. Sodium sulfate decahydrate (4.33g) was added to the reaction mixture, and the precipitate was removed by filtration. The filtrate was concentrated, and the residue was subjected to silica gel column chromatography to obtain [1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yl]lmethanol (6.31g, yield : 96%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane.
Melting point : 147~148T.
Reference Example 160
A mixture of [1-[4-(2-phenyl-4- . thiazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllmethanol (5.57 g), activated manganese dioxide (16.11 g). and tetrahydrofuran (100 ml) was stirred at room temperature overnight. After the manganese dioxide was removed by filtration, the filtrate was concentrated to : obtain 1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazole-4-carbaldehyde (5.39g, yield : 98%) : 5 as colorless crystals. This was recrystallized from acetone-hexane. Melting point : 115~116C.
Reference Example 161 :
A solution of DP -toluenesulfonylmethylisocyanide (0.95 g) in dimethoxyethane (10 ml) was added to a mixture of potassium tert-butoxide (1.01 g) and dimethoxyethane (10 ml) at -78C, and the mixture was stirred for 5 minutes.
A solution of 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazole-4- carbaldehyde (2.01g) in dimethoxyethane (20 ml) was added to the mixture, and then stirred at the same temperature for 1 hour, and at room temperature for 1 hour. Methanol (40ml) was added to the mixture, and reflux was conducted for 1 hour. After cooling, the reaction mixture was poured into saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgso,), and concentrated. The residue was subjected to silica gel chromatography to obtain [1-{4-(5-methyl- 2-phenyl-4-oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H- pyrazol-4-yllacetonitrile (1.69g, yield : 78%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 0: 2.44(3H, s), 3.69(2H, s), 4.99(2H, s), 5.24(2H, s), 6.96-7.48(11H, m), 7.95~8.08(2H, m).
Reference Example 162 : A mixture of 1-[4-(5-methyl-2-phenyl-4- : oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazole-4- carbaldehyde (5.02 g), diethyl malonate (2.12 g), piperidine (0.35 ml), benzoic acid (0.27 g), and toluene
(50 ml) was subjected to azeotropic dehydration for 1 hour.
The reaction mixture was poured into dilute hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride . 5 solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). Sodium } borohydride (170 mg) was added to a mixture of the obtained colorless oily substance, ethanol (20 ml), and tetrahydrofuran (20 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into dilute hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSo,), and concentrated. The residue was subjected to silica gel chromatography to obtain diethyl [1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H- pyrazol-4-yllmethyl malonate (6.08 g, yield : 92%) as a pale yellow oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0: 1.14-1.35(6H, m), 2.44(3H, s), 3.24(2H, 4,
J=7.6Hz), 3.61(1H, t, J=7.6 Hz), 4.05-4.18(4H, m), 4.98 (2H, s)., 5.20(2H, s), 6.92-7.34(8H, m), 7.38-7.48(3H, m), 7.96-8.06(2H, m).
Reference Example 163
A mixture of 1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazole-4- carbaldehyde (3.70g), diethyl malonate (1.56 g), piperidine (0.25 ml), benzoic acid (0.20 g), and toluene } (50 m1) was subjected to azeotropic dehydration for 1 hour.
The reaction mixture was poured into dilute hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel chromatography to obtain a colorless oily substance from the fraction eluted with : ethyl acetate-hexane (1:2, volume ratio). Sodium oo borohydride (150 mg) was added to a mixture of the obtained . 5 colorless oily substance, ethanol (30 ml), and tetrahydrofuran (30 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into dilute hydrochloric acid, and extracted : with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,). and concentrated. The residue was subjected to silica gel chromatography to obtain diethyl [1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllmethyl malonate (4.09g, yield : 84%) as a pale yellow oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 : 1.18(6H, t, J=7.0 Hz), 3.24(2H, 4, J=7.6 Hz), 3.62(1H, t, J=7.6 Hz), 4.12(4H, q, J=7.0 Hz), 5.20(2H, s), 5.26(2H, s), 6.94-7.04(2H, m), 7.09(1H, dd, J=3.6, 5.2 Hz), 7.15-7.36(6H, m), 7.40-7.48(3H, m), 7.90-7.99(2H, m).
Reference Example 164
Lithium aluminium hydride (210 mg) was added portionwise to a solution of ethyl 1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazole-4- carboxylate (2.73 g) in tetrahydrofuran(50 ml) at 0°C, which was stirred for 30 minutes. After sodium sulfate decahydrate (1.80 g) was added to the reaction mixture, and the precipitate was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography to obtain [1-[4-(2- ] | phenyl-4-oxazolylmethoxy)benzyl]-3~-(2-thienyl)-1H- pyrazol-4-yllmethanol (2.33 g, yield :94 %) as colorless crystals from the fraction eluted with ethyl acetate- hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point :155~156T.
Reference Example 165 . A mixture of [1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- . 5 yllmethanol (2.03 g), activated manganese dioxide (6.00 4g), and tetrahydrofuran (50 ml) was stirred at room temperature overnight. After the manganese dioxide was removed by filtration, the filtrate was concentrated to obtain 1- [4-(2-phenyl-4-0oxazolylmethoxy)benzyl]-3-(2-thienyl)- l1H-pyrazole-4-carbaldehyde (1.74 g, yield : 86%) as colorless crystals. This was recrystallized from ethyl acetate-hexane. Melting point :153~154T.
Reference Example 166
A mixture of 1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazole-4- carbaldehyde (1.60 g), diethyl malonate (0.69 g), piperidine (0.12 ml), benzoic acid (0.09 g), and toluene (50 m1) was subjected to azeotropic dehydration for 1 hour.
The reaction mixture was poured into dilute hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel chromatography to obtain a colorless oily substance from the fraction eluted with : ethyl acetate-hexane (1:2, volume ratio). Sodium borohydride (105 Ilg) was added to a mixture of the obtained colorless oily substance, ethanol (20 ml), and © tetrahydrofuran (20 ml) at 0°C, and the mixture was stirred : 30 at room temperature for 1 hour. The reaction mixture was poured into dilute hydrochloric acid, and extracted with. } ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), } and concentrated. The residue was subjected to silica gel chromatography to obtain diethyl [1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl])-3-(2-thienyl)-1H-pyrazol-4-
yl)lmethyl malonate (1.76 g, yield : 83%) as a colorless oily substance from the fraction eluted with ethyl acetate- : hexane (1:2, volume ratio).
NMR(CDC1,) 6: 1.18(6H, t, J=7.0 Hz), 3.24(2H, d, J=7.8 Hz), : '5 3.61(1H, , J=7.8 Hz), 4.11(2H, y, J=7.0 Hz), 4.12(2H, q,
J=7.2Hz), 5.07(2H, d, J=1.0Hz), 5.20(2H, 5), 6.95-7.01(2H, m), 7.0(1H, dd, J=%.0, 3.6 Hz), .7.17-7.32 (5H, m), 7.42-7.50(3H, m), 7.73(1H, J=1.0 Hz), 8.02-8.08(2H, m)_.
Reference Example 167
A mixture of 2-acetylthiophene (50.75 g), sodium hydride (60%, oily, 16.33 g), and diethyl carbonate (500 ml) was stirred at 80 C for 1 hour. Water was added to the reaction mixture and the water layer was neutralized with dilute hydrochloric acid. After stirring at room temperature for 30 minutes, the reaction mixture was extracted with ethyl acetate. The ethyl acetate layer was .washed with saturated aqueous sodium chloride solution, dried (MgsSoO,), and concentrated. A mixture of the residue and N, N-dimethylformamide dimethyl acetal (52.46 g) was refluxed for 1.5 hours. The reaction mixture was concentrated and the residue was dissolved in ethanol (500 ml). Hydrazine hydrate (20.09 g) was added to the solution, and refluxed for 3 hours. The reaction mixture was concentrated and saturated aqueous sodium bicarbonate solution was added to the residue. The mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting crystals were collected by filtration to obtain ethyl 3-(2- thienyl)-1H-pyrazole-4-carboxylate (73.22g, yield : 82%).
This was recrystallized from ethyl acetate-hexane.
Melting point : 123~124T.
Example 1
Sodium hydride (60%, oily, 2.55 g) was added to a mixture of methyl 4-phenylpyrrole-3-carboxylate (11.6149), . 4-benzyloxybenzyl chloride (15.23 g) and N,N- dimethylformamide (100 ml) at 0°C, and the mixture was . 5 stirred for one hour. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,), and then concentrated. The residue was subjected to silica gel column chromatography, and methyl 1-(4- benzyloxybenzyl)-4-phenylpyrrole-3-carboxylate (22.16 g, yield: 97%) was obtained from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 97 - 98°C.
Example 2
Sodium hydride (60%, oily, 2.13 g) was added to a mixture of 1-(4-benzyloxybenzyl)-4-phenylpyrrole-3- carbaldehyde (18.00 g), ethyl diethylphosphonoacetate (12.09 g) and N,N-dimethylformamide (150 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours.
The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated.
The residue was subjected to silica gel column . chromatography, and ethyl (E)-3-[1-(4-benzyloxybenzyl)- 4-phenyl-3-pyrrolyl]lpropenoate (20.16 g, yield: 94%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). This was . recrystallized from ethyl acetate-hexane. Melting point: 111 - 112°C.
Example 3
Sodium hydride (60%, oily, 298 mg) was added to a mixture of methyl 4-phenylpyrrole-3-carboxylate (1.50 g). . 4-(4-chloromethylphenoxymethyl)-5-methyl-2- phenyloxazole (2.34 g) and N,N-dimethylformamide (15 ml) . 5 at 0°C, and the mixture was stirred for one hour. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and methyl 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy) benzyl] -4-phenylpyrrole-3-carboxylate (3.12 g, yield: 88%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). Thiswas recrystallized fromethyl acetate-hexane.
Melting point: 115 - 116°C.
Example 4 .
Sodium hydride (60%, oily, 222 mg) was added to a mixture of 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-4-phenylpyrrole-3-carbaldehyde (2.37 g), ethyl diethylphosphonoacetate (1.1 ml) and tetrahydrofuran (30 ml) at 0°C, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with ~ saturated aqueous sodium chloride solution, dried (Mgso,), and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl (E)-3-[1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropenoate (2.13 g, yield: 78%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). This was . recrystallized from ethyl acetate-hexane. Melting point: 120 - 121°C.
Example 5
A mixture of ethyl (E)-3-[1-[4 (5 methyl 2. phenyl- : 4-oxazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropenoate (600 mg), a 1N agueous sodium hydroxide : 5 solution (5 ml), tetrahydrofuran (% ml) and ethanol (% ml) was stirred at 60°C for 3 hours and 1N hydrochloric acid (7 ml) was added, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The crystals obtained were collected by filtration to yield (E)-3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-4-phenyl-3-pyrrolyl]propenoic acid (521 mg, yield: 92%). This was recrystallized from ethyl acetate-hexane. Melting point: 154 - 155°C.
Example 6
A mixture of ethyl (E)-3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl] 4. -phenyl-3- pyrrolyl]lpropenoate (700mg), 5% palladium-carbon (1.00 g) and tetrahydrofuran (15 ml) was stirred for one hour at room temperature under a hydrogen atmosphere. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropionate (618 mg, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:7, volume ratio).
NMR(CDC1,) 0 :1.20(3H, t, J=7.1 Hz), 2.43(3H, s), 2.47- 2.56(2H, m), 2.91-3.00(2H, m), 4.08(2H, gq, J=7.1 Hz), 4.95(2H, s)., 4.98(2H, s), 6.51(1H, 4, J=2.2 Hz), 6.71(1H, . d, J=2.2 Hz), 6.98(2H, 4d, J=8.8 Hz), 7.10-7.47(10H, m), 7.97-8.04(2H, m).
Example 7
A mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]--4.--phenyl-3-pyrrolyl]propionate : (531 mg), lithium hydroxide monohydrate (128 mg), tetrahydrofuran (6 ml), ethanol (4 ml) and water (4 ml) was . 5 stirred at room temperature for: 2 hours and acidified by adding 1N hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropionic acid (451 mg, yield: 90%). This was recrystallized from ethyl acetate-hexane. Melting point: 124 - 125°C.
Example 8
A mixture of ethyl 3-{1-(4-hydroxybenzyl)-4- phenyl-3-pyrrolyl]propionate (1.01 g), 4-chloromethyl- 2-(2-furyl)-5-methyloxazole (0.75 9g), potassium carbonate (0.63 g) and N,N-dimethylformamide (15 ml) was stirred at room temperature overnight. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the oily substance obtained, 1N aqueous sodium hydroxide solution (6 ml), tetrahydrofuran (5 ml) and ethanol (10 ml) was stirred at room temperature for 3 hours and the organic solvent was . removed under reduced pressure. After adding water, the residue was acidified by adding 1N hydrochloric acid. The ) colorless crystals obtained were collected by filtration to yield 3-[1-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyl]-4-phenyl-3-pyrrolyl)propionic acid (1.02 g, yield: 73%). This was recrystallized from ethyl acetate-hexane. Melting point: 86 - 87°C.
Example 9 : 5 A mixture of ethyl 3-[1-(4-hydroxybenzyl) 4. phenyl-3-pyrrolyl)propionate (1.30 g), 4-chloromethyl- 5-methyl-2-(2-thienyl)oxazole (0.95 g), potassium carbonate (1.20 g) and N,N-dimethylformamide (15 ml) was stirred at room temperature overnight. The reaction mixture was poured into dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the oily substance obtained, 1N aqueous sodium hydroxide solution (8 ml), tetrahydrofuran (10 ml) and ethanol (8 ml) was stirred at room temperature for 3 hours and the organic solvent was removed under reduced pressure. After adding water, the residue was acidified by adding 1N hydrochloric acid. The colorless crystals obtained were collected by filtration to yield 3-[1-[4-[5-methyl-2-(2-thienyl)-4- oxazolylmethoxylbenzyl)-4-phenyl-3-pyrrolyl]propionic acid (1.43 g, yield: 77%). This was recrystallized from ethyl acetate-hexane. Melting point: 117 - 118°C. .
Example 10 oo
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-4- phenyl-3-pyrrolyl]propionate (1.55g), benzyl bromide (0.7 ml), potassium carbonate (0.92 g) and N,N- dimethylformamide (15 ml) was stirred at room temperature overnight. The reaction mixture was poured into dilute . hydrochloric acid, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgso,). and then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained . from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). A mixture of the oily substance obtained, : 5 IN aqueous sodium hydroxide solution (8 ml), tetrahydrofuran (8 ml) and cthanol (8 ml) was stirred at room temperature for 3 hours and the organic solvent was removed under reduced pressure. After adding water, the residue was acidified by adding 1N hydrochloric acid. The colorless crystals obtained were collected by filtration to yield 3-[1-(4-benzyloxybenzyl)-4-phenyl-3- pyrrolyll}propionic acid (1.53 g, yield: 84%). This was : recrystallized from ethyl acetate-hexane. Melting point: 130 - 131°C.
Example 11 :
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-4- phenyl-3-pyrrolyl]propionate (1.31 g). 2 -picolyl chloride hydrochloride (0.73 g), potassium carbonate (0.69 g) and
N,N-dimethylformamide (15 ml) was stirred at room temperature overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the oily substance obtained,
IN aqueous sodium hydroxide solution (8 ml), tetrahydrofuran (8 ml) and ethanol (8 ml) was stirred at room temperature for 3 hours and the organic solvent was removed under reduced pressure. After adding water, the residue was neutralized by adding 1N hydrochloric acid. . The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-{4-(2- pyridylmethoxy)benzyl]-3-pyrrolyl])propionic acid (1.06 g,
yield: 69%). This was recrystallized from ethanol-water.
Melting point: 109 - 110°C.
Example 12
A mixture of ethyl 3. [1.(4 hydroxybenzyl). 4. phenyl-3-pyrrolyl]}propionate (1.35 g), 3-picolyl chloride hydrochloride (0.76 g), potassium carbonate (0.85% g) and
N,N-dimethylformamide (15 ml) was stirred at room temperature overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). A mixture of the oily substance obtained,
IN aqueous sodium hydroxide solution (8 ml), tetrahydrofuran (8 ml) and ethanol (8 ml) was stirred at room temperature for 3 hours and the organic solvent was removed under reduced pressure. After adding water, the residue was neutralized by adding 1N hydrochloric acid.
The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4-(3- pyridylmethoxy)benzyl]-3-pyrrolyl]propionic acid (0.76 g, yield: 48%). This was recrystallized from ethanol-water.
Melting point: 131 - 132°C.
Example 13
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-4- phenyl-3-pyrrolyllpropionate (1.10 g), 4-picolyl chloride hydrochloride (0.60 g), potassium carbonate (0.88 g) and
N,N-dimethylformamide (15 ml) was stirred at room temperature overnight. The reaction mixture was poured . into water, which was extracted with ethyl acetate. The. ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained - from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). A mixture of the oily substance obtained, : 5 IN aqueous sodium hydroxide solution (6 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours and the organic solvent was removed under reduced pressure. After adding water, the residue was neutralized by adding 1N hydrochloric acid.
The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4-(4- pyridylmethoxy)benzyl]-3-pyrrolyl]propionicacid (0.98g, yield: 75%). This was recrystallized from acetone-hexane. ‘
Melting point: 124 - 125°C.
Example 14
A toluene solution (5.66 g) of 40% diethyl : azodicarboxylate was added dropwise slowly to a mixture of "ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyllpropionate (2.84 g), 2-(5-methyl-2-phenyl-4- oxazolyl)ethanol (2.48 g), triphenylphosphine (3.31 g) and tetrahydrofuran (25 ml) at room temperature. After the above solution was stirred at room temperature for 2 hours, the reaction solvent was removed under reduced pressure.
The residue was subjected to silica gel column chromatography, and an oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio). A mixture of the oily substance obtained, 1N aqueous sodium hydroxide solution (15 ml), tetrahydrofuran (15 ml) and ethanol (15 ml) was stirred at room temperature for 3 hours and the organic solvent was removed under . reduced pressure. After adding water, the residue was acidified by adding 1N hydrochloric acid. The colorless crystals obtained were collected by filtration to yield 3-[1-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxylbenzyl]-4-phenyl-3-pyrrolyl]lpropionic acid (2.72 g, yield: 57%). This was recrystallized from ethanol-water. Melting point: 147 - 148°C.
Example 15 : 5 Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3: [1 (4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]lpropionate (524 mg) in N,N-dimethylformamide (10 ml) at 0° C, and the mixture was stirred at room temperature for 15 minutes. 2-(4-Chloromethyl-2-thiazolyl)pyrazine (349 mg) was added to the mixture, which was stirred at room temperature for 15 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgso,)., and then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-([4-phenyl-1-[4-[2- (2-pyradinyl)-4-thiazolylmethoxylbenzyl]-3- . pyrrolyl]propionate (629 mg, yield: 80%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 : 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.2 Hz), 4.96(2H, s), 5.28(2H, s), 6.51(1H, 4, J=2.4 Hz), 6.72(1H, 4, J=2.4 Hz), 6.99(2H, 4d, J=8.8 Hz), 7.16(2H, 4, J=8.8 Hz), 7.19-7.42(5H, m), 7.50(1H, s), 8.56(1H, Add, J=2.4, 1.6 Hz), 8.61(1H, 4, . J=2.4 Hz), 9.43(1H, 4, J=1.6 Hz).
Example 16
A mixture of ethyl 3-[4-phenyl-1-[4-[2-(2- pyrazinyl)-4-thiazolylmethoxy]lbenzyl]-3- pyrrolyl]propionate (629 mg), 1N aqueous sodium hydroxide } solution (2.5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature overnight and 1N hydrochloric acid (2.5 ml) was added, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith saturated aqueous sodium chloride solution, dried (MgSoO,),
and then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4- [2-(2-pyrazinyl)-4-thiazolylmethoxy]benzyl]-3- : pyrrolyllpropionic acid (523 mg, yield: 88%) as colorless : 5 crystals. This was recrystallized from ethanol. Melting point: 137 -~ 138°C.
Example 17
A toluene solution (1.04 g) of 40% diethyl azodicarboxylate was added dropwise slowly to a mixture of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]propionate (699 mg), 3-furanmethanol (0.172 ml), _ triphenylphosphine (577 mg) and tetrahydrofuran (20 ml) at room temperature. After the solution was stirred at room temperature overnight, the reaction solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-(3- furylmethoxy)benzyl]-4-phenyl-3-pyrrolyl)propionate (385 mg, yield: 45%) was obtained as an oily substance from =. the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDCl1l,) 0 : 1.19(3H, t, J=7.0 Hz), 2.51(2H, t, J=7.8 Hz), 2.94(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.0 Hz), 4.91(2H, s), 4.94(2H, s), 6.48(1H, 4, J=1.8 Hz), 6.50(1H, 4, J=2.6 Hz), 6.71(1H, 4, J=2.6 Hz), 6.92(2H, 4, J=8.8 Hz), 7.12(2H, 4,
J=8.8 Hz), 7.16-7.43(5H, m), 7.49(1H, 4d, J=1.8 Hz).
Example 18
A mixture of ethyl 3-[1-[4-(3- furylmethoxy)benzyl]-4-phenyl-3-pyrrolyl]propionate (382 mg), 1IN aqueous sodium hydroxide solution (2 ml), . tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature overnight, and 1N hydrochloric acid (2 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, and dried (MgSO4). then concentrated. - The colorless crystals obtained were collected by filtration to yield 3-[1-[4-(3-furylmethoxy)benzyl]-4- : 5 phenyl-3-pyrrolyllpropionic acid (257 my, yield: 72%).
This was recrystallized from ethanol hexane. Melting point: 110 - 111°C.
Example 19
A toluene solution (1.74 g) of 40% diethyl azodicarboxylate was added dropwise slowly to a mixture of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]propionate (873 mg), 2-thiophenemethanol (0.237 ml), triphenyl phosphine (984 mg), and tetrahydrofuran (20 ml) at room temperature. After the solution was stirred overnight at room temperature, the reaction solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4- (2-thienylmethoxy)benzyl]}-4-phenyl-3- pyrrolyl]propionate (620 mg, yield: 56%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 0 : 1.19(3H, t, J=7.3 Hz), 2.51(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.2 Hz), 4.94(2H, s), ‘25 5.20(2H, s), 6.50(1H, 4, J=2.2 Hz), 6.70(1H, 4d, J=2.2 Hz), 6.90-7.02(3H, m), 7.14-7.25(4H, m), 7.30-7.41(5H, m).
Example 20
A mixture of ethyl 3-[4-phenyl-1-[4-(2- thienylmethoxy)benzyl]-3-pyrrolyl]lpropionate (620 mg),
IN aqueous sodium hydroxide solution (3 ml), . tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 7 hours, and 1N hydrochloric acid (3 . ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-(4-phenyl--1-[4-(2- . thienylmethoxy)benzyl]~3-pyrrolyl]propionic acid (272 mg, yield: 47%). This was recrystallized from ethyl acetate hexane. Melting point: 127 - 128°C
Example 21
A toluene solution (1.74 g) of 40% diethyl azodicarboxylate was added dropwise slowly to a mixture of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyllpropionate (873 mg), 3-thiophenemethanol (0.236 ml), triphenyl phosphine (984 mg), and tetrahydrofuran (20 ml) at room temperature. After the solution was stirred overnight at room temperature, the reaction solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4- (3-thienylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropionate (629 mg, yield: 56%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 6 : 1.19(3H, t, J=7.2 Hz), 2.51(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.0 Hz), 4.93 (2H, s), 5.05(2H, s), 6.50(1H, d. J=2.2 Hz), 6.71(1H, 4, J=2.2 Hz), 6.92(2H, 4, J=8.8 Hz), 7.08-7.22(4H, m), 7.31-7.41(6H, m).
Example 22
A mixture of ethyl 3-{4-phenyl-1-[4-(3- thienylmethoxy)benzyl]-3-pyrrolyl]jpropionate (624 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 5 hours, and 1N hydrochloric acid (3 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated } aqueous sodium chloride solution, dried (MgSO4), and then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4-(3-
thienylmethoxy)benzyl]-3-pyrrolyl]propionic acid (421 mg, yield: 72%). This was recrystallized from ethyl - acetate-hexane. Melting point: 118 - 119°C : 5 Example 23 p . A toluene solution (1.74 g) of 40% diethyl azodicarboxylate was added dropwise slowly to a mixture of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyllpropionate (873 mg), furfuryl alcohol (0.216 ml), triphenyl phosphine (984 mg), and tetrahydrofuran (20 ml) at room temperature. After the solution was stirred overnight at room temperature, the reaction solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4- (2-furylmethoxy)benzyl]-4-phenyl-3-pyrrolyl])propionate (624 mg, yield:58%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, gq, J=7.2 Hz), 4.94(2H, s), 4,99(2H, s), 6.38(1H, 44, J=3.2, 1.4 Hz), 6.43(1H, 4, J=3.2
Hz), 6.50(1H, 4, J=2.4 Hz), 6.71(1H, 4d, J=2.4 Hz), 6.95(2H, d, J=8.8 Hz), 7.10-7.45(8H, m).
Example 24
A mixture of ethyl 3-[1-[4-(2- furylmethoxy)benzyl)-4-phenyl-3-pyrrolyl]propionate (624 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 3 hours, and 1N hydrochloric acid (3 ml) was added to the mixture, which was extracted with ethyl . acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO4), then . concentrated. The residue was subjected to silica gel column chromatography, and 3-[1-[4-(2- furylmethoxy)benzyl)-4-phenyl-3-pyrrolyl]jpropionic acid
(386 mg, yield:66%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume . ratio).
NMR(CDC1,) 0 : 2.58(2H, t, J=7.8 Hz), 2.96(2H, t, J=7.8 Hz), 4.94(2H, s), 4.98(2H, ©), 6.37(1H, 4d, J-:3.4, 1.8 Hz), 6.42(1H, d, J~3.4 Hz), 6.52(1H, d, J=2.4 Hz), 6.71(1H, 4a,
J=2.4 Hz), 6.94(2H, d, J=8.8 Hz), 7.12(2H, 4, J=8.8 Hz), 7.19-7.44(8H, m). :
Example 25
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]propionate (524 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 3-Chloromethyl-2-methylpyridine (212 mg) was added to the mixture, which was stirred at room temperature for 15 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. ‘The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-(2-methyl-3- pyridylmethoxy)benzyl]}-4-phenyl-3-pyrrolyl]propionate (581 mg, yield: 85%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 2.52(2H, t, J=7.8 Hz), 2.59(3H, s), 2.96(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.0 Hz), 4.96(2H, s), 5.03(2H, s), 6.51(1H, 4, J=2.6 Hz), 6.72(1H, d, J=2.6 Hz), 6.72(1H, 4, J=2.6 Hz), 6.94(2H, d, J=8.8 Hz), 7.11-7.42(8H, m), 7.71(1H, 44, J=7.8, 1.8 Hz), 8.48(1H, dd,
J=4.8, 1.8 Hz). } Example 26
A mixture of ethyl 3-[1-[4-(2-methy-3- pyridylmethoxy)benzyl]-4-phenyl-3-pyrrolyl]propionate
(568 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at : room temperature for 4 hours, and 1N hydrochloric acid (3 ml ) was added to the mixture, which was extracted with ethyl : 5 acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3: [1:.[4-(2-methyl-3- pyridylmethoxy)benzyl]-4-phenyl-3-pyrrolyl]propionic acid (465 mg, yield: 87%). This was recrystallized from ethyl acetate-hexane. Melting point: 158 - 159°C
Example 27
Sodium hydride (60%, oily, 60.0 mg) was added to a © 15 solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyllpropionate (524 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 4-Chloromethyl-5-methyl-2- : phenylthiazole (336 mg) was added to the mixture, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-(5-methyl-2- © phenyl-4-thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyl]lpropionate (690 mg, yield: 86%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR (CDC1,) 0:1.19(3H, t, J=7.2 Hz), 2.51(2H, t, J=7.8 Hz), 2.52(3H, s), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.2 Hz), . 4.94(2H, s), 5.15(2H, s), 6.50(1H, 4d, J=2.4 Hz), 6.71(1H, d, J=2.4 Hz), 7.00(2H, d, J=8.8 Hz), 7.13(2H, 4, J=8.8 Hz), } 7.16-7.25(1H, m), 7.29-7.46(7H, m), 7.86-7.91(2H, m).
Example 28
A mixture of ethyl 3-[1-~[4-(5-methyl-2-phenyl-4- thiazolylmethoxy)benzyl]-4-phenyl-3-pyrrolyl]propionate : (671 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at : 5 room temperature overnight, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-([1-{4-(5-methyl-2- phenyl-4-thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyl]lpropionic acid (495 mg, yield: 78%). This was recrystallized from ethyl acetate-hexane. Melting point: 157 - 158°C.
Example 29
Sodium hydride (60%, oily, 60.0 mg) was added to a solution otf ethyl 3-{1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyllpropionate (524 mg) in N,N-dimethylformamide (10 ml) at 0° C, and the mixture was stirred at room temperature ~~ for 15 minutes. 4-Chloromethyl-2-phenylthiazole (315 mg) was added to the mixture, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[4-phenyl-1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-pyrrolyl]propionate (717 mg, yield: 91%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume . ratio).
NMR(CDC1,) 0 : 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), } 2.95(2H, t, J=7.8 Hz), 4.08(2H, gq, J=7.2 Hz), 4.95(2H, s), 5.25(2H, s), 6.51(1H, 4, J=2.4 Hz), 6.71(1H, 4, J=2.4 Hz), 6.98(2H, d, J=8.8 Hz), 7.13(2H, 4d, J=8.8 Hz), 7.18-7.25(1H,
m), 7.30--7.49(8H, m), 7.91-7.99(2H, m). - Example 30
A mixture of ethyl 3-[4-phenyl-1-[4-(2-phenyl-4- : 5 thiazolylmethoxy)benzyl]-3- pyrrolyllpropionate (706 mg),
IN aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 6 hours, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4-(2- phenyl-4-thiazolylmethoxy)benzyl]-3-pyrrolyl]propionic acid (619 mg, yield: 93%). This was recrystallized from ethanol-hexane. Melting point: 111 - 112°C.
Example 31
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]lpropionate (524 mg) in N,N-dimethylformamide (10 ml) at 0° C, and the mixture was stirred at room temperature for 15 minutes. 4-Chloromethyl-2-(2-pyridyl)thiazole (316 mg) was added to the mixture, which was stirred at room temperature for 30 minutes. The reaction mixture was " poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgS0O4), then concentrated...
The residue was subjected to silica gel column chromatography and ethyl 3-[4-phenyl-1l-{4-[2-(2- pyridyl)-4-thiazolylmethoxy)benzyl]-3- pyrrolyl propionate (590 mg, yield: 75%) was obtained as colorless crystals from the fraction eluted with ethyl . acetate-hexane (1:2, volume ratio). This was : recrystallized from ethyl acetate-hexane. Melting point: : 81 - 82°C.
Example 32 : A mixture of ethyl 3-[4-phenyl-1-[4-[2-(2- pyridyl)-4-thiazolylmethoxy)benzyl]-3- pyrrolyllpropionate (471 my), IN aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature overnight, and 1N hydrochloric acid (2 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer "10 was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4- phenyl-1-{4-[2-(2-pyridyl)-4-thiazolylmethoxy)benzyl]- 3-pyrrolyl]propionic acid (408 mg, yield: 91%). This was recrystallized fromethanol-hexane. Meltingpoint: 117 - : 118°C. :
Example 33
Sodium hydride (60%, oily,60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyllpropionate (524 mg) in N,N-dimethylformamide (10 ml) at 0° C, and the mixture was stirred at room temperature for 15 minutes. 4-Chloromethyl-2-(4-pyridyl)thiazole (316 mg) was added to the mixture, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O4). then concentrated.
The residue was subjected to silica gel column chromatography. and ethyl 3-[4-phenyl-1-{4-[2-(4- pyridyl)-4-thiazolylmethoxy)benzyl]-3- . pyrrolyl]lpropionate (867 mg, yleld: 89%) was obtained as an oily substance from the fraction eluted with ethyl . acetate-hexane (2:1, volume ratio).
NMR(CDC1,) 0:1.20(3H, t, J=7.2 Hz), 2.51(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, gq, J=7.2 Hz), 4.95(2H, s),
'5.27(2H, s), 6.51(1H, 4d, J=2.4 Hz), 6.71(1H, 4d, J=2.4 Hz). 6.98(2H, d, J=8.8 Hz), 7.14(2H, d, J=8.8 Hz), 7.18-7.26(1H, m), 7.29-7.41(4H, m), 7.45(1H, s), 7.81(2H, dd, J=4.8, 1.4
Hz), 8.71(2H, dd, J=4.8, 1.4 Hz). :
Example 34
A mixture of ethyl 3-[4-phenyl-1-[4-[2-(4- pyridyl)-4-thiazolylmethoxy)benzyl]-3- pyrrolyl]propionate (864 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature overnight, and 1N } hydrochloric acid (3 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4- phenyl-1-[{4-[2-(4-pyridyl)-4-thiazolylmethoxy)benzyl]- 3-pyrrolyl]lpropionic acid (771 my, yield: 94%). This was recrystallized from ethanol. Melting point: 149 - 150°C.
Example 35
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl) -4-phenyl-3- pyrrolyl]propionate (524 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 2-(3-Chloromethylphenyl)pyrazine (307 mg) was added to the mixture, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O4)., then concentrated.
The residue was subjected to silica gel column } chromatography, and ethyl 3-[4-phenyl-1-[4-[3-(2- pyrazinyl)benzyloxylbenzyl]-3-pyrrolyl]lpropionate (647 mg, yield: 83%) was obtained as an oily substance from the fraction eluted with ethyl rato. noxane (1:1, volume ratio). : NMR(CDC1,) 0: 1.19(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), . 2.95(2H, t, J=7.8 Hz), 4.08(2H, gq, J=7.2 Hz), 4.94(2H, s), : 5 5.15(2H, s), 6.51(1H, d, J=2.2 Hz), 6.71(1H, d, J=2.2 Hz), 6.96(2H, d, J=8.8 Hz), 7.13(2H, 4, J=8.8 Hz), 7.18-7.41(5H, m), 7.49-7.56(2H, m), 7.92-8.00(1H, m), 8.10(1H, s), 8.52(1H, 4, J=2.6 Hz), 8.64(1H, dd, J=2.6, 1.4 Hz), 9.04(1H, d, J=1.4 Hz). "Example 36
A mixture of ethyl 3-[4-phenyl-1-[4-[3-(2- pyrazinyl )benzyloxylbenzyl]-3-pyrrolyl]propionate (647 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature overnight, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl ‘ acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSQO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4-[3- (2-pyrazinyl)benzyloxylbenzyl]-3-pyrrolyl]propionic acid (470mg, yield:77%). This was recrystallized from ethyl acetate-hexane. Melting point: 91 - 92°C.
Example 37
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]propionate (524 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 4-Chloromethyl-2-(2-furyl)thiazole (299 mg) was added to the mixture, which was stirred at room temperature for 30 minutes. The reaction mixture was } poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[1-{4-[2-(2-furyl)-4- . thiazolylmethoxy]benzyl]-4-phenyl-3-pyrrolyl]propionate (643 mg, yield: 84%) was obtained as an oily substance trom the fraction eluted with ethyl acetate hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.0 Hz), 4.95(2H, s), 5.23(2H, s), 6.52-6.55(2H, m), 6.71(1H, 4, J=2.2 Hz), 6.96(2H, 4, J=8.8 Hz), 7.01(1H, 4, J=2.2 Hz), 7.13(2H, 4,
J=8.8 Hz), 7.16-7.41(6H, m), 7.51(1H, 4d, J=1.8, 0.6 Hz).
Example 38
A mixture of ethyl 3-[1-[4-[2-(2-furyl)-4- thiazolylmethoxy]benzyl]-4-phenyl-3-pyrrolyl]propionate (641 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 5 hours, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[4-[2-(2-furyl)- 4-thiazolylmethoxylbenzyl)]-4-phenyl-3- pyrrolyl]propionic acid (485 mg, yield:78%). This was recrystallized from ethanol-hexane. Melting point: 114 - ‘115°C.
Example 39
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl)propionate (524 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 4-Chloromethyl-2-(2-thienyl)thiazole (324 mg) was added to the mixture, which was stirred at room . temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO¢), then concentrated.
The residue was subjected to silica gel column : 5 chromatography, and ethyl 3--[4 phenyl-1-{4-[2-(2- thienyl)-4-thiazolylmethoxy]benzyl]-3- pyrrolyllpropionate (590 mg, yield: 74%) was obtained as an olly substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,)0: 1.20(3H, t, J=7.0 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.0 Hz), 4.94(2H, s), 5.22(2H, s), 6.51(1H, 4, J=2.2 Hz), 6.70(1H, 4, J=2.2 Hz), 6.96(2H, 4, J=8.8 Hz), 7.03-7.40(10H, m), 7.52(1H, dd,
J=3.6, 1.0 Hz). :
Example 40 }
A mixture of ethyl 3-[4-phenyl-1-[4-[2-(2- thienyl)-4-thiazolylmethoxylbenzyl]-3- pyrrolyl)proplonate (582 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature overnight. and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., and concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4- phenyl-1-[4-[2-(2-thienyl)-4-thiazolylmethoxylbenzyl]- 3-pyrrolyllpropionic acid (421 mg, yield: 76%). This was recrystallized from ethyl acetate-hexane. Melting point: 106 - 107°C.
Example 41
A mixture of ethyl 3-[1l-(4-hydroxybenzyl)-4- phenyl-3-pyrrolyl]propionate (349 mg), 4-chloromethyl- 2-methylthiazole hydrochloride (276 mg), potassium carbonate (276 mg) and N,N-dimethylformamide (5 ml) was stirred at 90°C for 6 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. } | The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mg$S04), and concentrated.
The residue was subjected to silica gel column chromatograpy, and ethyl 3-[1-[4-(2-methyl-4- thiazolylmethoxy)benzyl)] 4-phenyl-3-pyrrolyl]}propionate (373 mg, yield: 81%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.73(3H, s), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.2 Hz), ~ 4.94(2H, s), 5.15(2H, s), 6.50(1H, 4, J=2.2 Hz), 6.71(1H, d, J=2.2 Hz), 6.95(2H, 4, J=8.8 Hz), 7.12(2H, 4, J=8.8 Hz), 7.14-7.41(6H, m).
Example 42
A mixture of ethyl 3-[1-[4-(2-methyl-4- thiazolylmethoxy]benzyl]-4 - phenyl-3 -pyrrolyl lpropionate (368 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for 4 hours, and 1N hydrochloric acid (2 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[4-(2-methyl-4- thiazolylmethoxylbenzyl)-4-phenyl-3-pyrrolyl]propionic acid (251 mg, yield: 73%). This was recrystallized from ethanol-hexane. Melting point: 113 - 114°C.
Example 43
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3- pyrrolyl]propionate (524 mg) in N,N-dimethylformamide (10 ml) at 0° C, and the mixture was stirred at room temperature for 15 minutes. 4-Chloromethyl-2-phenyloxazole (290 mg) was added to the mixture, which was stirred at room , temperature for 30 minutes. The reaction mixture was poured into water. which was extracted with ethyl acetate. . 5 The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS04), then concentrated.
The residue was subjected to silica gel column chromatograpy, and ethyl 3-[4-phenyl-1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-pyrrolyllpropionate (550 mg, yield: 72%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.2 Hz), 4.95(2H, s),. 5.07(2H, s), 6.51(1H, 4, J=2.4 Hz), 6.71(1H, 4, J=2.4 Hz), 6.97(2H, 4, J=8.8 Hz), 7.01-7.50(10H, m), 7.73(1H, s), 8.01-8.10(2H, m).
Example 44 :
A mixture of ethyl 3-[4-phenyl-1l-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-pyrrolyl propionate (532 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature overnight, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[4-phenyl-1-[4-(2- phenyl-4-oxazolylmethoxy]lbenzyl]-3-pyrrolyl]propionic acid (428 mg, yield: 85%). This was recrystallized from ] ethanol-hexane. Melting point: 139 - 140°C. ] Example 45
Sodium hydride (60%. oily. 60.0 mg) was added to a solution of ethyl 3-[1-(4-hydroxybenzyl)-4-phenyl-3-
pyrrolyllpropionate (524 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature : for 15 minutes. 4-Chloromethyl-2-(3-pyridyl)thiazole (316 mg) was added to the mixture, which was stirred at room : 5 temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The residue was subjected to silica gel column chromatograpy. and ethyl 3-[4-phenyl-1-[4-[2-(3- pyridyl)-4-thiazolylmethoxylbenzyl]-3- pyrrolyllpropionate (657 mg, yield: 84%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1l,) 0: 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz), 4.08(2H, q, J=7.2 Hz), 4.96(2H, s), 5.27(2H, s), 6.51(1H, 4, J=2.4 Hz), 6.71(1H, 4, J=2.4 Hz), 6.99(2H, 4, J-8.6 Hz), 7.02-7.42(9H, m), 8.24(1H, dda,
J=8.2, 2.0, 1.2 Hz), 8.66(1H, 4d, J—~4.8, 1.2 Hz), 9.17(1H, : 4d, J=2.0 Hz).
Example 46
A mixture of ethyl 3-[4-phenyl-1-[4-[2-(3- pyridyl) -4-thiazolylmethoxylbenzyl]-3- pyrrolyllpropionate (655mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 6 hours, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals ; obtained were collected by filtration to yield 3-[4- phenyl-1-[4-[2-(3-pyridyl)-4-thiazolylmethoxy]benzyl]- 3-pyrrolyl]lpropionic acid (537 mg, yield: 92%). This was recrystallized from ethanol. Melting point: 118 - 119°C.
. Example 47 . Thionyl chloride (830 mg) was added dropwise to a solution of 4-[2-[N-methyl-N-(2- : 5 pyridyl)aminolethoxylbenzyl alcohol (1.50 q) in toluene (40 ml) at 0°C. After stirring at room temperature for 2 hours, the reaction mixture was concentrated. The residue and methyl 4-phenylpyrrole-3-carboxylate (1.40 g) were dissolved in N,N-dimethylformamide (40 ml). Sodium hydride (60%, oily, 465 mg) was added to the solution at 0° C, which was stirred at room temperature for 3 days. The reaction mixture was poured into saturated aqueous sodium chloride solution, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, then dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatograpy, and methyl 1-{4-[2-[N- methyl-N-(2-pyridyl)aminolethoxy]benzyl]-4- phenylpyrrole-3-carboxylate (1.80 g, yield: 7 0%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 3.15(3H, s), 3.70(3H, s), 3.99(2H, t, J=5.0
Hz), 4.19(2H, t, J=5.0 Hz), 4.97(2H, s), 6.5-6.6(2H, m), 6.64(1H, 4, J=2.5 Hz), 6.88(2H, 4d, J=8.5 Hz), 7.13(2H, 4,
J=8.5 Hz), 7.2-7.55(7H, m), 8.1-8.2(1H, m).
Example 48
Sodium hydride (60%, oily, 200.0 mg) was added to a solution of 1-[4-[2-[N-methyl-N-(2- pyridyl)amino)ethoxylbenzyl]-4-phenylpyrrole-3-
Co carbaldehyde (1.35g) and ethyl diethylphosphonoacetate (1.10 g) in N,N-dimethyltformamide (30 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The . reaction mixture was poured into ice water, then neutralized using 2N hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, dried (MgS0O4). then concentrated. The residue was , subjected to silica gel column chromatograpy, and ethyl (E)-3-[1-[4-(2-[N-methyl-N-(2- : 5 pyridyl)aminolethoxylbenzyl]-4-phenyl-3-~ pyrrolyllpropenoate (1.35 g, yield: 85%) was obtained as an oily substance from the fraction eluted with acetone-hexane (1:2, volume ratio).
NMR(CDC1,) 0 : 1.26(3H, t, J=7 Hz), 3.16(3H, s), 3.95- .10 4.25(6H, m), 4.98(2H, s), 6.05(1H, 4, J=16 Hz), 6.5-6.6(2H, m), 6.69(1H, 4, J=2.5 Hz), 6.88(2H, 4, J=9 Hz), 7.03(1H, d, J=2.5Hz), 7.14(2H, 4, J=9 Hz), 7.2-7.55(6H, m), 7.69(2H, d, J=16 Hz), 8.1-8.2(1H, m).
Example 49
Catalytic hydrogenation of a mixture of ethyl (E)- 3-[1-[4-[2-[N-methyl-N-( 2-pyridyl)amino]ethoxylbenzyl] - 4-phenyl-3.-pyrrolyl]propenoate (1.32 g), 5% palladium- carbon (1.0 g), tetrahydrofuran (40 ml) and ethanol (40 ml) was conducted at ordinary temperature and ordinary pressure. . After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was dissolved in a mixed solution of tetrahydrofuran (10 ml) and ethanol (10 ml), then 1N aqueous sodium hydroxide solution (10 ml) was added to the solution, which was stirred at room temperature for 2 hours. The reaction mixture was poured into water, then neutralized with 1N hydrochloric acid (10 ml), which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O4), and concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[4- [2- [N-methyl N-(2-pyridyl)amino]ethoxylbenzyl]-4- phenyl-3-pyrrolyl])propionic acid (900 mg, yield: 72%).
This was recrystallized from acetone-ethyl acetate.
Melting point: 110 - 111°C
Example 50 ~ 3-Phenoxybenzyl chloride (11.32 g) and ethyl 3-
R phenyl-1H-pyrazole-4-carboxylate (11.30 g) were dissolved in N,N-dimethylformamide (100 ml). Sodium hydride (60%. : 5 oily, 2.49 4) was added to the solution at 0°C, and the solution was stirred at room temperature for 20 hours. The reaction mixture was poured into saturated aqueous sodium chloride solution, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, dried (MgSO4). then concentrated. The residue was subjected to silica gel column chromatograpy, and an oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, . volume ratio). A mixture of the oily substance obtained, potassium hydroxide (8.53 g) and ethanol (150 ml) was refluxed for 5 hours. After the reaction solvent was removed under reduced pressure, water was added to the mixture, then the mixture was acidified using 1N hydrochloric acid. The colorless crystals obtained were "20 collected by filtration to yield 1-(3-phenoxybenzyl)-3- phenyl-1H-pyrazole-4-carboxylic acid (14.83 g, yield: 77%).
This was recrystallized from acetone-hexane. Melting point: 148 - 149°C. i
Example 51
Sodium hydride (60%, oily, 0.36 g) was added to a mixture of methyl 4-phenylpyrrole-3-carboxylate (1.81 g), 6-benzyloxy-2-chloromethylnaphthalene (2.54 g) and N,N- dimethylformamide (35 ml), and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, dried (MgSO4), } then concentrated. The residue was subjected to silica gel column chromatograpy., and methyl 1-(6-benzyloxy-2- naphthylmethyl)-4-phenylpyrrole-3-carboxylate (3.20 g,
~yield:80%) was obtained as colorless crystals from the fraction eluted with tetrahydrofuran-hexane (1:2, volume . ratio). This was recrystallized fromethyl acetate-hexane.
Melting point: 109 - 110°C. . 5
Example 52
Sodium hydride (60%, oily, 0.20 g) was added to a mixture of ethyl diethylphosphonoacetate (0.992 ml) and tetrahydrofuran (20 ml) at 0° C, and the mixture was stirred at room temperature for 30 minutes. A solution of 1- (6-benzyloxy-2-naphthylmethyl) -4-phenylpyrrole-3- carbaldehyde (2.09 g) in tetrahydrofuran (20 ml) was slowly added to the mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield ethyl (E)-3-[1-(6-benzyloxy 2-naphthylmethyl)-4-phenyl- 3-pyrrolyl]propenoate (1.65 g, yield: 68%). This was recrystallized from ethyl acetate-hexane. Melting point: 119 - 120°C.
Example 53 )
Sodium hydride (60%, oily, 36.0 mg) was added to a solution of ethyl 3-[1-(6-hydroxy-2-naphthylmethyl)-4- phenyl-3-pyrrolyllpropionate (360 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. 4-
Chloromethyl-5-methyl-2-phenyloxazole (207 mg) was added to the mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), and concentrated. The residue was subjected to silica gel column chromatograpy. and ethyl
3-[1-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-2- naphthylmethyl]-4-phenyl-3-pyrrolyl]propionate (304 mg, yield: 59%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 0 : 1.17(3H, t, J=7.0 Hz), 2.47(3H, $s), 2.52(2H, t, J=7.8 Hz), 2.97(2H, t, J=7.8 Hz), 4.06(2H, q, J=7.0 Hz), 5.11(2H, s)., 5.13(2H, s), 6.56(1H, d, J=2.2 Hz), 6.77(1H, : d, J=2.2 Hz), 7.15-7.48(11H, m), 7.56(1H, s), 7.71(2H, 4, :
J=8.8 Hz), 7.99-8.06(2H, m).
Example 54
A mixture of ethyl 3-[1-[6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-2-naphthylmethyl]-4-phenyl-3- pyrrolyllpropionate (304 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml) and ethanol (4 ml) was stirred at room temperature for 7 hours, and 1N. hydrochloric acid (2 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO4). then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[6- (5-methyl-2-phenyl-4-oxazolylmethoxy)-2- naphthylmethyl]-4-phenyl-3-pyrrolyl]propionic acid (243 mg, yield: 84%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 122 - 123°C.
Example 55
Sodium hydride (60%, oily, 36.0 mg) was added to a solution of ethyl 3-[1-(6-hydroxy-2-naphthylmethyl)-4- phenyl-3-pyrrolyl)propionate (360 mg) in N,N- . dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 2- . Fluorobenzyl chloride (0.119 ml) was added to this mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4). and concentrated. The residue was subjected to silica gel column chromatograpy., and ethyl 3-[1-[6-(2- ) 5 fluorobenzyloxy) 2 -naphthylmethyl] -4--phenyl-3- pyrrolyllpropionate (404 mg, yicld: 88%) was obtained as : an oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 1.17(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.96(2H, t, J=7.8 Hz) , 4.06(2H, gq, J=7.2 Hz), 5.12(2H, s)., 5.24(2H, s), 6.55(1H, 4, J=2.4 Hz), 6.76(1H, 4, J=2.4 Hz), 7.06-7.43(11H, m), 7.51-7.59(2H, m), 7.68-7.75(2H, m).
Example 56
A mixture of ethyl 3-[1-[6-(2-fluorobenzyloxy)-2- naphthylmethyl]-4-phenyl-3-pyrrolyl]propionate (401mg),
IN aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml) and ethanol (4 ml) was stirred at room temperature for 7 hours, and IN hydrochloric acid (2ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[6-(2~ fluorobenzyloxy)-2-naphthylmethyl]-4-phenyl-3- pyrrolyllpropionic acid (289 mg, yield: 76%). This was recrystallized from ethanol-hexane. Melting point: 143 - 144°C. .
Example 57
Sodium hydride (60%, oily, 60.0 mg) was added to a ‘ solution of ethyl 3-[1-(6-hydroxy-2-naphthylmethyl)-4- phenyl-3-pyrrolyl]propionate (599 mg) in N,N- . dimethylformamide (10 ml) at 0°C, and the mixture was gtirred at room temperature for 15 minutes. 3-Picolyl chloride (230 mg) was added to the mixture, which was stirred at room temperature for 15 minutes. The reaction mixture was poured into water, which was extracted with . ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4). : 5 and concentrated. The residue was subjected to silica gel column chromatograpy, and ethyl 3-[4.--phenyl-1--[6-(3- pyridylmethoxy)-2-naphthylmethyl]-3-pyrrolyl]propionate (647 mg, yield: 88%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0:1.17(3H, t, J=7.0Hz), 2.52(2H, t, J=7.6 Hz), 2.97(2H, t, J=7.6 Hz), 4.06(2H, q, J=7.0 Hz), 5.13(2H, s). 5.19(2H, s), 6.56(1H, 4, J=2.6 Hz), 6.76(1H, 4, J=2.6 Hz), 7.16-7.43(9H, m), 7.57(1H, s), 7.68-7.84(3H, m), 8.60(1H, d, J=4.4 Hz), 8.74(1H, s).
Example 58
A mixture of ethyl 3-[4-phenyl-1-[6-(3- -pyridylmethoxy)-2-naphthylmethyl]-3-pyrrolyllpropionate (638 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature overnight, and 1N hydrochloric acid (2.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated, The colorless crystals obtained were collected by filtration to obtain 3-[4-phenyl-1-[6-(3- pyridylmethoxy)-2-naphthylmethyl]-3-pyrrolyl]propionic acid (508 mg, yield: 84%). This was recrystallized from ethanol. Melting point: 158 - 159°C. . Example 59
Sodium hydride (60%, oily, 80.0 mg) was added to a . solution of ethyl 3-[1-(6-hydroxy-2-naphthylmethyl)-4- phenyl-3-pyrrolyllpropionate (799 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was
‘ stirred at room temperature for 15 minutes. 3-
Chloromethyl-2-methylpyridine (283 mg) was added to the . mixture, which was stirred at room temperature for 30 minutes. The reactionmixture was poured into water, which . 5 was extracted with ethyl acetate.” The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatograpy, and ethyl 3-[1-[6-(2-methyl-3-pyridylmethoxy)-2-naphthylmethyl]- 4-phenyl-3-pyrrolyl]propionate (959 mg, yield: 95%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). :
NMR(CDC1,) 6 : 1.17(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.63(3H, s), 2.97(2H, t, J=7.8 Hz), 4.07(2H, q, J=7.2 Hz), 5.13(2H, s), 5.15(2H, s), 6.56(1H, 4, J=2.6 Hz), 6.77(1H, d, J=2.6 Hz), 7.14-7.48(%9H, m), 7.57(1H, s), 7.69-7.79(3H, m), 8.49(1H, 44, J=4.8, 1.8 Hz). . Example 60
A mixture of ethyl 3-[1-[6-(2-methyl-3- pyridylmethoxy)-2-naphthylmethyl]-4-phenyl-3- pyrrolyl]propionate (959 mg), 1N aqueous sodium hydroxide solution (4 ml), tetrahydrofuran (8 ml) and ethanol (8 ml) was stirred at room temperature overnight, and 1N hydrochloric acid (4 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[6- (2-methyl-3-pyridylmethoxy)-2-naphthylmethyl]-4-phenyl- 3-pyrrolyl]lpropionic acid (750 mg, yield: 83%). This was recrystallized from ethanol. Melting point: 163 - 164°C. . Example 61
Sodium hydride (60%, oily, 0.22 g) was added to a mixture of ethyl 4-(2-pyridyl)pyrrole-3-carboxylate (1.10 g), 4-(4-chlorometylphenoxymethyl) -5-methyl-2- phenyloxazole (1.83 g) and N,N-dimethylformamide (25 ml) \ at 0° C, and the mixture was stirred for 1 hour. The reaction . mixture was poured into water, which was extracted with . 5 cthyl acetate. The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, dried (MgSO4), and concentrated. The residue was . subjected to silica gel column chromatograpy, and ethyl 1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4-(2- pyridyl)pyrrole-3-carboxylate (2.43 g, yield: 97%) was obtained as an oily substance from the fraction eluted with tetrahydrofuran-hexane (1:1, volume ratio).
NMR(CDC1,) 6: 1.28(3H, t, J=7.2 Hz), 2.44(3H, s), 4.22(2H, q, J=7.2 Hz), 4.99(2H, s), 5.02(2H, s), 6.94-7.24(6H, m), 7.35-7.48(4H, m), 7.60-7.72(1H, m), 7.84-7.92(1H, m), 7.96-8.08(2H, m), 8.51-8.58(1H, m).
Example 62
Sodium hydride (60%, oily, 0.17 g) was added to a mixture of ethyl diethylphosphonoacetate (1.00 g) and
N,N-dimethylformamide (5 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. A solution of 1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4- phenylpyrrole-3-carbaldehyde (1.65 g) in N,N- dimethylformamide (10 ml) was added slowly to the mixture, which was stirred at room temperature for 3 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith saturated agueous sodium chloride solution, dried (MgSOy4), then concentrated. The residue was subjected to silica gel column chromatograpy, and ethyl (E)-3-[1-[4-(5-methyl- 2-phenyl-4-oxazolylmethoxy)benzyl)-4-(2-pyridyl)-3- ) pyrrolyllpropenoate (1.83 g, yield: 96%) was obtained as . an oily substance from the fraction eluted with ethyl acetate-hexane (1:1 volume ratio).
NMR(CDC1,) 0: 1.29(3H, t, J=7.2 Hz), 2.44(3H, s), 4.21(2H,
a, J=7.2 Hz), 4.99(2H, s), 5.02(2H, s), 6.14(1H, 4, J=16.0
Hz), 6.94-7.24(74H, m), 7.34-7.52(4H, m), 7.58-7.72(1H, m), « 7.86-8.16(3H, m), 8.58-8.66(1H, m). . 5 Example 63
A mixture ot ethyl (E)-3-[1-~[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-4-(2-pyridyl)-3- pyrrolyl]lpropenoate (1.80 g), 5% palladium-carbon (2.32 g) and tetrahydrofuran (30 ml) was stirred overnight in a hydrogen atmosphere at room temperature. After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatograpy., and ethyl 3-[1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyll-4-(2-pyridyl)-3- pyrrolyllpropionate (1.61 g, yield: 89%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1l,) 6 : 1.21(3H, t, J=7.0 Hz), 2.43(3H, s), 2.56- 2.66(2H, m), 3.04-3.16(2H, m), 4.09(2H, q, J=7.0 Hz), 4.96(2H, s), 4.98(2H, s), 6.51(1H, d, J=2.6 Hz), 6.92- 7.18(6H, m), 7.34-7.66(5H, m), 7.94-8.04(2H, m), 8.50- 8.56(1H, m).
Example 64
A mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-4-(2-pyridyl)-3- pyrrolyl]lpropionate (1.46 g), 1N aqueous sodium hydroxide solution (6 ml), tetrahydrofuran (5 ml) and ethanol (10 ml) was stirred at room temperature for 5 hours, and 1N hydrochloric acid (6 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, : dried (MgSO4), and concentrated. The colorless crystals
R obtained were collected by filtration to obtain 3-[1- [4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4-(2- pyridyl) -3-pyrrolyl]propionic acid (1.20g, yield:87%).
This was recrystallized fromN,N-dimethylformamide-water.
Melting point: 155 - 156°C.
Example 65 r 5 Sodium hydride (60%, oily, 2.20 g) was added to a mixture of methyl 4-phenylpyrrole-3-carboxylate (11.1049). 3,5-dibenzyloxybenzyl methanesulfonate (21.9 g) and
N,N-dimethylformamide (200 ml) at 0°C, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ) ethyl acetate. The ethyl acetate layer was washed with water, then with saturated agueous sodium chloride solution, dried (MgSO4)., and concentrated. The residue was subjected to silica gel column chromatography, and methyl 1-(3,5-dibenzyloxybenzyl)-4-phenylpyrrole-3-carboxylate (26.4g, yield:95%) was obtained as an oily substance from the fraction eluted with tetrahydrofuran-hexane (1:2, volume ratio) .
NMR (CDC1,) 6 : 3.72(3H, ss), 4.95(2H, s), 4.99(4H, s), ‘ 20 6.41(1H, 4, J=2.6 Hz), 6.56(1H, t, J=2.2 Hz), 6.64(1H, 4,
J=2.6 Hz), 7.21-7.42(15H, m), 7.44-7.50(2H, m).
Example 66
Sodium hydride (60%, oily, 2.11 g) was added to a mixture of ethyl diethylphosphonoacetate (10.5 ml) and tetrahydrofuran (150 ml) at 0°C, which was stirred at room temperature for 30 minutes. A solution of 1-(3, 5- dibenzyloxybenzyl)-4-phenylpyrrole-3-carbaldehyde (22.7 g) in tetrahydrofuran (20 ml) was slowly added to the mixture, which was stirred at room temperature for 1 hour.
The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was ' washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and ethyl (E)-3-[1-(3,5-dibenzyloxybenzyl)-4-phenyl-3-
pyrrolyl]propenoate (21.9 g, yield: 84%) was obtained.
This was recrystallized from ethyl acetate-hexane. . Melting point: 98 - 99 °C.
P 5 Fxample 67 | :
After a mixture of ethyl (E)-3- [1.-(3,5- dibenzyloxybenzyl)-4-phenyl-3-pyrrolyllpropenoate (544 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred overnight at 50°C, and 1N hydrochloric acid (2 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The colorless crystal obtained was filtered, and E-3- [1-(3,5-dibenzyloxybenzyl)-4-phenyl-3- pyrrolyl]propenoic acid (479 mg, yield: 93%) was obtained.
This was recrystallized from ethanol. Melting point: 182 - 183 °C.
Example 68 :
Sodium hydride (60 %, oily, 0.54 g) was added to a: solution of ethyl 3-[1-(3,5-dihydroxybenzyl)-4-phenyl- 3-pyrrolyl]lpropionate (4.93 g) in N,N-dimethylformamide (50 ml) at 0 °C, and this solution was stirred at room temperature for 15 minutes. 2-(4-Chloromethyl-2- thiazolyl)pyrazine (2.86 g) was added to the solution, which was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSQ4), then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[3-hydroxy-5-[2- ) (2-pyrazinyl)-4-thiazolylmethoxylbenzyl]-4-phenyl- pyrrolyl]lpropionate (2.00 g, yield: 27%) was obtained as colorless crystals. This was recrystallized from tetrahydofuran-hexane. Melting point: 156 - 157 °C.
Example 69 ’ A mixture of ethyl 3-[1-[3-hydroxy-5-[2-(2- pyrazinyl) -4-thiazolylmethoxylbenzyl]-4-phenyl- ¢ 5 pyrrolyllipropionate (324mg), 1N aqueous sodium hydroxide solution (1.5 ml), tetrahydrofuran (3 ml), and ethanol (3 ml) was stirred at 50 °C for 2 hours, and 1N hydrochloric acid (1.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4). then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[3-hydroxy-5-[2- (2-pyrazinyl)-4-thiazolylmethoxy]benzyl]-4-phenyl- pyrrolyllpropionic acid (277 mg, yield: 90%). This was recrystallized from ethanol-hexane. Melting point: 206 - 207°C.
Example 70
Sodium hydride (60%, oily, 28.0 mg) was added to a solution of ethyl 3-[1-[3-hydroxy-5-[2-(2-pyrazinyl)-4- thiazolylmethoxylbenzyl]-4-phenyl-3-pyrrolyl propionate (378 mg) in N,N-dimethylformamide (5 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes.
Iodomethane (0.0523 ml) was added to the mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1:[3-methoxy-5-[2- (2-pyrazinyl)-4-thiazolylmethoxylbenzyl]-4-phenyl-3- ) pyrrolyl ]propionate (361 mg, yield:93%) was obtained as an olly substance from the fraction eluted with ethyl } acetate-hexane (1:1, volume ratio).
NMR(CDC1l,) 0: 1.20(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.96(2H, t, J=7.8 Hz), 3.77(3H, s), 4.09(2H, q, J=7.2 Hz),
4.95(2H, s), 5.23(2H, s), 6.36(1H, s), 6.43(1H, s), 6.52(1H, t, J=2.2 Hz), 6.53(1H, d, J=2.2 Hz), 6.73(1H, d, J=2.2 Hz), . 7.16-7.42(5H, m), 7.48(1H, s), 8.56(1H, dd, J=2.6, 1.4 Hz), 8.61(1H, d, J=2.6 Hz), 9.43(1H, 4, J=1.4 Hz). ¢ 5
Example 71
A mixture of ethyl 3-[l-[3-methoxy-5-[2-(2- pyrazinyl)-4-thiazolylmethoxylbenzyl])-4-phenyl-3- pyrrolyllpropionate (361 mg), 1N aqueous sodium hydroxide solution (1.5 ml), tetrahydrofuran (3 ml), and ethanol (3 ml) was stirred at room temperature for 4 hours, and 1N hydrochloric acid (1.5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[3- methoxy-5-[2-(2-pyrazinyl)-4-thiazolylmethoxylbenzyl]- 4-phenyl-3-pyrrolyl]propionic acid (338 mg, yield: 99%).
This was recrystallized from ethanol-hexane. Melting point: 111 - 112°C.
Example 72 ’
Sodium hydride (60%, oily, 28.0 mg) was added to a solution of ethyl 3-[1-[3-hydroxy-5-[2-(2-pyrazinyl)-4- thiazolylmethoxylbenzyl]-4-phenyl-3-pyrrolyl]lpropionate (378 mg) in N,N-dimethylformamide (5 ml) at 0°C, which was stirred at room temperature for 15 minutes. Iodoethane (0.0672 ml) was added to the mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The residue was subjected to silica gel column , chromatography, and ethyl 3-[1-[3-ethoxy-5-[2-(2- pyrazinyl)-4-thiazolylmethoxylbenzyl]-4-phenyl-3- pyrrolyllpropionate (385 mg, yield: 97%) was obtained as an oily substance from the fraction eluted with ethyl : acetate-hexane (1:1, volume ratio). } NMR(CDC1,) 0 : 1.20(3H, t, J=7.2 Hz), 1.39(3H, t, J=7.0 Hz), 2.52(2H, t, J=7.8 Hz), 2.96(2H, t, J=7.8 Hz), 3.98(2H, Aq. . 5 J=7.0 Hz), 4.09(2H, , J=7.2 Hz), 4.94(2H, 8), 5.23(2H, s), . 6.35(1H, s), 6.42(1H, s), 6.50-6.53(2H, m), 6.73(1H, 4,
J=2.6 Hz), 7.16-7.42(5H, m), 7.48(1H, s), 8.56(1lH, dd,
J=2.4, 1.2 Hz), 8.61(1H, d, J=2.4 Hz), 9.42(1H, 4, J=1.2
Hz).
Example 73
A mixture of ethyl 3-[1l-[3-ethoxy-5-[2-(2- pyrazinyl)-4-thiazolylmethoxylbenzyl]-4-phenyl-3- pyrrolyl]propionate (370 mg), 1N aqueous sodium hydroxide solution (6 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred overnight under reflux conditions, and then 1N hydrochloric acid (6 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[3- ethoxy-5-[2-(2-pyrazinyl)-4-thiazolylmethoxylbenzyl]-4- phenyl-3-pyrrolyl])propionic acid (210 mg, yield: 60%).
This was recrystallized from ethanol. Melting point: 97 =~ 98°C.
Example 74
Sodium hydride (60%, oily, 28.0 mg) was added to a solution of ethyl 3-[1l-[3-hydroxy-5-[2-(2-pyrazinyl)-4- thiazolylmethoxylbenzyl]-4-phenyl-3-pyrrolyl]lpropionate (378 mg) in N,N-dimethylformamide (5 ml) at 0°C., and the mixture was stirred at room temperature for 15 minutes.
Benzyl bromide (0.10 ml) was added to the mixture, which was stirred at room temperature for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSo04) . then concentrated. The residue was subjected to silica gel . column chromatography, and ethyl 3-[1-[3-benzyloxy-5- [2-(2-pyrazinyl)-4-thiazolyl methoxylbenzyl]-4-pheny-3- . 5 pyrrolyl]lpropionate (419 mg, yield: 95%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 126 - 127°C.
Example 75 } A mixture of ethyl 3-[1-[3-benzyloxy-5-[2-(2- pyrazinyl)-4-thiazolylmethoxylbenzyl]-4-pheny-3- pyrrolyllpropionate (347 mg), 1N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred overnight under reflux conditions, and then 1N hydrochloric acid (5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[3- benzyloxy-5-[2-(2-pyrazinyl)-4- thiazolylmethoxylbenzyl]-4-phenyl-3-pyrrolyl]propionic acid (274 mg, yield: 83%). This was recrystallized from ethanol-hexane. Melting point: 109 - 110°C.
Example 76
Sodium hydride (60%, oily, 1.85 g) was added to a mixture of 4-benzyloxybenzyl chloride (10.8 g), ethyl 3-phenyl-1H-pyrazole-4-carboxylate (10.0 g) and N,N- dimethylformamide (50 ml) at 0°C, and the mixture was stirred for 1.5 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The ‘colorless crystals obtained were collected by filtration to yield ethyl 1-(4-benzyloxybenzyl)-3-phenyl: 1H- pyrazole-4-carboxylate (15.3 g, yield: 80%). This was . crystallized from ethyl acetate-diisopropyl ether.
Melting point: 102 - 103°C. , 5
Example 77
A mixture of diethyl 2-[1-(4-benzyloxybenzyl)-3- phenyl-1H-pyrazol-4-ylmethyl]malonate (9.41 g), 4N aqueous potassium hydroxide solution (30 ml), and ethanol 100 (30 ml) was refluxed for 1 hour. The reaction mixture was . acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The residue was dissolved in pyridine (20 ml), which was stirred at 110°C for 2 hours. After removal of the solvent under reduced pressure, the residue was extracted with ethyl acetate.
The ethyl acetate layer was washed with dilute hydrochloric acid, then with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The crystals obtained were collected by filtration to yield . 3-[1-(4-benzyloxybenzyl)-3-phenyl-1H-pyrazol-4- vyllpropionic acid (7.52 g, yield: 99%). This was ° recrystallized from ethyl acetate-hexane. Melting point: 147 - 148°C.
Example 78
A mixture of 3-[1-(4-benzyloxybenzyl)-3-phenyl-1H- pyrazol-4-yl]propionic acid (7.01 g), iodomethane (2.12 ml), potassium carbonate (4.70 g) and N,N- dimethylformamide (30 ml) was stirred at room temperature for 48 hours. The reaction mixture was poured into water, . which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The residue was subjected to silica gel column chromatography, and methyl 3-[1-(4-benzyloxybenzyl)-3-phenyl-1H-pyrazol-4- yllpropionate (6.51 g, yield: 90%) was obtained as an oily . substance from the fraction eluted with ethyl acetate- hexane (1:3, volume ratio). ' 5 NMR(CDC1,) 0: 2.48-2.57(2H, m), 2.90-2.98(2H, m), 3.61 (3H, s), 5.06(2H, s), 5.23(2H, s), 6.95(2H, 4, J=8.8 Hz), 7.17-7.46(11H, m), 7.59-7.66(2H, m). :
Example 79
A mixture of 4-chloromethyl-2-(2-furyl)-5- methyloxazole (312 mg), methyl 3-[1-(4-hydroxybenzyl)- 3-phenyl-1H-pyrazol-4-yllpropionate (500 mg), potassium carbonate (397 mg) and N,N-dimethylformamide (7 ml) was stirred at room temperature for 18 hours. The reaction } mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and methyl 3-[1-[4-[2 (2-furyl)- 5-methyl-4-oxazolylmethoxyl]benzyl]-3-phenyl-1H-pyrazol- 4-yl)propionate (687mg, yield: 87%) was obtained as an oily substance from the fraction eluted with ethyl acetate- ‘hexane (5:6, volume ratio).
NMR (CDC1,) 0 : 2.42(3H, s), 2.49-2.58(2H, m), 2.90-2.99(2H, m), 3.61(3H, s), 4.98(2H, s), 5.24(2H, s), 6.51-6.54(1H, m), 6.94-7.02(3H, m), 7.18-7.46(6H, m), 7.52-7.55(1H, m), 7.60-7.66(1H, m).
Example 80
A mixture of methyl 3-[1-[4-[2-(2-furyl)-5-methyl- 4-oxazolylmethoxylbenzyl]-3-phenyl-1H-pyrazol-4- yllpropionate (610 mg), lithium hydroxide monohydrate (154 mg), tetrahydrofuran (6 ml), water (4 ml) and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N hydrochloric acid (3.7 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. Colorless crystals were collected by filtration to yield 3-[1-[4-[2-(2-furyl)- 5-methyl-4-oxazolylmethoxylbenzyl]-3-phenyl-1H-pyrazol- 4-yllpropionic acid (HH3 mg, yield:98%). ‘This was recrystallized from ethyl acetate-hexane. Melting point: 152 - 153°C. :
Example 81
A mixture of 4-chloromethyl-5-methyl-2-(2- thienyl)oxazole (338 mg), methyl 3-[1-(4- hydroxybenzyl) -3-phenyl-1H-pyrazol-4-yl]lpropionate (500 mg), potassium carbonate (397 mg) and N,N- dimethylformamide (7 ml) was stirred at room temperature for 18 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and methyl 3-[1-[4-[5-methyl-2-(2-thienyl)-4- oxazolylmethoxylbenzyl]-3-phenyl-1H-pyrazol-4- yl]propionate (715 mg, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio).
NMR (CDC1,) 0: 2.41(3H, s), 2.49-2.58(2H, m), 2.90-2.99(2H, m), 3.61(3H, s), 4.96(2H, s), 5.24(2H, s), 6.98(2H, 4, J=8.8
Hz), 7.06-7.12(1H, m), 7.17-7.46(7H, m), 7.60-7.66(3H, m).
Example 82
A mixture of methyl 3-[1-[4-[5-methyl-2-(2- thienyl)-4-oxazolylmethoxylbenzyl]-3-phenyl-1H-pyrazol- 4-yl]propionate (633 mg), lithium hydroxide monohydrate (155 mg), tetrahydrofuran (6 ml), water (4 ml) and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N hydrochloric acid (3.7 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer /
was washed with saturated agueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals . obtained were collected by filtration to yield 3-[1-[4- [5 -methyl-2-(2-thienyl)-4-oxazolylmethoxy]benzyl]-3- v 5 phenyl-1H-pyrazol-4-yllpropionic acid (581mg, yield: 95%).
This was recrystallized from ethyl acetate-hexane.
Melting point: 159 - 160°C.
Example 83
Diethyl azodicarboxylate (40% in toluene, 753 mg) was added dropwise slowly to a mixture of methyl 3-[1-(4- hydroxybenzyl)-3-phenyl-1H-pyrazol-4-yl]propionate (500 mg), [5-methyl-2-(4-pyridyl)-4-oxazolyl]methanol (274 mg), triphenylphosphine (414 mg) and tetrahydrofuran (7 ml) at room temperature. After stirring at room temperature for 4 hours, the reaction solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography, and an oily substance was obtained from the fraction eluted with ethyl acetate hexane (3:1, volume ratio). A mixture of the oily substance obtained, lithium hydroxide monohydrate (181 mg), tetrahydrofuran (6 ml), "water (4 ml) and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N hydrochloric acid (4.3 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[4-[5-methyl-2- (4-pyridyl)-4-oxazolylmethoxy]benzyl]-3-phenyl-1H- pyrazol-4-yl]propionic acid (470mg, yield:68%). This was recrystallized from tetrahydrofuran-hexane. Melting } point: 154 - 155°C. } Example 84
A mixture of 3-chloromethyl-5-phenyl-1,2,4- oxadiazole (307 mg), methyl 3-[1-(4-hydroxybenzyl)-3- /.
phenyl-1H-pyrazol-4-yl]propionate (500 mg), potassium carbonate (397 mg) and N,N-dimethylformamide (7 ml) was stirred at room temperature for 18 hours. The reaction mixture was poured into water, which was extracted with . 5 ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgs04), then concentrated. The residue was subjected to silica gel : column chromatography, and methyl 3-[3-phenyl-1-[4-(5- phenyl-1,2,4-oxadiazole-3-ylmethoxy)benzyl]-1H-pyrazol- 4-yl)lpropionate (651 mg, yield: 89%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR (CDC1,) 0 : 2.49-2.57(2H, m), 2.90-2.99(2H, m), 3.61(3H, s), 5.25(4H, s), 7.04(2H, 4, J=8.8 Hz), 7.18-7.66(11H, m), 8.13-8.19(2H, m).
Example 85
A mixture of methyl 3-[3-phenyl-1l-[4-(5-phenyl- : 1,2,4-oxadiazole-3-ylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (560mg), lithium hydroxide monohydrate (139 mg), tetrahydrofuran (6 ml), water (4 ml) and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N hydrochloric acid (3.4 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[3- phenyl-1-[4-(5-phenyl-1,2,4-oxadiazole-3- ylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (529mg, yield:97%). This was recrystallized from ethyl acetate-hexane. Melting point: 166 - 167°C.
Example 86
Diethyl azodicarboxylate (40% in toluene, 1.00 g) was added dropwise slowly to a mixture of methyl 3-[1-(4- hydroxybenzyl)-3-phenyl-1H-pyrazol-4-yl]lpropionate (500 mg), (2,5-dimethyl-4-oxazolyllmethanol (275 mg), triphenylphosphine (585 mg) and tetrahydrofuran (10 ml) at . room temperature. After the mixture was stirred at room temperature for 8 hours, the reaction solvent was removed . 5 under reduced pressure. The residue was subjected to silica gel column chromatography, and methyl 3-[1-[4- (2,5-dimethyl -4-oxazolylmethoxy)benzyl]3-phenyl-1H- pyrazol-4-yllpropionate (288 mg, yield: 44%) was obtained as an oily substance from the fraction eluted with ethyl acetate-hexane (6:5, volume ratio).
NMR (CDC1,) 6 : 2.31(3H, s), 2.41(3H, s), 2.49-2.58(2H, m), 2.90-2.99(2H, m), 3.62(3H, s), 4.86(2H, s), 5.24(2H, s),. 6.97(2H, d, J=8.8 Hz), 7.18-7.47(6H, m), 7.59-7.66(2H, m).
Example 87
A mixture of methyl 3-[1-[4-(2,5-dimethyl-4- oxazolylmethoxy)benzyl]3-phenyl-1H-pyrazol-4- yllpropionate (254 mg), lithium hydroxide monohydrate (69.9 mg), tetrahydrofuran (6 ml), water (4 ml) and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N hydrochloric acid (1.7 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, : dried (MgSO4), then concentrated to yield 3-[1-[4-(2,5- dimethyl-4-oxazolylmethoxy)benzyl]3-phenyl-1lH-pyrazol- 4-yllpropionic acid (243 mg, yield:99%) as an amorphous substance.
NMR(CDC1,) 0 : 2.30(3H, s), 2.41(3H, s), 2.54(2H, t, J=7.4
Hz), 2.92(2H, t, J=7.4 Hz), 4.85(2H, s), 5.21(2H, s), 6.94(2H, 4, J=8.4 Hz), 7.15-7.47(6H, m), 7.61(2H, 4, J=7.0
Hz).
Example 88
A mixture of 3-chloromethyl-5-methyl-2- phenyloxazole (324 mg), methyl 3-[1-(4-hydroxybenzyl)- 3-phenyl-1H-pyrazol-4-yllpropionate (500 mg), potassium carbonate (397 mg) and N,N-dimethylformamide (7 ml) was stirred at room temperature for 18 hours. The reaction . mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with . 5 saturated aqueous sodium chloride solution, dried (MgsS0O4). then concentrated. The residue was subjected to silica gel column chromatography, and methyl 3-[1-{4-(5-methyl-2- phenyl. 4. 0oxazolylmethoxy)benzyl]-3-phenyl-~1H-pyrazol-4- vllpropionate (657 mg, yield: 90%) was obtained as a colorless oily substance from the fraction eluted with : ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 2.43(3H,s), 2.49-2.58(2H, m), 2.95(2H, t,
J=7.7 Hz), 3.61(3H, s), 4.99(2H, s), 5.24(2H, s), 7.00(2H, d, J=8.8 Hz), 7.18-7.47(9H, m), 7.60-7.66(2H, m), 7.98- 8.04(2H, m).
Example 89
A mixture of methyl 3-[{1-[4-(5-methyl-2--phenyl-4- oxazolylmethoxy)benzyl]-3-phenyl:-1H-pyrazol-4- yllpropionate (640 mg), lithium hydroxide monohydrate (363 mg), tetrahydrofuran (6 ml), water (4 ml) and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N hydrochloric acid (9 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-[4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3-phenyl- 1H-pyrazol-4-yl]propionic acid (592 mg, yield:97%). This was recrystallized from ethyl acetate-hexane. Melting point: 179 - 180°C.
Example 90 4-[3-Methyl-1-(2-pyridyl)-1H-pyrazol-4- ylmethoxylbenzyl alcohol (400 mg) was added to thionyl chloride (1 ml) at 0°C, which was stirred at room temperature for 1 hour. After thionyl chloride was removed under reduced pressure, the residue was dissolved in ethyl . acetate, which was washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated . 5 aqueous sodium chloride solution, dried (MgS0O4), then concentrated. Sodium hydride (60%, oily, 60 mg) was added to a mixture of the residue, ethyl 3-(3-phenyl-1H- pyrazol-4-yl)propionate (320 mg) and N,N- dimethylformamide (20 ml), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-[3-methyl-1-(2- pyridyl) -1H-pyrazol-4-ylmethoxylbenzyl]-3-phenyl-1H- pyrazol-4-yllpropionate (340 mg, yield:50%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,)0: 1.18(3H, t, J=7.2 Hz), 2.39(3H,s), 2.52(2H, t, J=7.7 Hz), 2.94(2H, t, J=7.7 Hz), 4.07(2H, q, J=7.2 Hz), 4.97(2H, s), 5.24(2H, s), 6.94-6.99(2H, m), 7.11-7.45(7H, m), 7.61-7.65(2H, m), 7.74-7.82(1H, m), 7.91(1H, 4, J=8.4
Hz), 8.36-8.39(1H, m), 8.53(1H, s).
Example 91
A mixture of 3-picolyl chloride hydrochloride (148 mg), methyl 3-[1- (4-hydroxybenzyl )-3-phenyl-1H-pyrazol-4- yl]propionate (300 mg), potassium carbonate (357 mg) and
N,N-dimethylformamide (5ml) was stirred at 50° C for 3 hours,
The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, : dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography. and a colorless oily substance was obtained from the fraction eluted with ethyl acetate. A mixture of the oily substance obtained, lithium hydroxide monohydrate (108 mg), . tetrahydrofuran (6 ml), water (4 ml), and methanol (4 ml) was stirred at room temperature for 2 hours, and 1N . 5 hydrochloric acid (2.6 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS04) , then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[3- phenyl-1-[4-(3-pyridylmethoxy)benzyl]-lH-pyrazol-4- yllpropionic acid (279 mg, yield:78%). This was recrystallized from acetone-hexane. Melting point: 112 - 113°C.
Example 92
A mixture of ethyl 1-(4-benzyloxybenzyl)-3-phenyl- l1H-pyrazole-4-carboxylate (1.79 g), potassium hydroxide (0.75 g) and ethanol (30ml) was refluxed for 5 hours. After removal of the solvent under reduced pressure, water was added to the reaction mixture, then the mixture was : acidified with 1N hydrochloric acid. The crystals obtained were collected by filtration to yield 1-(4- benzyloxybenzyl)-3-phenyl-1H-pyrazol-4-carboxylic acid (1.36 g, yield: 82%). This was recrystallized from acetone-hexane. Melting point: 152 - 153°C.
Example 93
A mixture of 4-chloromethyl-5-methyl-2- phenyloxazole (2.42 g), ethyl 1-(4-hydroxybenzyl)-3- phenyl-lH-pyrazol-4-carboxylate (3.40 g), potassium "carbonate (2.51 g) and N,N-dimethylformamide (50 ml) was . stirred overnight at 80°C. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgSO4), then concentrated.
A mixture of the residue, potassium hydroxide (1.78 g) and ethanol (50 ml) was refluxed for 5 hours. After the reaction solvent was removed under reduced pressure, water . was added to the reaction mixture, then the mixture was acidified with 1N hydrochloric acid. The crystals . 5 obtained were collected by filtration to yield 1..[4-(5- . methyl-2 phenyl-4-oxazolylmethoxy)benzyl]-3-phenyl-1H- pyrazol-4-carboxylic acid (3.66 g, yield: 75%). This was recrystallized from acetone-hexane. Melting point: 165 - 166°C.
Example 94
Amixture of 4-chloromethyl-2-phenylthiazole (1.19g), ethyl 1-(4-hydroxybenzyl)-3-phenyl-lH-pyrazol-4- carboxylate (1.65 g), potassium carbonate (1.18 g) and
N,N-dimethylformamide (25ml) was stirred overnight at 80°C.
The reaction mixture was poured into water, which was ~ extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. A mixture of the residue, potassium hydroxide (0.93 g) and ethanol (50 ml) was refluxed for 5 hours. After the reaction solvent was removed under reduced pressure, water was added to the reaction mixture, then the mixture was acidified with 1IN “hydrochloric acid. The crystals obtained were collected by filtration to yield 3-phenyl-1-[{4-(2-phenyl-4- ‘thiazolylmethoxy)benzyl}-1H-pyrazol-4-carboxylic acid (1.82 g, yield: 76%). This was recrystallized from acetone-hexane. Melting point: 119 - 120°C.
Example 95
Thionyl chloride (1 ml) was added dropwise to a } solution of [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yllmethanol (3.01 g) in toluene (50 ml) at 0°C, and then the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure.
The residue was dissolved in ethyl acetate. The solution was washed with water, then with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was dissolved in N,N-dimethylformamide (50 ml). . 5 After sodium cyanide (0.82 g) was added to the solution at 0°C, the solution was stirred overnight at 70°C. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, thenwith saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and an amorphous substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the amorphous substance obtained, 4N aqueous potassium hydroxide solution (10 ml) and ethanol (20 ml) was refluxed overnight. After removal of the solvent, water was added to the mixture, then the mixture was acidified with 1N hydrochloric acid. The crystals obtained were collected by filtration to yield [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl}-3-phenyl-1H-pyrazol-4- yl]acetate (2.38 g, yield: 74%). This was recrystallized from ethyl acetate-hexane. Melting point: 156 - 157°C.
Example 96
A mixture of 4-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]}-3-phenyl-1H-pyrazol-4- yl)butyronitrile (1.27 g)., 4N aqueous potassium hydroxide solution (5 ml) and ethanol (10ml) was refluxed for 18 hours.
The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O4). then concentrated.
The colorless crystals obtained were collected by filtration to yield 4-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl)-3-phenyl-l1H-pyrazole-4- yl)butanoic acid (709 mg, yield: 54%). This was recrystallized from ethyl acetate-hexane. Melting point: 118 - 119°C.
Example 97 . 5 A mixture ot diethyl 2-[3-[1--[4-- (5 methyl-2- phenyl -4-oxazolylmethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yvl]lpropyl]lmalonate (1.56 g)., 4N aqueous potassium hydroxide solution (5 ml) and ethanol (10 ml) was refluxed for 30 minutes. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. A mixture of the residue and pyridine (10 ml) was stirred at 110°C for 2 hours. After removal of the solvent under reduced pressure, the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with dilute hydrochloric acid, then with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The colorless crystals obtained were collected by filtration to yield 5-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl}-3-phenyl-1H-pyrazol-4- yllpentanoic acid (857 mg, yield: 65%). This was recrystallized from ethyl acetate-hexane. Melting point: 109 - 110°C.
Example 98
Tetrakis(triphenolphosphine)palladium (120 mg) was added to a mixture of ethyl 3-{1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-3- trifluoromethanesulfonyloxy-1H-pyrazol-4-yl]propionate (1.20 g), 4-trifluoromethylphenylboronic acid (0.46 g), 2N } aqueous sodium carbonate solution (2.6 ml), ethanol (3 ml), and toluene (50 ml). This mixture was refluxed under an argon atmosphere for 13 hours. Ethyl acetate was added to the reaction mixture, and the mixture was washed with saturated aqueous sodium chloride solution, dried (MgSOg4),:
then concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was . obtained from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). A mixture of the oily substance obtained, 1N aqueous sodium hydroxide solution (5 ml), ethanol (5 ml) and tetrahydrofuran (5 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO4). then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[1-{4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3-(4- trifluoromethylphenyl)-1H~-pyrazol-4-yl]propionic acid (250 mg, yield: 22%). This was recrystallized from ethyl acetate-hexane. Melting point: 149 - 150°C.
Example 99
Tetrakis(triphenolphosphine)palladium (130 mg) was added to a mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-3- trifluoromethanesulfonyloxy-1H-pyrazol-4-yl]propionate (1.31 g), 4-fluorophenylboronic acid (0.31 g), 2N aqueous : sodium carbonate solution (2.9 ml), ethanol (3 ml), and toluene (50 ml). This mixture was refluxed under an argon atmosphere for 13 hours. Ethyl acetate was added to this reaction mixture, and the mixture was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-(4-fluorophenyl)- 1-[{4~(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H- pyrazol-4-yl]propionate (540 mg, yield 45%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 93 - 94°C.
Example 100 . A mixture of ethyl 3-[3-(4-fluorophenyl)-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (%00 mg), IN aqueous sodium hydroxide solution (2 ml), ethanol (3 ml), and tetrahydrofuran (5 ml) was stirred at room temperature for 1 hour. The reaction mixture was acidified with IN hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[3-(4- fluorophenyl)-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl])propionic acid (330 mg, yield: 69%). This was recrystallized from ethyl acetate-hexane. Melting point: 139 - 140°C.
Example 101
Tetrakis(triphenylphosphinec)palladium (790 mg) was added to a mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-3- trifluoromethanesulfonyloxy-1H-pyrazol-4-yllpropionate (2.00 g), 4-methoxyphenylboronic acid (0.77 g), 2N aqueous sodium carbonate solution (5.0 ml), ethanol (5 ml), and toluene (100ml). This mixture was refluxed under an argon atmosphere for 13 hours. Ethyl acetate was added to the reaction mixture, ‘which was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[3-(4-methoxyphenyl)-1-[4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H- : pyrazol-4-yl)lpropionate (450 mg, yield : 24%) was obtained as an oily substance from the fraction eluted with ethyl ) acetate-hexane (1:1, volume ratio).
NMR(CDCl,)0: 1.19(3H, t, J=7.0 Hz), 2.44(3H,s), 2.51(2H, t, J=7.5 Hz), 2.92(2H, t, J=7.5 Hz), 3.84(3H, s), 4.08(2H,
q, J=7.0 Hz), 4.99(2H, s), 5.22(2H, s), 6.93-7.02(4H, m). 7.16-7.26(3H, m), 7.52-7.59(2H, m), 7.99-8.04(2H, m).
Example 102 . 5 A mixture of ethyl 3-[3-(4-methoxyphenyl)--1-[4.(5- methyl 2-phenyl.- 4 -oxazolylmethoxy)benzyl]-1H-pyrazol-4- yl]lpropionate (450 mg), 1N aqueous sodium hydroxide solution (2 ml), ethanol (3 ml), and tetrahydrofuran (3 ml) was stirred at room temperature for 1 hour. The reaction mixture was acidified with 1N hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The colorless crystals obtained were collected by filtration to yield 3-[3-(4- methoxyphenyl)-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (350 mg, yield: 81%). This was recrystallized from ethyl acetate-hexane. Melting point: 137 - 138°C.
Example 103
Tetrakis(triphenylphosphine)palladium (990 mg) was added to a mixture of ethyl 3-[1-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxy)benzyl]-3- trifluoromethanesulfonyloxy- lH-pyrazol-4-yl]lpropionate (2.509), 4-trifluoromethylphenylboronic acid (1.23 g), 2N aqueous sodium carbonate solution (6.5ml), ethanol (7ml), and toluene (100 ml). This mixture was refluxed under an argon atmosphere for 13 hours. Ethyl acetate was added to this reaction mixture, which was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio). A mixture of the oily substance obtained, 1N aqueous sodium hydroxide solution (5 ml), ethancl (5 ml), and tetrahydrofuran (5 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with dilute hydrochloric acid, which was - extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS04), then concentrated. The colorless crystals obtained were collected by filltration to yield 3-[1-[4- [2-(2-furyl)-5-methyl-4-oxazolylmethoxy)benzyl]-3-(4- trifluoromethylphenyl)-1H-pyrazol-4-yllpropionic acid (680 mg, yield: 29%). This was recrystallized from ethyl acetate-hexane. Melting point: 92 - 93°C.
Example 104
Tetrakis(triphenylphosphine)palladium (878 mg) was added to a mixture of ethyl 3-[1-{4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxy)benzyl]-3- trifluoromethanesulfonyloxy-1H-pyrazol-4-yl]propionate (2.22 g). 4-fluorophenylboronic acid (798 mg). 2N aqueous sodium carbonate solution (10 ml), ethanol (10 ml), and } toluene (30 ml). This mixture was refluxed under an argon atmosphere for 13 hours. Ethyl acetate was added to this reaction mixture, which was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[3-(4-fluorophenyl)-1-[4- [2-(2-furyl)-5-methyl-4-oxazolylmethoxy]benzyl]-1H- pyrazol-4-yl)propionate (350 mg, yield: 17%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 1.19(3H, t, J=7.2 Hz), 2.42(3H,s). 2.51(2H, t, J=7.6 Hz), 2.91(2H, t, J=7.6 Hz), 4.08(2H, q, J=7.2 Hz), 4.98(2H, s), 5.22(?H, s), 6.53(1H, 4d, J=3.4, 1.8 Hz), 6.96-7.01(3H, m), 7.05-7.23(5H, m), 7.53-7.63(2H, m).
Example 105 :
A mixture of ethyl 3-[3-(4-fluorophenyl)-1-[4-[2- (2-furyl)-5-methyl-4-oxazolylmethoxy)benzyl]-1H-
pyrazol-4-yl propionate (350 mg), 1N aqueous sodium hydroxide solution (2 ml), ethanol (4 ml), and . tetrahydrofuran (4 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with dilute . 5 hydrochloric acid, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MygS0O4), then concentrated.
The colorless crystals obtained were collected by filtration to yield 3-[3-(4-fluorophenyl)-1-[4-[2-(2- furyl)-5-methyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yl]lpropionic acid (150 mg, yield: 45%). This was recrystallized from ethyl acetate-hexane. Melting point: 125 - 126°C.
Example 106 :
A mixture of 4-(4-chloromethylphenoxy)methyl-5- methyl-2-phenyloxazole (7.13 g), ethyl 3-isopropyl-1lH- pyrazol-4-carboxylate (6.17 g), potassium carbonate (4.72 g) and N,N-dimethylformamide (70 ml) was stirred at 80°C overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. A mixture of the residue, potassium hydroxide (4.83 g) and ethanol (150 ml) was refluxed for 5 hours. After the reaction solvent was removed under reduced pressure, water was added to the mixture, then the mixture was acidified with dilute hydrochloric acid. The crystals obtained were collected by filtration to yield 3-isopropyl-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol--4- carboxylic acid (11.39 g, yield: 78%). This was . recrystallized from tetrahydrofuran-hexane. Melting point: 194 - 195°C.
Example 107
A mixture of 3-isopropyl-1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-1H-pyrazol-4-carboxylic acid . ) (10.09 g), iodomethane (2 ml), potassium carbonate (4.83 g) and N,N-dimethylformamide (50 ml) was stirred at 80°C . 5 for 5 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The residue was subjected to silica gel column chromatography, and methyl 3-isopropyl-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-carboxylate (9.8049, yield:94%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). Thiswas recrystallized fromethyl acetate-hexane.
Melting point: 90 - 91°C.
Example 108
Methanesulfonyl chloride was added dropwise to a mixture of [3-isopropyl-1l-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-~1H-pyrazol-4-yl]methanol (2. 02 g). triethylamine (0.8 ml) and ethyl acetate (30 ml) at 0°C, which was stirred at room temperature for 3 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith saturated aqueous sodium chloride solution, dried (MgS04) . then concentrated. The residue was dissolved in tetrahydrofuran (20 ml). This solution was added dropwise at 0° C to separately-prepared tetrahydrofuran solution (30 ml) of sodium diethyl malonate using diethyl malonate (2.35 g) and sodium hydride (60%, oily, 0.55 g). The reaction mixture was poured into dilute hydrochloric acid, which was ] extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The residue was dissolved in ethanol (50 ml), then 1N aqueous sodium hydroxide solution (15 ml) was added to the solution, which was stirred at 60°C for 2 hours. After the reaction solvent was removed under reduced pressure, water was added to the . mixture, which was acidified with dilute hydrochloric acid.
After the crystals obtained were filtered and washed with a 5 water, the crystals were dissolved in pyridine (50 ml), which was stirred at 120°C for 2 hours. After pyridine was removed under reduced pressure, the residue was dissolved in ethyl acetate, which was washed with dilute hydrochloric acid, then with saturated aqueous sodium chloride solution, and dried (MgSO4). then concentrated. The crystals obtained were collected by filtration to yield 3-[3- isopropyl-1-{4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyl) -1H-pyrazol-4-yl]lpropionic acid (1.23 g, yield: 55%). This was recrystallized fromethyl acetate - hexane.
Melting point: 97 - 98°C.
Example 109
Sodium hydride (60%, oily, 110 mg) was added to a mixture of 4-[(4-chloromethylphenoxy)methyl]-S5-methyl- 2-phenyloxazole (910 mg), ethyl 3-(3-propyl-l1H-pyrazol- 4-yl)propionate (500 mg) and N,N-dimethylformamide (10ml), which was stirred for 12 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O4), then concentrated.
The residue was subjected to silica gel column chromatography. and ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl)-3-propyl-1H-pyrazol-4- yl]lpropionate (620 mg, yield: 53%) was obtained as a colorless oily substance.
NMR (CDC1l,) 0: 0.97(3H, t, J=7.2 Hz), 1.21(3H, t, J=7.2 Hz), , 1.60-1.75(2H, m), 2.43(3H, s), 2.45-2.59(4H, m), 2.66- 2.75(2H, m), 4.10(2H, gq, J=7.2 Hz), 4.98(2H, s), 5.14(2H, s), 6.94-7.04(3H, m), 7.11-7.16(2H, m), 7.42-7.45(3H, m), 7.98-8.04(2H, m).
Example 110
A mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl-4- . oxazolylmethoxy)benzyl]-3-propyl-l1H-pyrazol-4- yl]lpropionate (610 my), IN aqueous sodium hydroxide . 5 solution (2.6 ml), ethanol (3 ml), and tetrahydrofuran (3 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The crystals obtained were collected by filtration to yield 3-[1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3- propyl-1H-pyrazol-4-yljpropionic acid (480mg, yield: 80%).
This was recrystallized from ethyl acetate-hexane.
Melting point: 153 - 154°C.
Example 111
Ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl) -5-propyl-1H-pyrazol-4- yl]lpropionate (240 mg, yield: 21%) was obtained as a colorless oily substance from the fraction eluted subsequent to elution of the compound of Example 109, in . the silica gel column chromatography in Example 109.
NMR(CDC1,) 0 : 0.89(3H, t, J=7.2 Hz), 1.24(3H, t, J=7.2 Hz), 1.35-1.47(2H, m), 2.42(3H, s), 2.43-2.58(4H, m), 2.67- 2.75(2H, m), 4.13(2H, q, J=7.2 Hz), 4.96(2H, s), 5.20(2H, s), 6.91-7.06(4H, m), 7.33(1H, s), 7.41-7.45(3H, m), 7.98-8.03(2H, m).
Example 112
A mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-5-propyl-l1H-pyrazol-4- yl]lpropionate (210 mg), 1N aqueous sodium hydroxide solution (1 ml), ethanol (1 ml), and tetrahydrofuran (1 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, } : dried (MgSO4), then concentrated. The crystals obtained were collected by filtration to yield 3-[1-[4-(5- . 5 methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-5-propyl-1H- pyrazol -4-yl]lpropionic acid (170 mg, yield: 85%). This was recrystallized from ethyl acetate-hexane. Melting point: 158 - 159°C.
Example 113 E
A mixture of ethyl 3-[1-[4-[3-methyl-1-(2- pyridyl) -)-4-ylmethoxylbenzyl]-3-phenyl-1H-pyrazol-4- yl]lpropionate (340 mg), 1N aqueous sodium hydroxide solution (1.5 ml), ethanol (2 ml) and tetrahydofuran (2 ml) was stirred at room temperature for 1 hour. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The crystals obtained were collected by filtration to yield 3-[1-[4-(3- methyl-1-(2-pyridyl)-1H-pyrazol-4-ylmethoxylbenzyl]-3- phenyl-)-4-yl)propionic acid (320 mg, yield: 88%). This was recrystallized from ethyl acetate-hexane. Melting point: 131 - 132°C. : Example 114
Sodium hydride (60%, oily, 200 mg) was added to an
N,N-dimethylformamide solution (15 ml) of ethyl 3-(3- phenyl-1H-pyrazole-4-yl)propionate (1.04 g) at 0° C, which was stirred at 0°C for 30 minutes. 4-[2-(4-
Chloromethylphenoxy)ethyl]-5-methyl-2-phenyloxazole (1.43 g) was added to the reaction mixture, which was stirred at room temperature overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with ~ saturated aqueous sodium chloride solution, dried (MgSO4),
then concentrated. The residue was subjected to silica gel column chromatography, and an oily substance was obtained : from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the substance obtained, 1N . 5 aqueous sodium hydroxide solution (4 ml), ethanol (5 ml) and tetrahydrofuran (5 ml) was stirred for 2 hours at room temperature. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4). then concentrated. The crystals obtained were collected by filtration to yield 3-[1-[4-[2-(5-methyl-2-phenyl-4- oxazolyl)ethoxylbenzyl]-3-phenyl-1lH-pyrazol-4- yllpropionic acid (930 mg, yield: 71%). This was recrystallized from acetone-hexane. Melting point: 142 - 143°C.
Example 115
Sodium hydride (60%, oily, 170 mg) was added to an
N,N-dimethylformamide solution (50 ml) of ethyl 3-(3- phenyl-1H-pyrazole-4-yl)propionate (890 mg) at 0°C, and this mixture was stirred at 0°C for 30 minutes. 2-[4- (5-Methyl-2-phenyl-4-oxazolylmethoxy)phenyl]ethyl methane sulfonate (2.79 g) was added to the reaction mixture, which was stirred at 90°C for 1 hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4)., then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[2-[4-(5-methyl- 2-phenyl-4-oxazolylmethoxy)phenyl]ethyl]-3-phenyl-1H- pyrazol-4-yl]lpropionate (1.19 g, yield: 62%) was obtained as colorless crystals. This was recrystallized from ethyl . acetate-hexane. Melting point: 81 - 82°C.
Example 116
A mixture of ethyl 3-[1-[2-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)phenyl]ethyl]-3-phenyl-1H-pyrazol-4- } yYllpropionate (900 mg), 1N aqueous sodium hydroxide : solution (3.4 ml), ethanol (3 ml) and tetrahydrofuran (3 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO4), then concentrated. The crystals obtained were collected by filtration to yield 3-[1-[2-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)phenyl]ethyl]-3-phenyl-1H-pyrazol-4- yl]lpropionic acid (860 mg, yield: 91%). This was recrystallized from ethyl acetate-hexane. Melting point: 85 - 86°C.
Example 117
Thionyl chloride (0.31 ml) was added dropwise to a toluene solution (30 ml) of 4-[2-[N-methyl-N-(2- pyridyl)aminolethoxylbenzyl alcohol (900 mg) at 0°C. The reaction mixture was stirred at room temperature for 2 hours, " then concentrated. The residue was dissolved in ethyl acetate, which was washed with saturated aqueous sodium hydrogen carbonate solution, then with saturated aqueous sodium chloride solution, and dried (MgSO4), then : concentrated. The residue and ethyl 3-(3-phenyl-1H- pyrazol-4-yl)propionate (860 mg) were dissolved in N,N- dimethylformamide (15 ml). Sodium hydride (60%, oily, 100 mg) was added to the solution, which was then stirred at room temperature for 12 hours. The reaction mixture was poured into saturated aqueous sodium chloride solution, } which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, and dried (MgSO4), then concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-{1-{4-[2-[N-methyl-
N-(2-pyridyl)amino]ethoxy]benzyl])-3-phenyl-1H-pyrazol- 4-yl]propionate (0.75 g, yield: 68%) was obtained as a . colorless oily substance. :
NMR(CDC1l,) 6 : 1.17(3H, t, J=7.0 Hz), 2.46-2.54(2H, m), . 5 2.89..2.97(24H, m), 3.16(3H, 8), 3.99(2H, t, J=5.4 Hz), 4.06(2H, gq, J=7.0 Hz), 4.19(2H, t, J=5.4 Hz), 5.21(2H, s), 6.51-6.59(2H, m), 6.83-6.89(2H, m), 7.15-7.51(7H, m), 7.59-7.64(2H, m), 8.13-8.17(1H, m).
Example 118
A mixture of ethyl 3-[1-{4-[2-[N-methyl-N-(2- pyridyl)amino]ethoxylbenzyl]-3-phenyl-l1H-pyrazol-4- yllpropionate (750 mg), 1 N aqueous sodium hydroxide solution (3 ml), ethanol (3 ml), and tetrahydrofuran (3 ml) was stirred at room temperature for one hour. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained crystals were collected by filtration, and 3-[1-[4-[2~[N-methyl-
N-(2-pyridyl)amino}ethoxy]lbenzyl]-3-phenyl-1H-pyrazol- 4-yl)propionic acid (610 mg, yield: 90%) was obtained.
This was recrystallized from ethyl acetate-hexane.
Melting point: 110 - 111°C.
Example 119 2-Chloromethyl-6-(2-fluorobenzyloxy)naphthalene (540 mg) and ethyl 3-(3-phenyl-1H-pyrazol-4-yl]propionate (390 mg) were dissolved in N,N-dimethylformamide (10 ml).
Sodium hydride (60%, oily, 70 mg) was added to the solution at 0° C, which was stirred at room temperature for two hours.
The reaction mixture was poured into saturated aqueous sodium chloride solution, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[6-~(2- fluorobenzyloxy)-2-naphthylmethyl] -3-phenyl-1H- . _ pyrazole-4-yl)propionate (0.58 g, yield: 72%) was obtained as a colorless oily substance from the fraction eluted with . 5 ethyl acetate-hexane (1:4, volume ratio).
NMR (CDC1,) 0: 1.14(3H, t, J=7.0 Hz), 2.47-2.50(2H, m), 2.91-2.98(2H, m), 4.04(2H, g, J=7.0 Hz), 5.25(2H, s), 7.06-7.77(16H, m).
Example 120 : A mixture of ethyl 3-[1-[6-(2-fluorobenzyloxy-2- naphthylmethyl]-3-phenyl-1H-pyrazol-4-yl]propionate (580 mg), 1N aqueous sodium hydroxide solution (2.2 ml), ethanol (3 ml), and tetrahydrofuran (3 ml) was stirred at room temperature for two hours. The reaction mixture was : acidified with dilute hydrochloric acid, and the obtained colorless crystals were collected by filtration, and 3- [1-[6-(2-fluorobenzyloxy)-2-naphthylmethyl]-3-phenyl- 1H-pyrazol-4-yl]propionic acid (450 mg, yield: 85%) was obtained. This was recrystallized from ethanol. Melting point: 152 - 153. :
Example 121 : A mixture of 4-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-1l-ylmethyl]lbenzoic acid (500 mg), 4- trifluoromethylbenzylamine (250 mg), 1- hydroxybenzotriazole monohydrate (210 mg), WSC (270 mg), and N,N-dimethylformamide (10 ml) was stirred at room temperature for 13 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous ) sodium bicarbonate solution, 1 N hydrochloric acid, then, with saturated agueous sodium chloride solution, and dried } (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3- phenyl-1-[4-(4-
trifluoromethylbenzylaminocarbonyl)benzyl]-1H-pyrazol- 4-yl)propionate (550 mg, yield: 77%) was obtained as a . colorless amorphous substance from the fraction eluted with : ethyl acetate-hexane (3:1, volume ratio).
NMR(CDC1,)6: 1.18(3H, t, J=7.0 Hz), 2.47(3H, s), 2.53(2H, t, J=7.6 Hz), 2.95(2H, t, J=7.6 Hz), 4.07(2H, q, J~7.0 Hz), 4.52(2H, d, J=5.2 Hz), 5.33(2H, s), 6.83(1H, br.s). 7.24-7.47(9H, m), 7.60-7.65(2H, m), 7.76-7.81(2H, m), 7.96-8.01(2H, m).
Example 122
A mixture of ethyl 3-[3-phenyl-1-[4-(4- trifluoromethylbenzylaminocarbonyl)benzyl]-1H-pyrazol- 4-yl]lpropionate (680 mg), 1 N aqueous sodium hydroxide solution (1.7 ml), ethanol (2 ml), and tetrahydrofuran (2 ml) was stirred at room temperature for two hours. The reaction mixture was acidified with dilute hydrochloric acid, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The obtained crystals were collected by filtration, and 3- [3-phenyl-1-[4-(4- trifluoromethylbenzylaminocarbonyl)benzyl]-1H-pyrazol- 4-yl]lpropionic acid (620 mg, yield: 94%) was obtained.
This was recrystallized from ethyl acetate-hexane.
Melting point: 151 - 152TC.
Example 123
A mixture of 4-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-l-ylmethyl]benzoic acid (500 mg), (5- methyl-2-phenyl-4-oxazolyl)methylamine (260 mg), 1- hydroxybenzotriazole monohydrate (210 mg), WSC (270 mg), and N,N-dimethylformamide (10 ml) was stirred at room temperature for 13 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate solution, 1 N hydrochloric acid, then, with saturated aqueous sodium chloride solution, and dried } (MgSO,) and concentrated. The obtained yellow crystals were collected by filtration, and ethyl 3-[1-[4-(5- . 5 methyl. 2 phenyl-4-oxazolylmethylaminocarbonyl)benzyl]- 3-phenyl-1H-pyrazol--4-yllpropionate (600 mg, yield: 87%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 190 - 191C.
Example 124
A mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethylaminocarbonyl)benzyl]-3-phenyl-1H- pyrazol-4-yl]propionate (550 mg), 1 N agueous sodium hydroxide solution (1.3 ml), ethanol (2 ml), and tetrahydrofuran (2 ml) was stirred at room temperature for two hours. The reaction mixture was acidified with dilute hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The obtained crystals were collected by filtration, and 3-[1-[{4-(5-methyl-2-phenyl-4- oxazolylmethylaminocarbonyl)benzyl]-3-phenyl-1H- pyrazol-4-yllpropionic acid (500 mg, yield: 96%) was obtained. This was recrystallized from acetone-methanol.
Melting point: 177 - 178T.
Example 125
A mixture of 3-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-1l-ylmethyl]benzoic acid (700 mg), 4- trifluoromethylbenzylamine (390 mg), 1- hydroxybenzotriazole monohydrate (340 mg), WSC (430 mg), and N,N-dimethylformamide (30 ml) was stirred at room temperature for 18 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-phenyl-1-[3-(4- trifluoromethylbenzylaminocarbonyl)benzyl] 1H. -pyrazol- . 4-yl]propionate (900 mg, yield: 91%) was obtained as an oily substance from the fraction eluted with acetone-hexane (1:2, . 5 volume ratio).
NMR (CDC1,;) 0: 1.13(3H, t, J=7 Hz), 2.52(2H, t, J=7.3 Hz), 2.96(2H, t, J=7.3 Hz), 3.98(2H, q, J=7 Hz), 4.68(2H, 4, J=6
Hz), 5.35(2H, s), 6.80(1H, br.s), 7.25-7.65(13H, m), 7.7-7.8(1H, m).
Example 126
A mixture of ethyl 3-[3-phenyl-1-[3-(4- trifluoromethylbenzylaminocarbonyl)benzyl]-1H-pyrazol- 4-yl]propionate (870 mg), 1 N aqueous sodium hydroxide solution (2 ml), ethanol (6 ml), and tetrahydrofuran (4 ml) was stirred at room temperature for one hour. The reaction mixture was poured into water, then 1 N hydrochloric acid (2 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO,)., and concentrated. The obtained crystals were collected by filtration, and 3-[3-phenyl- 1-{3-(4-trifluoromethylbenzylaminocarbonyl)benzyl]-1H- pyrazol-4-yl]lpropionic acid (730 mg, yield: 89%) was obtained. This was recrystallized from acetone-isopropyl ether. Melting point: 165 - 166T.
Example 127
A mixture of 4-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-1-ylmethyllbenzoic acid (300 mg), 2- picolylamine (95 mg), l-hydroxybenzotriazole monohydrate (130 mg), WSC (170 mg). and N,N-dimethylformamide (10 ml) ] was stirred at room temperature for 2.5 days. The reaction mixture was poured into water, which was extracted with ) ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel
" column chromatography, and ethyl 3-[3-phenyl-1-[3-(2- picolylaminocarbonyl)benzyl]-1H-pyrazol-4-yl]lpropionate . (200 mg, yield: 54%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- . 5 methanol (50:1, volume ratio).
NMR(CDC1,) 0 : 1.17(3H, t, J=7.2 Hz), 2.53(2H, t, J=7.6 Hz), 2.96(2H, t, J=7.6 Hz), 4.06(2H, q, J=7.2 Hz), 4.76(2H, 4,
J=4.8Hz), 5.36(2H, s), 7.18-7.49(7H, m), 7.61-7.84(6H, m), 8.53(1H, 4, J=4.0 Hz).
Example 128
A mixture of ethyl 3-[3-phenyl-1-[{3-(2- . picolylaminocarbonyl)benzyl]-1H-pyrazol-4-yl]lpropionate (180 mg), 1 N aqueous sodium hydroxide solution (0.77 ml), . 15 ethanol (1 ml), and tetrahydrofuran (1 ml) was stirred at " room temperature for one hour. 1 N hydrochloric acid (0.77 ml) was added to the reaction mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The obtained crystals were collected by filtration, and 3-[3-phenyl-1-[3-(2- picolylaminocarbonyl)benzyl]-1H-pyrazol-4-yllpropionic acid (120 mg, yield: 71%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 83 - 85C (decomposition).
Example 129
A mixture of 4-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-1l-ylmethyl]benzoic acid (400 mg), 2- aminopyridine (120 mg), l-hydroxybenzotriazole monohydrate (200 mg), WSC (250 mg), and N,N- dimethylformamide (10 ml) was stirred at room temperature for 2.5 days. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate solution, 1 N hydrochloric acid, then, with saturated sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel . column chromatography, and ethyl 3-[3-phenyl-1-[3-(2- pyridylaminocarbonyl)benzyl]-1H-pyrazol-4-yl]propionate . : 5 (200 mg, yield: 40%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- hexane (5:1, volume ratio).
NMR(CDCL,) 6 : 1.18(3H, t, J=7.0 Hz), 2.54(2H, t, J=7.4 Hz), 2.97(2H, t, J=7.4 Hz), 4.08(2H, q, J=7.0 Hz), 5.37(2H, s). 7.05-7.12(1H, m), 7.26-7.86(11H, m), 8.30-8.39(2H, m), 8.56(1H, br s).
Example 130
A mixture of ethyl 3-[3-phenyl-1-[3-(2- pyridylaminocarbonyl)benzyl]-1H-pyrazol-4-yl]propionate (200 mg). 1 N aqueous sodium hydroxide solution (0.88 ml), ethanol (1 ml), and tetrahydrofuran (1 ml) was stirred at room temperature for one hour. 1 N hydrochloric acid (0.88 " ml) was added to the reaction mixture, which was extracted withethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgso,). and concentrated. The obtained crystals were collected by filtration, and 3-[3-phenyl-1-[3-(2- pyridylaminocarbonyl)benzyl]-1H-pyrazol-4-yl]propionic acid (110 mg, yield: 58%) was obtained. This was recrystallized from tetrahydrofuran-hexane. Melting point: 187 - 188°C.
Example 131
A mixture of 4-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-1-ylmethyllbenzoic acid (400 mg), 2- (2-pyridyl)ethylamine (17/0 mg), l-hydroxybenzotriazole monohydrate (200 mg), WSC (250 mg), and N,N- dimethylformamide (10 ml) was stirred at room temperature for 2.5 days. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate solution, 1 N hydrochloric acid, then, with saturated ) aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-phenyl-1-[3-[2. (2. pyridyl)ethylaminocarbonyl)benzyl]-1H-pyrazol-4- vl lpropionate (460 mg, yield: 87%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-methanol (50:1, volume ratio).
NMR (CDC1,) 0:1.17(3H, t, J=7.0 Hz), 2.52(2H, t, J=7.6 Hz), 2.95(2H, t, J=7.6 Hz), 3.08(2H, t, J=6.0 Hz), 3.85(2H, q,
J=6.0 Hz), 4.06(2H, gq, J=7.0 Hz), 5.33(2H, s), 7.07- 7.72(13H, m), 8.49(1H, 4d, J=4.0 Hz).
Example 132
A mixture of ethyl 3-[3-phenyl-1-[3-[2-(2- pyridyl)ethylaminocarbonyl]benzyl]-1H-pyrazol-4- yl]propionate (450 mg), 1 N aqueous sodium hydroxide solution (2 ml), ethanol (2 ml), and tetrahydrofuran (2 ml) was stirred at room temperature for one hour. After 1 N hydrochloric acid (2 ml) was added to the reaction mixture, the reaction mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO,). and concentrated.
The obtained crystals were collected by filtration, and 3-[3-phenyl-1-[3-[2-(2- pyridyl)ethylaminocarbonyl]benzyl]-1H-pyrazol-4- yllpropionic acid (400 mg, yield: 95%) was obtained. This was recrystallized from tetrahydrofuran-hexane. Melting point: 166 - 167C.
Example 133
A mixture of 4-[4-(2-ethoxycarbonylethyl)-3- phenyl-1H-pyrazol-1l-ylmethyl]benzoic acid (400 mg), 3- aminopyridine (160 mg), 1l-hydroxybenzotriazole monohydrate (200 mg), WSC (250 mg). and N,N-
dimethylformamide (10 ml) was stirred at room temperature for 2.5 days. The reaction mixture was poured into water, . which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate . 5 solution, 1 N hydrochloric acid, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography. and ethyl 3-[3-phenyl-1-[3-(3- pyridylaminocarbonyl)benzyl]-1H-pyrazol-4-yl]propionate (280mg, yield: 56%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-methanol (50:1, - volume ratio). Melting point: 111 - 112TC,
Example 134
A mixture of ethyl 3-[3-phenyl-1-[3-(3- pyridylaminocarbonyl)benzyl])-1H-pyrazol-4-yl}lpropionate (230 mg), 1 N aqueous sodium hydroxide solution (1.2 ml), ethanol (2 ml), and tetrahydrofuran (2 ml) was stirred at room temperature for one hour. After 1 N hydrochloric acid (1.2 ml) was added to the reaction mixture, the reaction mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained crystals were collected by filtration, and 3- [3-phenyl-1-[3-(3-pyridylaminocarbonyl)benzyl]-1H- pyrazol-4-yl]propionic acid (190 mg, yield: 86%) was obtained. This was recrystallized from tetrahydrofuran-hexane. Melting point: 131 - 1327TC.
Example 135
To amixture of 2-(4-benzyloxyphenyl)ethanol (1.19g), triethylamine (700 mg), and ethyl acetate (30 ml), methanesulfonyl chloride (790 mg) was added dropwise at oC, . and the mixture was stirred at room temperature for two hours. The reaction mixture was washed with water, saturated aqueous sodium bicarbonate solution, 1 N hydrochloric acid, then, with saturated sodium chloride solution, and dried (MgSO,) and concentrated. To a mixture, } of the residue, ethyl (3-phenyl-1H-pyrazol-4-yl)acetate (1.0 g), and N,N-dimethylformamide (50 ml), sodium hydride . 5 (60%, oily, 190 my) was added at 0, and the mixture was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The residue was subjected to silica gel column chromatography, and ethyl [1-[2-(4- benzyloxyphenyl)ethyl]-3-phenyl-1H-pyrazol-4-yllacetate (0.45 g, yield: 24%) was obtained as a colorless oily } substance in the fraction eluted with diethyl ether-hexane (2:3, volume ratio).
NMR(CDC1,) 0 : 1.22(3H, t, J=7.0 Hz), 3.15(2H, t, J=7.4 Hz), 3.57(2H, s), 4.13(2H, q, J=7.0 Hz), 4.31(2H, t, J=7.4 Hz), 5.05(2H, s), 6.87-6.92(2H, m), 7.02-7.07(2H, m), 7.31- 7.47(9H, m), 7.58:--7.64(2H, m).
Example 136
To a solution of ethyl 1-[2-(4- ‘ hydroxyphenyl)ethyl]-3-phenyl-1H-pyrazol-4-yllacetate (400 mg) in N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 50 mg) was added at 0C, and the solution was stirred at room temperature for 30 minutes. To this solution, 4-chloromethyl-5-methyl-2-phenyloxazole (290 mg) was added, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography, and ethyl [l1-[2-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)phenyllethyl]-3-phenyl-1H-pyrazol-4- yllacetate (260 mg, yield: 46%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6: 1.22(3H, t, J=7.0 Hz), 2.43(3H, s), 3.15(2H, t, J=7.4 Hz), 3.57(2H, s), 4.13(2H, q, J=7.0 Hz), 4.31(2H, . 5 t, J=7.4 Hz), 4.97(2H, s), 6.91-6.96(2H, m), 7.03 7.08(2H, m), 7.26--7.45(7H, m), 7.58--7.63(2H, m), 7.99-8.04(2H, m).
Example 137 : A mixture of ethyl [1-[2-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)phenyl)lethyl]-3-phenyl-l1H-pyrazol-4- yllacetate (260 mg), 1 N aqueous sodium hydroxide solution (1 ml), ethanol (2 ml), and tetrahydrofuran (2 ml) was stirred at room temperature for one hour. After 1 N hydrochloric acid (1 ml) was added to the reaction mixture, "15 the reaction mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The obtained crystals were collected by filtration, and 1-[2~-[4~-(5-methyl-2-phenyl-4- oxazolylmethoxy)phenyl]ethyl-3-phenyl-1H-pyrazol-4- ylacetic acid (170 mg, yield: 68%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 104 - 105T.,
Example 138
A mixture of 4-(4-chloromethylphenoxy)methyl-5- methyl-2-phenyloxazole (3.55 g), ethyl 1H-pyrazol-4- carboxylate (1.50 g), potassium carbonate (2.76 g), and
N,N-dimethylformamide (25 ml) was stirred at room temperature for 24 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, dried (Mgso,) and concentrated. The obtained crystals were collected by filtration, and ethyl 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1lH-pyrazol-4-carboxylate (3.79 g,
yield: 91%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 108 - 109TC.
Example 139 : 5 | Sodium hydride (60%, oily, 336 mg) was added at 0C to a solution of ethyl diethylphosphonoacetate (1.67 ml) in tetrahydrofuran (20 ml), which was stirred at 0C for 30 minutes. To this solution, a solution of 1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- carbaldehyde (2.61 g) in tetrahydrofuran (20 ml) was added dropwise at 0C, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated sodium chloride solution, dried (MgS0O,). and concentrated. The obtained crystals were collected by filtration, and ethyl (E)-3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazole-4-yl]propenoate (2.78 g, yield: 90%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 112 - 113T.
Example 140
A mixture of ethyl (E)-3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl])-1H-pyrazole-4-yl]propenoate (887 mg), 1 N aqueous sodium hydroxide solution (4 ml), ethanol (8 ml), and tetrahydrofuran (8 ml) was stirred at 40°C for 3 hours. After the reaction mixture was acidified with 1 N hydrochloric acid, the obtained crystals were collected by filtration, and (E)-3-[1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropenoic acid (672 mg, yield: 81%) was obtained. This was recrystallized from ethanol. Melting point: 186 - 187°C.
Example 141
A mixture of ethyl (E)-3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propenoate (1.78 g), 5% palladium-carbon (2.0 g), ethanol (20 ml), and tetrahydrofuran (20 ml) was stirred at room temperature for . 5 one hour under a hydrogen atmosphere. After removal of the catalyst by filtration, the filtrate was concentrated.
The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate (1.57 g, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- hexane (1:1, volume ratio).
NMR(CDC1,) 6 : 1.21(3H, t, J=7.0 Hz), 2.42(3H, s), 2.52(2H, t, J=7.2 Hz), 2.77(2H, t, J=7.2 Hz), 4.10(2H, q, J=7.0 Hz), 4.97(2H, s), 5.17(2H, s), 6.98(2H, 4, J=8.6 Hz), 7.15(1H, s), 7.18(2H, 4, J=8.6 Hz), 7.36(1H, s), 7.39-7.46(3H, m), 7.97-8.03(2H, m). :
Example 142
A mixture of ethyl 3-[1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yllpropionate (1.34 g), 1 N aqueous sodium hydroxide solution (6 ml), ethanol (12 ml), and tetrahydrofuran (12 ml) was stirred at room temperature for two hours. After 1 N hydrochloric acid (6 ml) was added to the reaction mixture, the reaction mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained crystals were collected by filtration, 3-[1- [4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H- pyrazol-4-yl]propionic acid (1.21 g, yield: 97%) was obtained. This was recrystallized from ethanol-hexane.
Melting point: 124 - 125TC.
Example 143
To a solution of 3,5-dimethyl-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- . carbaldehyde (900 mg) and ethyl diethylphosphonoacetate (1.10 g) in N,N-dimethylformamide (20 ml), sodium hydride : 5 (60%, oily, 200 mg) was added at 0C, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO,), and concentrated. The obtained 106 crystals were collected by filtration, and ethyl (E)-3- [3,5-dimethyl-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propenoate (740 mg) was obtained. After the mother liquor was concentrated, the residue was subjected to silica gel column chromatography, and 150 mg of crystals were additionally obtained from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio). The total was 890 mg (yield: 87%).
This was recrystallized from ethyl acetate-isopropyl. ether. Melting point: 98 - 99°C.
Example 144
A mixture of ethyl (E)-3-[3,5-dimethyl-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropenoate (800 mg), 5% palladium-carbon (400 mg), ethanol (30 ml), and tetrahydrofuran (10 ml) was stirred at room temperature for one hour under a hydrogen atmosphere.
After removal of the catalyst by filtration, and the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3,5- dimethyl-1-{4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl}-1H-pyrazol-4-yl]propionate (770 mg, yield: 96%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, } volume ratio).
NMR(CDC1,) 0 : 1.22(3H, t, J=7 Hz), 2.09(3H,s), 2.22(3H, s), 2.35-2.5(5H, m), 2.6-2.75(2H, m), 4.09 (2H, q, J=7 Hz),
4.96(2H, s), 5.14(2H, s), 6.94(2H, 4d, J=9 Hz), 7.02(2H, 4,
J=9 Hz), 7.4-7.5(3H, m), 7.95-8.1(2H, m).
Example 145 . 5 A mixture of ethyl 3-[3,5-dimethyl-1-[4-(5-methyl- 2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (760 mg), 1 N aqueous sodium hydroxide solution (5 ml), ethanol (5 ml.) , and tetrahydrofuran (5 ml) was stirred at room temperature for two hours. The reaction mixture was poured into water, which was acidified with 1
N hydrochloric acid, and precipitated crystals were collected by filtration. This was recrystallized from methanol-ethyl acetate, and 3-[3,5-dimethyl-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- vyl]lpropionic acid was obtained (550 mg, yield: 77%).
Melting point: 170 - 171TC.
Example 146
A mixture of ethyl [1-[2-(4- benzyloxyphenyl)ethyl]-3-phenyl-lH-pyrazol-4-yl]acetate (440 mg), 1 N aqueous sodium hydroxide solution (2 ml), ethanol (2 m1), and tetrahydrofuran (2 ml) was stirred at room temperature for 2 hours. The reaction mixture was acidified with 1 N hydrochloric acid. The obtained crystals were collected by filtration, and [1-[2-(4- benzyloxyphenyl)ethyl]-3-phenyl-lH-pyrazol-4-yl]lacetic acid was obtained (350 mg, yield: 85%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 199 - 200TC. © 30
Example 147 ] A mixture of ethyl 3-hydroxy-1lH-pyrazol-4- carboxylate (12.18 g), 4-(4-chloromethylphenoxymethyl)- ] 5-methyl-2-phenyloxazole (55.11 g), potassium carbonate (25.52 g), and N,N-dimethylformamide (300 ml) was stirred at 90C for 8 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with dilute hydrochloric acid. then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected } 5 to silica gel column chromatography, and ethyl 1-[4-(5- methyl. -2-phenyl-4-oxazolylmethoxy)benzyl]-3-[4- (5. methyl-2-phenyl-4-oxazolylmethoxy)benzyloxy]-1H- pyrazol-4- carboxylate (48.16 g, yield: 87%) was obtained as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from acetone-hexane. Melting point: 118 - 119TC.
Example 148
To a mixture of 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyloxy]-1H-pyrazol-4-carbaldehyde (25.20 g), ethyl diethylphosphonoacetate (9.50 g), and
N,N-dimethylformamide (200 ml), sodium hydride (60%, oily, 1.68 g) was added at 0C, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was added to ice water, and the obtained crystals were collected by filtration, and ethyl (E)-3-{1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl}-3-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyloxy]-1H-pyrazol-4- yllpropenoate (25.58 g, yield: 92%) was obtained. This was recrystallized from tetrahydrofuran-hexane. Melting point: 148 - 149TC.
Example 149
A mixture of ethyl (E)-3-[1-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)benzyl]-3-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyloxy]-1H-pyrazol-4-yl)propenoate (24.15 g), 5% palladium-carbon (34.22 g), and tetrahydrofuran (400 ml) was stirred at room temperature under a hydrogen atmosphere overnight. After removal of the catalyst by filtration, and the filtrate was concentrated. The residue was subjected to silica gel oo column chromatography, and ethyl 3-[3-hydroxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- . 5 vllpropionate was obtalued from the fraction eluted with ethyl acetate-hexane (2:1, volume ratio) as colorless crystals (13.93 g, yield: 92%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 137 - 138TC.
Example 150
After a mixture of ethyl 3-[3-hydroxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (650 mg), 1 N aqueous sodium hydroxide } solution (5 ml), tetrahydrofuran (5 ml), and ethanol (10 ml) was stirred at room temperature for three hours, 1 N hydrochloric acid (5 ml) was added to the mixture, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, oo dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3- hydroxy-1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy) benzyl] -1H-pyrazol-4-yllpropionic acid was obtained (560 mg, yield: 91%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 197 - 198.
Example 151
To a solution of ethyl 3-{3-hydroxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl)-1H-pyrazol-4- yl]propionate (1.00 g) in tetrahydrofuran (80 ml), sodium hydride (60%, oily, 100 mg) was added at 0T, and the solution was stirred for 30 minutes. N-
Phenyltrifluoromethanesulfonimide (930 mg) was added to the reaction mixture, which was stirred at room temperature for two hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate was washed with saturated aqueous sodium bicarbonate solution, 1 N hydrochloric acid, then, with saturated sodium chloride solution, and dried (MgSO,) and ) concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-(5-methyl-2- . 5 phenyl 4 -oxazolylmethoxy)benzyl]-3- trifluoromethanesulfonyloxy 1H-pyrazol -4-yl]propionate was obtained (1.31 g, yield: 100%) as a colorless oily substance from the fraction eluted with ethyl acetate- hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 1.20 (3H, t, J=7.0Hz), 2.43 (3H, s), 2.48-2.56 (2H, m), 2.69~2.76 (2H, m), 4.09 (2H, q, J=7.0 Hz), 4.99 (2H, s), 5.10 (2H, s), 6.98-7.02 (2H, m), 7.11-7.20 (3H, m), 7.42-7.46 (3H, m), 7.99-8.04 (2H, m).
Example 152
To a solution of ethyl 3-[3-hydroxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (462 mg) in N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 40.0 mg) was added at 0C, and the solution was stirred at room temperature for 30 minutes.
Jodomethane (0.187 ml) was added to the reaction mixture, which was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-methoxy-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl)-1H-pyrazol-4-yl]propionate was obtained (382 mg, yield: 80%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 :1.21 (3H, t, J=7.2 Hz), 2.43 (3H, s), 2.46-2.54 (2H, m), 2.60-2.68 (2H, m), 3.90 (3H, s), 4.09 (2H, gq, J=7.2
Hz), 4.98 (2H, s), 5.01 (2H, s), 6.93 (1H, s), 6.98 (2H, d, J=8.8 Hz), 7.15 (2H, 4, J=8.8 Hz), 7.40-7.47 (3H, m),
7.99-8.04 (2H, m). . Example 153
A mixture of ethyl 3-[3-methoxy-1-[4-(5-methyl-2- . 5 phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazole-4- vllpropionate (380 mg), 1 N aqueous sodium hydroxide " solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for 2 hours, diluted with 1 N hydrochloric acid (2 ml) , and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-methoxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl] -1H-pyrazol-4- vyl])propionic acid was obtained (319 mg, yield: 89%). This was recrystallized from ethanol-hexane. Melting point: 127 - 128TC.
Example 154
To a solution of ethyl 3-[3-hydroxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl)-1H-pyrazol-4- yl)propionate (462 mg) in N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 40.0 mg) was added at 0C, and the solution was stirred at room temperature for 30 minutes.
Iodoethane (0.240 ml) was added to the reaction mixture, which was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue. was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-(4-(5-methyl-2--phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate was obtained (452 mg, yield: 92%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). }
NMR(CDC1,) 6 :1.21 (3H, t, J=7.2Hz), 1.36 (3H, t, J=7.0 Hz). 2.43 (3H, s), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 4.09 . (2H, gq, J=7.2 Hz), 4.23 (2H, gq, J=7.0 Hz), 4.98 (2H, s). 5.00 (2H, s), 6.93 (1H, s), 6.97 (2H, 4d, J=8.8 Hz), 7.14 . 5 (2H, d, J=8.8 Hz), 7.40--7.47 (3H, m), 7.97-8.06 (2H, m).
Example 155
A mixture of ethyl 3-[3-ethoxy-1-{4-(5-methyl-2-~ phenyl-4-oxazolylmethoxy) benzyl] -1lH-pyrazole-4- yllpropionate (441 mg), 1 N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) : was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (2 ml) , and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSoO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl}-1H-pyrazol-4- yllpropionic acid was obtained (328 mg, yield: 79%). This was recrystallized from ethanol-hexane. Melting point: 96 - 97C.
Example 156
To a solution of ethyl 3-[3-hydroxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (710 mg) in N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 72.0 mg) was added at 0C, and the solution was stirred at room temperature for 30 minutes.
Iodopropane (0.33 g) was added to the reaction mixture, which was stirred at room temperature for two hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the obtained oily substance, 1 N aqueous sodium . hydroxide solution (3 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature tor two hours, . 5 diluted with 1 N hydrochloric acid (3 ml) , and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,). and concentrated. The obtained colorless crystals were collected by filtration, and 3-{1-{4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-3-propyloxy-1H- pyrazol-4-yllpropionic acid was obtained (0.59 g, yield: 81%). This was recrystallized from acetone-hexane.
Melting point: 108 - 109T.
Example 157
A mixture of ethyl 3-{3-hydroxy-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (700 mg), potassium carbonate (250 mg), iodoisopropane (1.03 g), and N,N-dimethylformamide (15 ml) was stirred at 80 - 90TC for four hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with - water, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-isopropoxy-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl)propionate was obtained as a colorless oily substance (460 mg, yield: 60%) from the fraction eluted with ethyl acetate-hexane (1:2, ) volume ratio).
NMR(CDCl,)0 :1.21 (3H, t, J=7 Hz), 1.32 (6H, d, J=6 Hz), 2.43 (3H, s), 2.45-2.7 (4H, m), 4.09 (2H, gq, J=7 Hz), 4.75-4.95 (1H, m), 4.98 (2H, s), 5.00 (2H, s), 6.92 (1H, s), 6.97 (2H, d, J=9 Hz), 7.14 (2H, 4, J=9 Hz), 7.4-7.5 (3H, m), 7.95-8.1 (2H, m).
Example 158
A mixture of ethyl 3-[3-isopropoxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)}benzyl)-1H-pyrazole- . 4-yl]propionate (440 mg), 1 N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) . 5 was stirred at room temperature for one hour, diluted with 1 N hydrochloric acid (5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-isopropoxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yvl]propionic acid was obtained (380 mg, yield: 91%). This was recrystallized from acetone-isopropyl ether. Melting point: 106 - 107TC.
Example 159
A mixture of ethyl 3-[3-hydroxy-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yl]lpropionate (500 mg), potassium carbonate (165 mg), benzyl bromide (205 mg), and N,N-dimethylformamide (10 ml) was stirred at 80°C for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with water, dried (MgsSo,), and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3- benzyloxy-1-[4-(5-methyl-2-phenyl-4-. oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate (385 mg, yleld: 64%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 8 : 1.19 (3H, t, J=7 Hz), 2.44 (3H, s), 2.45-2.7 (4H, m), 4.07 (2H, q, J=7 Hz), 4.99 (2H, s), 5.03 (2H, s), 5.24 (2H, s), 6.96 (1H, s), 6.98 (2H, 4, J=9 Hz), 7.14 (2H, d, J=9 Hz), 7.3-7.5 (8H, m), 7.95-8.1 (2H, m).
Example 160
A mixture of ethyl 3-[3-benzyloxy-1-[4-(5~methyl- 2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- . vllpropionate (380 mg), 1 N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (3 ml), and ethanol (3 ml) . 5 was stirred at. room temperature for one hour, and then diluted with 1 N hydrochloric acid (5ml) to give colorless crystals, which were collected by filtration. This was recrystallized from ethyl acetate-hexane, to yield 3- [3-benzyloxy-1- [4- (5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]lpropionic acid (300 mg, yield: 83%). Melting point: 108 - 109%T.
Example 161
To a solution of ethyl 3-[3-hydroxy-1-{4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1lH-pyrazol-~4- yllpropionate (1.00 g) in N,N-dimethylformamide (80 ml), sodium hydride (60%, oily, 100 mg) was added at 0C, and the solution was stirred at room temperature for 30 minutes. 2-Chloro-5-trifluoromethylpyridine (0.45 g) was added to the reaction mixture, which was stirred at 90°C for two hours. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). A mixture of the obtained oily substance, 1 N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml), and ethanol (10 ml) was stirred at room temperature overnight, diluted with 1 N hydrochloric acid (5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution,. dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3-(5-
trifluoromethyl-2-pyridyloxy)-1H-pyrazol-4-yl]propionic acid was obtained (960 mg, yield: 76%). This was recrystallized from ethyl acetate-hexane. Melting point: 107 - 108%. : 5
Example 162
A mixture of ethyl 3-hydroxy-l1H-pyrazol-4- carboxylate (5.50 g), 4-(4-chloromethylphenoxymethyl)- 2-(2-furyl)-5-methyloxazole (22.85 g), potassium carbonate (15.11 9g), and N,N-dimethylformamide (200 ml) was stirred at 90C for 8 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with dilute hydrochloric acid, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography. and ethyl 1-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyl]-3-[4-[2-(2-furyl)-5-methyl-4- - oxazolylmethoxy]lbenzyloxy]-1H-pyrazol-4 carboxylate (19.96 g, yield: 82%) was obtained as colorless crystals. from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 133 - 134TC,
Example 163 :
To a mixture of 1-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyl]-3-[4-[2-(2-furyl)-5-methyl-4- i oxazolylmethoxy]benzyloxy]-1H-pyrazol-4-carbaldehyde (14.09 g), ethyl diethylphosphonoacetate (5.88 g), and
N,N-dimethylformamide (100ml), sodiumhydride (60%, oily, 1.01 g) was added at 0C, and the mixture was stirred at room temperature for two hours. The reaction mixture was poured into ice water, and the obtained crystals were collected by filtration, and ethyl (E)-3-[1-[4-[2-(2- furyl)-5-methyl-4-oxazolylmethoxy]lbenzyl]}-3-[4-[2-(2- furyl)-5-methyl-4-oxazolylmethoxylbenzyloxy]-1H-
pyrazol-4-yl]propenoate was obtained (13.91 g, yield: 89%).
This was recrystallized from ethyl acetate-hexane.
Melting point: 138 - 139T. . 5 Example 164
A mixture of ethyl (E) 3. -[1-[4-[2-(2 furyl)-5- methyl-4-oxazolylmethoxylbenzyl]-3-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxylbenzyloxyl-1H-pyrazol-4- yl]lpropenoate (12.5 g), 5% palladium-carbon (20.0 g), ethanol (200 ml), and tetrahydrofuran (200 ml) was stirred under a hydrogen atmosphere at room temperature for 7 hours.
After removal of the catalyst by filtration, the filtrate was concentrated. The obtained crystals were collected by filtration, and ethyl 3-[1-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxylbenzyl]-3-hydroxy-1H-pyrazol-4- yl]lpropionate (4.40 g, yield: 56%) was obtained. This was recrystallized from tetrahydrofuran-hexane. Melting point: 145 - 146T.
Example 165
To a solution of ethyl 3-[1-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxylbenzyl]-3-hydroxy- l1H-pyrazol- 4-yl]propionate (4.29 g) in tetrahydrofuran (100 ml), sodium hydride (60%, oily, 420 mg) was added at 0C, and the solution was stirred for 10 minutes. N-
Phenyltrifluoromethanesulfonimide (3.75 g) was added to the reaction mixture, which was stirred at 0TC for 20 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate solution, 1 N hydrochloric acid, then with saturated aqueous sodium chloride solution, and dried (Mg$0,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-[4-[2-(2-furyl)- 5-methyl-4-oxazolylmethoxy]lbenzyl]-3- . trifluoromethanesulfonyloxy-l1H-pyrazol-4-yl]lpropionate
(5.02 g, yield: 91%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- } hexane (1:2, volume ratio). . :
NMR (CDC1,) 0 :1.20 (3H, t, J=7.2 Hz), 2.42 (3H, s), 2.53 (2H, ; 5 t, J=7.0 Hz), 2.73 (2H, t, J=7.0 Hz), 4.09 (2H, qq, J=7.2
Hz), 4.98 (2H, s), 5.10 (2H, s), 6.52 (1H, dd, J=3.6, 1.8
Hz), 6.96-7.01 (3H, m), 7.12 (1H, s), 7.17 (2H, d, J=8.8
Hz), 7.53 (1H, dd, J=1.8, 0.8 Hz).
Example 166
To a solution of ethyl 3-[1-{4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxy ]Jbenzyl]-3-hydroxy-1H-pyrazol- 4-yl]propionate (452mg) in N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 40.0 mg) was added at 0C. and the solution was stirred at room temperature for 30 minutes. ~ Iodoethane (0.240 ml) was added to the reaction mixture, which was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[4-[2-(2~furyl)-5-methyl-4- oxazolylmethoxy]benzyl]-1H-pyrazol-4-yllpropionate (348 . ) 25 mg, yield: 73%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 :1.21 (3H, t, J=7.0 Hz), 1.36 (3H, t, J=7.0
Hz), 2.47 (3H, s), 2.48-2.55 (2H, m), 2.61-2.69 (2H, m), 4.09 (2H, q, J=7.0 Hz), 4.22 (2H, q, J=7.0 Hz), 4.97 (2H, s), 5.00 (2H, s), 6.52 (1H, dd, J=3.6., 2.0 Hz), 6.92-6.99 (4H, m), 7.13 (2H, 4, J=8.8 Hz), 7.54 (1H, Ad, J=2.0, 0.6
Hz).
Example 167
A mixture of ethyl 3-[3-ethoxy-1-[4-[2-(2-furyl)- 5-methyl-4-oxazolylmethoxylbenzyl]-1H-pyrazole-4- yllpropionate (381 mg), 1 N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) . 5 was stirred at room temperature for four hours, diluted with : 1 N hydrochloric acid (2 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[4-[2-(2- furyl)-5-methyl-4-oxazolylmethoxy]lbenzyl]-1H-pyrazol-4- yl]propionic acid was obtained (327 mg, yield: 91%). This was recrystallized from ethanol-hexane. Melting point: 129 - 130TC.
Example 168
To a solution of ethyl 3-[1-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxylbenzyl]-3-hydroxy-1H--pyrazol- 4. yl)lpropionate (452 mg) in N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 40.0 mg) was added at 0C, and the solution was stirred at room temperature for 30 minutes.
Benzyl bromide (0.178 ml) was added to the reaction mixture, which was stirred at room temperature for one hour. The ‘reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-benzyloxy-1-[4-[2-(2-furyl)-5-methyl-4- ‘oxazolylmethoxylbenzyl]-1H-pyrazol-4-yl]propionate (383 mg, yield: 71%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 :1.19 (3H, t, J=7.2Hz), 2.42 (3H, s), 2.47-2.55 (2H, m), 2.63-2.71 (2H, m), 4.07 (2H, q, J=7.2 Hz), 4.97 (2H, s), 5.02 (2H, s), 5.23 (2H, s), 6.52 (1H, dd, J=3.6,
1.8 Hz), 6.90-6.99 (4H, m), 7.13 (2H, 4d, J=8.4 Hz), 7.27-7.47 (5H, m), 7.54 (1H, dd, J=1.8, 1.0 Hz).
Example 169 . 5 A mixture of ethyl 3-[3-benzyloxy-1-[4-[2-(2- furyl) 5 -methyl-4.-oxazolylmethoxylbenzyl]-1H pyrazol-4- yllpropionate (379 mg), 1 N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for S hours, diluted with 1 N hydrochloric acid (2 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-benzyloxy-1-[4-[2-(2- furyl)-S-methyl-4-oxazolylmethoxylbenzyl)]-1H-pyrazol-4- yl]lpropionic acid was obtained (299 mg, yield: 83%). This was recrystallized from ethanol-hexane. Melting point: 104 -~ 105TC.
Example 170
To a mixture of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl)propionate (1.59 g), 4-benzyloxy-3-methoxybenzyl chloride (1.97 g), and N,N-dimethylformamide (30 ml), sodium hydride (60%, oily, 0.30 g) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-(4-benzyloxy-3-methoxybenzyl)-3-ethoxy- l1H-pyrazol-4-yl]lpropionate (2.93 g, yield: 89%) was obtained as a colorless oily substance from the fractions eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 :1.20 (3H, t, J=7.2Hz), 1.36 (3H, t, J=7.0 Hz), 2.46-2.54 (2H, m), 2.60-2.68 (2H, m), 3.84 (3H, s), 4.08
(2H, q, J=7.2 Hz), 4.22 (2H, q, J=7.0 Hz), 4.97 (2H, s), 5.14 (2H, s), 6.66 (1H, dd, J=8.4, 2.0 Hz), 6.76 (1H, 4, . J=2.0 Hz), 6.81 (1H, 4, J=8.4 Hz), 6.93 (1H, s), 7.28-7.44 (5H, m).
Example 171
To a solution of ethyl 3-[3-ethoxy-1-(4-hydroxy-3- methoxybenzyl)-1H-pyrazol-4-yllpropionate (505 mg) in
N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 58.0 mg) was added at 0C, and then the solution was stirred at room temperature for 30 minutes. 4-Chloromethyl-5- } methyl-2-phenyloxazole (301 mg) was added to the reaction mixture, which was stirred at 60C for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography. and ethyl 3-[3-ethoxy-1-[3-methoxy-4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate (661 mg, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 :1.22 (3H, t, J=7.2 Hz), 1.37 (3H, t, J=7.2
Hz), 2.41 (3H, s), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 3.82 (3H, s), 4.09 (2H, q, J=7.2 Hz), 4.23 (2H, q, J=7.2
Hz), 5.00 (2H, s), 5.04 (2H, s), 6.72 (1H, 4d, J=8.2, 2.2
Hz), 6.76 (1H, 4, J=2.2 Hz), 6.95 (1H, s), 7.00 (1H, 4, J=8.2
Hz), 7.40-7.46 (3H, m), 7.98-8.03 (2H, m).
Example 172 . } A mixture of ethyl 3-[3-ethoxy-1-[3-methoxy-4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (660 mg), 1 N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 3 hours, diluted with
1 N hydrochloric acid (3 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated . aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3.-[3-ethoxy-1- [3 -methoxy- 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H~ pyrazol-4.yllpropionic acid (510 mg, yield: 82%) was obtained. This was recrystallized from ethanol-hexane.
Melting point: 122 - 123C.
Example 173 .
To a solution of ethyl 3-[{3-ethoxy-1-(4-hydroxy-3- methoxybenzyl) -1H-pyrazol-4-yl]lpropionate (505 mg) in
N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 58.0 mg) was added at 0C, and then the solution was stirred at room temperature for 30 minutes. 4-Chloromethyl-2- (2-furyl)-5-methyloxazole (573 mg) was added to the reaction mixture, which was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgS0O,) and concentrated. The residue was subjected to silica gel column chromatography, : and ethyl 3-[3-ethoxy-1-[{4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxy]-3-methoxybenzyl]-1H-pyrazol-4- yl]lpropionate (564 mg, yield: 76%) was obtained as a yellow oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0 : 1.21 (3H, t, J=7.2Hz), 1.37 (3H, t, J=7.2 Hz), 2.40 (3H, s), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 3.82 (3H, s), 4.09 (2H, q., J=7.2 Hz), 4.23 (2H, q. J=7.2 Hz), 4.99 (2H, s), 5.03 (2H, s), 6.52 (1H, 44, J=3.6, 1.8 Hz), 6.71 (1H, 4d, J=8.2, 2.0 Hz), 6.75 (1H, 4, J=2.0 Hz), 6.94 . (1H, s), 6.96 (1H, 4, J=8.2 Hz), 6.96 (1H, 4d, J=3.6, 0.8 35° Hz), 7.53 (1H, ad, J=1.8, 0.8 Hz).
Example 174
A mixture of ethyl 3-[3-ethoxy-1-[4-[2-(2-furyl)- . 5-methyl-4-oxazolylmethoxy]-3-methoxybenzyl]-1H- pyrazol-4-yl]propionate (561 mg), 1 N aqueous sodium 5S hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and } ethanol (5ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (2.5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,). and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[4-[2-(2- furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxybenzyl]-1H- pyrazol-4-yllpropionic acid (506 mg, yield: 96%) was obtained. This was recrystallized from ethanol-hexane.
Melting point: 133 - 1347.
Example 175 :
To a solution of ethyl 3-[3-ethoxy-1-(4-hydroxy-3- methoxybenzyl] 1H-pyrazol-4-yl]propionate (505 mg) in
N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 58.0 mg) was added at 0C, and then the solution was stirred at room temperature for 30 minutes. 4-Chloromethyl-5- methyl-2-(2-thienyl)oxazole (310 mg) was added to the reaction mixture, which was stirred at room temperature for onehour. The reaction mixture was pouredintowater, which was extracted with ethyl acetate. The ethyl acetate layer. was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[3-methoxy-4-[5-methyl-2-(2- thienyl)-4-oxazolylmethoxylbenzyl]-1H-pyrazol-4- yl)propionate (500 mg, yield: 66%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,)0 :1.21 (3H, t, J=7.2 Hz), 1.37 (3H, t, J=7.2 Hz), 2.39 (3H, s), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 3.82
(3H, s), 4.09 (2H, q, J=7.2 Hz), 4.23 (2H, q, J=7.2 Hz). 4.99 (2H, s), 5.01 (2H, s), 6.71 (1H, dd, J=8.0, 2.2 Hz), . 6.75 (1H, 4, J=2.2 Hz), 6.94 (1H, s), 6.96 (1H, d, J=8.0
Hz), 7.09 (1H, dd, J=4.8, 3.6 Hz), 7.39 (1H, dd, J=4.8, 1.2
Hz), 7.62 (1H, dd, J=3.6, 1.2 Hz).
Example 176
A mixture of ethyl 3-{3-ethoxy-1l-[3-methoxy-4-[5- methyl-2-(2-thienyl)-4-oxazolylmethoxy]benzyl)-1H- pyrazol-4-yllpropionate (499 mg), 1 N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for 3 hours, : diluted with 1 N hydrochloric acid (2 ml) , and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,). and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[3-methoxy- 4-[5-methyl-2-(2-thienyl)-4-oxazolylmethoxy]benzyl]-1H- pyrazol-4-yllpropionic acid (392 mg, yleld: 83%) was obtained. This was recrystallized from ethanol-hexane. :
Melting point: 123 - 1247T.
Example 177
A mixture of ethyl 3-[3-ethoxy-1-(4-hydroxy-3- methoxybenzyl)-l1H-pyrazol-4-yl]propionate (505 mg), 3- picolyl chloride hydrochloride .(476 mg), potassium carbonate (601 mg), and N,N-dimethylformamide (10 ml) was stirred at room temperature overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[3-methoxy-4-(3- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl] propionate (531 mg, yield: 83%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate. } NMR(CDC1,) 0 :1.21 (3H, t, J=7.0Hz), 1.37 (3H, t, J=7.0 Hz), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 3.84 (3H, s), 4.09 . 5 (2H, q, J=7.0 Hz), 4.22 (2H, qq, J=7.0 Hz), 4.99 (2H, s), 5.13 (2H, s), 6.68 (1H, dd, J=8.0, 2.2 Hz), 6.77 (1H, 4,
J=2.2 Hz), 6.84 (1H, 4d, J=8.0 Hz), 6.95 (1H, s), 7.31 (1H, dd, J=8.0, 4.8 Hz), 7.79 (1H, dt, J=8.0, 1.8 Hz), 8.57 (1H, d, J=4.8 Hz), 8.67 (1H, s).
Example 178 : A mixture of ethyl 3-[3-ethoxy-l1-[3-methoxy-4-(3- pyridylmethoxy)benzyl]-1H-pyrazole-4-yl]lpropionate (527 mg), 1 N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (2.5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS$O,). and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[3-methoxy- 4-(3-pyridylmethoxy)benzyl]-1H-pyrazol-4-yl}propionic acid (381 mg, yield: 77%) was obtained. This was recrystallized from ethanol-hexane. Melting point: 124 - 125TC. }
Example 179
To a mixture of ethyl 3-[3-ethoxy-1H-pyrazol-4- yl]propionate (1.50 g), 4-benzyloxybenzyl chloride (1.81 g), and N,N-dimethylformamide (30 ml), sodium hydride (60%, oily, 0.35 g) was added at 0C, and then the mixture was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,} and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[1-(4-benzyloxybenzyl)-3-ethoxy-1H-pyrazol 4- . yl])propionate (2.76 g, yield: 96%) was obtained as a colorless oily substance from the faction eluted with ethyl . 5 acetate hexane (1:4, volume ratio).
NMR(CDC1,) 6 : 1.21 (3H, t, J=7.0Hz), 1.37 (3H, t, J=7.0Hz), 2.44-2.70 (4H, m), 4.09 (2H, q, J=7.0Hz), 4.25 (2H, q, J=7.0
Hz), 5.03 (2H, s), 5.05 (2H, s), 6.88-6.98 (3H, m), 7.09-7.19 (2H, m), 7.30-7.48 (5H, m).
Example 180
A mixture of ethyl 3-{1-(4-benzyloxybenzyl)-3- ethoxy-1H-pyrazol-4-yllpropionate (490 mg), 1 N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (3 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[1-(4- benzyloxybenzyl)-3 -ethoxy- l1H-pyrazol-4-yllpropionic acid (430 mg, yield: 94%) was obtained. This was recrystallized from acetone-hexane. Melting point: 115 - 116. : :
Example 181 :
A mixture of ethyl 3-[3-ethoxy-1-(4- : hydroxybenzyl) -1H-pyrazol-4-yl]propionate (1.50 g), 4- chloromethyl-2-phenylthiazole (1.05 g), potassium carbonate (1.30 g), and N,N-dimethylformamide (20 ml) was stirred at room temperature overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with } water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A . mixture of the obtained oily substance, 1 N aqueous sodium hydroxide solution (10 ml), tetrahydrofuran (10 ml), and , 5 ethanol (10 ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (10 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, ‘dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration and 3-[3-ethoxy- 1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]-1H-pyrazol-4- vllpropionic acid (1.60 g, yield: 73%) was obtained. This was recrystallized from acetone-hexane. Melting point: 114 - 115TC. : :
Example 182
A mixture of ethyl 3-[3-ethoxy-1-(4- hydroxybenzyl) -1H-pyrazol-4-yl]lpropionate (1.20 gq), 4- chloromethyl-5-methyl-2-phenylthiazole (0.95 g). potassium carbonate (1.06 g), and N,N-dimethylformamide (20 ml) was stirred at room temperature overnight. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the obtained oily substance, 1 N aqueous sodium hydroxide solution (10 ml), tetrahydrofuran (10 ml), and ethanol (10 ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (10 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-
1-[4-(5-methyl-2-phenyl-4-thiazolylmethoxy)benzyl]-1H- pyrazol-4-yllpropionic acid (1.46 g, yield: 81%) was . obtained. This was recrystallized from ethyl acetate- hexane. Melting point: 73 - 74°C.
Example 183
To a mixture of ethyl 3-[3-ethoxy-lH-pyrazol-4- yllpropionate (318 mg), 5-chloromethyl-2-(5-methyl.2- phenyl-4-oxazolylmethoxy)pyridine (472 mg), and N,N- dimethylformamide (10 ml), sodium hydride (60%, oily, 60.0 mg) was added at 0C, and then the mixture was stirred at. room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. :
The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgsSo,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3- ethoxy-1-[2-(5-methyl--2-phenyl-4-oxazolylmethoxy)-5- pyridylmethyl]-1H-pyrazol-4-yl]lpropionate (651 mg, yield: 88%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 $1.21 (3H, t, J=7.2 Hz), 1.36 (3H, t, J=7.0
Hz), 2.47-2.55 (5H, m), 2.61-2.69 (2H, m), 4.09 (2H, q,
J=7.2 Hz), 4.21 (2B, q, J=7.0 Hz), 4.98 (2H, s), 5.28 (2H, s), 6.77 (1H, 4, J=8.4 Hz), 6.97 (1H, s), 7.39-7.46 (4H, m), 7.98-8.04 (3H, m).
Example 184
A mixture of ethyl 3-[3-ethoxy-1-[2-(5-methyl-2- phenyl-4-oxazolylmethoxy)-5-pyridylmethyl]-1H-pyrazol- 4-yl]lpropionate (638 mg), 1 N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ] ml) was stirred at room temperature for 3 hours, diluted with 1 N hydrochloric acid (2.5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). oe - and concentrated. The gbtained colorless crystals were .
BE. | collected by filtration, and-3-{3-ethoxy-1-[2-(5-methyl- . 2 -phenyl-4-oxazolylmethoxy)-5-pyridylmethyl])-1H- pyrazol-4-yl]propionic acid (495 mg, yield: 82%) was obtained. This was recrystallized from cthdnol-hexane.
Melting point: 143 - 144TC.
Example 185
To a mixture of ethyl 3-[3-ethoxy-1H-pyrazol-4- yl]propionate (318 mg), 4-(4- : ’ chloromethylphenoxymethyl)-2-phenyloxazole (450 mg), and
N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 60.0 mg) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The obtained colorless crystals were collected by filtration, and ethyl 3-[3- ethoxy-1-[4-(2-phenyl-4-oxazolylmethoxy)benzyl]-1H- pyrazol-4-yl]propionate (616 mg, yield: 86%) was obtained. “. This was recrystallized from ethyl acetate-hexane.
Melting point: 80 - 81°C.
Example 186 | :
A mixture of ethyl 3-[3-ethoxy-1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate (523 mg), 1 N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 3 hours, diluted with 1 N hydrochloric acid {2.5ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[4-(2-phenyl-4-
Amended Sheet - 2004-01-27 oxazolylmethoxy)benzyl]-1H-pyrazol-4-yllpropionic acid (456 mg, yield: 93%) was obtained. This was recrystallized from ethanol-hexane. Melting point: 135 - 136TC.
Example 187
To a mixture of ethyl 3-(3-ethoxy-l1H-pyrazol-4- yl]lpropionate (415 mg), 3-(4- chloromethylphenoxymethyl)pyridine (554 mg), and N,N-' dimethylformamide (10 ml), sodium hydride (60%, oily, 80.0 mg) was added at 0°C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[4-(3- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl] propionate (340 mg, yield: 55%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
N NMR (CDC1,) 0 $1.21 (3H, t, J=7.2 Hz), 1.36 (3H, t, J=7.0
Hz), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 4.09 (2H, q,
J=7.2 Hz), 4.22 (2H, q, J=7.0 Hz), 5.00 (2H, s), 5.07 (2H, s), 6.92 (2H, 4, J=8.8 Hz), 6.93 (1H, s), 7.14 (2H, d, J=8.8
Hz), 7.32 (1H, dd, J=7.4, 4.8 Hz), 7.77 (1H, dt, J=7.4, 2.0
Hz), 8.59 (1H, 44, J=4.8, 2.0 Hz), 8.68 (1H, 4, J=2.0 Hz).
Example 188
A mixture of ethyl 3-[3-ethoxy-1-[4-(3- pyridylmethoxy)benzyl]-lH-pyrazol-4-yl}propionate (340 mg), 1 N aqueous sodium hydroxide solution (2 ml), . tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for two hours, diluted with 1 N a. hydrochloric acid (2ml), and extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-{4-(3- - > : h " pyridylmethoxy)benzyl]-1H-pyrazol-4-yl)propionic acid : (260mg, yield: 82%) was obtained. This was recrystallized from ethanol-hexane. Melting point: 120 - 121°C.
Example 189
To a mixture of ethyl 3-(3-ethoxy-lH-pyrazole-4- vl]lpropicnate (300 mg), 4-(4- chloromethylphenoxymethyl)-5-methyl-2-(2- thienyl)oxazole (450mg), and N,N-dimethylformamide (5ml), sodium hydride (60%, oily, 70.0 mg) was added at oC, and ; then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The ’ residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction eluted with ethyl acetate-hexane (1:2, volume ’ ratio). A mixture of the obtained colorless oily substances, IN aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature oo overnight, diluted with 1 N hydrochloric acid (5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy- 1-{4-[5-methyl-2-(2-thienyl)-4-oxazolylmethoxy]benzyl]- lH-pyrazol-4-yl]propionic acid (460 mg, yield: 70%) was obtained. This was recrystallized from acetone-hexane.
Melting point: 156 - 157°C.
Example 190
To a mixture of ethyl 3-(3-ethoxy-lH-pyrazol-4- yl)propionate (415 mg), 2-[N-[2-(4-chloromethylphenoxy)
Amended Sheet —- 2004-01-27 ethyl]-N-methylamino]pyridine (554 mg), and N,N- dimethylformamide (10 ml), sodium hydride (60%, oily, 80.0 , mg) was added at 0C, and then the mixture was stirred at » ~ room temperature for 30 minutes. The reaction mixture was ' 5 poured into water, which was extracted with ethyl acetate.
The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (Mgso,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3- ethoxy-1-[4-[2-[N-methyl-N-(2- pyridyl)aminolethoxylbenzyl]-1H-pyrazol-4-yl]propionate (771 mg, yield: 85%) was obtained as a colorless oily ~ substance from the fraction eluted with ethyl acetate- hexane (1:1, volume ratio).
NMR(CDC1,) 0 1.20 (3H, t, J=7.2 Hz), 1.36 (3H, t, J=7.2
Hz), 2.47-2.54 (2H, m), 2.59-2.67 (2H, m), 3.14 (3H, s), 3.97 (2H, t, J=5.6 Hz), 4.08 (2H, q, J=7.2 Hz), 4.17 (2H, t, J=5.6 Hz), 4.21 (2H, q, J=7.2H=z), 4.97 (2H, 5s), 6.49: 6.58 (2H, m), 6.84 (2H, 4, J=8.6 Hz), 6.89 (1H, s), 7.10 (2H, d, J=8.6 Hz), 7.45 (1H, ddd, J=8.6, 7.2, 1.8 Hz), 8.15 (1H, ddd, J=5.0, 1.8, 1.0 Hz).
Example 191
A mixture of ethyl 3-[3-ethoxy-1-[4-[2-[N-methyl-
N-(2-pyridyl)aminolethoxy]benzyl]-1H-pyrazol-4- yllpropionate (769 mg), 1 N aqueous sodium hydroxide solution (4 ml), tetrahydrofuran (8 ml), and ethanol (8 ml) was stirred at room temperature for 3 hours, diluted with 1 N hydrochloric acid (4 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and . concentrated. The residue was subjected to silica gel column chromatography, and 3-[3-ethoxy-1-[4-[2-[N- , methyl-N-(2-pyridyl)amino]ethoxy)benzyl]-1H-pyrazol-4- yl}propionic acid (402 mg, yield: 56%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate. . NMR(CDC1,) 6 :1.34 (3H, t, J=7.0Hz), 2.50-2.68 (4H, m), 3.12 (3H, s), 3.94 (2H, t, J=5.4 Hz), 4.15 (2H, t, J=5.4 Hz), yr 5 4.21 (2H, q, J=7.0 Hz), 4.97 (2H, s), 6.506.558 (2H, m), 6.82 (2H, d, J=8.8 Hz), 6.90 (1H, s), 7.08 (2H, 4, J=8.8
Hz), 7.45 (1H, ddd, J=8.6, 7.2, 2.0 Hz), 8.15 (1H, ddd, J-7.2, 2.0, 1.0 Hz).
Example 192
To a mixture of ethyl 3-(3-ethoxy-1H-pyrazol-4- yllpropionate (318 mg), 2-[4-(4- chloromethylphenoxy)piperidine-1-yllpyridine (404 mg), . and N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 60.0 mg) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[4-[1-(2-pyridyl)piperidine-4- yloxy]benzyl]-1H-pyrazol-4-yl]propionate (609 mg, yield: 85%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0 $1.21 (3H, t, J=7.0 Hz), 1.37 (3H, t, J=7.0
Hz), 1.76-1.93 (2H, m), 1.98-2.12 (2H, m), 2.48-2.55 (2H, m), 2.61-2.69 (2H, m), 3.39-3.49 (2H, m), 3.85-3.97 (2H, m), 4.09 (2H, q, J=7.0Hz), 4.23 (2H, q, J=7.0Hz), 4.46-4.57 (1H, m), 4.99 (2H, s), 6.60 (1H, ddd, J=7.0, 5.0, 0.8 Hz), 6.69 (1H, dt, J=8.8, 0.8 Hz), 6.88 (2H, d, J=8.8 Hz), 6.93 (1H, s), 7.12 (2H, 4, J=8.8 Hz), 7.47 (1H, 4dd4, J=8.8, 7.0, . 1.8 Hz), 8.19 (1H, ddd, J=5.0, 1.8, 0.8 Hz).
Example 193
A mixture of ethyl 3-[3-ethoxy-1-[4-[1-(2- pyridyl)piperidine-4-yloxylbenzyl]-1H-pyrazole-4- - vllpropionate (598 mg), 1 N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ’ 5 ml) was stirred at room temperature for 3 hours, diluted with 1 N hydrochloric acid (2.5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0,), and concentrated. The obtained crystals were collected by filtration, and 3-[3-ethoxy-1-[4-[1-(2- pyridyl)piperidine-4-yloxylbenzyl]-1H-pyrazol-4- yllpropionic acid (408 mg, yield: 72%) was obtained. This was recrystallized from ethanol-hexane. Melting point: 142 - 143C. :
Example 194
To a mixture of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl]lpropionate (318 mg), 2-[2-(4- : chloromethylphenoxy)ethyl]-5-ethylpyridine (414 mg), and
N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 60.0 mg) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and : dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography. and ethyl 3-[3- ethoxy-1-[4-[2-(5-ethyl-2-pyridyl)ethoxylbenzyl]-1H- pyrazol-4-yl]propionate (520 mg, yield: 77%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). ; NMR (CDC1,) 6 11.20 (3H, t, J=7.0Hz), 1.24 (3H, t, J=7.6 Hz), 1.36 (3H, t, J=7.0 Hz), 2.46-2.54 (2H, m), 2.57-2.68 (4H, . m), 3.22 (2H, t, J=6.6 Hz), 4.08 (2H, q, J=7.0 Hz), 4.12 (2H, gq, J=7.0 Hz), 4.33 (2H, t, J=6.6 Hz), 4.97 (2H, s), 6.85 (2H, 4, J=8.6 Hz), 6.90 (1H, s), 7.11 (2H, 4, J=8.6
Hz), 7.18 (1H, 4, J=7.8 Hz), 7.45 (1H, 44, J=7.8, 2.0 Hz), 8.39 (1H, d, J=2.0 Hz).
Example 195 y 5 A mixture of ethyl 3 [3-ethoxy -1-[4-[2-(h-ethyl. 2- pyridyl)ethoxylbenzyl]-1H-pyrazol-4-yl]propionate ( 519 mg), 1 N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 3 hours, diluted with 1 N hydrochloric acid (2.5 ml) ,and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[4-[2-(5-ethyl-2- pyridyl)ethoxylbenzyl]-1H-pyrazol-4-yllpropionic acid (228 mg, yield: 47%) was obtained. This was recrystallized from ethanol-hexane. Melting point: 89 - 90TC.
Example 196 ' 20 To a mixture of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl]propionate (690 mg), 4-[2-(4- chloromethylphenoxy)ethyl)]-5-methyl-2-phenyloxazole (1.05g), and N,N-dimethylformamide (20 m1), sodiumhydride (60%, oily, 130 mg) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and a colorless oily substance was obtained from the fraction . eluted with ethyl acetate-hexane (1:2, volume ratio). A mixture of the obtained colorless oily substance, 1N . aqueous sodium hydroxide solution (6 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (6 ml),
and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated sodium chloride solution, dried . (Mgso,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy- / 5 1-14 [2 (5% methyl 2 phenyl 4-oxazolyl)ethoxylbenzyl]- 1H-pyrazol-4-yllpropionic acid (1.09 g, yield: 72%) was obtained. This was recrystallized from acetone-hexane.
Melting point: 142 - 1437.
Example 197
To a solution of ethyl 3-(3-ethoxy-1lH-pyrazol-4- yllpropionate (780 mg) in N,N-dimethylformamide (50 ml). sodium hydride (60%, oily, 180 mg) was added at 0C, and then the solution was stirred at room temperature for 30 minutes. 2-[4-(5-Methyl-2-phenyl-4- oxazolyl)methoxylphenyl]lethyl methanesulfonate (2.17 g) was added to the reaction mixture at 0C, and then the mixture was stirred at 90TC for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ~ ethyl 3-[3-ethoxy-1-[2-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)phenyllethyl]-1H-pyrazol-4- yl)propionate (1.08 g, yield: 58%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR (CDC1,) 0 1.23 (3H, t, J=7.0 Hz), 1.38 (3H, t, J=7.0
Hz), 2.43 (3H, s), 2.49-2.65 (4H, m), 3.00 (2H, t, J=7.0
Hz), 4.04 (2H, t, J=7.0 Hz), 4.11 (2H, q, J=7.0 Hz), 4.24
Rk (2H, q, J=7.0 Hz), 4.97 (2H, s), 6.78 (1H, s), 6.89-7.01 (4H, m), 7.42-7.46 (3H, m), 7.99-8.04 (2H, m).
Example 198
A mixture of ethyl 3-[3-ethoxy-1-[2-[4-(5-methyl- 2-phenyl-4-oxazolylmethoxy)phenyljethyl]- 1H-pyrazol-4- - yllpropionate (1.08 g), 1 N aqueous sodium hydroxide solution (4.2 ml), tetrahydrofuran (3 ml), and ethanol (3 . 5 ml) was stirred at room temperature for two hours, diluted ‘with 1 N hydrochloric acid (5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsoO,), and concentrated. The obtained crystals were collected by filtration, and 3-{3-ethoxy-1-[2-[4-(5-methyl-2-phenyl- 4-oxazolylmethoxy)phenyllethyl]-1H-pyrazol-4- yllpropionic acid (880 mg, yield: 88%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 110 - 111°C.
Example 199 : }
To a mixture of ethyl 3-(3-ethoxy-1H-pyrazol-4- yllpropionate (509 mg), 4-(2- chloromethylphenoxymethyl )-5-methyl-2-phenyloxazole (753mg), and N,N-dimethylformamide (10 m1), sodium hydride (60%, oily, 96.0 mg) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate . The ethyl acetate layer was washedwith water, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[2-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl)propionate (1.09 g, yield: 93%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- . hexane (1:2, volume ratio).
NMR (CDC1,) 6 :1.20 (3H, t, J=7.2Hz), 1.34 (3H, t, J=7.2Hz), 2.39 (3H, s), 2.46-2.54 (2H, m), 2.60-2.68 (2H, m), 4.08 (2H, gq, J=7.2 Hz), 4.20 (2H, q, J=7.2 Hz), 5.03 (2H, s), 5.11 (2H, s), 6.91-6.93 (2H, m), 7.01-7.06 (2H, m),
.7.22-7.31 (1H, m), 7.41-7.48 (3H, m), 7.98-8.05 (2H, m). . Example 200
A mixture of ethyl 3-[3-ethoxy-1-[2-(5-methyl-2- v 5 phenyl 4 oxazolylmethoxy)benzyl ]- 1H-pyrazol-4- yl]lpropionate (1.09 g), 1N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (10 m1), and ethanol (10 ml) was stirred at room temperature for two hours, diluted with 1 N hydrochloric acid (5 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The obtained colorless crystals were collected by filtration, and 3-[3-ethoxy-1-[2-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionic acid (834 mg, yield: 82%) was obtained. This was recrystallized from ethanol-hexane. Melting point: 127 - 1287.
Example 201
To a mixture of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl]propionate (509 mg), 4-(3- - chloromethylphenoxymethyl) -5-methyl-2-phenyloxazole . (753mg), and N,N-dimethylformamide (10 ml), sodium hydride (60%, oily. 96.0 mg) was added at 0C, and then the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washedwith water, then, with saturated aqueous sodium chloride : solution, dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-[3-(5-methyl.-2-phenyl-4- . oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]lpropionate (809 mg, yield: 69%) was obtained as a colorless oily substance . from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 0 :1.21 (3H, t, J=7.2 Hz), 1.36 (3H, t, J=7.2Hz),
2.42 (3H, s), 2.48--2.55 (2H, m), 2.61-2.69 (2H, m), 4.09 (2H, gq, J=7.2 Hz), 4.22 (2H, q, J=7.2 Hz), 4.95 (2H, s). oo 5.04 (2H, s), 6.74-6.83 (2H, m), 6.91-6.97 (2H, m), 7.25 (1H, t., J=7.8 Hz), 7.42-7.45 (3H, m), 7.99--8.04 (2H, m). ¢ 5
Example 202
A mixture of ethyl 3-[3-ethoxy-1-[3-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yl)propionate (808 mg). 1N aqueous sodium hydroxide solution ( 4 ml), tetrahydrofuran (8 ml), and ethanol (8 ml) was stirred at room temperature for 3 hours, diluted with 1 N hydrochloric acid (4 ml), and extracted with ethyl ‘acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography, and 3-[3-ethoxy-1-[3-(5-methyl- 2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionic acid (709 mg, yield: 93%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate-methanol (5:1, volume ratio).
NMR(CDC1,) 0 :1.35 (3H, t, J=7.0 Hz), 2.48 (3H, s), 2.67 (4B, s), 4.21 (2H, q, J=7.0 Hz), 4.96 (2H, s), 5.11 (2H, s), 6.42 (1H, s), 6.84-6.91 (2H, m), 7.19 (1H, s), 7.26 (1H, d, J=B.0 Hz), 7.43-7.47 (3H, m), 7.94-7.99 (2H, m).
Example 203
A mixture of ethyl 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyloxy]-1H-pyrazol-4-carboxylate (2.84 g), 5% palladium-carbon (5.00 g), ethanol (25 ml), and tetrahydrofuran (25 ml) was stirred under a hydrogen . atmosphere at room temperature for 4 hours. After removal oh the catalyst by filtration, the filtrate was ) concentrated. The obtained crystals were collected by filtration, and ethyl 3-hydroxy-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4-
carboxylate (968 mg, yield: 56%) was obtained. This was recrystallized from tetrahydrofuran-hexane. Melting point: 152 - 153TC. - 5 Example 204
A mixture of ethyl 3-hydroxy-lH-pyrazol--4- carboxylate (10.30 g), 4-benzyloxybenzyl chloride (18.60 g), potassium carbonate (16.60 g), and N,N dimethylformamide (200 ml) was stirred at 100C overnight.
The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was: washed with dilute hydrochloric acid, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 1-(4-benzyloxybenzyl)- 3-(4-benzyloxybenzyloxy)-1H-pyrazol-4-carboxylate (11.90 g, yield: 54%) was obtained as colorless crystals from the fraction eluted with ethyl acetate. This was recrystallized from ethyl acetate-hexane. Melting point: 124 - 125TC.
Example 205
To a solution of ethyl diethylphosphonoacetate (2.74 ml) in tetrahydrofuran (50 ml), sodium hydride (60%, oily, 552 mg) was added at 0, and then the solution was stirred at room temperature for 30 minutes. To the reaction mixture, a solution of 1-(4-benzyloxybenzyl)-3-(4- benzyloxybenzyloxy)-1H-pyrazol-4-carbaldehyde (6.31 g) in tetrahydrofuran (100 ml) was added slowly, and the solution was stirred at room temperature for 15 minutes.
The reaction mixture was poured into water, which was ) extracted with ethyl acetate. The ethyl acetate layer was washed with dilute hydrochloric acid, then, with saturated aqueous sodium chloride solution, and dried (MgSO,) and concentrated. The obtained crystals were collected by filtration, and ethyl 3-[1-(4-benzyloxybenzyl)-3-(4-
benzyloxybenzyloxy)-1H-pyrazol-4-yl]propionate (6.79 4d. yield: 95%) was obtained. This was recrystallized from ethyl acetate-hexane. Melting point: 98 - 99T. , | 5 Example 206
To a solution of ethyl 3-[3-hydroxy-1-(4- hydroxybenzyl)-1H-pyrazol-4-yl]propionate (435 mg) in
N,N-dimethylformamide (10 ml), sodium hydride (60%, oily, 120 mg) was added at 0C, and then the solution was stirred at room temperature for 30 minutes. 3-Picolyl chloride (574 mg) was added to the reaction mixture, which was stirred at room temperature for one hour. The reaction mixture was poured into water, which was extracted with ethyl acetate. The ethyl acetate layer was washed with dilute hydrochloric acid, then, with saturated aqueous sodium chloride solution, and dried (MgsoO,) and concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-(3- pyridylmethoxy)-1-[4-(3-pyridylmethoxy)benzyl] 1H- pyrazol-4-yl]propionate (533 mg, yield: 75%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate. } NMR (CDC1,;) 6 :1.19 (3H, t, J=7.2 Hz), 2.46-2.54 (2H, m), 2.62-2.70 (2H, m), 4.07 (2H, g, J=7.2 Hz), 5.01 (2H, s), 5.07 (2H, s), 5.25 (2H, s), 6.93 (2H, 4, J=8.8 Hz), 7.14 (2H, 4, J=8.8 Hz), 7.26-7.36 (2H, m), 7.74-7.80 (2H, m), 8.55-8.60 (2H, m), 8.69 (2H, s).
Example 207
A mixture of ethyl 3-[3-(3-pyridylmethoxy)-1-[4- (3-pyridylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate } (529 mg), 1 N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at ] room temperature for one hour, diluted with 1 N hydrochloric acid (3 ml), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The obtained colorless crystals were collected by filtration, . and 3-[3-(3-pyridylmethoxy)-1-[4-(3- pyridylmethoxy)benzyl]-1H-pyrazol. 4.yllpropionic acid ’ 5 (427 mg, yicld: 86%) was obtained. This was recrystallized : from ethanol-hexane. Melting point: 116 - 117°C.
Example 208
A mixture of ethyl 3-[1l-(4-benzyloxy-3- methoxybenzyl)-3-ethoxy-1H-pyrazol-4-yl]lpropionate (2.92 g), 5% palladium-carbon (6.00 g), ethanol (20 ml), and tetrahydrofuran (20 ml) was stirred at room temperature for one hour under a hydrogen atmosphere. After removal of the catalyst by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography, and ethyl 3-[3-ethoxy-1-(4- hydroxy-3-methoxybenzyl)-1H-pyrazol-4-yl]propionate (2.04 g, yield: 89%) was obtained as a colorless oily substance from the fraction eluted with ethyl acetate- hexane (1:1, volume ratio).
NMR (CDC1,) 0 :1.21 (3H, t, J=7.0Hz), 1.37 (3H, t, J=7.0 Hz), 2.47-2.55 (2H, m), 2.61-2.69 (2H, m), 3.85 (3H, s), 4.08 (2H, q, J=7.0 Hz), 4.23 (2H, q, J=7.0 Hz), 4.97 (2H, s), 5.65 (1H, br.s), 6.71 (1H, 4, J=8.0 Hz), 6.73 (1H, s), 6.86 (1H, 4, J=8.0 Hz), 6.93 (1H, s). y Example 209
A mixture of ethyl 3-[3-ethoxy-1-(4- hydroxybenzyl)-1H-pyrazol-4-yl]propionate (360 mg), 2-chloromethylquinoline hydrochloride (270 mg), potassium carbonate (300 mg) and N,N-dimethylformamide ) (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl . acetate. The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). After a mixture of the resulting oily substance, 1N aqueous sodium hydroxide , 5 solution (% ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-(2- gquinolylmethoxy)benzyl]}-1H-pyrazol-4-yl]propionic : acid (420 mg, yield : 86%). This was recrystallized from : acetone-hexane. Melting point: 140-141°C.
Example 210
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3--(3-ethoxy-lH-pyrazol-4- yl)propionate (318 mg) and 4-chloromethyl-2-(5- methyl-2-phenyl-4-oxazolylmethoxy)pyridine (472 mg) in
N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction . mixture was. poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-4- pyridylmethyl]-1lH-pyrazol-4-yl]propionate (640 mg, yield : 87%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0 : 1.21(3H, t, J=7.0 Hz), 1.35(3H, t, J=7.0 Hz), 2.46(3H, s), 2.49-2.57(2H, m), 2.62-2.70(2H, m), 4.10(2H, gq, J=7.0 Hz), 4.19(2H, q, J=7.0 Hz), 5.01(2H, s), 5.27(2H,
s), 6.46(1H, s), 6.63(1H, 4d, J=5.2 Hz), 7.03(1lH, s), 7.39-7.46(3H, m), 7.97-8.04(2H, m), 8.09(1H, 4, J=5.2 Hz).
Example 211 . 5 After a mixture of ethyl 4-[4-ethoxy-1-[2- (5H. methyl-2-phenyl-4-oxazolylmethoxy)~-4-~pyridylmethyl]- 1H-pyrazol-4-yl]lpropionate (638 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[2-(5-methyl-2- phenyl-4-oxazolylmethoxy)-4-pyridylmethyl]-1H- pyrazol-4-yl]propionic acid (495 mg, yield : 82%). This was recrystallized from ethanol-hexane. Melting point: 114-115°C.
Example 212
Sodium hydride (60%, oily, 60.0 mg) was added to . a solution of ethyl 3-(3-ethoxy-lH-pyrazol-4- yl)propionate (318 mg) and 3-chloromethyl-5-(5- methyl-2-phenyl-4-oxazolylmethoxy)pyridine (472 mg) in
N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[5-(5-methyl-2-phenyl-4-oxazolylmethoxy)-3- pyridylmethyl]-1H-pyrazol-4-yl]propionate (616 mg, yield : 84%) as a colorless oily substance from the fraction eluted with ethyl acetate.
NMR(CDC1,) 6: 1.21(3H, t, J=7.0 Hz), 1.36(3H, t, J=7.0 Hz), 2.43(3H, s), 2.47-2.55(2H, m), 2.61-2.69(2H, m), 4.10(2H, . qg. J=7.0 Hz), 4.21(2H, q, J=7.0 Hz), 5.00(2H, s), 5.07(2H, s), 7.02(1H, s), 7.14(1H, dd, J=1.4, 3.0Hz), 7.41-7.47(3H, . 5 m), 7.97-8.03(2H, m), 8.10( 1H, d, T=1.4 Hz), 8.34(1H, da,
J=3.0 Hz).
Example 213
After a mixture of ethyl 3-[3-ethoxy-1-[5-(5- methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]- 1H-pyrazol-4-yl]propionate (613 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous ‘sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[5-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-1H- pyrazol-4-yllpropionic acid (532 mg, yield : 92%). This was recrystallized from ethanol-hexane. Melting point: 133-134°C. :
Example 214 .
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-(3-ethoxy-1lH-pyrazol-4- yl)propionate (318 mg) and 4-(5-chloromethyl-2- methoxyphenoxymethyl)-5-methyl-2-phenyloxazole (516 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The . reaction mixture was poured into water, and extractedwith ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-
ethoxy-1-[4-methoxy-3-(5 -methyl~-2-phenyl-4- oxazolylmethoxy)benzyl]~-1H-pyrazol-4 -yl)lpropionate (647 mg, yield : 83%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume } 5 ration). 'This was recrystallized from ethyl acetate hexane. Melting point: 109-110°C.
Example 215
After a mixture of ethyl 3-[3-ethoxy-1-[4- methoxy-3-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1lH-pyrazol-4-yllpropionate (572 mg), 1N aqueous sodium hydroxide solution (3 ml), ' tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-{4-methoxy-3-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (498 mg, yield : 92%). This was recrystallized from ethanol-hexane. Melting point: 136-137°C.
Example 216
Sodium hydride (60%, oily, 50.0 mg) was added to a solution of ethyl 3-(3-ethoxy-1lH-pyrazol-4- yl)propionate (265 mg) and 4-(4-chloromethyl-2- ethoxyphenoxymethyl)-5-methyl-2-phenyloxazole (447 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture : was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-
ethoxy-1-[3-ethoxy-4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate } (548 mg, yield : 82%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, . 5 volume ratio).
NMR (CDC1,) 6:1.21(3H, t, J=7.0Hz), 1.37(3H, t, J=7.0 Hz), 1.42(3H, t, J=7.0 Hz), 2.43(3H, s), 2.47-2.55(2H, m), 2.61-2.69(2H, m), 4.05(2H, q, J=7.0 Hz), 4.09(2H, q, J=7.0
Hz), 4.23(2H, q, J=7.0 Hz), 4.98(2H, s), 5.06(2H, s), 6.70(1H, dd, J=1.8, 8.0Hz), 6.75(1H, 4, J=1.8 Hz), 6.94(1H, s), 6.98(1H, 4, J=8.0Hz), 7.40-7.49(3H, m), 7.96-8.03(2H, m).
Example 217 :
After a mixture of ethyl 3-[3-ethoxy-1-[3- ethoxy-4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionate (544 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[3-ethoxy-4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1lH-pyrazol-4-yl]lpropionic acid (466 mg, yield : 90%) This was recrystallized from ethanol-hexane. Melting point: 105-106°C. : Example 218
Sodium hydride (60%, oily, 60.0 mg) was added to ° a solution of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl)propionate (318 mg) and 5-chloromethyl-3-(5- methyl-2-phenyl-4-oxazolylmethoxy)isoxazole (457 mg) in
N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl ] acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5- isoxazolylmethyl]-1H-pyrazol-4-yl]lpropionate (653 mg, : yield : 91%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
This was recrystallized from ethyl acetate-hexane.
Melting point: 82-83°C.
Example 219
After a mixture of ethyl 3-[3-ethoxy-1-[3-(5- methyl-2-phenyl-4-oxazolylmethoxy) -5- isoxazolylmethyl]-1H-pyrazol-4-yl]lpropionate (519 mg),
IN aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer : was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[3-(5-methyl-2-phenyl-4- oxazolylmethoxy)-5-isoxazolylmethyl]-1H-pyrazol-4- yllpropionic acid (459 mg, yield : 94%). This was recrystallized from ethanol-hexane. Melting point: 142-143°C.
Example 220
Sodium hydride (60%, oily, 90.3 mg) was added to a solution of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl)propionate (400 mg) and 2-[2-(4- chloromethylphenoxy)ethyl]-1(2H)-phthalazinone (650 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature overnight. The . reaction mixture was poured into dilute hydrochloric acid, © and extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). After a mixture of the colorless oily substance, 1N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-[2-[1- oxophthalazin-2(1H)-yl]ethoxy]benzyl]-lH-pyrazol-4- yllpropionic acid (730 mg, yield : 84%). This was recrystallized from acetone-hexane. Melting point: 152-153°C.
Example 221
Sodium hydride (60%, oily, 90.3 mg) was added to a solution of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl)propionate (400 mg) and 2-[2-(3- chloromethylphenoxy)ethyl]-1(2H)-phthalazinone (650 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature overnight. The ] reaction mixture was poured into dilute hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and saturated aqueous sodium chloride solution, dried (MgsO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). After a mixture of the resulting colorless oily substance, 1N aqueous sodium . 5 hydroxide solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours,
IN hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[3-[2-[1- oxophthalazin-2(1H)-yl]lethoxy]benzyl]-1H-pyrazol-4- yllpropionic acid (690 mg, yield : 79%). This was recrystallized from acetone-hexane. Melting point: 146-147°C.
Example 222
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl)propionate (318 mg) and 2-chloromethyl-6-(5- methyl-2-phenyl-4-oxazolylmethoxy)pyridine (472 mg) in
N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-{3- ethoxy-1-[6-(5-methyl-2-phenyl-4-oxazolylmethoxy)-2- pyridylmethyl]-1H-pyrazol-4-yl]propionate (656 mg, yield : 89%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume } ratio).
NMR(CDC1l,)0: 1.22(3H, t, J=7.0 Hz), 1.37(3H, t, J=7.0 Hz), 2.47(3H, s), 2.51-2.59(2H, m), 2.66-2.74(2H, m), 4.11(2H,
{ gq, J=7.0 Hz), 4.23(2H, gq, J=7.0 Hz), 5.11(2H, s), 5.28(2H, te
Bh ss), 6.46(1H, 4d, J=7.2-Hz), 6.70(1H, d, J=8.0 Hz), 7.13(1H, ss ; . ~~: s), 7.41-7.46(3H, m), 7.48(1lH, dd, J=7.2, 8.0 Hz), 7.99-8.05(2H, m).
Example 223
After a mixture of ethyl 3-[3-ethoxy-1-[6-(5- methyl-2-phenyl-4-oxazolylmethoxy)-2-pyridylmethyl]- lH-pyrazol-4-yl]lpropionate (652 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and ; then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-([6-(5-methyl-2- phenyl-4-oxazolylmethoxy)~-2-pyridylmethyl]-1H- pyrazol-4-yl]lpropionic acid (522 mg, yield : 85%). This was recrystallized from ethanol-hexane. Melting point: 144-145°C.
Example 224
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[3-ethoxy-1-(4-hydroxybenzyl)- l1H-pyrazol-4-yllpropionate (302 mg) and 5-chloro-2- chloromethylimidazo[l,2-alpyridine (302 mg) in N,N- : ‘dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with ) saturated aqueous sodium chloride solution, dried (MgSoO,), : and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[4-(5- chloroimidazo[l,2-a)pyridin-2-ylmethoxy)benzyl]-3- ethoxy-1H-pyrazol-4-yl)propionate (625 mg, yield : 86%) :
Amended Sheet. - 2004-01-27 as colorless crystals from the fraction eluted with ethyl acetate. This was recrystallized from ethyl acetate- ) hexane. Melting point: 69-70°C.
Example 22%
After a mixture of ethyl 3-[1--[4-(5- chloroimidazo[l,2-alpyridin-2-ylmethoxy)benzyl]-3-~ ethoxy-1H-pyrazol-4-yllpropionate (507 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml) and ethanol (4 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) 15 .and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(5- chloroimidazo[l,2-a)pyridin-2-ylmethoxy)benzyl]-3- ethoxy-1H-pyrazol-4-yl)lpropionic acid (448 mg, yield : 94%). This was recrystallized from ethanol. Melting point: 153-154°C.
Example 226
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[3-ethoxy-1-(4-hydroxybenzyl)- 1H-pyrazol-4-yl]lpropionate (478 mg) and 2- chloromethyl-5-ethoxyimidazo[1l,2-a)lpyridine (316 mg) in
N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[4-(5-ethoxyimidazo[1l,2~-a)pyridin-2- ylmethoxy)benzyl]-1H-pyrazol-4-yllpropionate (442 mg, yield : 60%) as a colorless cily substance from the fraction eluted with ethyl acetate.
NMR(CDC1,) 0 : 1.20(3H, t, J=7.0 Hz), 1.36(3H, t, J=7.0 Hz), ; 1.55(3H, t, J=7.0Hz), 2.47-2.54(2H, m), 2.61-2.68(2H, m), 4.08(2H, q, J=7.0 Hz), 4.22(2H, gq, J=7.0 Hz), 4.29(2H, 4.
J=7.0 Hz), 4.99(2H, su), 5.25(2H, s), 6.02(1H, dd, J=2.0, 6.2 Hz), 6.92(1H, s), 7.00(2H, 4, J=8.8 Hz), 7.13(2H, 4,
J=8.8 Hz), 7.18-7.25(2H, m), 7.71(1H, Ss).
Example 227
After a mixture of ethyl 3-[3-ethoxy-1-[4-(5- ethoxyimidazo[l,2-alpyridin-2-ylmethoxy)benzyl]-1H- pyrazol-4-yl]lpropionate (441 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml) and ethanol (4ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-(5- ethoxyimidazo([l,2-a]lpyridin-2-ylmethoxy)benzyl]-1H- pyrazol-4-yllpropionic acid (335 mg, yield : 81%). This was recrystallized from ethanol-hexane. Melting point: 197-198°C.
Example 228 Co
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[3-ethoxy-1-(4-hydroxybenzyl)- 1H-pyrazol-4-yl]propionate (478 mg) and 1- chloromethyl-1H-benzotriazole (251 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction - mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[4- (1H-benzotriazol-1-ylmethoxy)benzyl]-3-ethoxy-1H- . pyrazol-4-yl]propionate (652 mg, yield : 97%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0: 1.19(3H, t, J=7.2 Hz), 1.35(3H, t, J=7.0 Hz), 2.45-2.53(2H, m), 2.59--2.67(2H, m), 4.08(2H, q, J=7.2 Hz), 4.20(2H, gq, J=7.0 Hz), 4.96(2H, s), 6.53(2H, s). 6.90(1H, s), 7.01-7.11(4H, m), 7.40(1H, ddd, J=1.2, 7.0, 8.4 Hz), 7.53(1H, ddd, J=1.2, 7.0, 8.4 Hz), 7.69(1lH, 44, J=1.2, 8.4
Hz), 8.07(1H, ad, J=1.2, 8.4 Hz).
Example 229
After a mixture of ethyl 3-[1-[4-(1H- 15 . benzotriazol-1l-ylmethoxy)benzyl)l-3-ethoxy-1H-pyrazol- 4-yl)propionate (652 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(1H-benzotriazol-1- ylmethoxy)benzyl]-3-ethoxy-1H-pyrazol-4-yl]propionic acid (576 mg, yield : 94%). This was recrystallized from ethanol-hexane. Melting point: 136-137°C.
Example 230
A mixture of ethyl 3-[3-ethoxy-1-(4- hydroxybenzyl) -1H-pyrazol-4-yl]lpropionate (690 mg), 5-chloromethyl-2-phenylpyridine (470 mg), potassium carbonate (450 mg) and N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel chromatography : to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). : 5 After amixture of the resulting colorless olly substance,
IN aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (5 ml) was added, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4- (6-phenyl-3-pyridylmethoxy)benzyl]}-1H-pyrazol-4- yl)propionic acid (900 mg, yield : 91%). This was recrystallized from acetone-hexane. Melting point: 140-141°C.
Example 231
A mixture of ethyl 3-[1-[4-(5- chloroimidazo[l,2-a)lpyridin-2-ylmethoxy)benzyl)-3- ethoxy-1H-pyrazol-4-yllpropionate (676 mg), phenylboronic acid (195 mg), tetrakis(triphenylphosphine)palladium (40.4 mg), sodium carbonate (339 mg), ethanol (3 ml), water (3 ml) and toluene (15 ml) was refluxed overnight under an argon atmosphere. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-ethoxy-1-[4-(5-phenylimidazo(1, 2- a]pyridin-2-ylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (707 mg, yield : 96%) as colorless crystals from the fraction eluted with ethyl acetate. This was recrystallized from ethyl acetate-hexane. Melting point: 104-105°C.
Example 232
After a mixture of ethyl 3-[3-ethoxy-1-[4-(5- : 5 phenylimidazo[l,2 alpyridin-2-ylmethoxy)henzyt]-1H- pyrazol-4-yl]lpropionate (551 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-(5- phenylimidazo[l,2-a]lpyridin-2-ylmethoxy)benzyl]-1H- pyrazol-4-yl]lpropionic acid (469 mg, yield : 90%). This was recrystallized from ethanol-hexane. Melting point: 160-161°C. =
Example 233
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-(3-ethoxy-1H-pyrazol-4- yl)propionate (318 mg) and 4-chloromethyl-2-[2-(2- furyl)-5-methyl-4-oxazolylmethoxy]lpyridine (457 mg) in -
N,N-dimethylformamide (10 ml) at 0°C., and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[2-[2~(2-furyl)-5-methyl-4-oxazolylmethoxy]- 4-pyridylmethyl]-1H-pyrazol-4-yl]propionate (643 mg, } yield : 89%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 : 1.22(3H, t, J=7.2 Hz), 1.36(3H, t, J=7.0 Hz), 2.46(3H, s), 2.49-2.57(2H, m), 2.63-2.71(2H, m), 4.10(2H, . gq, J=7.2 Hz), 4.20(2H, q, J=7.0 Hz), 5.01(2H, s), 5.25(2H, s), 6.44(1H, dd, J=0.8, 1.8 Hz), 6.51(1H, dd, J=1.8, 3.4
Hz), 6.63(1H, dd, J=1.8, %.4 Hz), 6.97(1H, 4d, J=0.8, 3.4
Hz), 7.03(1H, s), 7.52(1H, 4d, J=0.6, 1.8 Hz), 8.08(1H, dd,
J=0.6, 5.4 Hz).
Example 234 .
After a mixture of ethyl 3-[3-ethoxy-1-[2-[2- (2-furyl)-5-methyl-4-oxazolylmethoxy]-4- pyridylmethyl]-1H-pyrazol-4-yl]lpropionate (639 mg), 1N aqueous sodium hydroxide solution (3 ml), : tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride : solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[2-[2-(2-furyl)-5-methyl-4- oxazolylmethoxy]-4-pyridylmethyl]-1H-pyrazol-4- yllpropionic acid (569 mg, yield : 94%). This was recrystallized from ethanol-hexane. Melting point: 138-139°C.
Example 235
Sodium hydride (60%, oily, 160 mg) was added to a solution of ethyl 3-(3-ethoxy-lH-pyrazol-4- yl)propionate (849 mg) and 5-chloro-2-(4- chloromethyl -2 -pyridyloxymethyl )imidazo[1l, 2- ~ alpyridine (1230 mg) in N,N-dimethylformamide (20 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[2-(5-chloroimidazo[l,2-a]lpyridin- 2-ylmethoxy)-4-pyridylmethyl]-3-ethoxy-1H-pyrazol-4- yllpropionate (1570 mg, yield : 81%) as a colorless oily substance from the fraction elutecd with ethyl acetate.
NMR(CDC1,) 6 : 1.22(3H, t, J=7.2 Hz), 1.36(3H, t, J=7.2 Hz), 2.50-2.58(2H, m), 2.63-2.71(2H, m), 4.11(2H, q, J=7.2 Hz), 4.20(2H, q, J=7.2 Hz), 5.04(2H, s), 5.56(2H, 4, J=0.8 Hz), 6.50(1H, 4, J=0.6 Hz), 6.65(1H, dd, J=1.4, 5.2Hz), 6.89(1H, dda, J=0.8, 7.2 Hz), 7.05(1H, s), 7.18(1H, 4d, J=7.2,-9.2
Hz), 7.55-7.60(1H, m), 7.84(1H, 4, J=0.8 Hz), 8.12(1H, 4d,
J=0.6, 5.2 Hz).
Example 236
After a mixture of ethyl 3-[1-[2-(5- chloroimidazo({1l,2-alpyridin-2-ylmethoxy)-4- pyridylmethyl]-3-ethoxy-1H-pyrazol-4-yl]propionate (605 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[1-[2-(5-chloroimidazo[l,2-a}pyridin-2-ylmethoxy)- 4-pyridylmethyl])-3-ethoxy-1H-pyrazol-4-yl])propionic acid (534 mg, yield : 94%). This was recrystallized from ethanol-hexane. Melting point: 160-161°C.
Example 237
A mixture of ethyl 3-[1-[2-(5- chloroimidazo([1l,2-a]lpyridin-2-ylmethoxy)-4- pyridylmethyl]-3-ethoxy-1lH-pyrazol-4-yl]propionate (968 mg), phenylboronic acid (280 mg),
tetrakis(triphenylphosphine)palladium (57.8 mg), sodium carbonate (488 mg), ethanol (3 ml), water (3 ml) and } toluene (15 ml) was refluxed overnight under an argon atmosphere. The reaction mixture was poured into water . 5 and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-ethoxy-1-[2-(5-phenylimidazo[1l,2- alpyridin-2-ylmethoxy)-4-pyridylmethyl]-1H-pyrazol-4- yl]lpropionate (1040 mg, yield : 99%) as a colorless oily substance from the fraction eluted with ethyl acetate.
NMR (CDC1,) 0: 1.21(3H, t, J=7.0 Hz), 1.35(3H, t, J=7.0 Hz), 2.49-2.56(2H, m), 2.62-2.70(2H, m), 4.10(2H, q, J=7.0 Hz), 4.19(2H, q, J=7.0 Hz), 5.01(2H, s), 5.49(2H, s), 6.47(1H, s), 6.61(1H, 4, J=5.2 Hz), 6.74(1H, d, J=7.0 Hz), 7.02(1H, s), 7.27(1H, d48, J=7.0, 9.2 Hz), 7.42-7.72(78, m), 8.08(1H, a, J=5.2 Hz).
Example 238
After a mixture of ethyl 3-[3-ethoxy-1-[2-(5- phenylimidazol1l, 2- alpyridin-2-ylmethoxy)-4- pyridylmethyl]-1H-pyrazol-4-yl]propionate (1030 mg), 1N aqueous sodium hydroxide solution (4 ml), tetrahydrofuran (8 ml) and ethanol (8 ml) was stirred at room temperature for 3 hours, 1 N hydrochloric acid (4 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[2-(5-phenylimidazof1l,2-a]lpyridin-2- ylmethoxy)-4-pyridylmethyl]-1H-pyrazol-4-yl]propionic : acid (922 mg, yield : 95%). This was recrystallized from ethanol-hexane. Melting point: 177-178°C.
Fxample 239
A mixture of ethyl 3-[3-ethoxy-1-(4- } hydroxybenzyl) -1H-pyrazol-4-yllpropionate (700 mg), 3-chloromethyl-5-phenylpyridine (500 mg), potassium . 5 carbonate (500 mg) and N,N dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-ethoxy-1-[4-(5- phenyl-3-pyridylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (720 mg, yield : 67%) as a colorless oily substance from the fraction eluted with ethyl "15 acetate-hexane (1:1, volume ratio). :
NMR(CDC1,) 6 : 1.21(3H, t, J=7.0 Hz), 1.36(3H, t, J=7.0 Hz), 2.45-2.70(4H, m), 4.09(2H, q, J=7.0 Hz), 4.22(2H, q, J=7.0
Hz), 5.01(2H, s), 5.13(2H, s), 6.88:-7.02(2H, m), 7.10- 7.22(2H, m), 7.40-7.64(5H, m), 7.96(1H, t, J=2.2 Hz), 8.65(1H, 4, J=2.2 Hz), 8.82(1H, 4, J=2.2 Hz).
Example 240
After a mixture of ethyl 3-[3-ethoxy-1-[4-(5- phenyl-3-pyridylmethoxy)benzyl]-1H-pyrazol-4- 1yllpropionate (700 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml) and ethanol (5 ’ ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and : then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mg50,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-(5-phenyl-3- pyridylmethoxy)benzyl]-1H-pyrazol-4-yllpropionic acid (560 mg, yield : 85%). This was recrystallized from acetone-hexane. Melting point: 92-93°C.
Example 241 ) Sodium hydride (60%, oily, 70.0 mg) was added to a solution of ethyl 3-(3-ethoxy-l1lH-pyrazol-4- . 5 yl)propionate (371 mg) and 2. (5-chloromethyl-3- isoxazolylmethyl)quinoline (481 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,)., and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-{3- ethoxy-1-[3-(2-quinolylmethoxy)-5-isoxazolylmethyl]- lH-pyrazol-4-yl)lpropionate (722 mg, yield : 92%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 6:1.23(3H, t, J=7.0 Hz), 1.36(3H, t, J=7.0 Hz), 2.49-2.57(2H, m), 2.62-2.70(2H, m), 4.11(2H4, q, J=7.0 Hz), 4.20(2H, q, J=7.0 Hz), 5.06(2H, s), 5.54(2H, s), 5.86(1H, s), 7.09(1H, s), 7.51-7.60(2B, m), 7.73(1H, 44d, J=1.6, 7.0, 8.6 Hz), 7.83(1H, 4d, J=1.6, 8.0 Hz), 8.06-8.12(1H, m), 8.20(1H, 4d, J=8.6 Hz). | :
Example 242
After a mixture of ethyl 3-[3-ethoxy-1-[3-(2- quinolylmethoxy)-5-isoxazolylmethyl]-1H-pyrazol-4- yllpropionate (721 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The " ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[3-(2-
quinolylmethoxy)-5-isoxazolylmethyl]-1H-pyrazol-4- yl]lpropionic acid (608 mg, yield : 90%). This was . recrystallized from ethanol-hexane. Melting point: 123-124°C. . 5
Example 243
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[3-ethoxy-1l-(4-hydroxybenzyl)- 1H-pyrazol-4-yllpropionate (478 mg) and 3-chloro-2- chloromethyl-6-phenylpyridine (357 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was : stirred at room temperature for 1 hour. The reaction : mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[4-(3- chloro-6-phenyl-2-pyridylmethoxy)benzyl]-3-ethoxy-1H- pyrazol-4-yllpropionate (740 mg, yield : 95%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.2 Hz), 1.36(3H, t, J=7.2 Hz), 2.46-2.54(2H, m), 2.60-2.68(2H, m), 4.09(2H, q, J=7.2 Hz), 4.22(2H, q, J=7.2 Hz), 5.00(2H, s), 5.34(2H, s), 6.92(1H, s), 7.03(2H, 4, J=8.8 Hz), 7.15(2H, 4, J=8.8 Hz), 7.37- 7.51(3H, m), 7.67(1H, 4, J=8.4 Hz), 7.78(1H, 4, J=8.4 Hz), 7.91-7.98(2H, m). " Example 244
After a mixture of ethyl 3-[1-[4-(3-chloro-6- ‘phenyl-2-pyridylmethoxy)benzyl]-3-ethoxy-1H-pyrazol- 4-yllpropionate (738 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. ] The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(3-chloro-6-phenyl 2- pyridylmethoxy)benzyl]-3.- cthoxy 1H-pyrazol-4.. vllpropionic acid (66% mg, yield : 96%). This was recrystallized from ethyl acetate-hexane. Melting point: 120-121°C.
Example 245
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of ethyl 3-[3-ethoxy-1l-(4-hydroxybenzyl)- 1H-pyrazol-4-yl]propionate (478 mg) and 2- chloromethyl-6-phenylpyridine (306 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[4-(6-phenyl-2-pyridylmethoxy)benzyl]-1H- pyrazol-4-yl)propionate (689 mg, yield : 95%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR (CDC1,) 6: 1.20(3H, t, J=7.2 Hz), 1.36(3H, t, J=7.2 Hz), 2.46-2.55(2H, m), 2.60-2.68(2H, m), 4.12(2H, q, J=7.2 Hz), 4.22(2H, q, J=7.2 Hz), 5.00(2H, s), 5.28(2H, s), 6.93(1H, s), 6.97(2H, 4, J=8.8 Hz), 7.13(2H, 4, J=8.8 Hz), 7.38- 7.53(4H, m), 7.64(1H, 44, J=0.8, 7.6 Hz), 7.71(1H, t, J=7.6
Hz), 7.97-8.03(2H, m).
Example 246
After a mixture of ethyl 3-[3-ethoxy-1-[4-(6- phenyl-2-pyridylmethoxy)benzyl]-1H-pyrazol-4- yl]propicnate (685 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 3 hours, 1 N ) hydrochloric acid (3 ml) was added to the mixture, and ~ then the mixture was extracted with ethyl acetate. The } 5 ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-l1-[4-(6-phenyl-2- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (482 mg, yield : 75%). This was recrystallized from ethanol-hexane. Melting point: 95-96°C.
Example 247
A mixture of ethyl 3-[3-ethoxy-1-(4- hydroxybenzyl)-1H-pyrazol-4-yl]propionate (600 mg), 2-chloromethyl-1-methyl-1H-benzimidazole (360 mg), potassium carbonate (550 mg) and N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[4-(1l-methyl-1H-benzimidazol-2- vylmethoxy)benzyl]-1H-pyrazol-4-yl]lpropionate (730 mg, yield : 84%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 1.35(3H, t, J=7.0 Hz), 2.44-2.68(4H, m), 3.88(3H, s), 4.08(2H, g, J=7.0 Hz), : 4.21(2H, q, J=7.0 Hz), 4.98(2H, s), 5.38(2H, s), 6.91(1H, s), 6.98-7.17(4H, m), 7.23-7.41(3H, m), 7.72-7.82(1H, m).
Example 248
After a mixture of ethyl 3-[3-ethoxy-1-[4-(1- methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-1H-
pyrazol-4-yllpropionate (700 mg), 1N aqueous sodium " hydroxide solution (3 ml), tetrahydrofuran (5 ml) and . ethanol (5 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, . 5 and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-(1l-methyl-1H- benzimidazol-2-ylmethoxy)benzyl]-1H-pyrazol-4- yllpropionic acid (520 mg, yield : 79%). This was recrystallized from ethanol-water. Melting point: 177-178°C.
Example 249
A mixture of 5-phenyl-2-pyridylmethanol (300 mg), thionyl chloride (0.25ml) and toluene (10 ml) was stirred at 80°C for 1 hour. After the reaction mixture was concentrated under reduced pressure, the resulting crystals were filtered, and washed with hexane. A mixture of the resulting crystals, ethyl 3-[3-ethoxy- 1-(4-hydroxybenzyl)-1H-pyrazol-4-yl]propionate (500 mg), potassium carbonate (420 mg) and N,N- dimethylformamide (10 ml) was stirred at 70°C overnight.
The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSo0O,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3- [3-ethoxy-1-[4-(S5-phenyl-2-pyridylmethoxy)benzyl]-1H- pyrazol-4-yl]lpropionate (730 mg, yield : 96%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). } NMR (CDC1,) 0 : 1.20(3H, t, J=7.0Hz), 1.36(3H, t, J=7.0 Hz), 2.44--2.70(4H, m), 4.09(2H, gq, J=7.0 Hz), 4.22(2H, q, J=7.0
Hz). 5.00(2H, s), 5.24(2H, s), 6.90-7.02(3H, m), 7.07-
7.19(2H, m), 7.34-7.68(6H, m), 7.91(1H, 4d, J=2.2, 8.0Hz), 8.82(1H, d, J=2.2 Hz).
Example 250
After a mixture of ethyl 3-[3-ethoxy-1.-14..(5- phenyl-2-pyridylmethoxy)benzyl]}-1H-pyrazol-4- vllpropionate (700 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[4-(5-phenyl-2- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (620 mg, yield : 94%). This was recrystallized from acetone-hexane. Melting point: 127-128°C. - 20 Example 251
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of 2-(5-chloromethyl-2- pyridyloxymethyl)quinoline (498 mg), ethyl 3-(3- ethoxy-1H-pyrazol-4-yl)propionate (371 mg) in N,N-. dimethylformamide (10 ml) at 0°C, and the mixture was : stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[6-(2-quinolylmethoxy)-3-pyridylmethyl]-1H- pyrazol-4-yllpropionate (733 mg, yield : 91%) as a } colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 0: 1.20(3H, t, J=7.0 Hz), 1.36(3H, t, J=7.0 Hz),
: 2.47-2.55(2H, m), 2.60-2.68(2H,m), 4.09(2H, q, J=7.0 Hz), 4.21(2H, q, J=7.0 Hz), 4.98(2H, s), 5.67(2H, s), 6.87(1H, . dd, J=0.8, 8.4 Hz), 6.97(1H, s), 7.48(1H, 44, J=2.6, 8.4
Hz), 7.53(1H, ddd, J=1.4, 7.0, 8.4 Hz), 7.57(1H, 4, J=8.6 . 5 Hz), 7.72(WH, ddd, J-=1.4, 7.0, 8.4 Hz), 7.81(1H, dd, J-1.4, 8.4 Hz), 8.00(1H, 4d, J=0.8, 2.6 Hz), 8.07-8.13(1H, m), 8.15(1H, 4, J=8.6 Hz).
Example 252 :
After a mixture of ethyl 3-[3-ethoxy-1-[6-(2- quinolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- yl]propionate (732 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[6-(2- guinolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- yl]lpropionic acid (629 mg, yield : 91%). This was . recrystallized from ethanol-hexane. Melting point: 133-134°C.
Example 253
Sodium hydride (60%, oily, 60.0 mg) was added to a solution of 5-chloromethyl-2-(2-phenyl-4- thiazolylmethoxy)pyridine (475 mg), ethyl 3-(3- ethoxy-1H-pyrazol-4-yl)propionate (318 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- ethoxy-1-[6-(2-phenyl-4-thiazolylmethoxy) -3- i pyridylmethyl]-1H-pyrazol-4-yl]lpropionate (657 mg, vield : 89%) as a colorless oily substance from the . 5 fraction eluted with ethyl acetate-hexane (2:3, volume ratio). BE
NMR (CDC1,) 0 : 1.21(3H, t, J=7.0Hz), 1.36(3H, t, J=7.0 Hz). 2.47-2.56(2H, m), 2.61-2.69(2H,m), 4.10(2H, q, J=7.0 Hz), 4.22(2H, q, J=7.0 Hz), 5.00(2H, s), 5.54(2H, 4, J=0.8 Hz), 6.81(1H, 4, J=8.4 Hz), 7.31(1H, t, J=0.8 Hz), 7.40-7.49(4H, m), 7.92-8.01(2H, m), 8.04(1H, 4, J=2.6 Hz). .
Example 254
After a mixture of ethyl 3-[3-ethoxy-1-[6-(2- phenyl-4-thiazolylmethoxy)-3-pyridylmethyl]-1H- pyrazol-4-yllpropionate (655 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 2 hours,
Co 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-ethoxy-1-[6-(2-phenyl-4- thiazolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- yl]lpropionic acid (569 mg, yield : 92%). This was recrystallized from ethanol-hexane. Melting point: 121-122°C.
Example 255
A mixture of 2-(4-chloromethyl-3-methyl-1H- pyrazol-1l-yl)pyridine (350 mg), ethyl 3-[3-ethoxy-1- (4-hydroxybenzyl)-1H-pyrazol-4-yl]lpropionate (500 mg), potassium carbonate (500 mg) and N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted witk ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgso,). 3 and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-([3- ethoxy-1-[4-[3-methyl-1-(2-pyridyl)-1H-pyrazol-4. ylmethoxylbenzyl]l-1H-pyrazol-4-yllpropionate (700 mg, vield : 91%) as a colorless olly substance from the ] fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 : 1.21(3H, t, J=7.0 Hz), 1.36(3H, t, J=7.0 Hz), 2.38(3H, s), 2.44-2.71(4H, m), 4.09(2H, q, J=7.0 Hz), 4.22(2H, q, J=7.0 Hz), 4.96(2H, s), 5.00(2H, s), 6.88- 6.98(3H, m), 7.08-7.20(3H, m), 7.72-7.82(1H, m), 7.86- 7.94(1H, m), 8.35-8.40(1H, m), 8.53(1H, s).
Example 256
After a mixture of ethyl 3-[3-ethoxy-1-[4-[3- methyl-1-(2-pyridyl)-1H-pyrazol-4-ylmethoxylbenzyl]- 1H-pyrazol-4-yl]propionate (680 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, ‘ and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[{3-ethoxy-1-[4-(3-methyl-1-(2- pyridyl) -1H-pyrazol-4-ylmethoxy]lbenzyl)-1H-pyrazol-4- yllpropionic acid (620 mg, yield : 97%). This was recrystallized from acetone-hexane. Melting point: 126-127°C.
Example 257
A mixture of 5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-2-pyridylmethanol (550 mg) and thionyl chloride (10 ml) was stirred at 0°C for 2 hours, and the reaction mixture was concentrated under reduced pressure.
The residue was dissolved into ethyl acetate, washed . successively with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, . 5 dried (MygS0O,) and concentrated. A mixture of the resulting residue, ethyl 3-(3-ethoxy-lH-pyrazol-4- vl)propionate (400 mg), potassium carbonate (510 mg) and
N,.N-dimethylformamide (15 ml) was stirred at 80°C overnight. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The residue ’ was subjected to silica gel column chromatography to obtain ethyl 3-[3-ethoxy-1-[5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-2-pyridylmethyl]-1H-pyrazol-4- yllpropionate (730 mg, yield : 80%) as a colorless oily substance from the fraction eluted with ethyl acetate hexane (2:1, volume ratio).
NMR(CDC1,) 0 : 1.22(3H, t, J=7.2 Hz), 1.36(3H, t, J=7.0 Hz), 2.44(3H, s), 2.47-2.75(4H, m), 4.03-4.28(4H, m), 5.02(2H, s), 5.15(2H, s), 6.93(1H, d, J=8.8 Hz), 7.09(1H, s), 7.28(1H, dd, J=3.0, 8.8 Hz), 7.38-7.50(3H, m), 7.94-8.06(2H, m), 8.35(1H, 4, J=3.0 Hz).
Example 258
After a mixture of ethyl 3-[3-ethoxy-1-[5-(5- methyl-2-phenyl-4-oxazolylmethoxy)-2-pyridylmethyl]- l1H-pyrazol-4-yl]propionate (730 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml) and ethanol (5ml) was stirred at room temperature for 2 hours, . 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[{3-ethoxy-1-[5-(5-methyl-2-
phenyl-4-oxazolylmethoxy)-2-pyridylmethyl]}-1H- pyrazol-4-yl]lpropionic acid (650 mg, yield : 95%). This . was recrystallized from acetone-hexane. Melting point: 133-134°C. , 5
Example 259 :
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of 4-(4-chloromethylphenoxymethyl)-5- methyl-2-phenyloxazole (549 mg), ethyl 3-ethoxy-1H- “10 pyrazol-4-ylacetate (347 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-ethoxy-1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-1H-pyrazol-4-ylacetate (618 mg, yield : 74%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). }
NMR (CDC1,) 6:1.25(3H, t, J=7.0 Hz), 1.34(3H, t, J=7.0 Hz), 2.43(3H, s). 3.36(2H, s), 4.14(2H, q, J=7.0 Hz), 4.23(2H, q, J=7.0 Hz), 4.98(2H, s), 5.04(2H, s), 6.98(1H, d, J=8.8
Hz), 7.13(1H, s), 7.17(1H, 4, J=8.8 Hz), 7.40-7.50(3H, m), 7.97-8.04(2H, m).
Example 260
After a mixture of ethyl 3-ethoxy-1-[4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol- 4-ylacetate (618 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-ethoxy-1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-1H-pyrazol-4- . 5 vylacetic acid (502 my, yield : 86%). This was recrystallized from ethanol hexane. Melting point: : .125-126°C.
Example 261
Sodium hydride (60%, oily, 70.0 mg) was added to : a solution of S5-chloromethyl-2-(5-methyl-2-phenyl-4- oxazolylmethoxy)pyridine (551 mg), ethyl 3-ethoxy-1H- pyrazol-4-ylacetate (347 mg) in N,N-dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room © 15 temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-ethoxy-1-[6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridylmethyl] -1H-pyrazol-4- ylacetate (608 mg, yield : 73%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0: 1.25(3H, t, J=7.2 Hz), 1.35(3H, t, J=7.0 Hz), 2.47(3H, s), 3.36(2H, s), 4.15(2H, q, J=7.2 Hz), 4.22(2H, gq, J=7.0 Hz), 5.02(2H, s), 5.29(2H, s), 6.78(1H, 4, J=8.4
Hz), 7.19(1H, s), 7.39-7.49(4H, m), 7.98-8.07(3H, m).
Example 262
After a mixture of ethyl 3-ethoxy-1-[6-(5- methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]- 1H-pyrazol-4-ylacetate (605 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture,
and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous } sodium chloride solution, dried (MgSQ,) and concentrated.
The resulting colorless crystals were collected by ) 5 filtration to obtain 3-ethoxy 1-[6-(H5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-1H- pyrazol-4-ylacetic acid (518 mg, yield : 91%). This was recrystallized from ethanol-hexane. Melting point: : 126-127°C.
Example 263
Sodium hydride (60%, oily, 39.4 mg) was added to a solution of S-chloromethyl-2-[2-(2-furyl)-5-methyl- 4-oxazolylmethoxylpyridine (300 mg), ethyl 3-ethoxy- 1H-pyrazol-4-ylacetate (195 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-ethoxy-1- [6-[2-(2-furyl)-5-methyl-4-0oxazolylmethoxy]-3- pyridylmethyl]-1H-pyrazol-4-ylacetate (364 mg, yield : 79%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0:1.25(3H, t, J=7.2 Hz), 1.35(3H, t, J=7.0 Hz), 2.46(3H, s), 3.66(2H, s), 4.14(2H, q, J=7.2 Hz), 4.22(2H, gq. J=7.0Hz), 5.02(2H, s), 5.26(2H, s), 6.52(1H, 44, J=1.8, 3.2Hz), 6.76(1H, 4, J=8.6 Hz), 6.98(1H, 4d, J=0.8, 3.2 Hz), 7.19(1H, s), 7.46(1H, dd, J=2.4, 8.6 Hz), 7.52(1H, dd, J=0.8, 1.8 Hz), 8.05(1H, d, J=2.4 Hz).
Example 264
After a mixture of ethyl 3-ethoxy-1-[6-[2-(2- furyl)-5-methyl-4-oxazolylmethoxy}-3-pyridylmethyl)-
l1H-pyrazol-4-ylacetate (364 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml) and . ethanol (4 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (2 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-ethoxy-1-[6-[2-(2-furyl)-5- methyl-4-oxazolylmethoxy]-3-pyridylmethyl]-1H- pyrazol-4-ylacetic acid (308 mg, yield : 90%). This was recrystallized from ethanol-hexane. Melting point: 155-156°C.
Example 265
Sodium hydride (60%, oily, 0.30 g) was added to a solution of ethyl 3-[1-(3,5-dihydroxybenzyl)-4- phenyl-3-pyrrolyllpropionate (1.83 g) in N,N- dimethylformamide (20 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 4-
Chloromethyl-2-phenylthiazole (1.05 g) was added to the mixture and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[{1-[3,5-bis(2-phenyl-4- thiazolylmethoxy)benzyl]l-4-phenyl-3- pyrrolyl]propionate (513 mg, yield : 14%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6: 1.19(3H, t, J=7.2 Hz), 2.52(2H, t, J=7.8 Hz), 2.95(2H, t, J=7.8 Hz). 4.08(2H, q, J=7.2 Hz), 4.95(2H, s), 5.21(4H, s), 6.47(2H, 4, J=2.2 Hz), 6.52(1H, 4, J=2.4 Hz), 6.66(1H, t, J=2.2Hz), 6.72(1H, 4d, J=2.4Hz), 7.16-7.46(13H,
m), 7.90-7.97(4H, m). - a . - . . : ot
Example 266 : : -
After a mixture of ethyl 3-[1-[3,5-bis(2- phenyl-4-thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyl])propionate (498 mg), 1N aqueous sodinm hydroxide solution (2 ml), tetrahydrofuran (5 ml) and ethanol (5ml) was stirred at room temperature for 2 hours, : : 1 N hydrochloric acid (2 ml) was added to the mixture. and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated agueous : sodium chloride solution, dried (MgSO,) and concentrated. i
The resulting colorless crystals were collected by filtration to obtain 3-[1-[3,5-bis(2-phenyl-4- thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyl)propionic acid (378 mg, yield : 79%). This was recrystallized from ethyl acetate-hexane. Melting point: 78-79°C.
Example 267
Sodium hydride (60%, oily, 190 mg) was added to a solution of 1-[{6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridylmethyl]-4-phenyl-3- pyrrolecarbaldehyde (1.05 g) and ethyl diethylphosphonoacetate (1.05 g) in N,N- dimethylformamide (50 ml) at 0°C, and the mixture was stirred at 0°C for 2 hours. The reaction mixture was poured into water, and the precipitated crystals were collected by filtration to obtain ethyl (E)-3-[1-[6-(5- methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]- h 4-phenyl-3-pyrrolyl])propencate. The crystals were dissolved in ethanol (80 ml), and hydrogenated on 5% palladium-carbon (800 mg) at room temperature under a normal pressure. The catalyst was filtered, and the filtrate was concentrated. The residue was subjected to : silica gel column chromatography to obtain ethyl 3-
Amended Sheet — 2004-01-27
[1-[6-(5-methyl-2-phenyl-4-0xazolylmethoxy)-3- pyridylmethyl]-4-phenyl-3-pyrrolyl]lpropionate (1.05 g, . yield : 86%) as a colorless olly substance from the ' fraction eluted with ethyl acetate-hexane (1:2, volume } 5 ratio).
NMR(CDC1,) 0 : 1.20(3H, t, J=7Hz), 2.48(3H, 5s), 2.4-2.55(2H, m), 2.9-3.0(2H, m), 4.08(2H, q, J=7 Hz), 4.94(2H, s), ~ 5.29(2H, s), 6.51(1H, d, J=2.5 Hz), 6.70(1H, 4, J=2 Hz), 6.80(1H, 4, J=8.5 Hz), 7.15-7.5(9H, m), 7.95-8.1(3H, m).
Example 268
A mixture of ethyl 3-[1-{6-(5-methyl-2-phenyl- 4-oxazolylmethoxy)-3-pyridylmethyl]-4-phenyl-3- pyrrolyl]lpropionate (1.03 g), 1N aqueous sodium hydroxide solution (8 ml), ethanol (10 ml) and tetrahydrofuran (10 ml) was stirred at room temperature.
The reaction mixture was poured into water, neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain crystals of 3-[1-[6-(5-methyl-2-phenyl-4- } oxazolylmethoxy)-3-pyridylmethyl]-4-phenyl-3- pyrrolyl])propionic acid from the fraction eluted with acetone-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane to obtain colorless prisms (740 mg, yield : 74%). Melting point: 123-124°C.
Example 269
Sodium hydride (60%, oily. 0.56 g) was added to a solution of ethyl 3-[1-(3,5-dihydroxybenzyl)-4- phenyl-3-pyrrolyl]propionate (5.12 g) in N,N- dimethylformamide (50 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. Ethyl iodide (1.12 ml) was added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, and extracted with ethyl . acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsoO,), . 5 and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-(3,5- diethoxybenzyl)-4-phenyl-3-pyrrolyl)propionate (1040 mg, yield : 24%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 1.38(6H, t, J=7.0 Hz), 2.48-2.56(2H, m), 2.91-2.99(2H, m), 3.97(2H, q, J=7.0 Hz), 4.08(4H, gq, J=7.0 Hz), 4.91(2H, s), 6.29(2H, 4, J=2.2 Hz), 6.36(1H, t, J=2.2 Hz), 6.51(1H, 4d, J=2.4 Hz), 6.72(1H, 4d,
J=2.4 Hz), 7.15-7.25(1H, m), 7.29-7.42(4H, m).
Example 270
In silica gel column chromatography described in
Example 269, ethyl 3. [l-(3-ethoxy-5-hydroxybenzyl)-4- phenyl-3-pyrrolyllpropionate (2040 mg, yield : 37%) was obtained as a colorless oily substance from the fraction which eluted next to the compound described in Example 269.
NMR(CDC1,) 0 : 1.17(3H, t, J=7.0 Hz), 1.37(3H, t, J=7.0 Hz), 2.47-2.55(2H, m), 2.92-3.00(2H, m), 3.96(2H, q, J=7.0 Hz), ~ 4.09(2H, q, J=7.0 Hz), 4.89(2H, s), 5.67(1H, s), 6.06(1H, s), 6.29-6.32(2H, m). 6.50(1H, 4, J=2.4 Hz), 6.71(1H, 4,
J=2.4 Hz), 7.15-7.41(5H, m).
Example 271
Sodium hydride (60%, oily. 50.0 mg) was added to a solution of ethyl 3-[1-(3-ethoxy-5-hydroxybenzyl)- 4-phenyl-3-pyrrolyl)propionate (492 mg) in N,N- } dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 4-
Chloromethyl-5-methyl-2-phenyloxazole (260 mg) was added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was , poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous , 5 sodium chloride solution, dried (MgS0,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[3-ethoxy-5-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyl)propionate (622 mg, yield : 88%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 1.38(3H, t, J=7.0 Hz), 2.41(3H, s), 2.47-2.55(2H, m), 2.91-2.99(2H, m), 3.98(2H, g. J=7.0 Hz), 4.08(2H, q, J=7.0 Hz), 4.93(4H, s), 6.34(1H, s), 6.43(1H, s), 6.51(1H, s), 6.52(1H, d, J=2.4 Hz), 6.72(1H, d, J=2.4 Hz), 7.16-7.45(8H, m), 7.98-8.03(2H, m).
Example 272 :
After a mixture of ethyl 3-{1-[3-ethoxy-5-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-4-phenyl-3-. pyrrolyl]propionate (621 mg), 1N aqueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (2.5.ml) was added to the mixture, and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by . filtration to obtain 3-[1l-[3-ethoxy-5-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-4-phenyl-3- pyxrrolyl)propionic acid (439 mg, yield : 74%). This was recrystallized from ethanol-hexane. Melting point: 126-127°C.
Example 273
Sodium hydride (60%, oily, 50.0 mg) was added to a solution of ethyl 3-[1-(3-ethoxy-5-hydroxybenzyl)- 4-phenyl-3-pyrrolyl]lpropionate (492 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was ! stirred at room temperature for 15 minutes. 4- . 5 Chloromethyl-2-phenylthiazole (262 mg) was added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1l-[3-ethoxy-5-(2-phenyl-4- thiazolylmethoxy)benzyll-4-phenyl-3- pyrrolyllpropionate (601 mg, yield : 85%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR(CDC1,) 0: 1.20(3H, t, J=7.0 Hz), 1.38(3H, t, J=7.0 Hz), 2.48-2.56(2H, m), 2.91-2.99(2H, m), 3.97(2H, q, J=7.0 Hz), © 4.08(2H, q, J=7.0 Hz), 4.93(2H, s), 5.20(2H, 5), 6.34(1H, s), 6.42(1H, s), 6.50(1H, d, J=2.4 Hz), 6.52(1H, s), 6.72(1H, 4d, J=2.4 Hz), 7.15-7.46(9H, m), 7.92-7.96(2H, m).
Example 274
After a mixture of ethyl 3-[1l-[3-ethoxy-5-(2- phenyl-4-thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropionate (595 mg), 1N aqueous sodium . hydroxide solution (2.5 ml), tetrahydrofuran (5 ml) and ethanol (5ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (2.5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[1-[3-ethoxy-5-(2-phenyl-4- thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyllpropionic acid (538 mg, yield : 95%). This was recrystallized from ethanol-hexane. Melting point: 109-110°C. :
Example 275 } 5 Sodium hydride (60%, oily, 50.0 mg) was added to a solution of ethyl 3-[1-(3-ethoxy-5-hydroxybenzyl)- 4-phenyl-3-pyrrolyl]lpropionate (492 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 15 minutes. 4-
Chloromethyl-2-(2-thienyl)thiazole (270 mg) was added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS0O,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[3-ethoxy-5-[2- (2-thienyl)-4-thiazolylmethoxy)benzyl]--4--phenyl-3- pyrrolyl]propionate (657 mg, yield : 92%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:3, volume ratio).
NMR (CDC1,) 6: 1.20(3H, t, J=7.0Hz), 1.38(3H, t, J=7.0 Hz), 2.48-2.56(2H, m), 2.91-2.99(2H, m), 3.97(2H, q, J=7.0 Hz), 4.08(2H, gq, J=7.0 Hz), 4.92(2H, s), 5.16(2H, s), 6.33(1H, s), 6.41(1H, s), 6.48(1H, t, J=2.2 Hz), 6.51(1H, 4, J=2.4
Hz), 6.72(1H, 4, J=2.4 Hz), 7.06(1H, dd, J=3.6, 5.2 Hz), 7.19-7.25(2H, mm), 7.29-7.40(5H, m), 7.50(1H, 44, J=1.2, 3.6
Hz). :
Example 276
After a mixture of ethyl 3-[1-[3-ethoxy-5-[2- (2-thienyl)-4-thiazolylmethoxy)benzyl]-4-phenyl-3- pyrrolyl]propionate (653 mg), 1N agueous sodium hydroxide solution (2.5 ml), tetrahydrofuran (5 ml) and ethanol (5ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (2.5 ml) was added to the mixture,
and then the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous . sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by , : 5 filtration to obtain 3-[1-[3-ethoxy-5-[2-(2-thienyl)- .4-thiazolylmethoxy)benzyl]-4-phenyl 3 pyrrolyllpropionic acid (545 mg, yield : 88%). This was recrystallized from ethanol-hexane. Melting point: 104-105°C. :
Example 277
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-4- phenyl-3-pyrrolyl]propionate (600 mg), 5-chloromethyl- 2-phenylpyridine (370 mg), potassium carbonate (450 mg) and
N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgS$S0,) and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). After amixture of the : resulting colorless oily substance, 1N aqueous sodium . hydroxide solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[4-phenyl-1-[4-(6-phenyl-3- pyridylmethoxy)benzyl]-3-pyrrolyl]propionic acid (820mg, ’ yield : 98%). Thiswas recrystallized from acetone-hexane. } Melting point: 185-186°C.
Example 278
A mixture of 5-phenyl-2-pyridinemethanol (390 mg), thionyl chloride (0.3 ml) and toluene (10 ml) was stirred . at 80°C for 1 hour. After the reaction mixture was concentrated under reduced pressure, the resulting . 5 arystals were filtered und washed with hexane. A mixture of the resulting crystals, ethyl 3-[1-(4- hydroxybenzyl)-4-phenyl-3-pyrrolyl]lpropionate (790mg). potassium carbonate (700 mg) and N,N-dimethylformamide (15 ml) was stirred at 70°C overnight. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgSoO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[4-(5- phenyl-2-pyridylmethoxy)benzyl]-4-phenyl-3- pyrrolyl]lpropionate (1050 mg, yield : 96%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 6 : 1.20(3H, t, J=7.0 Hz), 2.46-2.58(2H, m), 2.88-3.00(2H, m), 4.08(2H, q, J=7.0 Hz), 4.95(2H, s), 5.25(2H, s), 6.51(1H, 4, J=2.6 Hz), 6.71(1H, 4, J=2.6 Hz), 6.94-7.04(2H, m), 7.08-7.64(13H, m), 7.91(1H, 44, J=2.2, 8.0 Hz), 8.82(1H, d, J=2.2 Hz).
Example 279
After a mixture of ethyl 3-[1-[4-(5-phenyl-2- pyridylmethoxy)benzyl]}-4-phenyl-3-pyrrolyl]propionate (1020 mg), 1N aqueous sodium hydroxide solution (4 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (4 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer : was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-{1-[4-(5-phenyl-2-pyridylmethoxy)benzyl]-4-phenyl-
3-pyrrolyllpropionic acid (930 mg, yield : 97%). This was recrystallized from acetone-hexane. Melting point:
R 169-170°C. . 5 Example 280
A mixture of 4-benzyloxybenzyl chloride (11.60 4), ethyl 3-(4-fluorophenyl)-1H-pyrazole- 4. carboxylate (11.70 g), potassium carbonate (13.80 g) and N,N- dimethylformamide (150 ml) was stirred at room temperature for 5 hours. The reaction mixture was poured . into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The resulting colorless crystals were collected by filtration to obtain ethyl 1-(4-benzyloxybenzyl)-3- '(4-fluorophenyl)-1lH-pyrazole-4-carboxylate (16.90 g, yield : 79%). This was recrystallized from ethyl acetate-hexane. Melting point: 103-104°C.
Example 281
Sodium hydride (60%, oily, 1.10 g) was added to a solution of 1-(4-benzyloxybenzyl)-3-(4-fluorophenyl)- 1H-pyrazole-4-carbaldehyde (9.66 g) and ethyl diethylphosphonoacetate (5.46 ml) in N,N- dimethylformamide (150 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours. Ice water was poured into the reaction mixture, and the resulting crystals were collected by filtration. After drying, recrystallization from ethyl acetate-hexane gave ethyl (E)-3-[1-(4-benzyloxybenzyl)-3-(4-fluorophenyl)-1H- pyrazol-4-yl]propenoate (10.60 g, yield : 93%). Melting point: 113-114°C.
Example 282 ’ 35 Sodium hydride (60%, oily. 140 mg) was added to a solution of 1-[{6-(5-methyl-2-phenyl-4-
oxazolylmethoxy)-3-pyridylmethyl]-3-phenyl-1H- pyrazole-4-carbaldehyde (1.20 g) and ethyl . diethylphosphonoacetate (780 mg) in N,N- dimethylformamide (30 ml) at 0°C, and the mixture was : 5 stirred at 0°C for 2 hours. The reaction mixture was poured into water, and the precipitated crystals were collected by filtration to obtain ethyl (E)-3-[1-[6- (5-methyl-2-phenyl-4-oxazolylmethoxy)- 3-pyridylmethyl]-3-phenyl-1H-pyrazol-4-yl]lpropionate.
The crystals were dissolved into ethanol (100 ml), and hydrogenated on 5% palladium-carbon (1.0 g) at room temperature under a normal pressure. The catalyst was removed by filtration, and the filtrate was concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[6-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-3-phenyl- : 1H-pyrazol-4-yllpropionate (1.20 g, yield : 86%) as a colorless oily substance.
NMR(CDC1,) 0 : 1.19(3H, t, J=7 Hz), 2.47(3H, s), 2.52(2H, t, J=7.5 Hz), 2.94(2H, t, J=7,5 Hz), 4.08(2H, gq, J=7 Hz), 5.23(2H, s), 5.29(2H, s), 6.80(1H, 4, J=8.5 Hz), 7.2- 7.65(10H, m), 7.95-8.15(3H, m).
Example 283
A mixture of ethyl 3-[1-[2-(5-methyl-2-phenyl- : 4-oxazolylmethoxy)-5-pyridylmethyl]-3-phenyl-1H- pyrazol-4-yllpropionate (1.20 g), a 1N agueous sodium hydroxide solution (10 ml) and ethanol (20 ml) was stirred at room temperature for 2 hours. After the reaction mixture was poured into water and neutralized with 1N ‘hydrochloric acid, the precipitated crystals of 3-[1l- [2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5- ' pyridylmethyl]-3-phenyl-1H-pyrazol-4-yl]propionic ‘ acid were collected by filtration. This was recrystallized from ethyl acetate to obtain colorless prism crystals (810 mg, yield : 71%). Melting point:
172-173°C. . Example 284
A mixture of 1-(4-benzyloxybenzyl)-3-phenyl-1H- -¢ 5 pyrazol-4-ylmethanol (26.39 g), activated manganese dioxide (70.26 g) and tetrahydrofuran (300ml) was stirred at room temperature overnight. After the manganese dioxide was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). Sodiumhydride (60%, : oily, 3.20 g) was added to a solution of the resulting colorless oily substance and ethyl diethylphosphonoacetate (18.19 g) in N,N- dimethylformamide (100 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours. Ice water was poured into the reaction mixture, and the resulting crystals were collected by filtration. After drying, recrystallization from ethyl acetate-hexane gave ethyl (E)-3-[1-(4-benzyloxybenzyl) -3-phenyl-1H-pyrazol-4- vl)}propenoate (26.71 g, yield : 86%). Melting point: 94-95°C.
Example 285
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-3- phenyl-1H-pyrazol-4-yllpropionate (600 mg), 2- chloromethylquinoline hydrochloride (380 mg), potassium carbonate (360 mg) and N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1,
volume ratio). After a mixture of the resulting colorless oily substance, 1N aqueous sodium hydroxide ; solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N ‘0 hydrochloric acid was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-phenyl-1-[4-(2- quinolylmethoxy)benzyl]-1H-pyrazol-4-yl]lpropionic acid (660 mg, yield : 83%). This was recrystallized from acetone-hexane. Melting point: 147-148°C.
Example 286
A mixture of ethyl 3-[1-[4-(2- bromoethoxy)benzyl]-3-phenyl-1H-pyrazol-4- vl]lpropionate (1050 mg), 1(2H)-phthalazinone (530 mg), potassium carbonate (1000 mg) and N,N-dimethylformamide . (15 ml) was stirred at 90°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). After a mixture of the resulting : colorless oily substance, IN aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 3 hours, 1N . hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The } - ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-[2-[1l-oxophthalazin- : 2(1H)-yllethoxylbenzyl)-3 phenyl-1lH-pyrazol-4- . yllpropionic acid (1460 mg, yield : 90%). This was recrystallized from acetone-hexane. Melting point: 155--156°C.
Example 287
A mixture of ethyl 3-[1-[4-(2- bromoethoxy)benzyl]-3-phenyl-1H-pyrazol-4- yllpropionate (883 mg), 2H-1,4-benzothiazin-3(4H)-one (320 mg), potassium carbonate (530 mg) and N,N- dimethylformamide (10 ml) was stirred at 80°C for 8 hours.
The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio)... After a mixture of the resulting colorless oily substance, 1N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml) and ethanol (5ml) was stirred at room temperature for 3 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain 3-[1-[4-[2-(3-0%x0-2,3-dihydro-4H-1,4- benzothiazin-4-yl)ethoxylbenzyl]-3-phenyl-1H-pyrazol- 4-yllpropionic acid (680 mg, yield : 69%) as a colorless amorphous substance.
Example 288
A mixture of ethyl 3-[1l-(4-hydroxybenzyl)-3- phenyl-1H-pyrazol-4-yl])propionate (600 mg), S5- chloromethyl-2-phenylpyridine (350 mg), potassium carbonate (460 mg) and N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was . poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous ¢ 5 sodium chloride solution, dried (MgS0,) and concentrated.
The residue was subjected to silica gel column chromatography to obtain a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). After a mixture of the resulting colorless oily substance, 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated agueous sodium chloride solution, dried (MgSO,). and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3..-[3-phenyl-1-[{4-(6-phenyl-3- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (710 mg, yield : 85%). This was recrystallized from acetone-hexane. Melting point: 155-156°C.
Example 289
A mixture of ethyl 3-[1-(4-hydroxybenzyl)-3- phenyl-1H-pyrazol-4-yl])propionate (840 mg), 3- chloromethyl-5-phenylpyridine (550 mg), potassium carbonate (500 mg) and N,N-dimethylformamide (10 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The residue was subjected to silica gel column ) chromatography to obtain ethyl 3-[3-phenyl-1-[4-(5- phenyl-3-pyridylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (1010 mg, yield : 81%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1l,) 0: 1.19(3H, t, J=7.0 Hz), 2.46-2.56(2H, m), . 2.88-3.00(2H, m), 4.12(2H, gq, J=7.0 Hz), 5.15(2H, s), 5.25(2H, s), 6.92-7.04(2H, m), 7.16-7.67(13H, m), 7.94- ) 5 7.99(1H, m), 8.65(1H, 4, J=:2.2 Hz), 8.82(1H, 4, J=2.2 Hz).
Example 290 -
After a mixture of ethyl 3-[3-phenyl-1-[4-(5- phenyl-3-pyridylmethoxy)benzyl]-1H-pyrazol-4- yl]lpropionate (980 mg), 1N aqueous sodium hydroxide solution (4 ml), tetrahydrofuran (10 ml) and ethanol (10 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (4 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-phenyl-l1l-[{4-(5-phenyl-3- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl]lpropionic acid (760 mg, yield : 82%). This was recrystallized from acetone-hexane. Melting point: 161-162°C.
Example 291
A mixture of ethyl 3-[{1-(4-hydroxybenzyl)-3- phenyl-lH-pyrazol-4-yllpropionate (460 mg), 2- chloromethyl-l-methyl-1H-benzimidazole (250 mg), potassium carbonate (360 mg) and N,N-dimethylformamide (15 ml) was stirred at 80°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,) and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[4-(1- methyl-1H-benzimidazol-2-ylmethoxy)benzyl]-3-phenyl- 1H-pyrazol-4-yllpropionate (550 mg, yield : 85%) as a colorless oily substance from the fraction eluted with
© 330 ethyl acetate-hexane (2:1, volume ratio).
NMR(CDC1,) 0 : 1.17(3H, t, J=7.0 Hz), 2.45-2.56(2H, m), ) 2.86-2.98(2H, m), 3.89(3H, s), 4.06(2H, q. J=7.0 Hz), 5.22(2H, s), 5.39(2H, s), 7.01-7.10(2H, m), 7.16-7.47(9H, ) 5 m), 7.58 -7.66(2H, m), 7.73-7.82(1H, m).
Example 292 : :
After a mixture of ethyl 3-[1-[4-(1l -methyl-1H- benzimidazol-2-ylmethoxy)benzyl]-3-phenyl-1H-pyrazol- 4-yllpropionate (520 mg), 1N aqueous sodium hydroxide solution (2 ml), tetrahydrofuran (5 ml) and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(1l-methyl-1H- benzimidazol-2-ylmethoxy)benzyl]-3-phenyl-1H-pyrazol- 4-yllpropionic acid (420 mg, yield : 86%). This was recrystallized from ethanol-hexane. Melting point: 225-226°C.
Example 293
A mixture of ethyl 3-[3-(4-fluorophenyl)-1-(4- hydroxybenzyl) -1H-pyrazol-4-yllpropionate (950 mg), 2-chloromethylquinoline hydrochloride (600 mg), potassium carbonate (700 mg) and N,N-dimethylformamide (15 ml) was stirred at 60°C for 5 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with : saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. The residue was subjected to silica : . gel column chromatography to obtain ethyl 3-[3-(4- £luorophenyl)-1-[4-(2-quinolylmethoxy)benzyl]-1H- pyrazol-4-yl]lpropionate (1210 mg, yield : 92%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). : NMR(CDC1,) 0: 1.18(3H, t, J=7.0 Hz), 2.45-2.56(2H, m), 2.83-2.96(2H, m), 4.07(2H, gq, J=7.0 Hz), 5.21(2H, s), : 5 5.38(2H, s&s), 6.94-7.26(711, m), 7.50 7.88(6H, m). 8.04 8.13(1H, m), 8.16-8.24(1H, m).
Example 294
After a mixture of ethyl 3-[3-(4-fluorophenyl)- 1-[4-(2-quinolylmethoxy)benzyl]-1H-pyrazol-4- yl]propionate (1150 mg), 1N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (10 ml) and ethanol (10 oo ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (5 ml) was added to the mixture, and © 15 then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[3-(4-fluorophenyl)-1-[4-(2- quinolylmethoxy)benzyl]-1lH-pyrazol-4-yl]propionic acid (1010 mg, yield : 93%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 178-179°C.
Example 295
A mixture of 5-phenyl-2-pyridinemethanol (330 mg), thionyl chloride (0.3 ml) and toluene (10 ml) was stirred at 80°C for 1 hour. After the reaction mixture was concentrated under reduced pressure, the resulting crystals were filtered and washed with hexane. A mixture of the resulting crystals, ethyl 3-[3-(4- fluorophenyl)-1-(4-hydroxybenzyl)-1H-pyrazol-4- : . yllpropionate (650 mg), potassium carbonate (550 mg) and
N,N-dimethylformamide (10 ml) was stirred at 70°C . overnight. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to : obtain ethyl 3-[3-(4-fluorophenyl)-1-[4-(5-phenyl-2- pyridylmethoxy)benzyl]-1H-pyrazol-4-yl]lpropionate ' 5 (850 my, yield : 90%) as a colorless olly substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR (CDCL1,) O : 1.18(3H, t, J=7.0 Hz), 2.44-2.56(2H, m), 2.85-2.97(2H, m), 4.07(2H, gq, J=7.0 Hz), 5.22(2H, s), 5.25(2H, s), 6.94-7.26(8H, m), 7.34-7.68(7H, m), 7.91(1H, dd, J=2.2, 8.4 Hz), 8.82(1H, d, J=2.2 Hz).
Example 296
After a mixture of ethyl 3-[3-(4-fluorophenyl)- 1-{4-(5-phenyl-2-pyridylmethoxy)benzyl]-1H-pyrazol-4- “yllpropionate (800 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (3 ml) and ethanol (3 ml) was stirred at room temperature for 5 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,) and concentrated. " The resulting colorless crystals were collected by filtration to obtain 3-[3-(4-fluorophenyl)-1-(4-(5- phenyl-2-pyridylmethoxy)benzyl]-1H-pyrazol-4- yllpropionic acid (700 mg, yield : 93%). This was recrystallized from ethanol-water. Melting point: 162-163°C.
Example 297
Sodium hydride (60%, oily, 70.0 mg) was added to . a solution of 2-(5-chloromethyl-2- pyridyloxymethyl)quinoline (498 mg), ethyl 3-(3- . phenyl-1H-pyrazol-4-yl)propionate (428 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with ‘ saturated aqueous sodium chloride solution, dried (MgSoO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- phenyl-1-[6-(2-quinolylmethoxy)~-3-pyridylmethyl]-1H- pyrazol--4--yllpropionate (651 mg, yield : 76%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR (CDC1,) 0 : 1.18(3H, t, J=7.2 Hz), 2.48-2.56(2H, m), 2.90-2.98(2H,m), 4.07(2H, gq, J=7.2 Hz), 5.22(2H, s), 5.68(2H, s), 6.89(1H, da, J=8.8 Hz), 7.23(1H, s)., 7.29- 7.65(8H, m), 7.53(1H, ddd, J=1.4, 7.0, 8.4 Hz), 7.72(1H, dad, J=1.8, 6.8, 8.4 Hz), 7.81(1H, 4d, J=1.8, 8.2 Hz), 8.08-8.18(3H, m).
Example 298
After a mixture of ethyl 3-[3-phenyl-1-[6-(2- quinolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- yllpropionate (650 mg), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml) and ethanol (6 ml) was stirred at room temperature for 2 hours, 1 N hydrochloric acid (3 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,) and concentrated .
The resulting colorless crystals were collected by filtration.to obtain 3-[3-phenyl-1-[6-(2- quinolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- vyllpropionic acid (489 mg, yield : 80%). This was recrystallized from acetone-hexane. Melting point: - 166-167°C. . Example 299
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of S-chloromethyl-2-(2-phenyl-4-
thiazolylmethoxy)pyridine (554 mg), ethyl 3-(3- phenyl-1lH-pyrazol-4-yl)propionate (428 mg) in N,N- co fo dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. "The ethyl acetale layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- phenyl-1-[2 -(2-phenyl-4-thiazolylmethoxy)-3- pyridylmethyl]-1H-pyrazol-4-yllpropionate (678 mg, yield : 74%) as colorless crystals from the fraction : eluted with ethyl acetate-hexane (2:3, volume ratio).
This was recrystallized from ethyl acetate-hexane.
Melting point: 88-89°C.
Example 300
After a mixture of ethyl 3-[3-phenyl-1-[2-(2- phenyl-4-thiazolylmethoxy)-5-pyridylmethyl]-1H- -20 pyrazol-4-yl)propionate (603 mg), 1N sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 2 hours, 1N ’ hydrochloric acid (3 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-phenyl-1-(6-(2-phenyl-4- thiazolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- yl]lpropionic acid (500 mg, yield : 88%). This was recrystallized from acetone-hexane. Melting point: 107-108°C.
Example 301 :
A mixture of 4-(5-phenyl-2-pyridylmethoxy)benzyl alcohol (600 mg), thionyl chloride (0.35ml), and toluene
Amended Sheet — 2004-01-27
(30 ml) was stirred at 80°C for 2 hours. The reaction mixture was concentrated under reduced pressure, and to dissolved in ethyl acetate. The solution was washed successively with saturated aqueous solution of sodium ' 5 bicarbonate and saturated aqueous sodium chloride solution, dried (MygsO,) ,and concentrated. Sodium hydride (60%, oily, 92.0 mg) was added to a solution of the residual oily substance and ethyl 3-(3-phenyl-1H- pyrazol-4-yl)propionate (510 mg) in N,N- dimethylformamide (15 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,).’ and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-(3- phenyl-1-[4-(5-phenyl-2-pyridylmethoxy)benzyl]-1H- pyrazol-4-yl]lpropionate (970 mg,. yield : 91%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). :
NMR (CDC1,) 0 : 1.18(3H, t, J=7.4 Hz), 2.47-2.57(2H, m), 2.90-3.00(2H, m), 4.07(2H, q, J=7.4 Hz), 5.24(2H, Ss), 5.26(2H, s), 7.00(2H, d, J=8.8 Hz), 7.19-7.68(14H, m), 7.91(1H, 4d, J=2.2, 8.0 Hz), 8.83(1H, d, J=2.2 Hz). :
Example 302 .
After a mixture of ethyl 3-[3-phenyl-1-[4-(5- phenyl-2-pyridylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (970 mg), 1N sodium hydroxide solution (5
J 30 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate : layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain
3-{3-phenyl-1-(4-(5-phenyl-2- pyridylmethoxy)benzyl]- ~ 1H-pyrazol-4-yllpropionic acid (820 mg, yield : 90%). ) ' This was recrystallized from acetone-hexane. Melting : point: 149-150°C.
Example 303
Sodium hydride (60%, oily, 110 my) was added to a solution of 4-(4-chloromethylphenoxymethyl)-2- phenylthiazole (760 mg) and ethyl 3-(3-phenyl-1H- pyrazol-4-yl)propionate (580 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (Mgso,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3- phenyl-1-[4-(2 phenyl-4-thiazolylmethoxy)benzyl]1H- © pyrazol-4-yllipropionate (1110 mg, yield : 89%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDC1,) 0 : 1.19(3H, t, J=7.0 Hz), 2.47-2.57(2H, m), 2.89-3.00(2H, m), 4.07(2H, q, J=7.0 Hz), 5.24(2H, s), 5.27(2H, s)., 6.96-7.05(2H, m), 7.18-7.49(10H, m), 7.59- 7.68(2H, m), 7.90-7.99(2H, m).
Example 304
After a mixture of ethyl 3-[3-phenyl-1-[4-(2- phenyl-4-thiazolylmethoxy)benzyl]-1H-pyrazol-4- yllpropionate (1110 mg), 1N sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was : stirred at room temperature for 2 hours, 1 N hydrochloric acid (5 ml) was added to the mixture, and then the mixture - was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-(3-phenyl-1-{4-(2-phenyl-4- : thiazolylmethoxy)benzyl]-1H-pyrazol-4-yl]propionic acid (630 mg, yield : 60%). Thiy was recrystallized from acetone -hexdine. Melting point: 132.133°C,
Example 305
A mixture of 5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-2-pyridinemethanol (630 mg) and thionyl chloride (10 ml) was stirred at 0°C for 2 hours, and the reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed successively with saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. A mixture of the resulting crystals, ethyl 3-(3-phenyl- l1H-pyrazol-4-yl)propionate (520 mg), potassium carbonate (590 mg) and N,N-dimethylformamide (15 ml) was . stirred at 80°C overnight. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous . sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 3-[1-[5-(5-methyl-2- phenyl-4-oxazolylmethoxy)-2-pyridylmethyl]-3-phenyl- l1H-pyrazol-4-yl]propionate (950 mg, yield : 85%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:1, volume ratio).
NMR(CDC1,) 0 : 1.20(3H, t, J=7.0 Hz), 2.44(3H, s), 2.48- 2.58(2H, m), 2.92-3.03(2H, m), 4.09(2H, q, J=7.0 Hz), 5.02(2H, s), $.38(2H, s), 7.08(1H, d, J=8.4 Hz), 7.20- : 7.54(8H, m), 7.60-7.68(2H, m), 7.95-8.08(2H, m), 8.38(1H, d, J=2.6 Hz).
Example 306
After a mixture of ethyl 3-[1-[5-(5-methyl-2-
phenyl-4-oxazolylmethoxy) -2-pyridylmethyl]-3-phenyl- lH-pyrazol-4-yl]propionate (930mg), 1N sodium hydroxide - solution (3 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 2 hours, 1IN . 5 hydrochloric acid (3 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[1-[5-(5-methyl-2-phenyl-4- oxazolylmethoxy)-2-pyridylmethyl]-3-phenyl-1H- pyrazol-4-yllpropionic acid (830 mg, yield : 94%). This was recrystallized from acetone-hexane. Melting point: 175-176°C.
Example 307
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of S-chloromethyl-2-(5-methyl-2-phenyl- 4. oxazolylmethoxy)pyridine (551 mg) and ethyl (3- phenyl-l1H-pyrazol-4-yl)acetate (403 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl [1-{6-(5- methyl-2-phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]- 3-phenyl-1H-pyrazol-4-yllacetate (513 mg, yield : 58%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio). } NMR(CDC1,) 6 : 1.21(3H, t, J=7.0 Hz), 2.48(3H, s), 3.60(2H, s),4.13(2H, q, J=7.0Hz), 5.26(2H, s), 5.30(2H, s), 6.81(1H, ) da, J=8.8 Hz), 7.30-7.47(7H, m), 7.53-7.62(3H, m), 7.98- 8.05(2H, m), 8.16(1H, 4, J=2.2 Hz}.
Example 308
After a mixture of ethyl [1-[6-(5-methyl-2- : phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-3-phenyl- l1H-pyrazol-4-yllacetate (509 mg), 1N sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The resulting colorless crystals were collected by filtration to obtain [1-[6-(5-methyl-2-phenyl-4- oxazolylmethoxy)-3-pyridylmethyl]-3-phenyl-1H- pyrazol-4-yllacetic acid (408 mg, yield : 85%). This was recrystallized from acetone hexane. Melting point: 144-145°C.
Example 309
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of 5-chloromethyl-2-(2-phenyl-4- thiazolylmethoxy)pyridine (554 mg)and ethyl (3- phenyl-1H-pyrazol-4-yl)acetate (403 mg) in N,N- dimethylformamide (10 ml) at o°c, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl [3-phenyl- 1-[6~-(2-phenyl-4-thiazolylmethoxy)-3-pyridylmethyl]- 1H-pyrazol-4-yllacetate (594 mg, yleld : 66%) as : colorless crystals from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 75-76°C.
Example 310
After a mixture of ethyl [3-phenyl-1-[6-(2- : } phenyl-4-thiazolylmethoxy)-3-pyridylmethyl]-1H- pyrazol-4-yl]acetate (536 mg), 1N sodium hydroxide ) 5 solutlon (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The resulting colorless crystals were collected by filtration to obtain [3-phenyl-1-[6-(2-phenyl-4- thiazolylmethoxy)-3-pyridylmethyl]-1H-pyrazol-4- yllacetic acid (459 mg, yield : 91%). This was recrystallized from ethanol-hexane. Melting point: 118-119°C.
Example 311
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of 5-chloromethyl-2-(5-methyl-2-phenyl-4- thiazolylmethoxy)pyridine (579 mg)and ethyl (3- phenyl-1H-pyrazol-4-yl)acetate (403 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica: ~ gel column chromatography to obtain ethyl [1-[6-(5- methyl-2-phenyl- 4-thiazolylmethoxy)-3-pyridylmethyl]- 3-phenyl-1lH-pyrazol-4-yllacetate (476 mg, yield : 52%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (2:3, volume ratio). : NMR(CDC1,) 6 : 1.21(3H, t, J=7.2 Hz), 2.56(3H, s), 3.60(2H, s), 4.13(2H, q, J=7.2Hz), 5.26(2H, s), 5.44(2H,; s), 6.82(1H, da, J=8.0 Hz), 7.29-7.47(7H, m), 7.53-7.62(3H, m), 7.86-
7.92(2H, m), 8.17(1H, d, J=2.2 Hz).
Example 312
After a mixture of ethyl [1-[6-(5-methyl-2- : 5 phenyl 4 thiazolylmethoxy) 3 pyridylmethyl] 3 phenyl- l1H-pyrazol -4-yllacetate (475 mg), 1N sodium hydroxide solution (2 ml), tetrahydrofuran (4 ml), and ethanol (4 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and. the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The resulting colorless crystals were collected by filtration to obtain [1-[6-(5-methyl-2-phenyl-4- thiazolylmethoxy)-3-pyridylmethyl]-3-phenyl-1H- pyrazol-4-yllacetic acid (402 mg, yield : 89%). This was recrystallized from ethanol-hexane. Melting point: 140-141°C.
Example 313
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of 5-chloromethyl-2-{2-(5-methyl-2-phenyl- 4-oxazolyl)ethoxylpyridine (575 mg) and ethyl (3- phenyl-1H-pyrazol-4-yl)acetate (403 mg) in N,N- dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl [1-[6-[2- (5-methyl-2-phenyl-4-oxazolyl)ethoxyl-3- pyridylmethyl]-3-phenyl-1lH-pyrazol-4-yl]acetate (575 mg, yield : 63%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDCLl,) 6 : 1.21(3H, t, J=7.0 Hz), 2.34(3H, s), 2.98(2H, t, J=6.8 Hz), 3.59(2H, s), 4.12(2H, q, J=7.0 Hz), 4.56(2H, t, J=6.8 Hz), 5.24(2H, s), 6.71L(1H, 4, J=8.4 Hz), 7.29- 7.47(7H, m), 7.51-7.61(3H, m), 7.94-8.01(2H, m), 8.12(1H, : 5 da, J=2.6 Hn).
Example 314
After a mixture of ethyl [1 [6 [2 (5-methyl-2- phenyl-4-oxazolyl)ethoxy]-3-pyridylmethyl]-3-phenyl- 1H-pyrazol-4-yllacetate (575 mg), 1N sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain [l-[6-[2-(5-methyl-2-phenyl-4- . oxazolyl)ethoxy]l-3-pyridylmethyl]-3-phenyl-1H- pyrazol-4-yllacetic acid (466 mg, yield : 86%). This was recrystallized from ethanol-hexane. Melting point: ~ 148-149°C.
Example 315
Sodium hydride (60%, oily, 70.0 mg) was added to a solution of S-chloromethyl-2-{2-(2-furyl)-5-methyl- 4-oxazolylmethoxylpyridine (533 mg) and ethyl (3- phenyl-1H-pyrazol-4-yl)acetate (403 mg) in N,N- : dimethylformamide (10 ml) at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water, and extracted with ethyl . acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSoO,), : and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl [1-[6-[2- (2-furyl)-5-methyl-4-oxazolylmethoxy]-3-
pyridylmethyl]-3-phenyl-1H-pyrazol -4-yllacetate (581 mg, yield : 67%) as a colorless oily substance from the ‘ fraction eluted with ethyl acetate-hexane (1:1, volume ratio). ' 5 NMR(CDC1,) 6: 1.21(30, t, J=7.0 Hz), 2.46(3H, 5s), 3.60(2H, s), 4.13(2H, q, J=7.0Hz), 5.26(2H, s), 5.28(2H, s), 6.51(1H, dd, J=1.8, 3.6 Hz), 6.79(1H, 4, J=8.4 Hz), 6.98(1H, dd,
J=0.6, 3.6 Hz), 7.30-7.46(4H, m), 7.52--7.61(4H, m), 8.14(1H, d, J=2.2 Hz).
Example 316
After a mixture of ethyl [1-[6-[2-(2-furyl)-5- methyl-4-oxazolylmethoxy]-3-pyridylmethyl]-3-phenyl- l1H-pyrazol-4-yllacetate (578 mg), 1N sodium hydroxide solution (3 ml), tetrahydrofuran (6 ml), and ethanol (6 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain [1-[6-[2-(2-furyl)-5-methyl-4- oxazolylmethoxyl-3-pyridylmethyl]-3-phenyl-1H- pyrazol-4-yllacetic acid (467 mg, yield : 86%). This was recrystallized from acetone-hexane. Melting point: 135-136°C.
Example 317
A mixture of [l-(4-benzyloxybenzyl)-3-(4- fluorophenyl)-1H-pyrazol-4-yl]acetonitrile (4.37 g), 4N sodium hydroxide solution (20 ml), tetrahydrofuran (20 . ml), and ethanol (20 ml) was refluxed for 2 days. After cooling, the mixture was neutralized with dilute : hydrochloric acid and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated to obtain [1l-(4-benzyloxybenzyl) 3-(4- -fluorophenyl)- l1H-pyrazol-4-yl]acetic acid (4.37 g, yield : 95%). This : was recrystallized from tetrahydrofuran-hexane.
Melting point: 194-195°C.
Example 318
A mixture of [l-(4-benzyloxybenzyl)-3-(4- fluorophenyl)-1H-pyrazol-4-yllacetic acid (4.16 g), methyl iodide (0.95 ml), potassium carbonate (2.76 g). and N,N-dimethylformamide (50 ml) was stirred at room temperature for 3 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium : chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain methyl [1-(4-benzyloxybenzyl)-3-(4- fluorophenyl)-1H-pyrazol-4-yllacetate (4.21 g, yield : 98%) as colorless crystals from the fraction eluted with . ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 58-59°C.
Example 319
A mixture of ethyl 3-hydroxy-lH-pyrazole-4- carboxylate (8.95 g), 4-phenoxybenzyl chloride (25.3549), : potassium carbonate (31.88 g), and N, N-dimethylformamide (200 ml) was stirred at 90°C for 8 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue . was subjected to silica gel column chromatography to obtain ethyl 1-(4-phenoxybenzyl)-3-(4- - . phenoxybenzyloxy)-1H-pyrazole-4-carboxylate (22.71 gq, yield : 76%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:4, volume ratio).
NMR (CDC1,) 0 : 1.31(3H, t, J=7.4 Hz), 4.25(2H, q, J=7.4 Hz). 5.09(2H, s), 5.31(2H, s), 6.93-7.50(18H, m), 7.67(1H, s). ' 5 Example 320
After a mixture of ethyl 1-(4--phenoxybenzyl) -3- (4-phenoxybenzyloxy) -1H-pyrazole-4-carboxylate (500 mg), 1N sodium hydroxide solution (2 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. : The resulting colorless crystals were collected by filtration to obtain 1-(4-phenoxybenzyl)-3-(4- - phenoxybenzyloxy)-1H-pyrazole-4-carboxylic acid (450 mg, yield : 95%). This was recrystallized from acetone- hexane. Melting point: 141 142°C.
Example 321 } A mixture of ethyl 3-hydroxy-1-(4- phenoxybenzyl) -1H-pyrazole-4-carboxylate (3.00 g), 4- (4-chloromethyl-2-methoxyphenoxymethyl)-2-(2-furyl)- 5-methyloxazole (3.00 g), potassium carbonate (2.52 g), and N,N-dimethylformamide (30 ml) was stirred at 80°C for 8 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and - aqueous sodium chloride solution, dried (MgsSoO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[4-[2-(2- : furyl)-5-methyl-4-oxazolylmethoxy]-3- methoxybenzyloxy]-1-(4-phenoxybenzyl)-1H-pyrazole-4- - carboxylate (5.30 g., yield : 94%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 98-99°C. : Example 322
After a mixture of ethyl 3-[4-[2-(2-furyl)-5- methyl-4-oxazolylwethoxy] 3-methoxybenzyloxy] 1 (4 phenoxybenzyl)-1H-pyrazole-4. carboxylate (1500 mg), 1N sodium hydroxide solution (5ml), tetrahydrofuran (10ml), and ethanol (10 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and the mixture was extractedwith ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The resulting colorless crystals were collected by filtration to obtain 3-[4-[{2-(2-furyl)-5-methyl-4- oxazolylmethoxy]-3-methoxybenzyloxy]-1-(4- phenoxybenzyl)-1H-pyrazole-4-carboxylic acid (1330 mg, yield : 93%). This was recrystallized from acetone- hexane. Melting point: 153-154°C.
Example 323
A mixture of 3-[4-[2-(2-furyl)-5-methyl-4- oxazolylmethoxy]-3-methoxybenzyloxyl-1-(4- phenoxybenzyl)-1H-pyrazole-4-carboxylic acid (0.80 g), 1H-1,2,3-benzotriazol-1-o0l1 ammonia complex (0.22 g), l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.28 g), and N,N-dimethylformamide (10 ml) was stirred at room temperature overnight. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and aqueous sodium chloride solution, dried (MgSO,). and concentrated. ’ ‘ The residue was subjected to silica gel column chromatography to obtain 3-[4-[2-(2-furyl)-5-methyl- . 4-oxazolylmethoxy)-3-methoxybenzyloxy]-1-(4- phenoxybenzyl)-1H-pyrazole-4-carbamide (0.75 g, yield : ‘ 94%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from acetone-hexane. Melting point: : 105-106°C. ) 5 Example 324
A mixture of ethyl 3-hydroxy-1l-(4- ~ phenoxybenzyl)-1H-pyrazole-4-carboxylate (3.00 g), 4- (4-chloromethyl-2-methoxyphenoxymethyl) 5-methyl-2- phenyloxazole (3.06 g), potassium carbonate (2.50 g), and
N,N-dimethylformamide (30 ml) was stirred at 80°C for 8 : hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and : aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-methoxy-4- (5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyl]-1-(4- phenoxybenzyl)-1H-pyrazole-4--carboxylate (5.43 g, yield : 95%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
This was recrystallized from acetone-hexane. Melting point: 127-128°C. :
Example 325
After a mixture of ethyl 3-[3-methoxy-4-(5- methyl-2-phenyl-4-oxazolylmethoxy)benzyloxy]-1-(4- phenoxybenzyl)-1H-pyrazole-4-carboxylate (750 mg), 1N sodium hydroxide solution (2 ml), tetrahydrofuran (5ml), and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (2 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. . The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. . The resulting colorless crystals were collected by filtration to obtain 3-[3-methoxy-4-(5-methyl-2- phenyl-4-oxazlylmethoxy)benzyloxyl-1-(4-
phenoxybenzyl)-1H-pyrazole-4- carboxylic acid (680 mg, yield : 95%). This was recrystallized: from ; tetrahydrofuran-hexane. Melting point: 176-177°C.
Example 326
After d mixture of ethyl 1-[4-[2-(2-Ffuiyl)-50H- ‘methyl-4-oxazolylmethoxy]benzyl]-3-[4-[2-(2-furyl)-5- methyl-4-oxazolylmethoxylbenzyloxy]-1lH--pyrazole-4- carboxylate (250mg). 1N sodiumhydroxide solution (1 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (1 ml) was added to the mixture, and the mixture was extracted ; with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The resulting colorless crystals were collected by filtration to obtain 1-[4- (2-(2-furyl)-5-methyl-4-oxazolylmethoxylbenzyl]-3-[4- [2-(2-furyl)-S-methyl-4-oxazolylmethoxy]benzyloxy]- ) l1H-pyrazole-4-carboxylic acid (230 mg, yield : 93%).
This was recrystallized from acetone-hexane. Melting point: 144-145°C.
Example 327
Sodium hydride (60%, oily, 310 mg) was added to a mixture of methyl 4-phenyl-3-pyrrolcarboxylate (1.204qg), 5-chloromethyl-2-(5-methyl-2-phenyl-4- oxazolylmethoxy)pyridine (1.88 g), and N,N- dimethylformamide (50 ml) at room temperature, and the mixture was stirred for 15 hours. The reaction mixture was poured into water, and extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodiumchloride solution, dried (MgS0O,). and concentrated. - The residue was subjected to silica gel column } chromatography to obtain methyl 1-[6-(5-methyl-2- phenyl-4-oxazolylmethoxy)-3-pyridylmethyl]-4-phenyl- lH-pyrrol-3-carboxylate (2.74 g, yield : 96%) as a }
Amended Sheet -- 2004-01-27 colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio).
NMR(CDCl,) 0 :2.48(3H, s), 3.72(2H, s), 5.00(2H, s), 5.30(2H, s)., 6.66(1H, d, J=1.5 Hz), 6.82(1H, d, J=8.5 Hz), 7.2 ) 5 7.5(10H, wm), 7.95-8.15(31, m).
Example 328
Sodium hydride (60%, oily, 270 mg) was added to a mixture of ethyl 3-phenyl-1H-pyrazole-4-carboxylate (1.20 g), S5S-chloromethyl-2-(5-methyl-2-phenyl-4- oxazolylmethoxy)pyridine (1.75 g), and N,N- dimethylformamide (50 ml) at 0°C, and the mixture was stirred at room temperature for 8 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried (MgSO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 1-[6-(5-mcthyl-2-phenyl-4-oxazolylmethoxy)-3- pyridylmethyl]-3-phenyl-1H-pyrazole-4-carboxylate (1.56 g, yield : 57%) as a colorless oily substance from the fraction eluted with diethyl ether-hexane (2:3, volume ratio).
NMR(CDC1,) 0 :1.14(3H, t, J=7 Hz), 2.45(3H, s), 4.13(2H, gq, J=7 Hz), 5.10(2H, s), 5.25(2H, s), 6.72(1H, d, J=8.5 Hz), 7.2-7.5(9H, m), 7.80(1H, 4, J=2 Hz), 7.95-8.05(3H, m).
Example 329 :
A mixture of ethyl 3-hydroxy-1-(4- phenoxybenzyl)-1H-pyrazole-4-carboxylate (4.07 g), 4- chloromethyl: 5 -methyl-2-phenyloxazole (2.58 g), potassium carbonate (1.73 g), and N,N-dimethylformamide - (30 ml) was stirred at 80°C for 8 hours. The reaction mixture was poured into water, and extracted with ethyl : acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl 3-(5-methyl-2-phenyl- 4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H-pyrazole-4- carboxylate (5.86 g, yield : 96%) as colorless crystals trom the fraction eluted with ethyl acetate hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 96-97°C.
Example 330
After a mixture of ethyl 3-(5-methyl-2-phenyl- 4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H-pyrazole-4- carboxylate (1600 mg), 1N sodium hydroxide solution (5 ml), tetrahydrofuran (10 ml), and ethanol (10 ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-1-(4- phenoxybenzyl) -1H-pyrazole-4-carboxylic acid (1470 mg, yield : 97%). This was recrystallized from tetrahydrofuran-hexane. Melting point: 222-223°C.
Example 331 A
A mixture of 3-(5-methyl-2-phenyl-4- | : oxazolylmethoxy)-1- (4-phenoxybenzyl) - IH-pyrazole-4- carboxylic acid (0.75 g), 1H-1,2,3-benzotriazol-1l-ol ammonia complex (0.26 g), l-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (0.339), and N,N-dimethylformamide (10 ml) was stirred at room : temperature overnight. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl : acetate layer was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgSO,). and concentrated. The residue was subjected to silica gel column chromatography to obtain 3-(5-methyl--2-phenyl-4-oxazolylmethoxy)-1-(4- phenoxybenzyl)-1H-pyrazole-4-carbamide (0.70 g, yield : 94%) as colorless crystals from the fraction eluted with ethyl acetate hexane (1:2, volume vatto). This was recrystallized from acetone-hexane. Melting point: 158--159°C.
Example 332
Sodium hydride (60%, oily, 220 mg) was added to a solution of 3-(5-methyl-2-phenyl-4-oxazolylmethoxy)- 1-(4-phenoxy)-1H-pyrazole-4-carbaldehyde (2.00 g) and ethyl diethylphosphonoacetate (1.06 g) in N,N- dimethylformamide (25 ml) at 0°C, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The residue was subjected to silica gel column chromatography to obtain ethyl (E)-3-([3-(5-methyl-2- phenyl-4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H- : pyrazol-4-yl]propenoate (2.19 g, yield : 95%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from acetone-hexane. Melting point: 93-94°C. :
Example 333
After a mixture of ethyl (E)-~3-[3-(5-methyl-2- phenyl-4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H- : pyrazol-4-yl]lpropenoate (450 mg), 1N sodium hydroxide solution (1.5 ml), tetrahydrofuran (5 ml), and ethanol : : (5 ml) was stirred at 50°C for 2 hours, 1N hydrochloric acid (1.5 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting ) colorless crystals were collected by filtration to obtain (E)-3-[3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-1-(4~- phenouxybeuzyl) -1H-pyrazol 4-yl]lpropenoic acid (410 mg, yield : 96%). This was recrystallized from acetone- hexane. Melting point: 210-211°C.
Example 334
A mixture of ethyl (E)-3-[3-(5-methyl-2-phenyl- 4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H-pyrazol-4- yl]propenoate (1100 mg), 5% palladium-carbon (390 mg). and tetrahydrofuran (30 ml) was stirred at room temperature for 5 hours under a hydrogen atmosphere.
After the palladium-carbon was removed by filtration, the filtrate was concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 3-[3-(5-methyl-2-phenyl 4-oxazolylmethxy)-1-(4- phenoxybenzyl)-1H-pyrazol-4-yl]propionate (980 mg, yield : 95%) as a colorless oily substance from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio).
NMR(CDC1,) 6 : 1.17(3H, t, J=7.0 Hz), 2.39(3H, s), 2.45- 2.72(4H, m), 4.06(2H, q, J=7.0 Hz), 5.05(2H, s), 5.15(2H, s), 6.90-7.46(13H, m), 7.94-8.06(2H, m).
Example 335 oo
After a mixture of ethyl 3-[3-(5-methyl-2- phenyl-4-oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H- pyrazol-4-yllpropionate (800 mg), 1N sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml), and ethanol (5 : ml) was stirred at room temperature for 2 hours, 1N hydrochloric acid (3 ml) was added to the mixture, and : the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[3-(5-methyl~2-phenyl-4- : oxazolylmethoxy)-1-(4-phenoxybenzyl)-1H-pyrazol-4- yl]}propionic acid (740 mg, yield : 97%). This was : 5 recrystallized from acetone hexane. Melting point: 120-121°C.
Example 336
A mixture of ethyl 3-(2-thienyl)-lH-pyrazole-4- caboxylate (10.23 g), 4-(4-chloromethylphenoxy)methyl- 5-methyl-2-phenyloxazole (14.66 g) potassium carbonate (13.09 g), and N,N-dimethylformamide (100 ml) was stirred at 80 for 8 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl 1-[4-(5-methyl-2-phenyl--4- oxazolylmethoxy)benzyl]j-3-(2-thienyl)-1H-pyrazole-4- carboxylate as colorless crystals (19.88 g, yield : 87%) from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 113~114TC.
Example 337
A mixture of ethyl 1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]}-3-(2-thienyl)-1H-pyrazole-4- carboxylate (900 mg), 1N sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at 80C for 5 hours. After cooling, 1N hydrochloric acid (3 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with: saturated aqueous sodium chloride solution, dried (MgSo,), and concentrated. - The resulting colorless crystals were collected by filtration to obtain 1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyll-3-(2-thienyl)-1H-
pyrazole-4-carboxylic acid (750 mg, yield : 88%). This was recrystallized from acetone-hexane. Melting point: - 204~205TC. ’ 5 Example 338
A mixture of [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllacetonitrile (1.69 g), 4N sodium hydroxide solution (10 ml), and ethanol (10 ml) was refluxed overnight. After cooling, 1N hydrochloric acid (40 ml) was added to the mixture, and the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The resulting colorless crystals were collected by filtration to obtain [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllacetic acid (1.13 g, yield : 64%). This was recrystallized from acetone-hexane. Melting point: 98 ~99T.
Example 339 " A mixture of diethyl [1-[4-(5-methyl-2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllmethylmalonate (6.08 g), 4N sodium hydroxide solution (10 m1), and ethanol (10 ml) was refluxed for 1 hour. After cooling, 1N hydrochloric acid (40 ml) was added to the mixture, and the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsSO,), and concentrated.
The resulting colorless oily substance was dissolved in pyridine (50 ml), and stirred at 110 C for 2 hours. After . pyridine was removed under reduced pressure, ethyl acetate was added to the residue. The resulting solution was washed . successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(5-methyl-2- phenyl-4-oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H- : pyrazol-4-yl]propionic acid (4.02 g, yield : 80%). This - was recrystallized from acetone-hexane. Melting point: 172°173C.,
Example 340
Sodium hydride (60%, oily, 150 my) was added to a solution of 1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]- 100 3-(2-thienyl)-1H-pyrazole-4-carbaldehyde (1.54 g) and ethyl diethylphosphonoacetate (0.82 g) in N,N- dimethylformamide (15 ml) at 0C, and the mixture was stirred at room temperature for 2 hours. The reaction ‘ mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed successively with dilute hydrochloric acid and saturated agueous sodium chloride solution, dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl (E)-3-{1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-(2-thienyl)-1lH-pyrazol-4- yllpropenoate (1.65g, yield : 93%) as colorless crystals from the fraction eluted with ethyl acetate-hexane (1: 2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point: 104~105T.
Example 341 i
After a mixture of ethyl (E)-3-[1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]}-3-(2-thienyl)-1H-pyrazol-4- yllpropenoate (1.25 g}. 1N aqueous sodium hydroxide solution (5 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at 50C for 2 hours, 1N hydrochloric acid (5 ml) was added to the mixture, and then the mixture was extracted with ethyl acetate. The ethyl acetate layer was . washed with saturated aqueous sodium chloride solution, dried (MgSO,)., and concentrated. The resulting colorless crystals were collected by filtration to obtain (E)-3-
[(1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazol-4-yl]propenoic acid (970 mg, yield : : 82%). This was recrystallized from ethyl acetate-hexane.
Melting point: 137~138TC.
Example 342
A mixture of diethyl [1-[4-(2-phenyl-4- : thiazolylmethoxy)benzyl]-3-(2--thienyl) 1H -pyrazol-4- vl]methylmalonate (4.09 g), 1N aqueous sodium hydroxide solution (30 ml), tetrahydrofuran (30 ml), and ethanol (30 ml) was refluxed for 1 hour. After cooling, 1Nhydrochloric acid (30 ml) was added to the mixture, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgsoO,), and concentrated. The resulting colorless oily substance was dissolved in pyridine (50 ml), and the mixture was stirred at 110TC for 2 hours. After removing pyridine under reduced pressure, ethyl acetate was added to the residue. The resulting solution was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgS0O,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllpropionic acid (3.25g, yield : 95%). This was recrystallized fromethyl acetate-hexane. Meltingpoint: 133~134TC.
Example 343
A mixture of ethyl 3-(2-thienyl)-1H-pyrazole-4- caboxylate (1.43 g), 4-(4-chloromethylphenoxy)methyl-2- : phenyloxazole (1.88 g), potassium carbonate (1.30 g). and
N,N-dimethylformamide (30 ml) was stirred at 80°C for 8 . hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution,
dried (MgSO,), and concentrated. The residue was subjected to silica gel column chromatography to obtain ethyl : 1-[4-(2-phenyl-4-oxazolylmethoxy)benzyl]-3-(2-thienyl)- 1H-pyrazole-4-carboxylate as colorless crystals (2.81 g, yleld :92 %) from the traction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Melting point:114~115T.
Example 344
A mixture of diethyl [1-(4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- : yvllmethylmalonate (1.75 g), 2N sodium hydroxide solution (10 ml), and ethanol (10 ml) was refluxed for 2 hour. After cooling, 1N hydrochloric acid (20 ml) was added to the mixture, and the mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated.
The resulting colorless oily substance was dissolved in pyridine (30 ml), and stirred at 110 C for 2 hours. After pyridine was removed under reduced pressure, ethyl acetate was added to the residue. The resulting solution was washed successively with dilute hydrochloric acid and saturated aqueous sodium chloride solution, dried (MgsSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 3-[1-[4-(2-phenyl-4- oxazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazol-4- yllpropionic acid (1.24 g, yield : 85%). This was recrystallized from ethyl acetate-hexane. Melting point: 145~146T,
Example 345
A mixture of ethyl 3-(2-thienyl)-1H-pyrazole-4- . carboxylate (5.60 g). 4-(4-chloromethylphenoxy)methyl- 2-phenylthiazole (7.96 g), potassium carbonate (6.98 g), and N,N-dimethylformamide (75 ml) was stirred at 80C for
8 hours. The reaction mixture was poured into water, and extracted with ethyl acetate. The ethyl acetate layer was : washed with saturated aqueous sodium chloride solution, dried (MgSO4), and concentrated. The residue was : 5 subjected to silica gel column chromatography to obtain ethyl 1-[4-(2-phenyl4-thiazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazole-4-carboxylate as colorless crystals (10.93 g, yield : 87%) from the fraction eluted with ethyl acetate-hexane (1:2, volume ratio). This was recrystallized from ethyl acetate-hexane. Meltingpoint: 94~95T.
Example 346
A mixture of ethyl 1-[4-(2-phenyl-4- thiazolylmethoxy)benzyl]-3-(2-thienyl)-1H-pyrazole-4- carboxylate (750 Img), 1N aqueous sodium hydroxide solution (3 ml), tetrahydrofuran (5 ml), and ethanol (5 ml) was stirred at 80C for 5 hours. After cooling, 1N hydrochloric acid (3 ml) was added to the mixture and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium chloride solution, dried (MgSO,), and concentrated. The resulting colorless crystals were collected by filtration to obtain 1-[4- (2-phenyl-4-thiazolylmethoxy)benzyl}-3-(2-thienyl)-1H- pyrazole-4-carboxylic acid (640 mg, yield : 90%). This was recrystallized from acetone-hexane. Melting point: 187~188TC.
Preparation Example 1 (Production of capsules) 1) Compound of Example 4 30 mg 2) Finely divided cellulose 10 mg . 3) Lactose 19 mg 4) Magnesium stearate 1 mg . Total 60 mg 1), 2), 3) and 4) are admixed and filled into a gelatin capsule.
Preparation Example 2 (Production of tablets) ; 1) Compound of Example 4 30 g 2) Lactose 50 g ’ 5 3) Corn starch 15 g 4) Carboxymethylcellulose calcium 44 g 5) Magnesium stearate I 1000 tablets 140 g
The whole amounts of 1), 2) and 3) and 30 g of 4) are kneaded together with water and the mixture, after vacuum drying, is granulated. The granular mixture is admixed with 14 g of 4) and 1 g of 5) and the resulting mixture is tableted using a tableting machine, to give 1000 tablets each containing 30 mg of compound of Example 4.
The compound of the present invention and the pharmaceutical composition of the present invention are of low toxicity and can be used as an agent for preventing or treating diabetes (e.g., type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus): an agent for preventing or treating hyperlipidemia (e.g., hypertriglycemia, hypercholesterolemia, hypo-high- density-lipoproteinemia, postprandial hyperlipemia):; an agent for enhancing insulin sensitivity: an agent for : improving insulin resistance; an agent for preventing or treating impaired glucose tolerance (IGT): and an agent for preventing progress from impaired glucose tolerance to diabetes mellitus.
The compound of the present invention and the pharmaceutical composition of the present invention can be : used also as an agent for preventing or treating diabetic complications (e.g., neuropathy, nephropathy, retinopathy, : cataract, macroangiopathy, osteopenia, diabetic hyperosmolar coma, infectious diseases (e.g., respiratory infection, urinary tract infection, gastrointestinal tract infection, dermal soft tissue infection, inferior limb infection), diabetic gangrene, xerostomia, lowered sense ’ of hearing, cerebrovascular disease, peripheral circulatory disturbance, etc.), obesity, osteoporosis, cachexia (e.y., cvdrcelnowmatons cachexia, tuberculous cachexia, diabetic cachexia, hemopathic cachexia, endocrinopathic cachexia, infectious cachexia, cachexia induced by acquired immunodeficiency syndrome), fatty liver, hypertension, polycystic ovary syndrome, renal diseases (e.g., diabetic nephropathy, glomerular nephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, terminal renal disorder), muscular dystrophy, myocardiac infarction, angina pectoris, : cerebrovascular disease (e.g., cerebral infarction, cerebral apoplexy), insulin resistant syndrome, syndrome
X, hyperinsulinemia, hyperinsulinemia-induced sensory i disorder, tumor (e.g., leukemia, breast cancer, prostate cancer, skin cancer), irritable intestinum syndrome, acute or chronic diarrhea, inflammatory diseases (e.g., chronic rheumatoid arthritis, spondylitis deformans, osteoarthritis, lumbago, gout, postoperative or traumatic inflammation, remission of swelling, neuralgia, pharyngolaryngitis, cystitis, hepatitis (including steatohepatitis such as non-alcoholic steatohepatitis), pneumonia, pancreatitis, inflammatory colitis, ulcerative colitis), visceral obesity syndrome, arteriosclerosis (e.g., atherosclerosis), etc.
Also, the compound of the present invention and the pharmaceutical composition of the present invention can be used for ameliorating bellyache, nausea, vomiting, or dysphoria in epigastrium, each of which is accompanied by . gastrointestinal ulcer, acute or chronic gastritis, biliary dyskinesia, or cholecystitis. . Further, the compound of the present invention and the pharmaceutical composition of the present invention can control (enhance or inhibit) appetite and food intake, and therefore, can be used as an agent for treating leanness and cibophobia (the weight increase in administration : subjects suffering from leanness or cibophobia) or an agent for treating obesity. {
Claims (35)
1. A compound of the formula:. X'-R’ R'-X- (CH,) -Y —)- (CH), Fyn (c=0)-R' (I Ne wherein R! represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR‘(OR®)- or -NR®- wherein each of R‘ and R® represents a hydrogen atom or a hydrocarbon group which may be substituted, R® represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, or a group of the formula: -SO-, -NR’-, -CONR’- or -NR’CO- wherein R’ represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X' represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -S0,-, -0-SO,- or -NR- wherein R'® represents a hydrogen atom or a hydrocarbon group which may be substituted; : R’ represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted: W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms; R’ represents a group of the formula: -OR® (R° represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR’R (each of R’ and R'’, whether Amended 18 October 2005 identical or not, represents a hydrogen atom, a hydrocarbon group.which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted: R’ and R' may bind together to form a ring); provided that R' is a heterocyclic group which may be substituted or R* is an aromatic hydrocarbon gronp which may be substituted or a heterocyclic group which may be substituted, when ring A is a benzene ring which may be substituted, and Y is an oxygen atom, NH: or -CONHK-; or a salt thereof.
2. A compound according to claim 1, wherein X' is a bond and ring B is a nitrogen-containing 5-membered heterocyclic ring.
3. A compound according to claim 1, wherein R' is a heterocyclic group which may be substituted or a cyclic hydrocarbon group which may be substituted.
4. A compound according to claim 1, wherein R' is a heterocyclic group which may be substituted.
5. A compound according to claim 1, wherein X is a bond.
6. A compound according to claim 1, wherein m is 1 or 2,
’ 7. A compound according to claim 1, wherein Y is an oxygen atom.
8. A compound according to claim 1, wherein ring A is a benzene ring or pyridine ring, each of which may further have 1 to 3 substituents.
9. A compound according to claim 1, wherein n is an integer of 1 to 3. Amended 18 October 2005
10. A compound according to claim 1, wherein X' is a bond or an oxygen atom.
11. A compound according to claim 1, wherein W is a ‘ i] divalent hydrocarbon residue having 1 to 8 carbon atoms.
12. A compound according to claim 1, wherein R? is a group otf the tormula: OR? (R? represents a hydrogen atom or a hydrocarbon group which may be substituted).
13. A compound according to claim 1, which is 3-[3-ethoxy-1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]- 1H-pyrazol-4-yllpropionic acid, 3-[3-ethoxy-1-{4-(2-phenyl-4-~oxazolylmethoxy)benzyl]- l1H-pyrazol-4-yl]lpropionic acid, 3-[3-ethoxy-1-{4-[3-methyl-1-(2-pyridyl)-1H-pyrazol- 4-ylmethoxylbenzyl]-1H-pyrazol-4-yl]propionic acid,
3.[1-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyl]-3- (2-thienyl)-1H-pyrazol-4-yl]lpropionic acid, 3-[1-[4-(2-phenyl-4-thiazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazol-4-yl]lpropionic acid, or 3-[1-{4-(2-phenyl-4-oxazolylmethoxy)benzyl]-3-(2- thienyl)-1H-pyrazol-4-yljpropionic acid.
14. A prodrug of a compound as defined in claim 1.
15. A pharmaceutical composition comprising a compound of the formula: X'-R®
! . 3 R'-X= (CH) Y {A CH), in (c=0)-R an ) 30 wherein R' represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR‘(OR®’)- or -NR®- _ y wherein each of R* and R® represents a hydrogen atom or a hydrocarbon group which may be substituted, .R® represents a hydrogen atom or a protective group for a hydroxyl group: m represents an integer of 0 to 3: Y represents an oxygen atom, or a group of the formula: -SO-, Nr’, -CONR'- or -NR'CO- wherein R’ represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further bé substituted by an alkyl group: X' represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -S0-, -S0,-, -0-S0,- or -NRY- wherein R!® represents a hydrogen atom or a hydrocarbon group which may be substituted: R? represents a hydrogen atom, a hydrocarbon group : which may be substituted or a heterocyclic group which may be substituted; | . W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms; R® represents a group of the formula: -OR® (R® : represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NR’R!® (each of R’ and R'’, whether identical or not, represents a hydrogen atom, a hydrqcarbon : group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R’ and R' may bind together to form a ring): or a salt thereof or a prodrug thereof.
16. A composition according to Claim 15, wherein X! is a bond and ring B is a nitrogen-containing 5-membered : heterocyclic ring. Amended 18 October 2005
17. An agent for preventing or treating diabetes mellitus . comprising a compound of the formula:
1.2 X -R 1 3 R'-X~(CH,) -Y —ry- (CH), —N pa (C=0) -R (11) wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof.
18. An agent for preventing or treating hyperlipidemia comprising a compound of the formula: 1,2 X -R 1 3 R'-X- (CH), =Y CA) (OH), —5 yw (C=0)-R (10 wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof.
19. An agent for preventing or treating impaired glucose tolerance comprising a compound of the formula: X'-R’ 1 : 3 R'X= (cH) ~C A) (0H), —5 yw (c=0)-R (In wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof.
20. A retinoid-related receptor function regulating agent comprising a compound of the formula:
1.2 X'-R 1 3 R'-X=(CH,) -Y ~r- (CH), Tw (C=0)-R (1D wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof. - 25 21. An agent according to claim 20, which is a ligand for peroxisome proliferator-activated receptors.
22. An agent according to claim 20, which is a ligand for retinoid X receptors.
BIW) - 23. An insulin resistance improving agent comprising a : compound of the formula: 142 Xx -R 1 —Y- _ 1 R'-X-(CH,) =A, 5 Jno (110) wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof.
24. Use of a compound of the formula: : Ll X -R : glox-(CH,) -Y (CH), — =0) -R’ 2) n J, —N8 —W-(C=0)-R (11) ; wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof, for the manufacture of a pharmaceutical preparation for preventing or treating diabetes mellitus.
25. Use of a compound of the formula: 2 X'-R ! 3 ) ’ R-1- (0H), Y —L A (OH), 5 co (LD) wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof, for the manufacture of a pharmaceutical preparation for preventing or treating hyperlipidemia.
26. Use of a compound of the formula: 12
: ~. X-R ly _ _ 1 sR (CH,) (01), 8 J-tec | (11) wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof, for the manufacture of a pharmaceutical preparation for preventing or treating impaired glucose tolerance. Amended Sheet — 2004-01-27 vo
27. Use of a compound of the formula: x'-R? 1 3 R “X= (0,) YL A) (CH), 0 (10) S wherein the symbols have the same meanings as in claim 15, or a salt thereof or a prodrug thereof, for the manufacture of an agent for regulating a : retinoid-related receptor function.
28. A compound according to claim 1, other than the compounds of claim 13, as specifically described : herein.
29. A prodrug according to claim 14, substantially as herein described.
30. A composition according to claim 15, substantially as herein described with reference to any one of the illustrative examples.
31. An agent according to claim 17, substantially as herein described with reference to any one of the illustrative examples.
32. An agent according to claim 18, substantially as herein described with reference to any one of the illustrative examples.
33. An agent according to claim 19, substantially as herein described with reference to any one of the illustrative examples. Amended Sheet — 2004-01-27
34. An agent according to claim 20, substantially as herein described with reference to any one of the illustrative examples.
35. An agent according to claim 23, substantially as herein described with reference to any one of the illustrative examples. Amended Sheet — 2004-01-27
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32031799 | 1999-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200203824B true ZA200203824B (en) | 2003-10-15 |
Family
ID=32587985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200203824A ZA200203824B (en) | 1999-11-10 | 2002-05-14 | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200203824B (en) |
-
2002
- 2002-05-14 ZA ZA200203824A patent/ZA200203824B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU780948B2 (en) | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity | |
US7238716B2 (en) | Alkanoic acid derivatives process for their production and use thereof | |
US7368578B2 (en) | Five-membered heterocyclic compounds | |
US7223791B2 (en) | Function regulator for retinoid relative receptor | |
US20060148858A1 (en) | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | |
US20040063775A1 (en) | Five-membered heterocyclic alkanoic acid derivative | |
JPWO2006057448A1 (en) | Arylalkanoic acid derivatives | |
JP4148681B2 (en) | Alkanoic acid derivatives, their production and use | |
EP1229026A1 (en) | Alkoxyiminoalkanoic acid derivatives | |
JP2004277397A (en) | 1, 2-azole derivative | |
ZA200203824B (en) | 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity. | |
JP2004123732A (en) | Five-membered heterocyclic compound | |
JP2002348281A (en) | Five-membered heterocyclic alkane acid derivative |